Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Habitual
[Effect of antiphospholipid antibodies on the formation and lysis of fibrin network in patients with recurrent miscarriage].
Abortion, Spontaneous
Pregnancy-triggered antiphospholipid syndrome in a patient with multiple late miscarriages.
Abscess
Skin infections are eliminated by cooperation of the fibrinolytic and innate immune systems.
Abscess
Staphylokinase Promotes the Establishment of Staphylococcus aureus Skin Infections While Decreasing Disease Severity.
Abscess
Stimulation of plasmin activity in cultured human fibroblast cells by Porphyromonas endodontalis.
Abscess
The treatment of acute abscesses with human plasmin (fibrinolysin).
Acantholysis
Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation.
Acantholysis
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Acantholysis
Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG.
Acantholysis
Pathogenesis of pemphigus. The role of epidermal plasminogen activators in acantholysis.
Acantholysis
Pemphigus IgG induces expression of urokinase plasminogen activator receptor on the cell surface of cultured keratinocytes.
Acantholysis
Penicillamine-induced pemphigus. Immunoglobulin from this patient induces plasminogen activator synthesis by human epidermal cells in culture: mechanism for acantholysis in pemphigus.
Acantholysis
Plasmin induces acantholysis in skin organ cultures.
Acantholysis
Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis.
Acantholysis
Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis.
Acidosis
Histidine-proline-rich glycoprotein as a plasma pH sensor. Modulation of its interaction with glycosaminoglycans by ph and metals.
Acidosis
Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid.
Acquired Immunodeficiency Syndrome
Dysregulated proteolysis in AIDS.
Acquired Immunodeficiency Syndrome
Enolase of Mycobacterium tuberculosis is a surface exposed plasminogen binding protein.
Acquired Immunodeficiency Syndrome
Haemophilus influenzae uses the surface protein E to acquire human plasminogen and to evade innate immunity.
Acquired Immunodeficiency Syndrome
Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.
Acquired Immunodeficiency Syndrome
Wound fluid from venous leg ulcers degrades plasminogen and reduces plasmin generation by keratinocytes.
Activated Protein C Resistance
A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: a comprehensive study.
Activated Protein C Resistance
Atherosclerosis in women with endometriosis.
Activated Protein C Resistance
Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population.
Activated Protein C Resistance
Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.
Activated Protein C Resistance
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Activated Protein C Resistance
Diagnostic testing for coagulopathies in patients with ischemic stroke.
Activated Protein C Resistance
Disturbances of anticoagulation and fibrinolytic systems in monoclonal gammopathies-another mechanism of M-protein interference with hemostasis.
Activated Protein C Resistance
Haemocoagulative modifications correlated with pregnancy.
Activated Protein C Resistance
Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17?-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study.
Activated Protein C Resistance
Hyperprothrombinaemia-induced APC resistance: Differential influence on fibrin formation and fibrinolysis.
Activated Protein C Resistance
Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation.
Activated Protein C Resistance
Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis.
Activated Protein C Resistance
Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease.
Activated Protein C Resistance
Primary thrombophilia in Mexico III: A prospective study of the sticky platelet syndrome.
Activated Protein C Resistance
Primary thrombophilia in Mexico. V. A comprehensive prospective study indicates that most cases are multifactorial.
Activated Protein C Resistance
Prothrombotic disorders in children with moyamoya syndrome.
Activated Protein C Resistance
Prothrombotic disorders in infants and children with cerebral thromboembolism.
Activated Protein C Resistance
Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis.
Activated Protein C Resistance
[Hematological changes and related gene mutation of post-severe acute respiratory syndrome patients with osteonecrosis]
Activated Protein C Resistance
[Primary thrombophilia in México. VI: lack of statistical association among the inherited thrombophilic conditions]
Activated Protein C Resistance
[Screening methods in genetic diagnosis of hereditary protein C deficiency]
Activated Protein C Resistance
[Type I protein C deficiency caused by a novel protein C gene mutation]
Acute Coronary Syndrome
Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease.
Acute Coronary Syndrome
Inflammation, the endothelium, and the acute coronary syndromes.
Acute Coronary Syndrome
Lack of an association between connexin-37, stromelysin-1, plasminogen activator-inhibitor type 1 and lymphotoxin-alpha genes and acute coronary syndrome in Czech Caucasians.
Acute Coronary Syndrome
Relationship between myocardial injury and soluble P-selectin in non-ST elevation acute coronary syndromes.
Acute Coronary Syndrome
[Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events]
Acute Kidney Injury
Reduced fibrinolytic capacity and its restoration by plasminogen substitution in acute renal failure.
Acute Kidney Injury
The proteinase inhibitor complexes (antithrombin III-thrombin, alpha 2antiplasmin-plasmin and alpha 1antitrypsin-elastase) in septicemia, fulminant hepatic failure and cardiac shock: value for diagnosis and therapy control in DIC/F syndrome.
Acute Kidney Injury
[Fibrinolysin (uroplasmin) therapy of initial manifestations of acute renal insufficiency transfusion]
Acute Lung Injury
Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury.
Acute-On-Chronic Liver Failure
Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure.
adamts13 endopeptidase deficiency
ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis.
adamts13 endopeptidase deficiency
Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.
adamts13 endopeptidase deficiency
Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy.
adamts13 endopeptidase deficiency
Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura.
Adenocarcinoma
Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis.
Adenocarcinoma
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen.
Adenocarcinoma
Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Adenocarcinoma
Appearance of plasminogen activator activity during a synchronous cycle of a rat adenocarcinoma cell line, PA-III.
Adenocarcinoma
Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model.
Adenocarcinoma
Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.
Adenocarcinoma
Identification of the plasminogen activator(s) produced by the transformed liver cell line, SK-HEP-1.
Adenocarcinoma
Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: correlation with CEA distribution and tumor cell kinetics.
Adenocarcinoma
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Adenocarcinoma
Iron-mediated stability of PAI-1 mRNA in adenocarcinoma cells-involvement of a mRNA-binding nuclear protein.
Adenocarcinoma
Localization of plasminogen activator(s) in primary and secondary rat adenocarcinoma cells.
Adenocarcinoma
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Adenocarcinoma
Plasminogen Activation System in Rectal Adenocarcinoma.
Adenocarcinoma
Plasminogen activators and inhibitors in ovarian adenocarcinomas.
Adenocarcinoma
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Adenocarcinoma
Plasminogen-induced aggregation of PANC-1 cells requires conversion to plasmin and is inhibited by endogenous plasminogen activator inhibitor-1.
Adenocarcinoma
Plasminogen/plasmin affects expression of glycolysis regulator TIGAR and induces autophagy in lung adenocarcinoma A549 cells.
Adenocarcinoma
Proteases in human tumors.
Adenocarcinoma
Purification and properties of a plasminogen activator from cultured rat prostate adenocarcinoma cells.
Adenocarcinoma
Role of plasminogen activators, metalloproteinases and the tissue inhibitor of metalloproteinase-1 in the metastatic process of human salivary-gland adenocarcinoma cells.
Adenocarcinoma
Tamoxifen exerts oestrogen-agonistic effects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression, in cultures of oestrogen-responsive human endometrial adenocarcinoma cells.
Adenocarcinoma
The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study.
Adenocarcinoma
Tumor-associated universal inhibitors and free plasmin in adenocarcinoma of stomach and pancreatic head.
Adenocarcinoma
Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice.
Adenocarcinoma
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
Adenocarcinoma
Varying distribution of tissue plasminogen activators in gastrointestinal adenocarcinoma.
Adenocarcinoma of Lung
Characterization of the high-affinity interaction between human plasminogen and pro-urokinase.
Adenocarcinoma of Lung
HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis.
Adenocarcinoma of Lung
Plasminogen/plasmin affects expression of glycolysis regulator TIGAR and induces autophagy in lung adenocarcinoma A549 cells.
Adenocarcinoma of Lung
Rhenium-188 labeled recombinant human plasminogen kringle5 (rhk5) and preliminary biodistribution. Evaluation in mice bearing A549 tumours.
Adenocarcinoma, Follicular
Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
Adenoma
Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.
Adenoma
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Adenoma
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Adenoma
Role of urokinase in colorectal neoplasia.
Adenoma
The Plasminogen System in Microdissected Colonic Mucosa Distant from an Isolated Adenoma.
Adenoma
[Blood coagulation disorder in islet cell adenoma]
Adenoma
[Protease activities in gastric and colon cancer tissues]
Adenoma, Islet Cell
[Blood coagulation disorder in islet cell adenoma]
Adenoma, Villous
A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate.
Adenomatous Polyposis Coli
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Adenomatous Polyps
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Adenomatous Polyps
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Adenomatous Polyps
Plasminogen activators in human colorectal neoplasia.
Afibrinogenemia
Fibrinogen deficiency, but not plasminogen deficiency, increases mortality synergistically in combination with sickle hemoglobin SAD in transgenic mice.
Afibrinogenemia
Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner.
Afibrinogenemia
Plasminogen interacts with human platelets through two distinct mechanisms.
Afibrinogenemia
[Plasmin and congenital afibrinogenemia]
Agammaglobulinemia
Intravenous administration of plasmin treated immunoglobulins in 10 patients with agammaglobulinemia.
Aggressive Periodontitis
A haplotype block downstream of plasminogen is associated with chronic and aggressive periodontitis.
Aggressive Periodontitis
Periodontitis associated with plasminogen deficiency: a case report.
AIDS-Associated Nephropathy
Podocyte Injury: The Role of Proteinuria, Urinary Plasminogen and Oxidative Stress.
Airway Obstruction
Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene.
Albinism, Ocular
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Albuminuria
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Albuminuria
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
Albuminuria
Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease.
Albuminuria
Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy.
Albuminuria
[Urinary excretion of extracellular matrix proteins in insulin dependent diabetes mellitus]
Alopecia
Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression.
Alopecia Areata
The role of plasminogen activators in alopecia areata.
Alveolar Bone Loss
Association of gene polymorphisms for plasminogen activators with alveolar bone loss.
Alveolar Bone Loss
Ligneous periodontitis and Ehlers-Danlos syndrome.
Alzheimer Disease
Activated alpha2macroglobulin increases beta-amyloid (25-35)-induced toxicity in LAN5 human neuroblastoma cells.
Alzheimer Disease
Activators and inhibitors of the plasminogen system in Alzheimer's disease.
Alzheimer Disease
Amyloid beta soluble forms and plasminogen activation system in Alzheimer's disease: Consequences on extracellular maturation of brain-derived neurotrophic factor and therapeutic implications.
Alzheimer Disease
Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model.
Alzheimer Disease
Amyloid-beta-stimulated plasminogen activation by tissue-type plasminogen activator results in processing of neuroendocrine factors.
Alzheimer Disease
Analysis of Matrix Metallo-Proteases and the Plasminogen System in Mild Cognitive Impairment and Alzheimer's Disease Cerebrospinal Fluid.
Alzheimer Disease
Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2.
Alzheimer Disease
Association studies between the plasmin genes and late-onset Alzheimer's disease.
Alzheimer Disease
Beta-amyloidolysis and glutathione in Alzheimer's disease.
Alzheimer Disease
Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease.
Alzheimer Disease
Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.
Alzheimer Disease
Plasmin deficiency in Alzheimer's disease brains: causal or casual?
Alzheimer Disease
Plasmin system of Alzheimer's disease patients: CSF analysis.
Alzheimer Disease
Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain.
Alzheimer Disease
Plasminogen and plasmin in Alzheimer's disease.
Alzheimer Disease
Proteolysis in Alzheimer's disease. Can plasmin tip the balance?
Alzheimer Disease
Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains.
Alzheimer Disease
Statins may act through increasing tissue plasminogen activator/plasmin activity to lower risk of Alzheimer's disease.
Alzheimer Disease
The conflicting role of brain cholesterol in Alzheimer's disease: lessons from the brain plasminogen system.
Alzheimer Disease
The plasminogen activating system in the pathogenesis of Alzheimer's disease.
Alzheimer Disease
Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.
Ameloblastoma
Fibrinolytic activity in cystic lesions of jaw bones.
Amyloidosis
Amyloidosis associated bleeding diatheses in the surgical patient.
Amyloidosis
Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis.
Amyloidosis
Serum, salivary, and tissue levels of plasminogen in familial Mediterranean fever, amyloidosis, and chronic periodontitis.
Amyloidosis
[Activators and inhibitors of fibrinolysis in chronic glomerulonephritis and amyloidosis]
Amyloidosis
[The levels of antigens to plasminogen activators compared to their functional activity and inhibitor activity in patients with glomerulonephritis and amyloidosis]
Amyloidosis
[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis]
Anaphylaxis
Anaphylactic shock in dogs. Role of fibrinolysin and vasoactive polypeptide systems.
Anaphylaxis
Controlled insect-sting challenge in 55 patients: correlation between activation of plasminogen and the development of anaphylactic shock.
Anaphylaxis
Fibrinolysis and anaphylaxis. I. Activation of blood fibrinolysin during anaphylactic shock in guinea pigs.
Anaphylaxis
Study of fibrinogen and plasminogen concentrations in rabbits during anaphylactic shock.
Anemia
Effect of a Congolese herbal medicine used in sickle cell anemia on the expression of plasminogen activators in human coronary aortic endothelial cells culture.
Anemia
Lonomia genus caterpillar toxins: biochemical aspects.
Anemia, Sickle Cell
Coagulopathies and arterial stroke.
Anemia, Sickle Cell
Effect of a Congolese herbal medicine used in sickle cell anemia on the expression of plasminogen activators in human coronary aortic endothelial cells culture.
Aneurysm
Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms.
Aneurysm
Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms.
Aneurysm
Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall.
Aneurysm
Clearance of plasmin-PN-1 complexes by vascular smooth muscle cells in human aneurysm of the ascending aorta.
Aneurysm
Elastase-induced experimental aneurysms in rats.
Aneurysm
Fibrinolytic activity of human brain.
Aneurysm
Genes predisposing to rapid aneurysm growth.
Aneurysm
Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses.
Aneurysm
Intraluminal thrombus enhances proteolysis in abdominal aortic aneurysms.
Aneurysm
Molecular analysis of blood vessel formation and disease.
Aneurysm
Perioperative changes in coagulative and fibrinolytic function during surgical treatment of abdominal aortic aneurysm and arteriosclerosis obliterans.
Aneurysm
Plasmin and matrix metalloproteinases in vascular remodeling.
Aneurysm
Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1.
Aneurysm
Reduced transplant arteriosclerosis in plasminogen-deficient mice.
Aneurysm
Role of matrix metalloproteinases (MMPs) and MMP inhibitors on intracranial aneurysms: a review article.
Aneurysm
Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with tranexamic acid (AMCA). Report of three cases.
Aneurysm
Thrombus versus Wall Biological Activities in Experimental Aortic Aneurysms.
Aneurysm
Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation.
Aneurysm
Vascular aneurysms: a perspective.
Aneurysm
Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review).
Aneurysm
Vascular extracellular matrix remodeling in cerebral aneurysms.
Aneurysm, Dissecting
Thrombolytic therapy and acute aortic dissection.
Angina Pectoris
Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Angina Pectoris
Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis.
Angina Pectoris
[Newly developed stenocardia: effect of intensive physical training on the indicators of the blood coagulation system and fibrinolysis]
Angina, Stable
Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
Angina, Stable
Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation.
Angina, Unstable
Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction.
Angina, Unstable
Elevated levels of plasmin-alpha2 antiplasmin complexes in unstable angina.
Angina, Unstable
One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction.
Angina, Unstable
Platelet activation in the pathogenesis of unstable angina: importance in determining the response to plasminogen activators.
Angina, Unstable
Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris.
Angina, Unstable
[Unstable angina: tissue plasminogen activator, tissue plasminogen activator inhibitors, protein C and other factors of the blood fibrinolytic system]
Angioedema
A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration.
Angioedema
Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity.
Angioedema
Angioedema in Stroke Patients With Thrombolysis.
Angioedema
Assessing Plasmin Generation in Health and Disease.
Angioedema
Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor.
Angioedema
Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants.
Angioedema
Pathophysiology and underlying mechanisms in hereditary angioedema.
Angioedema
Plasminflammation-An Emerging Pathway to Bradykinin Production.
Angioedema
Protease inhibitors in the treatment of hereditary angioedema.
Angioedema
The Role of the Plasminogen Activation System in Angioedema: Novel Insights on the Pathogenesis.
Angioedema
Tissue Plasminogen Activator-Induced Angioedema Involving a Posterior Cerebral Artery Infarct: A Case Presentation.
Angioedema
Unilateral orolingual angioedema in a patient with sarcoidosis after intravenous thrombolysis due to acute stroke without improvement after treatment with icatibant.
Angioedemas, Hereditary
A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor.
Angioedemas, Hereditary
A missense mutation of the plasminogen gene in hereditary angioedema with normal C1 inhibitor in Japan.
Angioedemas, Hereditary
Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency.
Angioedemas, Hereditary
Angioedema without urticaria: novel findings which must be measured in clinical setting.
Angioedemas, Hereditary
Complexes between C1-inhibitor, kallikrein, high molecular weight kininogen, plasma thromboplastin antecedent, and plasmin in normal human plasma and hereditary angioneurotic edema plasmas containing dysmorphic C1-inhibitors: role of cold activation.
Angioedemas, Hereditary
Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema.
Angioedemas, Hereditary
Definition and classification of hereditary angioedema.
Angioedemas, Hereditary
Generation of plasmin during acute attacks of hereditary angioedema.
Angioedemas, Hereditary
Hereditary angioedema in a single family with specific mutations in both plasminogen and SERPING1 genes.
Angioedemas, Hereditary
Hereditary angioedema with a mutation in the plasminogen gene.
Angioedemas, Hereditary
Hereditary angioedema.
Angioedemas, Hereditary
Identification of the recently described plasminogen gene mutation p.Lys330Glu in a family from Northern Germany with hereditary angioedema.
Angioedemas, Hereditary
Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor.
Angioedemas, Hereditary
Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants.
Angioedemas, Hereditary
On the pathogenicity of the plasminogen K330E mutation for hereditary angioedema.
Angioedemas, Hereditary
Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations.
Angioedemas, Hereditary
Plasminogen activation in hereditary angioneurotic edema.
Angioedemas, Hereditary
Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: Three additional French families.
Angioedemas, Hereditary
Proteomic Analysis of the Acid-Insoluble Fraction of Whole Saliva from Patients Affected by Different Forms of Non-histaminergic Angioedema.
Angioedemas, Hereditary
Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma.
Angioedemas, Hereditary
Screening for Plasminogen Mutations in Hereditary Angioedema Patients.
Angioedemas, Hereditary
sgp120 and the contact system in hereditary angioedema: A diagnostic tool in HAE with normal C1 inhibitor.
Angioedemas, Hereditary
Specific functional and immunologic assay of plasma plasminogen in hereditary angioedema, in hereditary angioedema treated with tranexamic acid, and in normal subjects.
Angioedemas, Hereditary
Study of angiopoietin and plasminogen genes in hereditary angioedema.
Angioedemas, Hereditary
Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene.
Angioedemas, Hereditary
Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies.
Anovulation
Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.
Anthracosilicosis
[Effect of fibrinolysin and heparin on the formation of fibrosis in experimental anthracosilicosis]
Anthrax
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Anthrax
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Antiphospholipid Syndrome
Antibodies against the N-terminal domain of annexin A2 in antiphospholipid syndrome.
Antiphospholipid Syndrome
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Antiphospholipid Syndrome
beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation.
Antiphospholipid Syndrome
Coagulopathies and arterial stroke.
Antiphospholipid Syndrome
Immunoglobulin G from patients with antiphospholipid syndrome impairs the fibrin dissolution with plasmin.
Antiphospholipid Syndrome
Modulation of fibrinolysis by the combined action of phospholipids and immunoglobulins.
Antiphospholipid Syndrome
Plasmin immunization preferentially induces potentially prothrombotic IgG anticardiolipin antibodies in MRL/MpJ mice.
Antiphospholipid Syndrome
Prevalence of anti-S100A10 antibodies in antiphospholipid syndrome patients.
Antiphospholipid Syndrome
Proteolytic cleavage of beta(2)-glycoprotein I: reduction of antigenicity and the structural relationship.
Antiphospholipid Syndrome
The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
Antiphospholipid Syndrome
The role of beta2-glycoprotein I (beta(2)GPI) in the activation of plasminogen.
Antiphospholipid Syndrome
The role of beta2-glycoprotein I (beta2GPI) in the activation of plasminogen.
Antiphospholipid Syndrome
[Diagnosis and treatment of coagulation disorders]
Antiphospholipid Syndrome
[Effect of antiphospholipid antibodies on the formation and lysis of fibrin network in patients with recurrent miscarriage].
Antiphospholipid Syndrome
[Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome].
Antiphospholipid Syndrome
[The levels of plasminogen and inhibitor of plasminogen activators of type 1 in antiphospholipid syndrome].
Antithrombin III Deficiency
Coagulopathies and arterial stroke.
Antithrombin III Deficiency
Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan.
Antithrombin III Deficiency
Plasminogen and antithrombin III deficiencies in the childhood nephrotic syndrome associated with plasminogenuria and antithrombinuria.
Antithrombin III Deficiency
The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis.
Antithrombin III Deficiency
[Molecular basis of thrombosis]
Aortic Aneurysm
Doxycycline treatment in a model of early abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
Activators of plasminogen and the progression of small abdominal aortic aneurysms.
Aortic Aneurysm, Abdominal
Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta.
Aortic Aneurysm, Abdominal
Haemostasis during infrarenal aortic aneurysm surgery: effect of volume loading and cross-clamping.
Aortic Aneurysm, Abdominal
Increased PAI-1 in Females Compared to Males is Protective for Abdominal Aortic Aneurysm Formation in a Rodent Model.
Aortic Aneurysm, Abdominal
Plasma levels of plasmin-antiplasmin-complexes are predictive for small abdominal aortic aneurysms expanding to operation-recommendable sizes.
Aortic Aneurysm, Abdominal
Possible key role for plasmin in the pathogenesis of abdominal aortic aneurysms.
Aortic Aneurysm, Abdominal
Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms.
Aortic Aneurysm, Abdominal
Tissue plasminogen activator-assisted hematoma evacuation to relieve abdominal compartment syndrome after endovascular repair of ruptured abdominal aortic aneurysm.
Aortic Diseases
Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease.
Aortic Valve Stenosis
Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves.
Aortic Valve Stenosis
[A successful perioperative anticoagulation therapy and monitoring of a patient with hereditary plasminogen abnormality undergoing aortic valve replacement]
Arrhythmias, Cardiac
Biological risk factors for sudden death in patients with coronary artery disease and without heart failure.
Arterial Occlusive Diseases
[Results of in situ arterial thrombolysis by the combination of urokinase and lysyl plasminogen in acute arterial occlusive diseases of the lower limbs]
Arteriosclerosis
Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction.
Arteriosclerosis
Elevated levels of plasminogen-activator inhibitor type 1 in atherosclerotic aorta.
Arteriosclerosis
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.
Arteriosclerosis
Plasmin- and thrombin-accelerated shedding of syndecan-4 ectodomain generates cleavage sites at Lys(114)-Arg(115) and Lys(129)-Val(130) bonds.
Arteriosclerosis
Reduced transplant arteriosclerosis in plasminogen-deficient mice.
Arteriosclerosis
Treatment of experimental pulmonary arteriosclerosis with cortisone, heparin and fibrinolysin.
Arteriosclerosis
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site.
Arteriosclerosis
[Effect of fibrinolysin on the development of experimental cholesterol arteriosclerosis in rabbits]
Arteriosclerosis
[Lipoprotein (a)--a further risk factor in arteriosclerosis?]
Arteriosclerosis
[Lypolytic activity of aorta and liver under the effect of fibrinolysin in rabbits with experimental cholesterol arteriosclerosis]
Arteriosclerosis
[Symposium: Arteriosclerosis (with special reference to thrombosis and anticoagulants). 2. Significance of plasmin in arteriosclerosis.]
Arteriosclerosis Obliterans
Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans.
Arteriovenous Fistula
Local fibrinolysis in native arteriovenous fistulas of haemodialysis patients.
Arteriovenous Fistula
[The use of thrombolytic preparations for the functional restoration of the arteriovenous fistula in patients on programmed hemodialysis]
Arteritis
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
Arteritis
[Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age].
Arthritis
Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis.
Arthritis
Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis.
Arthritis
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Arthritis
Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models.
Arthritis
Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues.
Arthritis
Fibrin dissolution in synovial fluid.
Arthritis
Investigation of the enzymatic activity in rheumatoid arthritis. I. The activity of plasmin in plasma from patients with rheumatoid arthritis.
Arthritis
Mini-plasminogen-like fragments of plasminogen in synovial fluid in acute inflammatory arthritis.
Arthritis
Novel aspects and new roles for the serine protease plasmin.
Arthritis
Plasma apolipoprotein(a) co-deposits with fibrin in inflammatory arthritic joints.
Arthritis
Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease.
Arthritis
Plasminogen activator/plasmin system in arthritis and inflammation: friend or foe?
Arthritis
Plasminogen activators in synovial fluid and plasma from patients with arthritis.
Arthritis
Plasminogen is a joint-specific positive- or negative-determinant of arthritis pathogenesis.
Arthritis
Protective effects of plasmin(ogen) in a mouse model of Staphylococcus aureus-induced arthritis.
Arthritis
Role of plasminogen activator inhibitor - 1 (PAI-1) in regulating the pathogenesis of S. aureus arthritis via plasminogen pathway.
Arthritis
The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.
Arthritis
Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis.
Arthritis
TSG-6 regulates bone remodeling through inhibition of osteoblastogenesis and osteoclast activation.
Arthritis
Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells.
Arthritis
[Experimental plasmin arthritis]
Arthritis, Experimental
Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis.
Arthritis, Experimental
Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models.
Arthritis, Experimental
Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis.
Arthritis, Infectious
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Arthritis, Infectious
Protective effects of plasmin(ogen) in a mouse model of Staphylococcus aureus-induced arthritis.
Arthritis, Infectious
Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis.
Arthritis, Juvenile
[Disorders of the system of hemostasis in patients with juvenile rheumatoid arthritis and rheumatic fever]
Arthritis, Rheumatoid
Analysis of autoantibodies to plasminogen in the serum of patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Are plasminogen antibodies in rheumatoid arthritis of pathogenic significance?
Arthritis, Rheumatoid
Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Arthritis, Rheumatoid
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Arthritis, Rheumatoid
Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis.
Arthritis, Rheumatoid
Characterization of the plasminogen receptors of normal and rheumatoid arthritis human synovial fibroblasts.
Arthritis, Rheumatoid
Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models.
Arthritis, Rheumatoid
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Arthritis, Rheumatoid
Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis.
Arthritis, Rheumatoid
Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Arthritis, Rheumatoid
Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis.
Arthritis, Rheumatoid
Investigation of the enzymatic activity in rheumatoid arthritis. I. The activity of plasmin in plasma from patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Lack of effect of tranexamic acid on rheumatoid arthritis.
Arthritis, Rheumatoid
Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction.
Arthritis, Rheumatoid
Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients.
Arthritis, Rheumatoid
No therapeutic effect of plasmin antagonist tranexamic acid in rheumatoid arthritis. A double-blind placebo-controlled pilot study.
Arthritis, Rheumatoid
Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.
Arthritis, Rheumatoid
Plasminogen activation stimulates an increase in intracellular calcium in human synovial fibroblasts.
Arthritis, Rheumatoid
Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more.
Arthritis, Rheumatoid
Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease.
Arthritis, Rheumatoid
Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees.
Arthritis, Rheumatoid
Regulation of plasminogen receptors.
Arthritis, Rheumatoid
Serum antiplasmin and plasmin in rheumatoid arthritis.
Arthritis, Rheumatoid
Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis.
Arthritis, Rheumatoid
Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface.
Arthritis, Rheumatoid
Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis.
Arthritis, Rheumatoid
The primary plasmin inhibitor in rheumatoid synovial fluid.
Arthritis, Rheumatoid
The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets.
Arthritis, Rheumatoid
Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis.
Arthritis, Rheumatoid
[Activity of plasminogen activators and plasmin inhibitors in the joint capsule in various articular diseases (author's transl)]
Arthritis, Rheumatoid
[Experimental plasmin arthritis]
Arthus Reaction
Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin.
Aspergillosis
Plasminogen alleles influence susceptibility to invasive aspergillosis.
Asthma
Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells.
Asthma
Cyclic adenosine monophosphate induces plasminogen activator inhibitor-1 expression in human mast cells.
Asthma
Genetic susceptibility to severe asthma with fungal sensitization.
Asthma
PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model.
Asthma
Plasmin system regulation in an ovalbumin-induced rat model of asthma.
Asthma
Plasminogen Activation by Airway Smooth Muscle is Regulated by Type I Collagen.
Asthma
Plasminogen is an important regulator in the pathogenesis of a murine model of asthma.
Asthma
Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling.
Asthma
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
Asthma
The plasminogen activation system: new targets in lung inflammation and remodeling.
Asthma
Up-regulation of the extrinsic coagulation pathway in acute asthma--a case study.
Asthma
Urokinase receptor orchestrates the plasminogen system in airway epithelial cell function.
Asthma
[Effectiveness of the calcium antagonist nifedipine and the protease inhibitor with plasmin inactivating effect para-aminomethylbenzoic acid on stress-induced bronchial asthma]
Astrocytoma
Cytokines regulate plasminogen activation system in astrocytoma cells.
Astrocytoma
Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells.
Astrocytoma
Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas.
Atherosclerosis
A basic study on theglobal coagulation and fibrinolysis of hyperlipaemic and atherosclerotic patients.2. Plasminogen activator, plasminogen, a2-macroglobulin in atherosclerosis and endogenous hypertriglyceridaemia.
Atherosclerosis
A haplotype block downstream of plasminogen is associated with chronic and aggressive periodontitis.
Atherosclerosis
A new hypothesis: possible mechanisms in the involvement of the increased plasminogen activator activity in branching regions of the aorta in the initiation of atherosclerosis.
Atherosclerosis
A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion.
Atherosclerosis
A role of plasminogen in atherosclerosis and restenosis models in mice.
Atherosclerosis
Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro.
Atherosclerosis
Acute myocardial ischemia in a patient with heterozygous alpha-2-plasmin inhibitor deficiency.
Atherosclerosis
Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome?
Atherosclerosis
Angiostatin inhibits monocyte/macrophage migration via disruption of actin cytoskeleton.
Atherosclerosis
Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis.
Atherosclerosis
Assembly of plasmin-generating proteins on the surface of human endothelial cells.
Atherosclerosis
Atherogenesis and fibrinogen: historical perspective and current status.
Atherosclerosis
Atherogenesis and vascular calcification in mice expressing the human LPA gene.
Atherosclerosis
Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1.
Atherosclerosis
Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis.
Atherosclerosis
Changes in arterial expression of fibrinolytic system proteins in atherogenesis.
Atherosclerosis
Coagulation Factors II, V, IX, X, XI, and XII, Plasminogen, and alpha-2 Antiplasmin and Risk of Coronary Heart Disease.
Atherosclerosis
Consistent differences in protein distribution along the longitudinal axis in symptomatic carotid atherosclerotic plaques.
Atherosclerosis
Current understanding of pathogenesis of coronary artery disease and its future implications.
Atherosclerosis
Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation.
Atherosclerosis
Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells.
Atherosclerosis
Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance.
Atherosclerosis
Effects of lipids on thrombotic mechanisms in atherosclerosis.
Atherosclerosis
Endothelial cell fibrinolytic assembly.
Atherosclerosis
Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis.
Atherosclerosis
Fibrin, lipoprotein(a), plasmin interactions: a model linking thrombosis and atherogenesis.
Atherosclerosis
Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.
Atherosclerosis
Fibrinolysis and plasminogen concentration in aortic intima in relation to death following myocardial infarction.
Atherosclerosis
Genetic deletion of tissue-type plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosis.
Atherosclerosis
Human Aortic Vascular Smooth Muscle Cells Digest Extracellular Matrix by Elaboration of Plasminogen Activators: Implications for Atherogenesis.
Atherosclerosis
Human plasminogen kringle 1-5 reduces atherosclerosis and neointima formation in mice by suppressing the inflammatory signaling pathway.
Atherosclerosis
Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease.
Atherosclerosis
Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease.
Atherosclerosis
Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties.
Atherosclerosis
Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes.
Atherosclerosis
Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a).
Atherosclerosis
Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces.
Atherosclerosis
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.
Atherosclerosis
LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trial.
Atherosclerosis
Level of Macrophage uPA Expression Is an Important Determinant of Atherosclerotic Lesion Growth in Apoe-/- Mice.
Atherosclerosis
Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.
Atherosclerosis
Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease.
Atherosclerosis
Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.
Atherosclerosis
Lipoprotein(a) and coronary heart disease risk.
Atherosclerosis
Lipoprotein(a) and ischemic heart disease-A causal association? A review.
Atherosclerosis
Lipoprotein(a) as a cardiovascular risk factor: current status.
Atherosclerosis
Lipoprotein(a) as a risk factor for coronary artery disease.
Atherosclerosis
Lipoprotein(a), atherosclerosis and thrombosis.
Atherosclerosis
Lipoprotein(a), atherosclerosis, and apolipoprotein(a) gene polymorphism.
Atherosclerosis
Lipoprotein(a), plasmin modulation, and atherogenesis.
Atherosclerosis
Lipoprotein(a): an emerging cardiovascular risk factor.
Atherosclerosis
Lipoprotein(a): Current Perspectives.
Atherosclerosis
Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease?
Atherosclerosis
Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.
Atherosclerosis
Molecular analysis of blood vessel formation and disease.
Atherosclerosis
Novel aspects and new roles for the serine protease plasmin.
Atherosclerosis
Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression.
Atherosclerosis
Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis.
Atherosclerosis
Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?
Atherosclerosis
Plasmin and kallikrein reduce HDL-induced cholesterol efflux from foam cells.
Atherosclerosis
Plasmin and matrix metalloproteinases in vascular remodeling.
Atherosclerosis
Plasmin induces intercellular adhesion molecule 1 expression in human endothelial cells via nuclear factor-?B/mitogen-activated protein kinases-dependent pathways.
Atherosclerosis
Plasmin triggers chemotaxis of monocyte-derived dendritic cells through an Akt2-dependent pathway and promotes a T-helper type-1 response.
Atherosclerosis
Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.
Atherosclerosis
Plasminogen activators in vascular remodeling and angiogenesis.
Atherosclerosis
Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis.
Atherosclerosis
Plasminogen inhibits TNFalpha-induced apoptosis in monocytes.
Atherosclerosis
Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice.
Atherosclerosis
Plasminogen-induced foam cell formation by macrophages occurs through a histone 2B (H2B)-PAR1 pathway and requires integrity of clathrin-coated pits.
Atherosclerosis
Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.
Atherosclerosis
Quantitative trait locus on chromosome 12q14.1 influences variation in plasma plasminogen levels in the San Antonio Family Heart Study.
Atherosclerosis
Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery.
Atherosclerosis
Regulation of baboon arterial smooth muscle cell plasminogen activators by heparin and growth factors.
Atherosclerosis
Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
Atherosclerosis
Role of fibrinolytic parameters and plasminogen activator inhibitor 1 (PAI-1) promoter polymorphism on premature atherosclerosis in SLE patients.
Atherosclerosis
Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy.
Atherosclerosis
Studies in experimental atherosclerosis. IV. Serum fibrinolysin activity in cholesterol atherosclerosis.
Atherosclerosis
The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels.
Atherosclerosis
The role of the fibrinolytic system in corneal angiogenesis.
Atherosclerosis
Transmembrane signaling pathway mediates oxidized low-density lipoprotein-induced expression of plasminogen activator inhibitor-1 in vascular endothelial cells.
Atherosclerosis
Vascular accumulation of Lp(a): in vivo analysis of the role of lysine-binding sites using recombinant adenovirus.
Atherosclerosis
[A study of problems of the diagnosis and pathogenesis of atherosclerosis using fibrinolysin labeled with I-131]
Atherosclerosis
[Experimental cholesterin atherosclerosis in the rabbit: action of a duodenal heparinoid. III. Modifications in the factors of hemocoagulation, plasmin and plasminogen, and in the thromboplastin and fibrinolytic activity of the aortic wall.]
Atherosclerosis
[Experimental substantiation of the diagnosis of atherosclerosis by the use of fibrinolysin labeled with I-131]
Atherosclerosis
[Expression of tissue-type plasminogen activator (t-PA) in smooth muscle cells of injured iliac arteries in rabbits]
Atherosclerosis
[Expression of urokinase plasminogen activator, its receptor and plasminogen activator inhibitor type 1 in different types of atherosclerotic lesion in human aorta]
Atherosclerosis
[Lipids and atherosclerosis]
Atherosclerosis
[Lipoprotein (a) and plasminogen in atherosclerosis]
Atherosclerosis
[Lipoprotein (a). An additional marker of atherosclerosis]
Atherosclerosis
[Lipoprotein(a). Its importance as an additional atherosclerosis marker]
Atherosclerosis
[Lipoprotein(a): a link between thrombogenesis and atherogenesis]
Atherosclerosis
[New data about lipoprotein(a): a curious molecule or a causal cardiovascular risk factor?]
Atherosclerosis
[Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy]
Atherosclerosis
[Plasminogen, antiplasmins and the rate of fibrinolysis in hypertension and atherosclerosis]
Atherosclerosis
[Protective effect of combined injection of fibrinolysin and heparin against thrombogenesis in animals during the pre-thrombotic state and in experimental atherosclerosis]
Atherosclerosis
[Relations between fibrinolysis and human atherosclerosis. Tissue activator of plasminogen of the arterial wall]
Atherosclerosis
[Some biochemical indices of the blood under the effect of fibrinolysin in rabbits with experimental cholesterol atherosclerosis]
Atherosclerosis
[The mysteries of lipoprotein (a): a bridge between thrombosis and atheroma]
Atherosclerosis
[The rate of activation of plasminogen and intrasvascular thrombus formation in rheumatism and atherosclerosis]
Atherosclerosis
[Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease]
Atrial Fibrillation
Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction.
Autoimmune Diseases
A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis.
Autoimmune Diseases
alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci.
Autoimmune Diseases
Analysis of autoantibodies to plasminogen in the serum of patients with rheumatoid arthritis.
Autoimmune Diseases
Autoantibodies to plasminogen and tissue plasminogen activator in women with recurrent pregnancy loss.
Autoimmune Diseases
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Autoimmune Diseases
Plasmin as a proinflammatory cell activator.
Autoimmune Diseases
Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.
Autoimmune Pancreatitis
No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort.
Babesiosis
Blood markers of fibrinolysis and endothelial activation in canine babesiosis.
Bacteremia
Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).
Bacteremia
Elevated concentrations of cross-linked fibrin degradation products in plasma. An early marker of gram-negative bacteremia.
Bacteremia
Immobilization of plasminogen on Escherichia coli flagella.
Bacteremia
Prophylaxis of catheter-related bacteremia using tissue plasminogen activator-tobramycin locks.
Bacterial Infections
A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection.
Bacterial Infections
Procalcitonin and Other Biomarkers of Sepsis in Newborns in the Intensive Care Unit.
Bacterial Infections
Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.
Bacterial Infections
Reduced fibrinolytic capacity and its restoration by plasminogen substitution in acute renal failure.
Bacterial Infections
The interaction of two novel putative proteins of Leptospira interrogans with E-cadherin, plasminogen and complement components with potential role in bacterial infection.
Bacterial Infections
Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles.
Behcet Syndrome
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
beta-Thalassemia
Impact of ?-thalassemia trait carrier state on inflammatory status in patients with newly diagnosed hypertension.
Blister
An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid.
Blister
Cantharidin-induced acantholysis in Darier's disease: does acantholysis initiate dyskeratosis?
Blister
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Blister
Collagen XVII Processing and Blistering Skin Diseases.
Blister
Different effects of pemphigus antibody and plasmin on the distribution of keratin intermediate filaments and desmoplakins between cultured oral and epidermal keratinocytes.
Blister
Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.
Blister
Fibrinolysis inhibition in human burn blister fluid.
Blister
Plasmin-like proteinase associated with high molecular weight complexes in blister fluid of bullous pemphigoid.
Blister
Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann.
Blister
Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression.
Blister
Studies on two siblings with recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) and the plasminogen activator and its inhibitor in the lesion.
Blister
The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.
Blister
The extra-articular deposition of fibrinogen antigenic material in patients with rheumatoid arthritis.
Blister
[Coagulation factors in human born blisters (author's transl)]
Bone Diseases
The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer.
Bone Diseases
Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization.
Bone Resorption
Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor.
Bone Resorption
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
Bone Resorption
Effects of plasminogen and interleukin-1 beta on bone resorption in vitro.
Bone Resorption
Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency.
Bone Resorption
Modulation of plasminogen activators and plasminogen activator inhibitors by TGF-beta, IL-1 alpha and EGF in fetal rat calvaria cells at different times of culture.
Bone Resorption
Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells.
Bone Resorption
Relationship of the plasminogen activator/plasmin cascade to osteoclast invasion and mineral resorption in explanted fetal metatarsal bones.
Bone Resorption
The role of the plasminogen system in bone resorption in vitro.
Bone Resorption
Thrombomodulin is synthesized by osteoblasts, stimulated by 1,25-(OH)2D3 and activates protein C at their cell membrane.
Brain Diseases
Cellular mechanisms regulating non-haemostatic plasmin generation.
Brain Diseases
[Change in the concentration of plasmin and its inhibitors in the blood of patients with dyscirculatory encephalopathy before and after treatment]
Brain Edema
Epsilon Aminocaproic Acid Pretreatment Provides Neuroprotection Following Surgically Induced Brain Injury in a Rat Model.
Brain Edema
Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat.
Brain Edema
MRI predicts area of increased plasminogen activation in permanent focal cerebral ischemia.
Brain Edema
Plasminogen activators potentiate thrombin-induced brain injury.
Brain Edema
Proteolytic cascade enzymes increase in focal cerebral ischemia in rat.
Brain Infarction
[Revising the principles and improving the methods of differential therapy of ischemic stroke]
Brain Injuries
Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats.
Brain Injuries
Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischemic brain injury in vivo.
Brain Injuries
Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases.
Brain Injuries
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Brain Injuries
Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury.
Brain Injuries
Plasminogen activators potentiate thrombin-induced brain injury.
Brain Injuries
Platelet-Derived Growth Factor Receptor-? Regulates Vascular Smooth Muscle Cell Phenotypic Transformation and Neuroinflammation After Intracerebral Hemorrhage in Mice.
Brain Injuries
Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
Brain Injuries
Tissue plasminogen activator-independent roles of neuroserpin in the central nervous system.
Brain Injuries
[The permeability of the hemato-encephalic barrier and the proteolytic potential of the cerebrospinal fluid in severe craniocerebral trauma]
Brain Injuries, Traumatic
Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury.
Brain Injuries, Traumatic
Fibrinolysis: from blood to the brain.
Brain Injuries, Traumatic
Genotype and Injury Effect on the Expression of a Novel Hypothalamic Protein Sushi Repeat-Containing Protein X-Linked 2 (SRPX2).
Brain Injuries, Traumatic
The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans.
Brain Injuries, Traumatic
tPA in the central nervous system: relations between tPA and cell surface LRPs.
Brain Injuries, Traumatic
Tranexamic Acid Influences the Immune Response, but not Bacterial Clearance in a Model of Post-Traumatic Brain Injury Pneumonia.
Brain Injuries, Traumatic
Traumatic brain injury: Tissue-type plasminogen activator-harmful or beneficial?
Brain Injuries, Traumatic
Using antifibrinolytics to tackle neuroinflammation.
Brain Ischemia
Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity.
Brain Ischemia
Cerebral ischemia and neuroregeneration.
Brain Ischemia
Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice.
Brain Ischemia
Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia.
Brain Ischemia
GSK-3? as a target for protection against transient cerebral ischemia.
Brain Ischemia
Intracerebral transplantation of bone marrow stromal cells ameliorates tissue plasminogen activator-induced brain damage after cerebral ischemia in mice detected by in vivo and ex vivo optical imaging.
Brain Ischemia
Ischemic stroke in PAR1 KO mice: Decreased brain plasmin and thrombin activity along with decreased infarct volume.
Brain Ischemia
Modulation by the Noble Gas Helium of Tissue Plasminogen Activator: Effects in a Rat Model of Thromboembolic Stroke.
Brain Ischemia
MRI predicts area of increased plasminogen activation in permanent focal cerebral ischemia.
Brain Ischemia
Neuroendocrine Targeting of Tissue Plasminogen Activator (t-PA).
Brain Ischemia
Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank Samples.
Brain Ischemia
Plasminogen activation in experimental permanent focal cerebral ischemia.
Brain Ischemia
Plasminogen activation in focal cerebral ischemia and reperfusion.
Brain Ischemia
Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
Brain Ischemia
The effect of age on expression of endogenous plasminogen activators after focal cerebral ischemia in mice.
Brain Ischemia
Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system?
Brain Ischemia
Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.
Brain Ischemia
[Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia]
Brain Neoplasms
Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.
Brain Neoplasms
Brain tumors and plasmin inhibitors.
Brain Neoplasms
Genes Encoding Mammalian Oviductal Proteins Involved in Fertilization are Subjected to Gene Death and Positive Selection.
Brain Neoplasms
Induction of tissue-type plasminogen activator and 72-kDa type-IV collagenase by ionizing radiation in rat astrocytes.
Brain Neoplasms
Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells.
Brain Neoplasms
Plasma fibrinolytic profile in patients with brain tumors.
Brain Neoplasms
Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours.
Brain Neoplasms
The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis.
Brain Neoplasms
[A plasminogen regulation system in brain tumors].
Brain Stem Infarctions
[Defects of antithrombin III, protein C, and plasminogen in Wilson's disease with brainstem infarction]
Breast Cyst
Breast cyst fluid plasmin activity and its effect on TGF-beta2 activation.
Breast Cyst
Urokinase and tissue-type plasminogen activators are present in breast cyst fluids.
Breast Diseases
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Breast Neoplasms
A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols.
Breast Neoplasms
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
Breast Neoplasms
Alendronate promotes plasmin-mediated MMP-9 inactivation by exposing cryptic plasmin degradation sites within the MMP-9 catalytic domain.
Breast Neoplasms
Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression.
Breast Neoplasms
Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.
Breast Neoplasms
Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin.
Breast Neoplasms
Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model.
Breast Neoplasms
Association of plasminogen activator activity and steroid receptors in human breast cancer.
Breast Neoplasms
Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Breast Neoplasms
Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation.
Breast Neoplasms
Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment.
Breast Neoplasms
Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator.
Breast Neoplasms
Characteristics of fibrinolysin secreted by cultured rat breast carcinoma cells.
Breast Neoplasms
Clinical implications of urokinase and tissue type plasminogen activators and their inhibitor (PAI-1) in breast cancer tissue.
Breast Neoplasms
Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.
Breast Neoplasms
Clinicopathologic analysis of macrophage infiltrates in breast carcinoma.
Breast Neoplasms
Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
Breast Neoplasms
Correlation of tissue and blood plasminogen activation system in breast cancer.
Breast Neoplasms
Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.
Breast Neoplasms
Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Breast Neoplasms
Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation.
Breast Neoplasms
ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1).
Breast Neoplasms
Enterolactone Suppresses Proliferation, Migration and Metastasis of MDA-MB-231 Breast Cancer Cells Through Inhibition of uPA Induced Plasmin Activation and MMPs-Mediated ECM Remodeling
Breast Neoplasms
Epsilon-aminocaproic acid prevents high glucose and insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system.
Breast Neoplasms
Estradiol preferentially enhances extracellular tissue plasminogen activators of MCF-7 breast cancer cells.
Breast Neoplasms
Estrogen receptor cleavage and plasminogen activation by enzymes in human breast tumor cytosol.
Breast Neoplasms
Evidence for the clinical use of tumour markers.
Breast Neoplasms
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Breast Neoplasms
Expression of proteinases and inhibitors in human breast cancer progression and survival.
Breast Neoplasms
Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
Breast Neoplasms
Factors involved in the plasminogen activation system in human breast tumours.
Breast Neoplasms
Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
Breast Neoplasms
Full kringles of plasminogen (aa 1-566) mediate complete regression of human MDA-MB-231 breast tumor xenografted in nude mice.
Breast Neoplasms
Functional evaluation of plasmin formation in primary breast cancer.
Breast Neoplasms
Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231.
Breast Neoplasms
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
Breast Neoplasms
HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells.
Breast Neoplasms
Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity.
Breast Neoplasms
Human cytomegalovirus interleukin-10 enhances matrigel invasion of MDA-MB-231 breast cancer cells.
Breast Neoplasms
Immunolocalization of the components of the plasminogen activating system in breast carcinoma tissue.
Breast Neoplasms
Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis.
Breast Neoplasms
Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.
Breast Neoplasms
Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins.
Breast Neoplasms
Inhibition of human MDA-MB-231 breast cancer cell invasion by matrix metalloproteinase 3 involves degradation of plasminogen.
Breast Neoplasms
Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression.
Breast Neoplasms
Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.
Breast Neoplasms
Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
Breast Neoplasms
Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence.
Breast Neoplasms
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Breast Neoplasms
microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling.
Breast Neoplasms
Monoclonal antibody to cytokeratin VKIALEVEIATY sequence motif reduces plasminogen activation in breast tumour cells.
Breast Neoplasms
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Breast Neoplasms
Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue.
Breast Neoplasms
Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Breast Neoplasms
Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53.
Breast Neoplasms
Pathway-Based Biomarker Search by High-Throughput Proteomics Profiling of Secretomes.
Breast Neoplasms
PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.
Breast Neoplasms
Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer.
Breast Neoplasms
Plasmin induces the formation of multicellular spheroids of breast cancer cells.
Breast Neoplasms
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Breast Neoplasms
Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties.
Breast Neoplasms
Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Breast Neoplasms
Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.
Breast Neoplasms
Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.
Breast Neoplasms
Prognosis and prediction of response in breast cancer: the current role of the main biological markers.
Breast Neoplasms
Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
Breast Neoplasms
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.
Breast Neoplasms
Proteases as prognostic markers in cancer.
Breast Neoplasms
Proteolysis of CCN1 by plasmin: functional implications.
Breast Neoplasms
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
Breast Neoplasms
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Breast Neoplasms
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Breast Neoplasms
Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Breast Neoplasms
Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Breast Neoplasms
Sanguisorba minor extract suppresses plasmin-mediated mechanisms of cancer cell migration.
Breast Neoplasms
Serpins promote cancer cell survival and vascular co-option in brain metastasis.
Breast Neoplasms
Sialylated Lewis x Antigen Bearing Glycoproteins in Human Plasma.
Breast Neoplasms
Silencing of the annexin II gene down-regulates the levels of S100A10, c-Myc, and plasmin and inhibits breast cancer cell proliferation and invasion.
Breast Neoplasms
Spontaneous metastasis in congenic mice with transgenic breast cancer is unaffected by plasminogen gene ablation.
Breast Neoplasms
Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
Breast Neoplasms
Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor.
Breast Neoplasms
Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.
Breast Neoplasms
Synthetic substrates specific to activated plasmin can monitor the enzymatic functional status in situ in breast cancer cells.
Breast Neoplasms
Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer.
Breast Neoplasms
Targeting uPAR with Antagonistic Recombinant Human Antibodies in Aggressive Breast Cancer.
Breast Neoplasms
The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells.
Breast Neoplasms
The topology of plasminogen binding and activation on the surface of human breast cancer cells.
Breast Neoplasms
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
Breast Neoplasms
The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue.
Breast Neoplasms
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Breast Neoplasms
Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
Breast Neoplasms
Tissue plasminogen activators in breast cancer.
Breast Neoplasms
Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
Breast Neoplasms
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.
Breast Neoplasms
Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Breast Neoplasms
Type-1 plasminogen activator inhibitor in human breast carcinomas.
Breast Neoplasms
Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase.
Breast Neoplasms
Urokinase is a negative modulator of Egf-dependent proliferation and motility in the two breast cancer cell lines MCF-7 and MDA-MB-231.
Breast Neoplasms
Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
Breast Neoplasms
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Breast Neoplasms
[A plasminogen regulation system in brain tumors].
Breast Neoplasms
[The clinical prospects for the study of the plasminogen activation system in breast cancer]
Breast Neoplasms
[The concentration of tissue--type plasminogen activator (t-PA) in extracts of breast cancer tissue]
Breast Neoplasms
[The immunoenzyme determination of plasminogen activators and their inhibitor in breast tumors: the connection to clinico-morphological prognostic factors]
Bronchiectasis
Potentiative effects of neutral proteinases in an inflamed lung: relationship of neutrophil procollagenase (proMMP-8) to plasmin, cathepsin G and tryptase in bronchiectasis in vivo.
Bronchiolitis
Effective treatment of ligneous conjunctivitis with topical plasminogen.
Bronchitis
[Plasminogen activators in assessing the reaction of patients with chronic obstructive bronchitis to physical loading]
Budd-Chiari Syndrome
Post-traumatic membranous obstruction of the inferior vena cava associated with a hypercoagulable state.
Bundle-Branch Block
Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries.
Bundle-Branch Block
Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators.
Bundle-Branch Block
[Fibrinolysis or angioplasty in acute myocardial infarction?]
Carcinogenesis
Active Plasma Kallikrein Localizes to Mast Cells and Regulates Epithelial Cell Apoptosis, Adipocyte Differentiation, and Stromal Remodeling during Mammary Gland Involution.
Carcinogenesis
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Carcinogenesis
Epsilon-aminocaproic acid prevents high glucose and insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system.
Carcinogenesis
Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): No overt alteration in phenotype.
Carcinogenesis
Global transcriptomic analysis identifies SERPINE1 as a prognostic biomarker associated with epithelial-to-mesenchymal transition in gastric cancer.
Carcinogenesis
Helicobacter pylori interactions with plasminogen.
Carcinogenesis
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Carcinogenesis
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Carcinogenesis
On the contribution of S100A10 and annexin A2 to plasminogen activation and oncogenesis: an enduring ambiguity.
Carcinogenesis
Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.
Carcinogenesis
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Carcinogenesis
Post-transcriptional stabilization of urokinase plasminogen activator mRNA by 2,3,7,8-tetrachlorodibenzo-p-dioxin in a human keratinocyte cell line.
Carcinogenesis
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Carcinogenesis
Prognostic value of plasminogen activators and their inhibitors in colorectal cancer.
Carcinogenesis
SERPINE1 intron polymorphisms affecting gene expression are associated with diffuse-type gastric cancer susceptibility.
Carcinogenesis
The biochemistry and regulation of S100A10: a multifunctional plasminogen receptor involved in oncogenesis.
Carcinogenesis
The interplay between hemostasis and malignancy: the oral cancer paradigm.
Carcinogenesis
The molecular biology of colorectal cancer development and the associated genetic events.
Carcinogenesis
The plasminogen activator inhibitor "paradox" in cancer.
Carcinogenesis
The role of plasmin in the pathogenesis of murine multiple myeloma.
Carcinogenesis
Three are better than one: plasminogen receptors as cancer theranostic targets.
Carcinogenesis
Tissue plasminogen activator-independent roles of neuroserpin in the central nervous system.
Carcinogenesis
[Endothelial cell proteases and their modulation by platelets]
Carcinoma
A comparative study of the localization of plasminogen and apolipoprotein(a) in human carcinomas.
Carcinoma
A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate.
Carcinoma
A receptor for plasminogen and plasmin on human and rat carcinoma cells. Evidence for strong interspecific reactivity.
Carcinoma
Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.
Carcinoma
Activation of the {beta}-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells.
Carcinoma
Alterations in fibrinogen, plasminogen, and inhibitors of plasmin with the growth of V2 carcinoma in rabbits.
Carcinoma
Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion.
Carcinoma
An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture.
Carcinoma
Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease.
Carcinoma
Androgen-dependent fibrinolytic activity in a murine mammary carcinoma (Shionogi SC-115 cells) in vitro.
Carcinoma
Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin.
Carcinoma
Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells.
Carcinoma
Angiostatin generation by human pancreatic cancer.
Carcinoma
Annexin 2 and hemorrhagic disorder in vascular intimal carcinomatosis.
Carcinoma
Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action.
Carcinoma
Bound plasminogen is rate-limiting for cell-surface-mediated activation of plasminogen by urokinase.
Carcinoma
Cell signalling associated with fibrinolytic ligand binding to human colorectal carcinoma cells.
Carcinoma
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Carcinoma
Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas.
Carcinoma
Characterization of plasminogen system on rat yolk sac carcinoma (L2) cells.
Carcinoma
Circulating fibrinolysin in a case of prostatic carcinoma with bony metastases.
Carcinoma
Circulating fibrinolysin in carcinoma of the prostate.
Carcinoma
Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect.
Carcinoma
Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Carcinoma
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Carcinoma
Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells.
Carcinoma
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Carcinoma
Effect of human fibrinolysin on hepatic metastases in simulated colon carcinoma in rats.
Carcinoma
Effect of human plasmin on the toxic effects and growth of blood borne metastatis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbit.
Carcinoma
Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells.
Carcinoma
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Carcinoma
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Carcinoma
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Carcinoma
Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Carcinoma
Expression and activation of proteases in co-cultures.
Carcinoma
Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population.
Carcinoma
Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
Carcinoma
Expression of plasminogen activators in basal cell carcinoma.
Carcinoma
Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation.
Carcinoma
Fibrinolytic activity of in vitro cultivated human bladder cell lines.
Carcinoma
Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets.
Carcinoma
Ganglioside GM3 promotes carcinoma cell proliferation via urokinase plasminogen activator-induced extracellular signal-regulated kinase-independent p70S6 kinase signaling.
Carcinoma
Genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells.
Carcinoma
Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231.
Carcinoma
Glucocorticoid sensitivity of OVCA 433 human ovarian carcinoma cells: inhibition of plasminogen activators, cell growth, and morphological alterations.
Carcinoma
Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
Carcinoma
HEPATIC AND PULMONARY METASTASES FROM A RESECTABLE EXPERIMENTAL CECAL CARCINOMA: THE EFFECT OF HEPATIC PERFUSION WITH NITROGEN MUSTARD COMBINED WITH SYSTEMIC HEPARIN AND FIBRINOLYSIN.
Carcinoma
Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator.
Carcinoma
Human primary colon carcinomas xenografted into nude mice. I. Characterization of plasminogen activators expressed by primary tumors and their xenografts.
Carcinoma
Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment.
Carcinoma
Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.
Carcinoma
Immunocytochemical localization of plasminogen activators in carcinomas in the cervix and vulva.
Carcinoma
Immunohistochemical analysis of PAI-2 (plasminogen activator inhibitor type 2) and p53 protein in early gastric cancer patients with recurrence: a preliminary report.
Carcinoma
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Carcinoma
Immunolocalization of the components of the plasminogen activating system in breast carcinoma tissue.
Carcinoma
In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Carcinoma
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Carcinoma
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Carcinoma
Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion.
Carcinoma
Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
Carcinoma
Intramuscular electroporation of a plasmid encoding human plasminogen kringle 5 induces growth inhibition of Lewis lung carcinoma in mice.
Carcinoma
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
Carcinoma
Invasive neoplastic uroepithelial cells express high-levels of urokinase receptor and plasminogen receptor, alpha-enolase.
Carcinoma
Involvement of plasmin-mediated extracellular activation of progalanin in angiogenesis.
Carcinoma
Isolation and spontaneous transformation of cloned lines of hamster tracheal epithelial cells.
Carcinoma
Laminin degradation by human colon carcinoma cells: a role for urinary and tissue plasminogen activators.
Carcinoma
Localization of blood coagulation factors in situ in pancreatic carcinoma.
Carcinoma
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Carcinoma
Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
Carcinoma
Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells.
Carcinoma
Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators.
Carcinoma
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Carcinoma
Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.
Carcinoma
Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
Carcinoma
Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro.
Carcinoma
Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Carcinoma
Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin.
Carcinoma
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Carcinoma
Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas.
Carcinoma
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Carcinoma
Plasminogen activators in oesophageal carcinoma.
Carcinoma
Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.
Carcinoma
Plasminogen receptors on rat colon carcinoma cells.
Carcinoma
Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.
Carcinoma
Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
Carcinoma
Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma.
Carcinoma
Protease and antiprotease concentrations in serum and vaginal fluid of patients with carcinoma of the cervix.
Carcinoma
Proteinase activity in invasive cancer of the breast. Correlation with tumor progression.
Carcinoma
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Carcinoma
Proteolytic patterns of head and neck squamous cell carcinoma.
Carcinoma
Receptor for plasmin on human carcinoma cells.
Carcinoma
Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma.
Carcinoma
Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
Carcinoma
Relationship between plasminogen activators and stomach carcinoma stage.
Carcinoma
Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma.
Carcinoma
S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma.
Carcinoma
Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
Carcinoma
Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.
Carcinoma
Simultaneous stimulation of urokinase and tissue-type plasminogen activators by phorbol esters in human ovarian carcinoma cells.
Carcinoma
Specific stimulation by estradiol of tissue-type plasminogen activator production in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.
Carcinoma
Surface-bound plasmin induces selective proteolysis of insulin-like-growth-factor (IGF)-binding protein-4 (IGFBP-4) and promotes autocrine IGF-II bio-availability in human colon-carcinoma cells.
Carcinoma
Synthesis and evaluation of tripeptidic plasmin inhibitors with nitrile as warhead.
Carcinoma
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Carcinoma
Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
Carcinoma
The accumulation of angiostatin-like fragments in human prostate carcinoma.
Carcinoma
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
Carcinoma
The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.
Carcinoma
The presence of plasmin receptors on three mammary carcinoma MCF-7 sublines.
Carcinoma
The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
Carcinoma
Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
Carcinoma
Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.
Carcinoma
uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Carcinoma
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Carcinoma
Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Carcinoma
Visualization of the plasmin receptor on carcinoma cells.
Carcinoma
Visualization of the plasmin receptor on sections of human mammary carcinoma cells.
Carcinoma
Vitronectin in human breast carcinomas.
Carcinoma
[Behavior of plasminogen in prostatic carcinoma treated with cytonal]
Carcinoma
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma]
Carcinoma
[Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma]
Carcinoma
[Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
Carcinoma
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Carcinoma
[Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor]
Carcinoma
[The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma]
Carcinoma
[Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma]
Carcinoma
[[Gender Differences in Tissue Cascade of Activation of Plasminogen and PAI-1 in Esophageal Squamous Cell Carcinoma].]
Carcinoma in Situ
Protease and antiprotease concentrations in serum and vaginal fluid of patients with carcinoma of the cervix.
Carcinoma, Basal Cell
Expression of plasminogen activators in basal cell carcinoma.
Carcinoma, Bronchogenic
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Carcinoma, Brown-Pearce
Effect of human plasmin on the toxic effects and growth of blood borne metastatis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbit.
Carcinoma, Ehrlich Tumor
Action of antibodies and plasmin on Ehrlich ascites tumour cells.
Carcinoma, Ehrlich Tumor
Proteases during the growth of Ehrlich ascites tumor. I. The fibrinolysin system.
Carcinoma, Ehrlich Tumor
Studies on the fibrinolysis in tumor bearing mice. 3. Demonstration of the plasminogen activator in Ehrlich ascites tumor cells.
Carcinoma, Embryonal
Plasmin regulating system from embryonal carcinoma F9 cells: plasminases A, B and embrinogen.
Carcinoma, Hepatocellular
Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
Carcinoma, Hepatocellular
Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells.
Carcinoma, Hepatocellular
Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1.
Carcinoma, Hepatocellular
Cyclic nucleotide regulation of PAI-1 mRNA stability. Identification of cytosolic proteins that interact with an a-rich sequence.
Carcinoma, Hepatocellular
Cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor messenger RNAs in rat hepatoma cells.
Carcinoma, Hepatocellular
Cyclic nucleotide regulation of type-1 plasminogen activator-inhibitor mRNA stability in rat hepatoma cells. Identification of cis-acting sequences.
Carcinoma, Hepatocellular
Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Carcinoma, Hepatocellular
Dietary administration of tannic acid lowers plasminogen activator activity in the liver of C3H hepatoma bearing male mice.
Carcinoma, Hepatocellular
Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1? pathway.
Carcinoma, Hepatocellular
Glucocorticoid induction of plasminogen activator and plasminogen activator-inhibitor messenger RNA in rat hepatoma cells.
Carcinoma, Hepatocellular
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Carcinoma, Hepatocellular
HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Carcinoma, Hepatocellular
Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.
Carcinoma, Hepatocellular
Immunoaffinity purification of HTC rat hepatoma cell plasminogen activator-inhibitor-1.
Carcinoma, Hepatocellular
Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2.
Carcinoma, Hepatocellular
Kringle 5 of Human Plasminogen Suppresses Hepatocellular Carcinoma Growth Both in Grafted and Xenografted Mice by Anti-Angiogenic Activity.
Carcinoma, Hepatocellular
Plasmid transfer of plasminogen K1-5 reduces subcutaneous hepatoma growth by affecting inflammatory factors.
Carcinoma, Hepatocellular
Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model.
Carcinoma, Hepatocellular
Recycling of Apolipoprotein(a) After PlgRKT-Mediated Endocytosis of Lipoprotein(a).
Carcinoma, Hepatocellular
Regulation of plasminogen gene expression by interleukin-6.
Carcinoma, Hepatocellular
Suppression of Plasminogen Activators and the MMP-2/-9 Pathway by a Zanthoxylum avicennae Extract to Inhibit the HA22T Human Hepatocellular Carcinoma Cell Migration and Invasion Effects in Vitro and in Vivo via Phosphatase 2A Activation.
Carcinoma, Hepatocellular
The dexamethasone-induced inhibitor of fibrinolytic activity in hepatoma cells. A cellular product which specifically inhibits plasminogen activation.
Carcinoma, Hepatocellular
Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
Carcinoma, Hepatocellular
[Blood coagulation and fibrinolysis in relation to endotoxemia in liver cirrhosis and hepatocellular carcinoma]
Carcinoma, Hepatocellular
[Clinical studies of serum protease inhibitors in hepatoma]
Carcinoma, Hepatocellular
[Enzymatic activity of cathepsin B, cathepsin B and L, plasmin, trypsin and collagenase in hepatocellular carcinoma]
Carcinoma, Lewis Lung
Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action.
Carcinoma, Lewis Lung
Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect.
Carcinoma, Lewis Lung
Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
Carcinoma, Lewis Lung
Intramuscular electroporation of a plasmid encoding human plasminogen kringle 5 induces growth inhibition of Lewis lung carcinoma in mice.
Carcinoma, Lewis Lung
Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.
Carcinoma, Lewis Lung
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Carcinoma, Lewis Lung
Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma.
Carcinoma, Non-Small-Cell Lung
Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Carcinoma, Non-Small-Cell Lung
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis.
Carcinoma, Ovarian Epithelial
Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade.
Carcinoma, Ovarian Epithelial
Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.
Carcinoma, Ovarian Epithelial
Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism.
Carcinoma, Papillary
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Carcinoma, Renal Cell
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Carcinoma, Renal Cell
Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Carcinoma, Renal Cell
Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
Carcinoma, Renal Cell
Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma.
Carcinoma, Renal Cell
Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.
Carcinoma, Squamous Cell
Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells.
Carcinoma, Squamous Cell
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Carcinoma, Squamous Cell
In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Carcinoma, Squamous Cell
Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
Carcinoma, Squamous Cell
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Carcinoma, Squamous Cell
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Carcinoma, Squamous Cell
Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
Carcinoma, Squamous Cell
Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions.
Carcinoma, Squamous Cell
Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas.
Carcinoma, Squamous Cell
Plasminogen activators in normal and malignant oral epithelium in vivo and in vitro.
Carcinoma, Squamous Cell
Proteolytic patterns of head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
Carcinoma, Squamous Cell
uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Carcinoma, Squamous Cell
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Carcinoma, Transitional Cell
Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion.
Carcinoma, Transitional Cell
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
Carcinosarcoma
The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinosarcoma.
Carcinosarcoma
The effect of human fibrinolysin on survival of carcinosarcoma 256 Walker cells in the blood.
Cardiomyopathies
Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy.
Cardiomyopathy, Dilated
Exercise-induced hemostatic activation in patients with dilated cardiomyopathy in sinus rhythm.
Cardiovascular Diseases
A Multimodality Machine Learning Approach to Differentiate Severe and Nonsevere COVID-19: Model Development and Validation.
Cardiovascular Diseases
A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
Cardiovascular Diseases
A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage.
Cardiovascular Diseases
Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome?
Cardiovascular Diseases
Alcohol, heart disease, and mortality: a review.
Cardiovascular Diseases
Biochemistry of protein tyrosine nitration in cardiovascular pathology.
Cardiovascular Diseases
Cardiovascular diseases (CVD) risk factors, physical activity (PA) and plasma plasminogen (Plg) in a random sample of community-dwelling elderly.
Cardiovascular Diseases
Effects of Different Protein Sources on Plasminogen Inhibitor-1 and Factor VII Coagulant Activity Added to a Fat-Rich Meal in Type 2 Diabetes.
Cardiovascular Diseases
Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.
Cardiovascular Diseases
Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK '92 Hemostasis Study.
Cardiovascular Diseases
Intra- and interindividual variability of hemostatic factors and traditional cardiovascular risk factors in a three-year follow-up.
Cardiovascular Diseases
Lp(a)/apo(a) Modulate MMP-9 Activation and Neutrophil Cytokines in Vivo in Inflammation to Regulate Leukocyte Recruitment.
Cardiovascular Diseases
Molecular analysis of blood vessel formation and disease.
Cardiovascular Diseases
Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction.
Cardiovascular Diseases
New developments in thrombolytic therapy.
Cardiovascular Diseases
Plasminogen activator inhibitor-1 is associated with impaired endothelial function in women with systemic lupus erythematosus.
Cardiovascular Diseases
Plasminogen activator system and vascular disease.
Cardiovascular Diseases
Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin.
Cardiovascular Diseases
Recent developments in depsipeptide research.
Cardiovascular Diseases
Reduced lung function in patients with abdominal aortic aneurysm is associated with activation of inflammation and hemostasis, not smoking or cardiovascular disease.
Cardiovascular Diseases
Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation.
Cardiovascular Diseases
Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
Cardiovascular Diseases
Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
Cardiovascular Diseases
Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness.
Cardiovascular Diseases
Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance.
Cardiovascular Diseases
The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
Cardiovascular Diseases
The functions of plasminogen in cardiovascular disease.
Cardiovascular Diseases
The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies.
Cardiovascular Diseases
Understanding the enzymology of fibrinolysis and improving thrombolytic therapy.
Cardiovascular Diseases
[Biochemical markers of endothelial dysfunction and cardiovascular system state in patients with occupationai bronchopulmonary diseases].
Caroli Disease
Matrix proteins of basement membrane of intrahepatic bile ducts are degraded in congenital hepatic fibrosis and Caroli's disease.
Carotid Artery Diseases
Hemostatic function and carotid artery disease.
Carotid Artery Injuries
Endoluminal arterial injury in plasminogen-deficient mice.
Carotid Artery Thrombosis
Antithrombotic effects and related mechanisms of Salvia deserta Schang root EtOAc extracts.
Carotid Artery Thrombosis
Combined use of fibrinolysin and endarterectomy. Results in stenosis with recent carotid artery thrombosis.
Catalepsy
Lack of effects of fibrinogen degradation products on specific binding of [3H]spiroperidol and [3H]ADTN.
Cataract
Fibrinolytic factors in aqueous humour and serum from patients with Fuchs' dystrophy and patients with cataract.
Cataract
Tissue plasminogen activator-assisted vitrectomy in the early treatment of acute massive suprachoroidal hemorrhage complicating cataract surgery.
Cataract
[Densitometric analysis of changes in the vitreous body after cataract extraction]
Cataract
[The efficacy of using enzymes in treating toxic-allergic reactions after cataract extraction with intraocular lens implantation]
Cataract
[Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery]
Celiac Disease
Duodenal ulceration in a patient with celiac disease and plasminogen I deficiency: coincidence or cofactors?
Central Nervous System Diseases
Interventional use of plasminogen activators in central nervous system diseases.
Cerebral Amyloid Angiopathy
An Enzyme from Aristolochia indica Destabilizes Fibrin-? Amyloid Co-Aggregate: Implication in Cerebrovascular Diseases.
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy and the Fibrinolytic System: Is Plasmin a Therapeutic Target?
Cerebral Amyloid Angiopathy
Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.
Cerebral Amyloid Angiopathy
Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer's disease.
Cerebral Hemorrhage
An emerging role of mast cells in cerebral ischemia and hemorrhage.
Cerebral Hemorrhage
Antithrombotic treatments in acute ischemic stroke.
Cerebral Hemorrhage
Blood-brain barrier disruption by low-frequency ultrasound.
Cerebral Hemorrhage
Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits.
Cerebral Hemorrhage
Comparative safety of thrombolytic agents.
Cerebral Hemorrhage
Coronary artery disease, myocardial infarction, and brain embolism.
Cerebral Hemorrhage
Hemostatic factors as risk markers for intracerebral hemorrhage: a prospective incident case-referent study.
Cerebral Hemorrhage
Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
Cerebral Hemorrhage
Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage.
Cerebral Hemorrhage
Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function.
Cerebral Hemorrhage
Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat.
Cerebral Hemorrhage
Normobaric Hyperoxia Reduces Blood Occludin Fragments in Rats and Patients With Acute Ischemic Stroke.
Cerebral Hemorrhage
Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity.
Cerebral Hemorrhage
Plasminogen potentiates thrombin cytotoxicity and contributes to pathology of intracerebral hemorrhage in rats.
Cerebral Hemorrhage
Platelet-Derived Growth Factor Receptor-? Regulates Vascular Smooth Muscle Cell Phenotypic Transformation and Neuroinflammation After Intracerebral Hemorrhage in Mice.
Cerebral Hemorrhage
Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
Cerebral Hemorrhage
Renal Dysfunction and In-Hospital Outcomes in Patients With Acute Ischemic Stroke After Intravenous Thrombolytic Therapy.
Cerebral Hemorrhage
Role of tissue-type plasminogen activator in ischemic stroke.
Cerebral Hemorrhage
Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke.
Cerebral Hemorrhage
Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding.
Cerebral Hemorrhage
Symptomatic Intracerebral Hemorrhage Among Eligible Warfarin-Treated Patients Receiving Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke.
Cerebral Hemorrhage
The Effects of the Contact Activation System on Hemorrhage.
Cerebral Hemorrhage
The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.
Cerebral Hemorrhage
The Relationship of the Type of Intracerebral Hemorrhage to Early Disease Evolution and Long-Term Prognosis After r-tPA Thrombolysis.
Cerebral Hemorrhage
Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.
Cerebral Hemorrhage
Thrombolytic therapies: the current state of affairs.
Cerebral Hemorrhage
[Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease]
Cerebral Infarction
Blood coagulation and plasma fibrinolytic enzyme system pathophysiology in stroke.
Cerebral Infarction
Coagulation and fibrinolytic activity in patients with acute cerebral infarction.
Cerebral Infarction
Early fibrinogen degradation coagulopathy: a predictive factor of parenchymal hematomas in cerebral rt-PA thrombolysis.
Cerebral Infarction
Early Infarct Growth Rate Correlation With Endovascular Thrombectomy Clinical Outcomes: Analysis From the SELECT Study.
Cerebral Infarction
Hematologic abnormalities occur in both cortical and lacunar infarction.
Cerebral Infarction
Hemorrhagic complications of thrombolytic therapy in experimental stroke.
Cerebral Infarction
Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke.
Cerebral Infarction
Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets.
Cerebral Infarction
Polymorphism of plasminogen in healthy individuals and patients with cerebral infarction.
Cerebral Infarction
Prothrombotic risk factors in childhood stroke and venous thrombosis.
Cerebral Infarction
Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality.
Cerebral Infarction
Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis.
Cerebral Infarction
SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: a study in rodents and primates.
Cerebral Infarction
The Relationship of the Type of Intracerebral Hemorrhage to Early Disease Evolution and Long-Term Prognosis After r-tPA Thrombolysis.
Cerebral Infarction
[Frequency and clinical significance of congenital plasminogen abnormality in cerebral infarction]
Cerebrovascular Disorders
A study of hemostasis in ischemic cerebrovascular disease. III. Abnormalities in vascular plasminogen activators, antiactivators and alpha 2-antiplasmin.
Cerebrovascular Disorders
Congenitally abnormal plasminogen in juvenile ischemic cerebrovascular disease.
Cerebrovascular Disorders
Fibrinolysin in cerebrovascular diseases.
Cerebrovascular Disorders
Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke.
Cerebrovascular Disorders
Therapeutic problems in cerebrovascular disease. The experimental use of plasmin in dogs.
Cerebrovascular Disorders
[Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease]
Chagas Disease
Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease.
Charcot-Marie-Tooth Disease
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Cholangiocarcinoma
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Cholelithiasis
[Hemostatic indices of oncological patients with different forms of jaundice]
Cholera
Correlation between macrophages and their membrane fraction. Cytocidal activities on neoplastic cells.
Cholestasis
Changes of coagulation inhibitors and fibrinolysis system in newborn infants with transitory neonatal cholestasis.
Cholesteatoma
Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma.
Cholesteatoma, Middle Ear
Plasminogen activators in tissue extract of aural cholesteatoma.
Chondrosarcoma
Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Chondrosarcoma
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Chondrosarcoma
Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Choriocarcinoma
Plasmin modulators, aprotinin and anti-catalytic plasmin antibody, efficiently inhibit destruction of bovine vascular endothelial cells by choriocarcinoma cells.
Choroidal Neovascularization
Anti-inflammatory and anti-angiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor.
Choroidal Neovascularization
Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization.
Choroidal Neovascularization
Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration.
Choroidal Neovascularization
Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trial.
Choroidal Neovascularization
[Intravitreal injection. Drugs to treat subretinal hemorrhage].
Chronic Limb-Threatening Ischemia
tPA-MMP-9 Axis Plays a Pivotal Role in Mobilization of Endothelial Progenitor Cells from Bone Marrow to Circulation and Ischemic Region for Angiogenesis.
Chronic Periodontitis
Neutrophil elastase is involved in the initial destruction of human periodontal ligament.
Chronic Periodontitis
Plasmin is essential in preventing periodontitis in mice.
Chronic Periodontitis
Serum, salivary, and tissue levels of plasminogen in familial Mediterranean fever, amyloidosis, and chronic periodontitis.
coagulation factor xia deficiency
Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency.
Coinfection
Syphilis and Human Immunodeficiency Virus (HIV)-1 Coinfection: Influence on CD4 T-Cell Count, HIV-1 Viral Load, and Treatment Response.
Colic
Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases.
Colic
Use of newly developed assays for protein C and plasminogen in horses with signs of colic.
Colitis
Inhibition of Plasmin Protects Against Colitis in Mice by Suppressing Matrix Metalloproteinase 9-Mediated Cytokine Release From Myeloid Cells.
Colitis, Ulcerative
Plasminogen activators in the intestine of patients with inflammatory bowel disease.
Colitis, Ulcerative
Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality.
Colonic Diseases
Expression of binding of plasminogen, thrombospondin, vitronectin, and fibrinogen, and adhesive properties by Escherichia coli strains isolated from patients with colonic diseases.
Colonic Neoplasms
Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway.
Colonic Neoplasms
Butyrate regulates gene expression of the plasminogen activating system in colon cancer cells.
Colonic Neoplasms
Cancer cells in the blood in simulated colon cancer, resectable and unresectable: effect of fibrinolysin and heparin on growth potential.
Colonic Neoplasms
Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer.
Colonic Neoplasms
Insensitivity of laminin degradation directed by receptor bound urokinase to PAI-1 in cultured colon cancer.
Colonic Neoplasms
Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display.
Colonic Neoplasms
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.
Colonic Neoplasms
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Colonic Neoplasms
Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.
Colonic Neoplasms
Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
Colonic Neoplasms
Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer.
Colonic Neoplasms
Mouse macrophage metalloelastase generates angiostatin from plasminogen and suppresses tumor angiogenesis in murine colon cancer.
Colonic Neoplasms
NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
Colonic Neoplasms
Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation.
Colonic Neoplasms
Requirement of the enzymatic and signaling activities of plasmin for phorbol-ester-induced scattering of colon cancer cells.
Colonic Neoplasms
Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer.
Colonic Neoplasms
Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in human colon cancer.
Colonic Neoplasms
The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.
Colonic Neoplasms
Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer.
Colonic Neoplasms
Ulinastatin reduces cancer recurrence after resection of hepatic metastases from colon cancer by inhibiting MMP-9 activation via the antifibrinolytic pathway.
Colonic Neoplasms
[Protease activities in gastric and colon cancer tissues]
Colorectal Neoplasms
Antiplasmin activity of a peptide that binds to the receptor-binding site of angiogenin.
Colorectal Neoplasms
Cell signalling associated with fibrinolytic ligand binding to human colorectal carcinoma cells.
Colorectal Neoplasms
Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
Colorectal Neoplasms
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.
Colorectal Neoplasms
Differences in the activation mechanism between the alpha and beta subunits of human meprin.
Colorectal Neoplasms
Evidence for the clinical use of tumour markers.
Colorectal Neoplasms
Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
Colorectal Neoplasms
Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers.
Colorectal Neoplasms
Plasminogen activation system and colorectal cancer biology.
Colorectal Neoplasms
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Colorectal Neoplasms
Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells.
Colorectal Neoplasms
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?
Colorectal Neoplasms
Plasminogen activators in human colorectal neoplasia.
Colorectal Neoplasms
Plasminogen activators in the intestine of patients with inflammatory bowel disease.
Colorectal Neoplasms
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
Colorectal Neoplasms
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Colorectal Neoplasms
Prognostic role of tumor-associated proteases in colorectal cancer.
Colorectal Neoplasms
Prognostic value of plasminogen activators and their inhibitors in colorectal cancer.
Colorectal Neoplasms
Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer.
Colorectal Neoplasms
RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells.
Colorectal Neoplasms
Role of urokinase in colorectal neoplasia.
Colorectal Neoplasms
Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
Colorectal Neoplasms
Tumor associated proteases -- prognostic markers of colorectal cancer.
Colorectal Neoplasms
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Colorectal Neoplasms
[The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer]
Colorectal Neoplasms
[The role of proteolytic enzymes in skin neoplasm progression and development of metastasis]
Coma
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
Communicable Diseases
Exploration of the host haemostatic system by group A streptococcus: implications in searching for novel antimicrobial therapies.
Communicable Diseases
Inherited thrombophilia in pediatric ischemic stroke: an Egyptian study.
Communicable Diseases
Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases.
Communicable Diseases
Stroke in children: inherited and acquired factors and age-related variations in the presentation of 48 paediatric patients.
Communicable Diseases
Use of Intraoperative Tranexamic Acid and Wound Complications in Spine Surgery: A Retrospective Cohort Study.
Congenital Abnormalities
Clinical application of fibrinolysis laboratory tests: a review.
Congenital Abnormalities
Clinical disorders of fibrinolysis: a critical review.
Congenital Abnormalities
Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis.
Congenital Abnormalities
[Congenital abnormality of plasminogen]
Congenital Abnormalities
[Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age].
Conjunctivitis
A large deletion in the Plasminogen gene is associated with ligneous membranitis in a Maltese dog.
Conjunctivitis
Adult-Onset Ligneous Conjunctivitis with Detection of a Novel Plasminogen Gene Mutation and Anti-Plasminogen IgA Antibody: A Clinicopathologic Study and Review of Literature.
Conjunctivitis
Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases.
Conjunctivitis
Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis.
Conjunctivitis
Congenital hydrocephalus as a rare association with ligneous conjunctivitis and type I plasminogen deficiency.
Conjunctivitis
Conjunctival instillation of plasminogen eliminates ocular lesion in B6.129P2-Plg(tm1Jld) transgenic mice, a model of ligneous conjunctivitis.
Conjunctivitis
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis.
Conjunctivitis
Destructive Membranous Periodontal Disease (Ligneous Gingivitis): A Literature Review.
Conjunctivitis
Diagnosis of a case of ligneous gingivitis in a patient with moderate plasminogen deficiency.
Conjunctivitis
Difficulties in mutation screening of the plasminogen (PLG) gene in patients with ligneous conjunctivitis and severe hypoplasminogenemia.
Conjunctivitis
Difficulties in the mutation analysis of plasminogen gene: a study in two patients with ligneous conjunctivitis.
Conjunctivitis
Effective treatment of ligneous conjunctivitis with topical plasminogen.
Conjunctivitis
Features and outcome of a glomerulonephropathy associated with ligneous conjunctivitis in a Doberman pinscher dog.
Conjunctivitis
Fresh frozen plasma (Octaplas) and topical heparin in the management of ligneous conjunctivitis.
Conjunctivitis
Functional Fibrinolysis Assays Reveal Different Mechanisms underlying Plasminogen Dysfunction in Ligneous Conjunctivitis.
Conjunctivitis
Heparin in the long-term management of ligneous conjunctivitis: a case report and review of literature.
Conjunctivitis
Homozygous and compound-heterozygous type I plasminogen deficiency is a common cause of ligneous conjunctivitis.
Conjunctivitis
Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis.
Conjunctivitis
Human homozygous type I plasminogen deficiency and ligneous conjunctivitis.
Conjunctivitis
Identification of three novel plasminogen (PLG) gene mutations in a series of 23 patients with low PLG activity.
Conjunctivitis
Letter Regarding "Adult-Onset Ligneous Conjunctivitis with Detection of a Novel Plasminogen Gene Mutation and Anti-Plasminogen IgA Antibody: A Clinicopathologic Study and Review of Literature" by Y. Tu et al.
Conjunctivitis
Ligneous conjunctivitis associated with type I plasminogen deficiency: A rare case.
Conjunctivitis
Ligneous conjunctivitis due to plasminogen deficit: Diagnostic and therapeutic approach. With literature review.
Conjunctivitis
Ligneous conjunctivitis in a Dandy-Walker syndrome: A rare case report.
Conjunctivitis
Ligneous conjunctivitis in a girl with severe type I plasminogen deficiency.
Conjunctivitis
Ligneous conjunctivitis in a Mexican patient with a mutation in the plasminogen (PLG) gene.
Conjunctivitis
Ligneous conjunctivitis in a plasminogen-deficient dog: clinical management and 2-year follow-up.
Conjunctivitis
Ligneous conjunctivitis in a young patient with homozygous K19E plasminogen gene mutation: a diagnostic and therapeutic challenge.
Conjunctivitis
Ligneous conjunctivitis in plasminogen-deficient mice.
Conjunctivitis
Ligneous conjunctivitis secondary to a congenital plasminogen deficiency in a dog.
Conjunctivitis
Ligneous conjunctivitis with oral mucous membrane involvement and decreased plasminogen level.
Conjunctivitis
Ligneous conjunctivitis with plasminogen deficiency.
Conjunctivitis
Ligneous conjunctivitis, hydrocephalus, hydrocele, and pulmonary involvement in a child with homozygous type I plasminogen deficiency.
Conjunctivitis
Ligneous conjunctivitis.
Conjunctivitis
Ligneous conjunctivitis: a clinicopathological, immunohistochemical, and genetic study including the treatment of two sisters with multiorgan involvement.
Conjunctivitis
Ligneous conjunctivitis: a local manifestation of a systemic disorder?
Conjunctivitis
Ligneous periodontitis in a child with plasminogen deficiency.
Conjunctivitis
Long-term efficacy of surgical removal of pseudomembranes in a child with ligneous conjunctivitis treated with plasminogen eyedrops.
Conjunctivitis
Management of hydrocephalus in children with plasminogen deficiency.
Conjunctivitis
Management of ligneous conjunctivitis in a child with plasminogen deficiency.
Conjunctivitis
Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis.
Conjunctivitis
Novel homozygous mutation of plasminogen in ligneous conjunctivitis: a case report and literature review.
Conjunctivitis
Novel plasminogen and hyaluronate sodium eye drop formulation for a patient with ligneous conjunctivitis.
Conjunctivitis
Oral lesions indicative of plasminogen deficiency (hypoplasminogenemia).
Conjunctivitis
Otolaryngological manifestations of ligneous conjunctivitis.
Conjunctivitis
Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease.
Conjunctivitis
Plasminogen deficiency as a rare cause of conjunctivitis and lymphadenopathy.
Conjunctivitis
Plasminogen deficiency.
Conjunctivitis
Polymorphonuclear elastase in patients with homozygous type I plasminogen deficiency and ligneous conjunctivitis.
Conjunctivitis
Prenatal diagnosis in a family with severe type I plasminogen deficiency, ligneous conjunctivitis and congenital hydrocephalus.
Conjunctivitis
Prophylactic protocol for dental care in ligneous gingivitis due to severe plasminogen deficiency: Case report and review of literature.
Conjunctivitis
Pulmonary involvement in a child with ligneous conjunctivitis and homozygous type I plasminogen deficiency.
Conjunctivitis
Repurposing of Plasminogen: An Orphan Medicinal Product Suitable for SARS-CoV-2 Inhalable Therapeutics.
Conjunctivitis
Retraction: Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in An 8-Week-Old Female Infant.
Conjunctivitis
Systemic and topical fresh-frozen plasma treatment in a newborn with ligneous conjunctivitis.
Conjunctivitis
The first two Japanese cases of severe type I congenital plasminogen deficiency with ligneous conjunctivitis: Successful treatment with direct thrombin inhibitor and fresh plasma.
Conjunctivitis
Therapeutic approaches in the treatment of ligneous conjunctivitis, the most common clinical manifestation of a systemic disease, caused by severe type I plasminogen deficiency.
Conjunctivitis
Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency.
Conjunctivitis
Topical Plasminogen as Adjunctive Treatment in Recurrent Ligneous Conjunctivitis.
Conjunctivitis
Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in an 8-Week-Old Female Infant.
Conjunctivitis
Treatment of ligneous conjunctivitis with topical plasmin and topical plasminogen.
Conjunctivitis
[Ligneous conjunctivitis in a patient with plasminogen type I deficiency--case report with review of literature]
Conjunctivitis
[Ligneous conjunctivitis: complication of inborn plasminogen deficiency (a case report)]
Conjunctivitis
[Pharmaceutical supply of human plasminogen replacement therapy for the treatment of ligneous conjunctivitis: Logistics for a university hospital].
Conjunctivitis, Allergic
Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Conjunctivitis, Bacterial
Effective treatment of ligneous conjunctivitis with topical plasminogen.
Connective Tissue Diseases
Decrease in matrix metalloproteinase?3 activity in systemic sclerosis fibroblasts causes ?2?antiplasmin and extracellular matrix deposition, and contributes to fibrosis development.
Connective Tissue Diseases
The role of inflammatory cells and their proteases in extravascular fibrinolysis.
Corneal Diseases
Elevation of tear fluid plasmin in corneal disease.
Corneal Dystrophies, Hereditary
[Secretion of plasminogen activators and their inhibitors in corneal fibroblasts. Modification of this secretion in Schnyder's lens corneal dystrophy]
Corneal Injuries
Analysis of fibronectin, plasminogen activators and plasminogen in tear fluid as markers of corneal damage and repair.
Corneal Injuries
Enzyme histochemistry of corneal wound healing.
Corneal Injuries
The histochemical pattern of mechanically or chemically injured rabbit cornea after aprotinin treatment: relationships with the plasmin concentration of the tear fluid.
Corneal Neovascularization
Acidic/Neutral Amino Acid Residues Substitution in NH2 Terminal of Plasminogen Kringle 5 Exerts Enhanced Effects on Corneal Neovascularization.
Corneal Neovascularization
Anti-angiogenic role of angiostatin during corneal wound healing.
Corneal Neovascularization
Gene transfer of kringle 5 of plasminogen by electroporation inhibits corneal neovascularization.
Corneal Neovascularization
Inhibitory effects of plasminogen fragment on experimentally induced neovascularization of rat corneas.
Corneal Neovascularization
Plasmin and epidermal growth factor in the tear fluid of contact-lens wearers: effect of wearing different types of contact lenses and association with clinical findings.
Corneal Neovascularization
Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization.
Corneal Neovascularization
Recombinant kringle 1-3 of plasminogen inhibits rabbit corneal angiogenesis induced by angiogenin.
Corneal Neovascularization
The inhibitory effects of recombinant plasminogen kringle 1-3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF.
Corneal Neovascularization
The role of the fibrinolytic system in corneal angiogenesis.
Corneal Neovascularization
Towards a closed eye model of the pre-ocular tear layer.
Corneal Neovascularization
[Fibrinolysis components and angiogenesis regulation by example of burn-induced corneal neovascularization in rabbits].
Corneal Opacity
[Etiology of corneal opacities after plasminogen activator-induced fibrinolysis of the anterior chamber]
Corneal Ulcer
Plasmin in tear fluid of patients with corneal ulcers: basis for new therapy.
Coronary Aneurysm
Decreased plasminogen activator inhibitor-1 levels in coronary artery aneurysmatic patients.
Coronary Artery Disease
Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty.
Coronary Artery Disease
Association of fibrinogen and plasmin inhibitor, but not coagulation factor XIII gene polymorphisms with coronary artery disease.
Coronary Artery Disease
Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction.
Coronary Artery Disease
Effects of human tissue plasminogen gene transfer on allograft coronary atherosclerosis.
Coronary Artery Disease
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Coronary Artery Disease
Genetic Evidence for PLASMINOGEN as a Shared Genetic Risk Factor of Coronary Artery Disease and Periodontitis.
Coronary Artery Disease
Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease.
Coronary Artery Disease
Identification of novel serum markers for the progression of coronary atherosclerosis in WHHLMI rabbits, an animal model of familial hypercholesterolemia.
Coronary Artery Disease
Inflammation, the endothelium, and the acute coronary syndromes.
Coronary Artery Disease
Lipoprotein (a) and fibrinolytic system in liver cirrhosis. Coagulation Abnormalities in Liver Cirrhosis (CALC) Study Group.
Coronary Artery Disease
Plasminogen and fibrinogen plasma levels in coronary artery disease.
Coronary Artery Disease
Plasminogen and plasmin activity in patients with coronary artery disease.
Coronary Artery Disease
Plasminogen levels and risk of coronary artery disease.
Coronary Artery Disease
Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation.
Coronary Artery Disease
Severity of coronary artery disease and basal fibrinolysis.
Coronary Artery Disease
The interactions between hemostasis and resistance training: a review.
Coronary Artery Disease
The peculiar evolution of apolipoprotein(a) in human and rhesus macaque.
Coronary Artery Disease
Thrombin and plasmin activity in coronary artery disease.
Coronary Artery Disease
Urokinase plasminogen activator system in humans with stable coronary artery disease.
Coronary Artery Disease
[The use of heparin and fibrinolysin in patients with coronary arteriosclerosis]
Coronary Artery Disease
[Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease]
Coronary Disease
Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain.
Coronary Disease
Coagulation Factors II, V, IX, X, XI, and XII, Plasminogen, and alpha-2 Antiplasmin and Risk of Coronary Heart Disease.
Coronary Disease
Genetic linkage between lipoprotein(a) phenotype and a DNA polymorphism in the plasminogen gene.
Coronary Disease
Lipid-thrombosis interface.
Coronary Disease
The effect of exercise on thrombin and plasmin generation in middle-aged men.
Coronary Disease
[A study on the circadian variation of tissue-type plasminogen activator and its rapid inhibitor in patients with coronary heart disease]
Coronary Disease
[Effect of puerarin on fibrinolytic activity and lipid peroxide in patients with coronary heart disease]
Coronary Disease
[Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease]
Coronary Occlusion
Intracoronary thrombolysis in evolving myocardial infarction.
Coronary Occlusion
[Blood coagulation shifts in patients with myocardial infarction treated with streptokinase]
Coronary Stenosis
Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Coronary Stenosis
Streptokinase inhibits acute platelet thrombus formation in stenosed dog coronary arteries.
Coronary Thrombosis
Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
Coronary Thrombosis
Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis.
Coronary Thrombosis
Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
Coronary Thrombosis
Dynamics of the multidomain fibrinolytic protein urokinase from two-dimensional NMR.
Coronary Thrombosis
Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis.
Coronary Thrombosis
FIBRINOLYSIN AND ITS RELATION TO THE MANAGEMENT OF CORONARY THROMBOSIS.
Coronary Thrombosis
Novel antithrombotic approaches to coronary artery disease.
Coronary Thrombosis
Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Coronary Thrombosis
Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
Coronary Thrombosis
Role of nitrates in acute myocardial infarction.
Coronary Thrombosis
Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding.
Coronary Thrombosis
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site.
COVID-19
A Matter of Caution: Coagulation Parameters in COVID-19 Do Not Differ from Patients with Ruled-Out SARS-CoV-2 Infection in the Emergency Department.
COVID-19
Assessing Plasmin Generation in Health and Disease.
COVID-19
Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study.
COVID-19
Circulating Plasminogen Concentration at Admission in Patients with Coronavirus Disease 2019 (COVID-19).
COVID-19
Comparison of the coagulopathies associated with COVID-19 and sepsis.
COVID-19
COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity.
COVID-19
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
COVID-19
Fibrinolysis and COVID-19: A plasmin paradox.
COVID-19
Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.
COVID-19
Low level of plasminogen increases risk for mortality in COVID-19 patients.
COVID-19
Lung Epithelial Cell Transcriptional Regulation as a Factor in COVID-19-associated Coagulopathies.
COVID-19
Plasminogen improves lung lesions and hypoxemia in patients with COVID-19.
COVID-19
Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant.
COVID-19
The multifaceted role of plasminogen in inflammation.
COVID-19
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
COVID-19
Unique transcriptional changes in coagulation cascade genes in SARS-CoV-2-infected lung epithelial cells: A potential factor in COVID-19 coagulopathies.
Cowpox
The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
Craniocerebral Trauma
[The possible mechanisms of a fibrinolytic disorder in patients with severe craniocerebral trauma]
Creutzfeldt-Jakob Syndrome
Plasminogen activities and concentrations in patients with sporadic Creutzfeldt-Jakob disease.
Crohn Disease
Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in Crohn's disease.
Crohn Disease
Plasminogen activators in the intestine of patients with inflammatory bowel disease.
Cushing Syndrome
Further studies on the hypercoagulable state of patients with Cushing's syndrome.
Cystic Fibrosis
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
Cysts
Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Cysts
Fluid characteristics of benign ovarian cysts: correlation with recurrence after puncture.
Cysts
Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells.
Cysts
Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids.
Cysts
PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS.
Cysts
Role of tissue-plasminogen activator (t-PA) in a mouse model of neonatal white matter lesions: interaction with plasmin inhibitors and anti-inflammatory drugs.
Cysts
Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
Cytomegalovirus Infections
Human cytomegalovirus infection induces mRNA expression and secretion of plasminogen inhibitor type-1 in endothelial cells.
Darier Disease
Cantharidin-induced acantholysis in Darier's disease: does acantholysis initiate dyskeratosis?
Darier Disease
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Darier Disease
Cell adhesion in Hailey-Hailey disease and Darier's disease: immunocytological and explant-tissue-culture studies.
Darier Disease
Darier's disease: an immunohistochemical study using antibodies to proteases.
Death, Sudden, Cardiac
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Death, Sudden, Cardiac
Unusual cause of aborted sudden cardiac death in a teen athlete: homozygosity for the 4G allele of the plasminogen activase inhibitor type 1 gene.
Dehydration
Expression, purification, and biological characterization of Anaplasma phagocytophilum enolase.
Dehydration
Stress down regulates milk yield in cows by plasmin induced beta-casein product that blocks K+ channels on the apical membranes.
Dehydration
[Effects of dehydration and infusion of blood substitutes on the hemostasis system in an experiment with 21-hour bed rest]
Dementia
Plasminogen activities and concentrations in patients with sporadic Creutzfeldt-Jakob disease.
Dementia, Vascular
Plasminogen and plasmin in Alzheimer's disease.
Dementia, Vascular
tPA in the central nervous system: relations between tPA and cell surface LRPs.
Demyelinating Diseases
Complement potentiates the degradation of myelin proteins by plasmin: implications for a mechanism of inflammatory demyelination.
Demyelinating Diseases
Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases.
Demyelinating Diseases
Plasminogen activator activity and plasmin inhibition in nerves.
Demyelinating Diseases
Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system.
Demyelinating Diseases
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
Demyelinating Diseases
The modification of experimental allergic encephalomyelitis with epsilon aminocaproic acid.
Demyelinating Diseases
Tissue plasminogen activator gene expression in multiple sclerosis brain tissue.
Demyelinating Diseases
Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury.
Dengue
Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity.
Dengue
Antibodies against thrombin in dengue patients contain both anti-thrombotic and pro-fibrinolytic activities.
Dengue
Coagulation abnormalities in dengue hemorrhagic Fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome.
Dengue
Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection.
Dengue
Current Understanding of the Pathogenesis of Dengue Virus Infection.
Dengue
Dengue Virus Nonstructural Protein 1-Induced Antibodies Cross-React with Human Plasminogen and Enhance Its Activation.
Dengue
Dengue virus-induced autoantibodies bind to plasminogen and enhance its activation.
Dengue
Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection.
Dengue
GRP78: a multifunctional receptor on the cell surface.
Dengue
Increased Mosquito Midgut Infection by Dengue Virus Recruitment of Plasmin Is Blocked by an Endogenous Kazal-type Inhibitor.
Dengue
Modulation of ?-enolase post-translational modifications by dengue virus: increased secretion of the basic isoforms in infected hepatic cells.
Dengue
Participation of the Dengue virus in the fibrinolytic process.
Dengue
Peptide Bbeta(15-42) preserves endothelial barrier function in shock.
Dental Plaque
Cellular source, activation and inhibition of dental plaque collagenase.
Dental Plaque
Plasminogen binding by oral streptococci from dental plaque and inflammatory lesions.
Dental Plaque
Relationship between fibrinolytic activity and gingival inflammatory reaction in young individuals.
Dermatitis
The effect of tamol on human mast cell chymase and plasmin.
Dermatitis, Atopic
Early-life regional and temporal variation in filaggrin-derived natural moisturizing factor, filaggrin-processing enzyme activity, corneocyte phenotypes and plasmin activity: implications for atopic dermatitis.
Dermatitis, Atopic
Plasminogen activators and antiplasmin activity in atopic dermatitis.
Dermatomyositis
Circadian variations of plasma levels of blood coagulation/fibrinolysis molecular markers in progressive systemic sclerosis (PSS).
Diabetes Complications
Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study.
Diabetes Complications
Evaluation of Coagulation Profile in Children with Type 1 Diabetes Mellitus Using Rotational Thromboelastometry.
Diabetes Complications
Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes.
Diabetes Complications
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
Diabetes Mellitus
Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus.
Diabetes Mellitus
Association of PAI-1 and Fibrinogen with Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT).
Diabetes Mellitus
Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus.
Diabetes Mellitus
Hyperbaric Oxygen Reduces Infarction Volume and Hemorrhagic Transformation Through ATP/NAD(+)/Sirt1 Pathway in Hyperglycemic Middle Cerebral Artery Occlusion Rats.
Diabetes Mellitus
Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease.
Diabetes Mellitus
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Diabetes Mellitus
Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease.
Diabetes Mellitus
Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus.
Diabetes Mellitus
Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro.
Diabetes Mellitus
Plasminogen activation in diabetes mellitus. Kinetic analysis of plasmin formation using components isolated from the plasma of diabetic donors.
Diabetes Mellitus
Plasminogen activation in diabetes mellitus. Kinetics of plasmin formation with tissue plasminogen activator and plasminogen from individual diabetic donors and with in vitro glucosylated plasminogen.
Diabetes Mellitus
Plasminogen activation in diabetes mellitus: kinetics of plasmin formation with plasminogen and tissue plasminogen activator from diabetic donors.
Diabetes Mellitus
Plasminogen activation in diabetes mellitus: normalization of blood sugar levels improves impaired enzyme kinetics in vitro.
Diabetes Mellitus
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
Diabetes Mellitus
Regulation of plasminogen activation by TGF-beta in cultured human retinal endothelial cells.
Diabetes Mellitus
Risk Factors for Thrombosis Development in Mexican Patients.
Diabetes Mellitus
Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Diabetes Mellitus
The association of fibrinolysis and hyperlipidaemia with quantitative sensory tests in an epidemiological study of Swedish type 1 diabetic patients.
Diabetes Mellitus
Thrombin and plasmin activity in diabetes mellitus and their association with glycaemic control.
Diabetes Mellitus
[Effect of venous stasis on plasminogen activation and plasma alpha 2-antiplasmin levels in type II diabetes mellitus]
Diabetes Mellitus
[Lipoprotein and plasminogen serum levels in patients with diabetes mellitus type 2: risk factors for macroangiopathy? Preliminary study]
Diabetes Mellitus
[Lipoprotein(a) and plasminogen patients with diabetes mellitus complicated with peripheral angiopathy and hypertension]
Diabetes Mellitus
[Plasma fibrinopeptide A, fibrinopeptide B beta 15-42 and 4 other coagulation factors levels in patients with diabetic retinopathy]
Diabetes Mellitus
[Plasminogen activation and erythrocyte aggregation in diabetic patients]
Diabetes Mellitus, Type 1
Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study.
Diabetes Mellitus, Type 1
Hemostatic variables in Arab diabetics.
Diabetes Mellitus, Type 2
Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Association of PAI-1 and Fibrinogen with Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT).
Diabetes Mellitus, Type 2
Blood coagulation and fibrinolysis in obese NIDDM patients.
Diabetes Mellitus, Type 2
Effects of Different Protein Sources on Plasminogen Inhibitor-1 and Factor VII Coagulant Activity Added to a Fat-Rich Meal in Type 2 Diabetes.
Diabetes Mellitus, Type 2
Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria.
Diabetes Mellitus, Type 2
Hemobiological properties of gliclazide.
Diabetes Mellitus, Type 2
Hemostatic variables in Arab diabetics.
Diabetes Mellitus, Type 2
Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes.
Diabetes Mellitus, Type 2
Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro.
Diabetes Mellitus, Type 2
[Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia]
Diabetes Mellitus, Type 2
[Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)]
Diabetic Foot
Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers.
Diabetic Nephropathies
Diabetic nephropathy is associated with increased urine excretion of proteases plasmin, prostasin and urokinase and activation of amiloride-sensitive current in collecting duct cells.
Diabetic Nephropathies
Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy.
Diabetic Nephropathies
Extracellular matrix degradation by cultured mesangial cells: mediators and modulators.
Diabetic Nephropathies
Fibrinolysis in patients with diabetic nephropathy determined by plasmin-alpha 2 plasmin inhibitor complexes in plasma.
Diabetic Nephropathies
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
Diabetic Nephropathies
Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy.
Diabetic Nephropathies
The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation.
Diabetic Nephropathies
[Effects of shear stress on expression of plasminogen activator (tPA and uPA) in cultured kidney proximal tubular epithelial cells and its significance]
Diabetic Nephropathies
[Lipid metabolism and fibrinolysis in diabetic nephropathy in the course of diabetes type II]
Diabetic Nephropathies
[Studies on coagulation-fibrinolytic system in diabetic nephropathy--with reference to plasma TAT and alpha 2PIC]
Diabetic Nephropathies
[The vascular wall and fibrinolysis--pathologic aspects]
Diabetic Nephropathies
[Urinary-plasmin alpha 2 plasmin inhibitor complex (PIC) in patients with diabetic nephropathy]
Diabetic Retinopathy
Association of PAI-1 and Fibrinogen with Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT).
Diabetic Retinopathy
Autologous plasmin enzyme in the surgical management of diabetic retinopathy.
Diabetic Retinopathy
Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema.
Diabetic Retinopathy
Human plasminogen-derived N-acetyl-Arg-Leu-Tyr-Glu antagonizes VEGFR-2 to prevent blood-retinal barrier breakdown in diabetic mice.
Diabetic Retinopathy
Human retinal vascular cells differ from umbilical cells in synthetic functions and their response to glucose.
Diabetic Retinopathy
Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization.
Diabetic Retinopathy
Pharmacologic Vitreolysis in Diabetic Retinopathy.
Diabetic Retinopathy
Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study.
Diabetic Retinopathy
The metabolism of fibrinogen and plasminogen related to diabetic retinopathy in man.
Diabetic Retinopathy
uPA, tPA and PAI-1 mRNA expression in periretinal membranes.
Diabetic Retinopathy
Utilizing network pharmacology to explore the underlying mechanism of Radix Salviae in diabetic retinopathy.
Diabetic Retinopathy
[Studies on diabetic retinopathy and plasmin activity in the blood (with reference to duration and blood sugar)]
Diphtheria
Antibody spectrum and anticomplementary activity of a plasmin-treated human immunoglobulin preparation.
Disseminated Intravascular Coagulation
A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis.
Disseminated Intravascular Coagulation
Acute generalized, widespread bleeding. Diagnosis and management.
Disseminated Intravascular Coagulation
Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas.
Disseminated Intravascular Coagulation
Coagulation and fibrinolysis study after local thrombolysis of a cerebral artery with urokinase.
Disseminated Intravascular Coagulation
Comparative effects of proteinase inhibitors, plasminogen antiactivators, heparin and acetylsalicylic acid on the experimental disseminated intravascular coagulation induced by thormbin.
Disseminated Intravascular Coagulation
Consumption coagulopathy associated with shock in acute African swine fever.
Disseminated Intravascular Coagulation
Depressed plasma activity of plasminogen or alpha2 plasmin inhibitor is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation: antithrombin, plasminogen, and coagulation abnormalities in 41 dogs.
Disseminated Intravascular Coagulation
DNA-bound elastase of neutrophil extracellular traps degrades plasminogen, reduces plasmin formation, and decreases fibrinolysis: proof of concept in septic shock plasma.
Disseminated Intravascular Coagulation
Effect of urokinase on disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Effects of intravenous infusion of human prostate tissue substances in dogs.
Disseminated Intravascular Coagulation
Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
Disseminated Intravascular Coagulation
Experimental study of rabbit fibrinogen degradation products. Influence of plasminogen level for the interpretation of serum concentration of fibrinogen degradation products in consumption coagulopathies.
Disseminated Intravascular Coagulation
Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation.
Disseminated Intravascular Coagulation
Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Fibrinogen proteolysis by thrombin, plasmin and platelet release in relation to disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Fibrinolysis in disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Fibronectin, platelet factor 4 and beta-thromboglobulin in endemic hepatosplenic schistosomiasis: relation to acute hematemesis.
Disseminated Intravascular Coagulation
Hematin: unique effects of hemostasis.
Disseminated Intravascular Coagulation
High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia.
Disseminated Intravascular Coagulation
Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio.
Disseminated Intravascular Coagulation
Massive pulmonary embolism presenting as disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
New rapid assay for factor XIa-alpha 1 antitrypsin complex--application to DIC.
Disseminated Intravascular Coagulation
Pathways of coagulation/fibrinolysis activation in malignancy.
Disseminated Intravascular Coagulation
Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis.
Disseminated Intravascular Coagulation
Plasmin-alpha 2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Postoperative bleeding in a patient with normal screening coagulation tests.
Disseminated Intravascular Coagulation
Role of Vascular Endothelial Cells in Disseminated Intravascular Coagulation Induced by Seawater Immersion in a Rat Trauma Model.
Disseminated Intravascular Coagulation
Studies on the purification and characterization of human urinary plasminogen and plasmin.
Disseminated Intravascular Coagulation
Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin.
Disseminated Intravascular Coagulation
The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
Disseminated Intravascular Coagulation
The hemostatic defect of chronic liver disease. Kinetic studies using 75Se-selenomethionine.
Disseminated Intravascular Coagulation
Thrombin generation in patients with thrombotic thrombocytopenic purpura.
Disseminated Intravascular Coagulation
Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders.
Disseminated Intravascular Coagulation
Treatment of severe acute respiratory distress syndrome: a final report on a phase I study.
Disseminated Intravascular Coagulation
Vitamin K reduces bleeding in left ventricular assist device recipients.
Disseminated Intravascular Coagulation
[Advancement in the diagnosis of disseminated intravascular coagulation for the surgeon]
Disseminated Intravascular Coagulation
[Protease inhibitors and plasminogen in leukemia--with special reference to disseminated intravascular coagulation (author's transl)]
Disseminated Intravascular Coagulation
[Serial changes in protein C, antithrombin III, alpha 2-plasmin inhibitor, plasminogen and von Willebrand factor during the course of disseminated intravascular coagulation (DIC)]
Down Syndrome
Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?
Down Syndrome
Nerve growth factor metabolic dysfunction in Down's syndrome brains.
Dry Eye Syndromes
Tear fluid plasmin activity of dry eye patients with Sjögren's syndrome.
Dry Eye Syndromes
Tear Proteases and Protease Inhibitors: Potential Biomarkers and Disease Drivers in Ocular Surface Disease.
Dry Socket
Plasminogen activators and inhibitor type-1 in alveolar osteitis.
Duodenal Ulcer
Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer.
Duodenal Ulcer
[Vascular component of the fibrinolytic system of blood (plasminogen activator of vascular wall) in patients with duodenal ulcer with a history of hemorrhagic complications]
Dysentery
[Activity of the plasmin enzymatic system and of serum hyaluronidase in dysentery]
Dysentery
[Correlations of the level of plasmin system and blood serum hyaluronidase activity with pathology of the large intestine in dysentery]
Dyslipidemias
Dyslipidemia and the risk of Alzheimer's disease.
Dyslipidemias
Impaired fibrinolytic activity is present in children with dyslipidemias.
Dyslipidemias
Metabolic abnormalities in hypertension.
Ehlers-Danlos Syndrome
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Embolic Stroke
Alterations of haemostatic markers in various subtypes and phases of stroke.
Embolic Stroke
Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke.
Embolic Stroke
Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke.
Embolic Stroke
PI3K? (Phosphoinositide 3-Kinase-?) Inhibition Attenuates Tissue-Type Plasminogen Activator-Induced Brain Hemorrhage and Improves Microvascular Patency After Embolic Stroke.
Embolic Stroke
Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study.
Embolic Stroke
Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
Embolic Stroke
Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study.
Embolic Stroke
[Changes of haemostatic parameters in patients with acute cardioembolic stroke].
Embolism
Fibrinolysin (Actase) in the treatment of peripheral embolism.
Embolism
Fibrinolytic effect of tissue plasminogen activator on cerebral embolism in stroke-prone spontaneously hypertensive rats.
Embolism
LYSIS OF THE EXPERIMENTAL RADIOACTIVE PULMONARY EMBOLUS INDUCED BY STREPTOKINASE AND SK-ACTIVATED PLASMIN.
Embolism
Mechanisms by which thrombolytic therapy results in nonuniform lysis and residual thrombus after reperfusion.
Embolism
Non-penetrating trauma to the carotid artery with secondary thrombosis and embolism: treatment by thrombolysin.
Embolism
Thrombolytic effect of tissue plasminogen activator in a cerebral embolic model.
Embolism
[EXPERIENCE WITH THE TREATMENT OF THROMBOSIS AND EMBOLISM WITH FIBRINOLYSIN AND HEPARIN.]
Embolism
[Lipoprotein(a): structure, metabolism and atherosclerotic disease]
Embolism
[Physiopathological shifts in the blood coagulation system in embolism of major arteries of the limbs]
Embolism
[The use of fibrinolysin and heparin in the treatment of acute thrombophlebitis, thrombosis and embolism]
Embolism
[Treatment of thrombosis and embolisms with human fibrinolysin.]
Embolism and Thrombosis
Non-penetrating trauma to the carotid artery with secondary thrombosis and embolism: treatment by thrombolysin.
Embolism and Thrombosis
[EXPERIENCE WITH THE TREATMENT OF THROMBOSIS AND EMBOLISM WITH FIBRINOLYSIN AND HEPARIN.]
Embolism and Thrombosis
[The use of fibrinolysin and heparin in the treatment of acute thrombophlebitis, thrombosis and embolism]
Embolism, Cholesterol
Cholesterol embolism after intravenous anisoylated plasminogen streptokinase activator complex (APSAC)
Empyema
Management of Pleural Infection.
Empyema
Treatment of thoracic multiloculated empyemas with intracavitary urokinase: a prospective study.
Encephalitis
An alternative elastase-mediated degradation of fibrinogen and fibrin observed in a patient with herpes simplex encephalitis and pneumonia.
Encephalitis
Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease.
Encephalitis
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Encephalitis
The fibrinolytic system: A new target for treatment of depression with psychedelics.
Encephalitis, Herpes Simplex
An alternative elastase-mediated degradation of fibrinogen and fibrin observed in a patient with herpes simplex encephalitis and pneumonia.
Encephalomyelitis
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
Encephalomyelitis, Autoimmune, Experimental
Observations on the effects of protease inhibitors on the suppression of experimental allergic encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
Encephalomyelitis, Autoimmune, Experimental
The modification of experimental allergic encephalomyelitis with epsilon aminocaproic acid.
End Stage Liver Disease
Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure.
Endarteritis
Can the activation of plasminogen/plasmin system of the host by metabolic products of Dirofilaria immitis participate in heartworm disease endarteritis?
Endarteritis
Fibrinolysis and proliferative endarteritis: two related processes in chronic infections? The model of the blood-borne pathogen Dirofilaria immitis.
Endarteritis
Glyceraldehyde 3-phosphate dehydrogenase and galectin from Dirofilaria immitis participate in heartworm disease endarteritis via plasminogen/plasmin system.
Endemic Diseases
Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni.
Endocarditis
Activation of plasminogen by Streptococcus mutans.
Endocarditis
Antibiotic modulation of the plasminogen binding ability of viridans group streptococci.
Endocarditis
The role of streptococcal plasmin(ogen) binding in infective endocarditis.
Endocarditis, Non-Infective
The role of streptococcal plasmin(ogen) binding in infective endocarditis.
Endometrial Hyperplasia
[Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia]
Endometrial Neoplasms
A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study.
Endometrial Neoplasms
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Endometrial Neoplasms
Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Endometrial Neoplasms
Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (u-PA, t-PA) in endometrial carcinoma.
Endometrial Neoplasms
High pretreatment plasma D-dimer levels are related to shorter overall survival in endometrial carcinoma.
Endometrial Neoplasms
Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
Endometrial Neoplasms
Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells.
Endometrial Neoplasms
[Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia]
Endometriosis
A role for the fibrinolytic system in postsurgical adhesion formation.
Endometriosis
Fibrinolysis in the peritoneal fluid during adhesions, endometriosis and ongoing pelvic inflammatory disease.
Endometriosis
Fibrinolytic properties of peritoneal fluid in endometriosis.
Endometriosis
Gonadotropin-releasing hormone agonist (GnRH-a) therapy alters activity of plasminogen activators, matrix metalloproteinases, and their inhibitors in rat models for adhesion formation and endometriosis: potential GnRH-a-regulated mechanisms reducing adhesion formation.
Endometriosis
Local activation of TGF-beta1 at endometriosis sites.
Endometriosis
Plasminogen activators and plasminogen activator inhibitors in endometriosis.
Endometriosis
Plasminogen activators in endometriosis.
Endometritis
Involvement of the plasminogen activation system in cow endometritis.
Endometritis
Ligneous cervicitis and endometritis: A gynaecological presentation of congenital plasminogen deficiency.
Endotoxemia
Effect of polymyxin B and colimycin on induction of plasminogen antiactivator by lipopolysaccharide in human endothelial cell culture.
Endotoxemia
Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia.
Endotoxemia
Interaction of leukocytes and endotoxin with the plasmin and kinin systems.
Endotoxemia
Use of newly developed assays for protein C and plasminogen in horses with signs of colic.
Endotoxemia
[Blood coagulation and fibrinolysis in relation to endotoxemia in liver cirrhosis and hepatocellular carcinoma]
Eosinophilia
Plasminogen levels in subjects with eosinophilia.
Epidermolysis Bullosa Dystrophica
Studies on two siblings with recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) and the plasminogen activator and its inhibitor in the lesion.
Epilepsy, Rolandic
Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR.
Epiretinal Membrane
Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.
Epiretinal Membrane
Plasminogen activation in epiretinal membranes.
Epiretinal Membrane
Plasminogen in proliferative vitreoretinal disorders.
Epiretinal Membrane
SURGICAL OUTCOMES OF EPIRETINAL MEMBRANES ASSOCIATED WITH COMBINED HAMARTOMA OF THE RETINA AND RETINAL PIGMENT EPITHELIUM.
Epiretinal Membrane
[Enzymatic vitrectomy by intravitreal autologous plasmin injection as initial treatment for macular epiretinal membranes and vitreomacular traction syndrome.]
Epiretinal Membrane
[Thrombospondin and its importance in proliferative retinal diseases]
Esophageal Neoplasms
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
Esophageal Neoplasms
Serine proteinase activation in esophageal cancer.
Esophageal Squamous Cell Carcinoma
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
[[Gender Differences in Tissue Cascade of Activation of Plasminogen and PAI-1 in Esophageal Squamous Cell Carcinoma].]
Essential Hypertension
Abnormalities of fibrinolysis in essential hypertension.
Essential Hypertension
Fibrinolytic system in normotensive subjects and hypertensive patients.
Essential Hypertension
Haemostatic variables in arterial hypertension.
Essential Hypertension
Hemostatic disorders associated with arterial hypertension and peripheral arterial disease.
Essential Hypertension
[Changes in the fibrinolytic activity in hypertension and acute cerebral infarction]
Essential Hypertension
[Sympathetic responsiveness and antihypertensive effect of beta-receptor blockade in essential hypertension: the effect of atenolol (author's transl)]
Essential Hypertension
[The State of Coagulation Hemostasis and Fibrinolysis in Children With Essential Arterial Hypertension].
Exostoses
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Eye Diseases
A study of plasmin in eye disease.
Eye Hemorrhage
[Mechanism of action of fibrinolysin and a verification of the efficacy of its use in traumatic hemophthalmos]
Eye Hemorrhage
[Phonophoresis of fibrinolysin and potassium iodide in complex treatment of hemophthalmos]
Eye Infections
Tear Proteases and Protease Inhibitors: Potential Biomarkers and Disease Drivers in Ocular Surface Disease.
Fabry Disease
Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR.
Factor V Deficiency
Familial association of hypoplasminogenemia and heterozygous factor V deficiency.
Factor XI Deficiency
Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency.
Factor XII Deficiency
Chloroform-induced fibrinolysis. Its dependence on Hageman factor, plasma prekallikrein, and high molecular weight kininogen.
Factor XIII Deficiency
Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency.
Familial Mediterranean Fever
Serum, salivary, and tissue levels of plasminogen in familial Mediterranean fever, amyloidosis, and chronic periodontitis.
Familial Primary Pulmonary Hypertension
A patient with congenital plasminogen deficiency manifesting primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Impairment of the plasmin activation system in primary pulmonary hypertension: evidence for gender differences.
Familial Primary Pulmonary Hypertension
Plasminogen activation by blood monocytes and alveolar macrophages in primary pulmonary hypertension.
Fatty Liver
ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis.
Fatty Liver
Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury.
Febrile Neutropenia
The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
Fetal Alcohol Spectrum Disorders
Plasminogen activator system homeostasis and its dysregulation by ethanol in astrocyte cultures and the developing brain.
Fetal Death
Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies.
Fetal Growth Retardation
Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation.
Fetal Growth Retardation
Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies.
Fetal Growth Retardation
[Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor]
Fibroadenoma
Factors involved in the plasminogen activation system in human breast tumours.
Fibroadenoma
PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS.
Fibrocystic Breast Disease
PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS.
Fibrosarcoma
Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin.
Fibrosarcoma
Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro.
Fibrosarcoma
Antiplasmin activity of a peptide that binds to the receptor-binding site of angiogenin.
Fibrosarcoma
Cumulative influence of elastin peptides and plasminogen on matrix metalloproteinase activation and type I collagen invasion by HT-1080 fibrosarcoma cells.
Fibrosarcoma
Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Fibrosarcoma
Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids.
Fibrosarcoma
Forskolin down-regulates type-1 plasminogen activator inhibitor and tissue-type plasminogen activator and their mRNAs in human fibrosarcoma cells.
Fibrosarcoma
Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2.
Fibrosarcoma
HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.
Fibrosarcoma
Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells.
Fibrosarcoma
p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells.
Fibrosarcoma
Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase.
Fibrosarcoma
Plasminogen activator activity in clonogenic cell populations separated from a murine fibrosarcoma.
Fibrosarcoma
Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass.
Fibrosarcoma
Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency.
Fibrosarcoma
Prokaryotic expression, purification, and reconstitution of biological activities (Antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2.
Fibrosarcoma
Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor.
Fibrosarcoma
Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin.
Fibrosarcoma
Seahorse-derived peptide suppresses invasive migration of HT1080 fibrosarcoma cells by competing with intracellular ?-enolase for plasminogen binding and inhibiting uPA-mediated activation of plasminogen.
Fibrosarcoma
Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells--role in metastasis.
Fibrosarcoma
Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
Follicular Cyst
Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
Foot Ulcer
Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers.
Fuchs' Endothelial Dystrophy
Fibrinolytic factors in aqueous humour and serum from patients with Fuchs' dystrophy and patients with cataract.
Galactosemias
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Gastritis
Glycoproteomic analysis of serum from patients with gastric precancerous lesions.
Gastritis
Plasminogen binding and activation at the surface of Helicobacter pylori CCUG 17874.
Gastrointestinal Diseases
Human Plasminogen Exacerbates Clostridioides difficile Enteric Disease and Alters the Spore Surface.
Gastrointestinal Neoplasms
Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.
gelatinase b deficiency
Matrix metalloproteinase-2 or -9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion.
Genetic Diseases, Inborn
Type 1 Plasminogen Deficiency With Pulmonary Involvement: Novel Treatment and Novel Mutation.
Giant Cell Arteritis
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
Giardiasis
Insights into the Giardia intestinalis enolase and human plasminogen interaction.
Gingival Hyperplasia
Effective treatment of ligneous conjunctivitis with topical plasminogen.
Gingival Hyperplasia
Periodontitis associated with plasminogen deficiency: a case report.
Gingival Hyperplasia
Recurrent recalcitrant gingival hyperplasia and plasminogen deficiency: a case report.
Gingival Overgrowth
Oral lesions indicative of plasminogen deficiency (hypoplasminogenemia).
Gingival Overgrowth
Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients.
Gingivitis
Destructive Membranous Periodontal Disease (Ligneous Gingivitis): A Literature Review.
Gingivitis
Diagnosis of a case of ligneous gingivitis in a patient with moderate plasminogen deficiency.
Gingivitis
Immunohistochemical analysis of the gingiva with periodontitis of type I plasminogen deficiency compared to gingiva with gingivitis and periodontitis and healthy gingiva.
Gingivitis
Ligneous alveolar gingivitis in the absence of plasminogen deficiency.
Gingivitis
Ligneous gingivitis associated with plasminogen deficiency: a challenge in diagnosis.
Gingivitis
Ligneous gingivitis secondary to plasminogen deficiency: a multidisciplinary diagnostic challenge.
Gingivitis
Ligneous periodontal lesions in a young child with severe plasminogen deficiency: a case report.
Gingivitis
Prophylactic protocol for dental care in ligneous gingivitis due to severe plasminogen deficiency: Case report and review of literature.
Gingivitis
Successful treatment of ligneous gingivitis with warfarin.
Glaucoma
Glaucoma is associated with plasmin proteolytic activation mediated through oxidative inactivation of neuroserpin.
Glaucoma
Tissue and urokinase plasminogen activators instigate the degeneration of retinal ganglion cells in a mouse model of glaucoma.
Glaucoma
[Level of tear endothelin-1 and plasminogen in patients with glaucoma and proliferative diabetic retinopathy].
Glaucoma
[Use of fibrinolysin after microsurgical operations for glaucoma]
Glaucoma, Open-Angle
Plasminogen activator inhibitor-1 4G/5G gene polymorphism and primary open-angle glaucoma.
Glioblastoma
Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system.
Glioblastoma
Antifibrinolytic therapy of experimentally grown malignant brain tumors.
Glioblastoma
Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
Glioblastoma
Plasmin Activation of Glial Cells through Protease-Activated Receptor 1.
Glioblastoma
Plasminogen activating enzyme in cultured glioblastoma cells. An immunofluorescence study with monoclonal antibody.
Glioblastoma
Plasminogen-dependent internalization of soluble melanotransferrin involves the low-density lipoprotein receptor-related protein and annexin II.
Glioblastoma
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.
Glioblastoma
[A plasminogen regulation system in brain tumors].
Glioma
Annexin A2 promotes glioma cell invasion and tumor progression.
Glioma
Binding of bovine, ovine, porcine, canine, and rat plasminogen to rat hepatocytes and rat C6 glioma cells in vitro.
Glioma
CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4 positive astroglioma cells.
Glioma
Ebselen abrogates TNFalpha induced pro-inflammatory response in glioblastoma.
Glioma
Endothelial cell-derived plasmin promotes human glioma cell proliferation.
Glioma
Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
Glioma
Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines.
Glioma
Expression of plasminogen receptors on C6 glioma cells.
Glioma
High-molecular-mass and low-molecular-mass kininogens block plasmin-induced platelet aggregation by forming a complex with kringle 5 of plasminogen/plasmin.
Glioma
Human glioma cell BT325 expresses a proteinase that converts human plasminogen to kringle 1-5-containing fragments.
Glioma
Hyaluronic acid facilitates glioma cell invasion in vitro.
Glioma
Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy.
Glioma
Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin.
Glioma
Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3.
Glioma
Investigation of serum proteome alterations in human glioblastoma multiforme.
Glioma
Lithium chloride inhibits thrombin-induced intracellular calcium mobilization in C6 rat glioma cells.
Glioma
Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells.
Glioma
Plasmin modulates the thrombin-evoked calcium response in C6 glioma cells.
Glioma
Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Glioma
Plasminogen activators and inhibitors in gliomas: an immunohistochemical study.
Glioma
Plasminogen carbohydrate side chains in receptor binding and enzyme activation: a study of C6 glioma cells and primary cultures of rat hepatocytes.
Glioma
Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression.
Glioma
Protease nexin 1 is expressed in the human placenta.
Glioma
Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.
Glioma
The role of the plasminogen activation cascade in glioma cell invasion: a review.
Glioma
Tristetraprolin Inhibits the Growth of Human Glioma Cells through Downregulation of Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor mRNAs.
Glioma
[Biological profiles of malignant gliomas]
Glioma
[Effects of plasminogen and streptokinase on the vital functions of nervous tissue cells in culture]
Glomerulonephritis
A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.
Glomerulonephritis
A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.
Glomerulonephritis
Attributes of antiangiogenic factor plasminogen kringle 5 in glomerulonephritis.
Glomerulonephritis
Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
Glomerulonephritis
Elevated urinary plasmin activity resistant to alpha2-antiplasmin in acute poststreptococcal glomerulonephritis.
Glomerulonephritis
Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat.
Glomerulonephritis
Further investigations on the significance of a plasma coagulation-accelerating factor in glomerular disease.
Glomerulonephritis
Galactose-deficient IgA1 and nephritis-associated plasmin receptors as markers for IgA-dominant infection-related glomerulonephritis: A case report.
Glomerulonephritis
Glomerular Deposition of Nephritis-Associated Plasmin Receptor (NAPlr) and Related Plasmin Activity: Key Diagnostic Biomarkers of Bacterial Infection-related Glomerulonephritis.
Glomerulonephritis
Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency.
Glomerulonephritis
Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis.
Glomerulonephritis
Nephritis-associated plasmin receptor (NAPlr)-positive glomerulonephritis in a case of ANCA-negative small vessel vasculitis.
Glomerulonephritis
Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis.
Glomerulonephritis
Relationship between elevation in the plasma concentration of elastase-alpha 1 proteinase inhibitor complex (E-alpha 1 PI) and haemostatic parameters during haemodialysis.
Glomerulonephritis
Studies on the purification and characterization of human urinary plasminogen and plasmin.
Glomerulonephritis
Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin.
Glomerulonephritis
t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis.
Glomerulonephritis
Urinary plasminogen and chronic glomerulonephritis.
Glomerulonephritis
Urinary UK, t-PA and urinary trypsin inhibitor in health and glomerular diseases.
Glomerulonephritis
[Activators and inhibitors of fibrinolysis in chronic glomerulonephritis and amyloidosis]
Glomerulonephritis
[The effect of membrane-stabilizing therapy on the status of the hemostatic system in patients with glomerulonephritis with a hematuric component]
Glomerulonephritis
[The levels of antigens to plasminogen activators compared to their functional activity and inhibitor activity in patients with glomerulonephritis and amyloidosis]
Glomerulonephritis
[Urinary excretion of plasmin and fibrin-fibrinogen degradation products in various types of glomerulonephritis (author's transl)]
Glomerulonephritis
[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis]
Glomerulonephritis, IGA
Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
Glomerulonephritis, IGA
Intraglomerular deposition of intact cross-linked fibrin in IgA nephropathy and Henoch-Schönlein purpura nephritis.
Glomerulonephritis, IGA
Role of tubulointerstitial plasmin in the progression of IgA nephropathy.
Glomerulonephritis, Membranous
A novel autoantibody to plasminogen and its characterization in Heymann nephritis.
Glomerulonephritis, Membranous
Analysis of a 45-kDa protein that binds to the Heymann nephritis autoantigen GP330.
Glomerulonephritis, Membranous
Analysis of plasmin binding and urokinase activation of plasminogen bound to the Heymann nephritis autoantigen, gp330.
Glomerulonephritis, Membranous
Characterization of plasminogen system on rat yolk sac carcinoma (L2) cells.
Glomerulonephritis, Membranous
Effect of TGF-beta 1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells.
Glomerulonephritis, Membranous
Effect of the nephritogenic autoantibody of Heymann's nephritis on plasminogen-binding to gp330 and activation by urokinase.
Glomerulonephritis, Membranous
Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen.
Glomerulosclerosis, Focal Segmental
Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
Glomerulosclerosis, Focal Segmental
Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease.
Glomerulosclerosis, Focal Segmental
Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis.
Glucose Intolerance
Assay of pig growth hormone preparations for metabolic activities in the rat and in man.
Glucose Intolerance
Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
Goiter
[Thyroid tissue link of hemostasis in diffuse toxic and euthyroid goiter]
Gout
Fibrin dissolution in synovial fluid.
Gout
Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients.
Graft vs Host Disease
Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking.
Granuloma
An immunoperoxidase study of immunological factors in high immune and low resistance granulomas in leprosy.
Granuloma
Detection of granuloma-associated plasminogen activator in experimental murine schistosomiasis.
Granuloma
Exploring the interaction between Mycobacterium tuberculosisEnolase and human plasminogen using computational methods and experimental techniques.
Granuloma
The monocyte-macrophage system in granulomatous inflammation.
Granulomatosis with Polyangiitis
Alterations of serum levels of plasminogen, TNF-?, and IDO in granulomatosis with polyangiitis patients.
Gray Platelet Syndrome
Plasminogen interacts with human platelets through two distinct mechanisms.
Guillain-Barre Syndrome
Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases.
Hamartoma
SURGICAL OUTCOMES OF EPIRETINAL MEMBRANES ASSOCIATED WITH COMBINED HAMARTOMA OF THE RETINA AND RETINAL PIGMENT EPITHELIUM.
Healthcare-Associated Pneumonia
Klebsiella pneumoniae enolase-like membrane protein interacts with human plasminogen.
Hearing Loss
Acute sensorineural hearing loss and vertigo in a young adult with congenital plasminogen disorder.
Hearing Loss
[A case of Behçet's disease with chronic and repeated sudden hearing loss: successful treatment with intravenous cyclophosphamide pulse therapy]
Hearing Loss, Sensorineural
Acute sensorineural hearing loss and vertigo in a young adult with congenital plasminogen disorder.
Hearing Loss, Sensorineural
Asymmetric sudden sensorineural hearing loss: is all this testing necessary?
Heart Arrest
Pediatric In-Hospital Cardiac Arrest Secondary to Acute Pulmonary Embolism.
Heart Arrest
Protective effect of plasmin in marginal donor lungs in an ex vivo lung perfusion model.
Heart Arrest
Pulmonary thromboembolism after carbon monoxide poisoning.
Heart Arrest
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
Heart Block
Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-? and potentiates fibrosis.
Heart Defects, Congenital
Pre- and post-operative studies of fibrinolysis and prothrombin in cyanotic congenital heart disease.
Heart Diseases
Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis.
Heart Diseases
Apolipoproteins(a): a puzzling evolutionary story.
Heart Diseases
Effect of anabolic steroids on plasma antithrombin III. alpha2 macroglobulin and alpha1 antitrypsin levels.
Heart Diseases
Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Heart Diseases
Inherited thrombophilia in pediatric ischemic stroke: an Egyptian study.
Heart Diseases
Plasma fibrinogen and plasminogen levels in health and in ischaemic heart disease.
Heart Diseases
Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
Heart Diseases
Platelet function and antithrombin, plasminogen, and fibrinolytic activities in cats with heart disease.
Heart Diseases
Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics.
Heart Diseases
Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis.
Heart Diseases
Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease.
Heart Diseases
Stroke in children: inherited and acquired factors and age-related variations in the presentation of 48 paediatric patients.
Heart Diseases
[Chronic recurrent pulmonary thromboembolism associated with sedentary work]
Heart Diseases
[Plasmin-mediated activation of the coagulation system. A study of patients with acute ischemic heart disease treated with recombinant tissue-plasminogen activator]
Heart Failure
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.
Heart Failure
Pathogenesis of venous thromboembolism: when the cup runneth over.
Heart Failure
Plasminogen regulates cardiac repair after myocardial infarction through its non-canonical function in stem cell homing to the infarcted heart.
Heart Failure
Prevention of incipient diabetic cardiomyopathy by high-dose thiamine.
Heart Rupture
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.
Hemangioma
Giant hemangioma of the liver (Kasabach-Merritt syndrome): successful suppression of intravascular coagulation permitting surgical removal.
Hemangioma
Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells.
Hemarthrosis
Does Tranexamic Acid Reduce Knee Swelling and Improve Early Function Following Arthroscopic Meniscectomy? A Double-Blind Randomized Controlled Trial.
Hematocolpos
Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases.
Hematologic Diseases
[Study of hemostasis in patients with a recent thromboembolic complication]
Hematologic Neoplasms
Plasminogen activation in human leukemia and in normal hematopoietic cells.
Hematologic Neoplasms
Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases.
Hematologic Neoplasms
The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
Hematologic Neoplasms
[The clinical value of soluble urokinase plasminogen activation receptor in febrile neutropenic patients with hematological malignancies after chemotherapy].
Hematoma, Subdural
Fibrinolytic enzyme in the lining walls of chronic subdural hematoma.
Hematoma, Subdural, Chronic
Degradation of fibrinogen and fibrin by plasmin and nonplasmin proteases in the chronic subdural hematoma: evaluation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot.
Hematoma, Subdural, Chronic
Factors affecting coagulation: fibrinolysis in chronic subdural fluid collections.
Hematoma, Subdural, Chronic
Fibrinolytic enzyme in the lining walls of chronic subdural hematoma.
Hematoma, Subdural, Chronic
Tissue-type plasminogen activator in the chronic subdural hematoma.
Hemoglobinuria
Effect of streptokinase, epinephrine and plasmin on the paroxysmal nocturnal hemoglobinuria serum hemolytic system.
Hemoglobinuria
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Hemoglobinuria, Paroxysmal
Effect of streptokinase, epinephrine and plasmin on the paroxysmal nocturnal hemoglobinuria serum hemolytic system.
Hemoglobinuria, Paroxysmal
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Hemolytic-Uremic Syndrome
Streptococcus pneumoniae From Patients With Hemolytic Uremic Syndrome Binds Human Plasminogen via the Surface Protein PspC and Uses Plasmin to Damage Human Endothelial Cells.
Hemophilia A
Assessing Plasmin Generation in Health and Disease.
Hemophilia A
Development and application of global assays of hyper- and hypofibrinolysis.
Hemophilia A
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Hemophilia A
Fibrinolysin studies in hemophilia.
Hemophilia A
Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients.
Hemophilia A
Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation.
Hemophilia A
THE ROLE OF FIBRINOLYSIN AND PROFIBRINOLYSIN ACTIVATOR IN HEMOPHILIA.
Hemophilia A
Therapies for the treatment of abnormal uterine bleeding.
Hemophilia A
[Evaluation of the results of studying fibrinase in patients with hemophilia A]
Hemorrhagic Disorders
A single thymine nucleotide deletion responsible for congenital deficiency of plasmin inhibitor.
Hemorrhagic Disorders
Decreased plasmin resistance by clots of a homophenotypic Aalpha R 16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release).
Hemorrhagic Disorders
Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate.
Hemorrhagic Disorders
Studies on the plasminogen proactivator of plasma in children with hemorrhagic disorders.
Hemorrhagic Fever with Renal Syndrome
Epidemic hemorrhagic fever. The mechanism of coagulation and fibrinolysis.
Hemorrhagic Fever with Renal Syndrome
[A dynamic study of plasminogen, antithrombin III, fibrinogen and DIC in epidemic hemorrhagic fever]
Hemorrhagic Fever with Renal Syndrome
[Detection of plasma AT-III and plasminogen in patients with epidemic hemorrhagic fever and its clinical significance]
Hemorrhagic Stroke
After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study.
Hemorrhagic Stroke
Immunotherapy blocking the tissue plasminogen activator-dependent activation of N-methyl-d-aspartate glutamate receptors improves hemorrhagic stroke outcome.
Hemorrhagic Stroke
Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study.
Hemorrhagic Stroke
[The endothelial dysfunction in patients with arterial hypertension after old hemorrhagic stroke.]
Hemothorax
STUDY OF FIBRINOLYSIN ON CLOTTED HEMOTHORAX.
Hemothorax
Treatment of clotted hemothorax with fibrinolysin.
Hemothorax
[Coagulative and fibrinolytic properties of blood effused into the pleural cavity after lung surgery]
Hepatic Encephalopathy
Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure.
Hepatic Insufficiency
Plasminogen abnormalities in patients with Argentine hemorrhagic fever.
Hepatic Insufficiency
[The disorders of hemostasis system and thrombotic complications in oncologic patients having liver operation.]
Hepatic Veno-Occlusive Disease
Hepatic Veno-Occlusive Disease: A Role for Tissue Plasminogen Activator?
Hepatitis
Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease.
Hepatitis
Bilirubin or plasminogen--which is better in the assessment of the severity of viral hepatitis?
Hepatitis
Importance of measuring plasma thrombin-antithrombin III complex levels when using antithrombin III concentrate therapy in fulminant hepatic failure.
Hepatitis
Observations of increased levels of blood coagulation factors and other plasma proteins in cholestatic liver disease.
Hepatitis
Potency of fragmented IgG: two studies of postexposure prophylaxis in type A hepatitis.
Hepatitis
Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients.
Hepatitis
Prognostic significance of antithrombin III, plasminogen and proactivator of plasminogen activity in viral hepatitis.
Hepatitis
[Diagnostic value of plasminogen in viral hepatitis]
Hepatitis
[Reduced fibrinolysin activity in fatal epidemic hepatitis.]
Hepatitis A
Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Hepatitis A
Platelet and fibrinogen survival with 75Se selenomethionine in acute infectious hepatitis.
Hepatitis A
Robustness of nanofiltration for increasing the viral safety margin of biological products.
Hepatitis B
Contributions to the optimal use of human blood. IX. Elimination of hepatitis B transmission by (potentially) infectious plasma derivatives.
Hepatitis B
Immunohistological investigations of PAS-negative globular intracisternal hyalin in human liver biopsy specimens.
Hepatitis B
Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure.
Hepatitis C
Formulated Minimal-Length Synthetic Small Hairpin RNAs are Potent Inhibitors of Hepatitis C Virus in Mice with Humanized Livers.
Hepatitis E
Hepatitis E virus open reading frame 3 protein interacts with porcine liver-specific plasminogen and ?2-antiplasmin.
Hepatitis, Chronic
Observations of increased levels of blood coagulation factors and other plasma proteins in cholestatic liver disease.
Hepatitis, Chronic
Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients.
Hepatitis, Chronic
[The activity of fibrinase in cirrhosis of the liver and chronic hepatitis]
Hepatolenticular Degeneration
[Defects of antithrombin III, protein C, and plasminogen in Wilson's disease with brainstem infarction]
Herpes Simplex
Herpesviruses enhance fibrin clot lysis.
Herpes Zoster
Changes in the bovine zona pellucida induced by plasmin or embryonic plasminogen activator.
Herpes Zoster
Effects of plasmin on sperm-oocyte interactions during in vitro fertilization in the pig.
Herpes Zoster
How Is Plasminogen/Plasmin System Contributing to Regulate Sperm Entry Into the Oocyte?
Herpes Zoster
Localization of plasminogen in the extracellular matrix of hamster eggs: exogenous activation by streptokinase.
Herpes Zoster
nompA encodes a PNS-specific, ZP domain protein required to connect mechanosensory dendrites to sensory structures.
Herpes Zoster
Plasminogen detection in oocytes and plasminogen activator activities in the porcine oviduct during the estrous cycle.
Herpes Zoster
The effects of plasminogen on in vitro ovine embryo development.
Herpes Zoster
Tissue plasminogen activator (tPA) of paternal origin is necessary for the success of invitro but not of invivo fertilisation in the mouse.
Histiocytosis, Langerhans-Cell
Cutaneous infiltrates of histiocytosis X contain plasminogen activator-bearing epidermotropic dendritic cells different from Langerhans cells.
Hodgkin Disease
PLASMINOGEN DEFICIENCY IN HODGKIN'S DISEASE.
Homocystinuria
Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group.
Huntington Disease
Changes in nine enzyme markers for neurons, glia, and endothelial cells in agonal state and Huntington's disease caudate nucleus.
Hyaline Membrane Disease
Ontogeny of fibrinolysin system and its role in pathogenesis of hyaline membrane disease of infants.
Hyaline Membrane Disease
Plasminogen in the prevention of hyaline membrane disease.
Hyaline Membrane Disease
Prevention of hyaline membrane disease with plasminogen. A cooperative study.
Hyaline Membrane Disease
Prevention of hyaline membrane disease with plasminogen. Preliminary report of a cooperative study.
Hyaline Membrane Disease
Studies on hyaline membrane disease. I. The fibrinolysin system in pathogenesis and therapy.
Hyaline Membrane Disease
STUDIES ON HYALINE MEMBRANE DISEASE. II. THE ONTOGENY OF THE FIBRINOLYSIN SYSTEM.
Hyaline Membrane Disease
Studies on the prevention of respiratory distress syndrome of infants due to hyaline membrane disease with plasminogen.
Hyaline Membrane Disease
[Treatment of hyaline membrane disease with the plasminogen urokinase combination]
Hydatidiform Mole
Coagulation and fibrinolysis in intact hydatidiform molar pregnancy.
Hydrocephalus
Cerebrospinal fluid plasminogen activator inhibitor-1: a prognostic factor in posthaemorrhagic hydrocephalus.
Hydrocephalus
Congenital hydrocephalus as a rare association with ligneous conjunctivitis and type I plasminogen deficiency.
Hydrocephalus
Ligneous conjunctivitis, hydrocephalus, hydrocele, and pulmonary involvement in a child with homozygous type I plasminogen deficiency.
Hydrocephalus
Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis?
Hydrocephalus
Management of hydrocephalus in children with plasminogen deficiency.
Hydrocephalus
Prenatal diagnosis in a family with severe type I plasminogen deficiency, ligneous conjunctivitis and congenital hydrocephalus.
Hydrocephalus
The ventriculocholecystic shunt: two case reports and a review of the literature.
Hydrocephalus
[Fibrinolytic treatment of cerebral intraventricular hemorrhage]
Hydronephrosis
Causes of venous thrombosis in fifty Chinese patients.
Hydronephrosis
Hydronephrosis is associated with elevated plasmin in urine in pediatric patients and rats and changes in NCC and ?-ENaC abundance in rat kidney.
Hyperalgesia
The p75 receptor is associated with inflammatory thermal hypersensitivity.
Hypercholesterolemia
Cardiovascular issues in hypogonadism and testosterone therapy.
Hyperemia
[Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review]
Hyperglycemia
Biochemical pharmacology of the fibrinolysin system of the rat. I. The effect of alloxan-induced hyperglycemia.
Hyperglycemia
Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
Hyperglycemia
Epsilon-aminocaproic acid prevents high glucose and insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system.
Hyperglycemia
Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.
Hyperglycemia
Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease.
Hyperglycemia
Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by Increasing superoxide production.
Hyperglycemia
The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation.
Hyperhomocysteinemia
Coagulopathies and arterial stroke.
Hyperhomocysteinemia
Prothrombotic disorders and ischemic stroke in children.
Hyperhomocysteinemia
Thrombophilic screening in retinal artery occlusion patients.
Hyperhomocysteinemia
[Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age].
Hyperinsulinism
Assay of pig growth hormone preparations for metabolic activities in the rat and in man.
Hyperinsulinism
Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia.
Hyperinsulinism
Metabolic abnormalities in cardiac ischemia.
Hyperinsulinism
Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
Hyperkalemia
Deterioration of Kidney Function by the (Pro)renin Receptor Blocker Handle Region Peptide in Aliskiren-treated Diabetic Transgenic (mRen2)27 Rats.
Hyperlipidemias
Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). population-based reference values in an area with low incidence of cardiovascular disease.
Hyperlipidemias
Hyperlipemia, fibrinolysis and arteriosclerosis.
Hyperlipidemias
Influence of Etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia.
Hyperlipidemias
Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis.
Hyperlipidemias
Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components.
Hyperlipidemias
[Hemostasis profiles in thrombotic disease]
Hyperlipidemias
[Hemostatic changes during pregnancy in reference to hyperlipidemia]
Hyperlipoproteinemias
Influence of Etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia.
Hyperlipoproteinemias
[Changes in the level of certain hemostatic factors during treatment with lovastatin in patients with primary hyperlipoproteinemia and phenotype IIa and IIb]
Hyperpigmentation
Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial.
Hypersensitivity
Enzymatic investigation for delayed-type hypersensitivity reaction. Assay for thrombin and plasmin activities in tuberculin reaction sites.
Hypersensitivity
Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA in Occluded Coronary Arteries.
Hypersensitivity
Rapid appearance of plasmin in tear fluid after ocular allergen exposure.
Hypersensitivity
Review and application of serine protease inhibition in coronary artery bypass graft surgery.
Hypersensitivity
Tear Proteases and Protease Inhibitors: Potential Biomarkers and Disease Drivers in Ocular Surface Disease.
Hypersensitivity
[Allergic reactions to fibrinolysin]
Hypersensitivity
[On the role of plasmin in the mechanism of allergy.]
Hypersensitivity
[Round table conference. V. Plasmin and allergy]
Hypersensitivity
[The efficacy of using enzymes in treating toxic-allergic reactions after cataract extraction with intraocular lens implantation]
Hypersensitivity, Delayed
Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin.
Hypertension
A Multimodality Machine Learning Approach to Differentiate Severe and Nonsevere COVID-19: Model Development and Validation.
Hypertension
Abnormalities of fibrinolysis in essential hypertension.
Hypertension
Advances in diabetes for the millennium: the heart and diabetes.
Hypertension
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Hypertension
Association of Red Blood Cell Distribution Width With Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection.
Hypertension
Biological risk factors for sudden death in patients with coronary artery disease and without heart failure.
Hypertension
Comparison of plasma total plasmin activities in male and female hypertensive rats.
Hypertension
Correlation between family history of hypertension and haemostatic disorders.
Hypertension
Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats.
Hypertension
Functional and morphologic evidence of the presence of tissue-plasminogen activator in vascular nerves: implications for a neurologic control of vessel wall fibrinolysis and rigidity.
Hypertension
Haemostatic and other cardiovascular risk factors, and socioeconomic status among middle-aged Finnish men and women.
Hypertension
Haemostatic parameters in patients with primitive venous hypertension.
Hypertension
Hemostasis and fibrinolysis factors in first-degree relatives of patients with Type 2 diabetes without hypertension.
Hypertension
Is urinary excretion of plasminogen associated with development of pre-eclampsia? An observational, explorative case-control study.
Hypertension
Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease.
Hypertension
Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10?years of follow-up.
Hypertension
Mechanisms of renal NaCl retention in proteinuric disease.
Hypertension
Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro.
Hypertension
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
Hypertension
Renal function and cardiovascular mortality in elderly men: the role of inflammatory, procoagulant, and endothelial biomarkers.
Hypertension
Risk Factors for Thrombosis Development in Mexican Patients.
Hypertension
The effect of experimental chronic hypertension on tissue plasminogen activator activity, plasminogen activator inhibition and plasmin inhibition.
Hypertension
The endocrine function of adipose tissue: an update.
Hypertension
Urinary Plasmin Activates Collecting Duct ENaC Current in Preeclampsia.
Hypertension
Urine albumin is a superior predictor of preeclampsia compared to urine plasminogen in type I diabetes patients.
Hypertension
[Changes of relative variables about prethrombosis state and its clinical significance in patients with pregnancy induced hypertension]
Hypertension
[Comparative evaluation of the kallikrein-kinin, plasmin and thrombin blood systems in hypertension]
Hypertension
[Effect of heparin on the fibrinase activity of the blood in patients with hypertension]
Hypertension
[Levels of kallikrein, plasmin and thrombin precursors and the activity of their inhibitors in hypertension patients]
Hypertension
[Lipoprotein(a) and plasminogen patients with diabetes mellitus complicated with peripheral angiopathy and hypertension]
Hypertension
[Neurology in the 21st century--the era of preventive neurology utilizing new diagnostic and therapeutic techniques]
Hypertension
[Plasminogen, antiplasmins and the rate of fibrinolysis in hypertension and atherosclerosis]
Hypertension
[The endothelial dysfunction in patients with arterial hypertension after old hemorrhagic stroke.]
Hypertension
[The influence of antihypertensive agents on plasmatic and vascular-thrombocytic homeostasis in metabolic syndrome]
Hypertension, Pregnancy-Induced
[Changes of relative variables about prethrombosis state and its clinical significance in patients with pregnancy induced hypertension]
Hypertension, Pulmonary
Association of plasma fibrinogen and plasminogen with prognosis of inoperable chronic thromboembolic pulmonary hypertension.
Hypertension, Pulmonary
Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice.
Hypertension, Pulmonary
High Fibrinogen Plus Low Plasminogen Levels Predict Poor Post-Surgical Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension.
Hypertension, Pulmonary
Neutrophil extracellular traps (NETs): the role of inflammation and coagulation in COVID-19.
Hypertension, Pulmonary
Recurring thromboembolic disease and pulmonary hypertension associated with severe hypoplasminogenemia.
Hypertension, Pulmonary
[High-altitude pulmonary hypertension and fibrinolysis]
Hyperthyroidism
Coagulation and fibrinolysis in thyroid disease.
Hyperthyroidism
Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment.
Hyperthyroidism
[Disorders of hemostasis in dysthyroidism]
Hypertriglyceridemia
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Hypertrophy, Left Ventricular
Increased gene expression of plasminogen activators and inhibitors in left ventricular hypertrophy.
Hypertrophy, Left Ventricular
[The indices of the fibrinolysis, blood coagulation and lipid transport systems in hypertension patients]
Hypertrophy, Right Ventricular
Gene expression in a swine model of right ventricular hypertrophy: intercellular adhesion molecule, vascular endothelial growth factor and plasminogen activators are upregulated during pressure overload.
Hyphema
Fibrinolysin irrigation in traumatic secondary hyphema.
Hyphema
Fibrinolysis and hyphema. The effect of thrombolysin and Kabikinas on clotted blood in camera anterior of the eye in rabbits.
Hyphema
Treatment of experimental vitreous hemorrhage with tissue plasminogen activator.
Hyphema
Treatment of total hyphema with fibrinolysin.
Hyphema
[Thrombolytic effect of plasmin, miniplasmin and fibrinolysin in simulated intraocular hemorrhage]
Hyphema
[Treatment of experimental hyphema in rabbits by Sevac plasmin]
Hyphema
[TREATMENT OF TOTAL HYPHEMAS OF THE ANTERIOR CHAMBER WITH FIBRINOLYSIN.]
Hypoglycemia
Biochemical pharmacology of the fibrinolysin system of the rat. II. The effect of insulin induced hypoglycemia.
Hypogonadism
Cardiovascular issues in hypogonadism and testosterone therapy.
Hypotension
A stable prostacyclin-like substance produced by the medicinal leech Hirudo medicinalis.
Hypotension
Acute blood pressure effects of selected serine proteases in normotensive rats and dogs.
Hypotension
Acute haemodilution and prostaglandin E1-induced hypotension: effects on the coagulation-fibrinolysis system.
Hypotension
[ROLE OF PLASMIN IN PEPTONE-INDUCED ARTERIAL HYPOTENSION IN RATS.]
Hypothyroidism
Effect of levothyroxine replacement therapy on coagulation and fibrinolysis in severe hypothyroidism.
Hypothyroidism
Experimental hypothyroidism increases plasminogen activator inhibitor activity in rat plasma.
Hypoxia-Ischemia, Brain
Deleterious effects of plasminogen activators in neonatal cerebral hypoxia-ischemia.
Hypoxia-Ischemia, Brain
[Changes and significance of endogenous tissue plasminogen activators in cerebral hypoxia-ischemia in neonatal rats]
Idiopathic Pulmonary Fibrosis
Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis
Matrix metalloproteinase-1 activation via plasmin generated on alveolar epithelial cell surfaces.
Idiopathic Pulmonary Fibrosis
The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.
Idiopathic Pulmonary Fibrosis
The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF.
Immunoglobulin G4-Related Disease
No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort.
Infant, Newborn, Diseases
Studies on the ontogeny and significance in neonatal disease of the fibrinolysin system and of fibrin stabilizing factor.
Infarction, Middle Cerebral Artery
Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke.
Infarction, Middle Cerebral Artery
Increased brain plasmin levels following experimental ischemic stroke in male mice.
Infarction, Middle Cerebral Artery
Mechanistic insight into Neurotoxicity of Tissue Plasminogen Activator-Induced Thrombolysis Products in a Rat Intraluminal Middle Cerebral Artery Occlusion Model.
Infarction, Middle Cerebral Artery
Plasminogen activation in focal cerebral ischemia and reperfusion.
Infarction, Middle Cerebral Artery
Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice.
Infarction, Middle Cerebral Artery
PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.
Infarction, Middle Cerebral Artery
Protective Effect of ApoA1 (Apolipoprotein A1)-Milano in a Rat Model of Large Vessel Occlusion Stroke.
Infarction, Middle Cerebral Artery
Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.
Infarction, Middle Cerebral Artery
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice.
Infarction, Middle Cerebral Artery
The Effects of the Contact Activation System on Hemorrhage.
Infarction, Middle Cerebral Artery
Thrombolysis with plasmin: implications for stroke treatment.
Infarction, Middle Cerebral Artery
[Evaluation for antithrombotic agents by a thrombotic model in animals].
Infections
A rapid fluorometric assay for tear fluid plasmin activity.
Infections
A study of cutaneous lesions caused by Leishmania mexicana in plasminogen-deficient mice.
Infections
Acquisition of the Sda1-encoding bacteriophage does not enhance virulence of the M1 Streptococcus pyogenes strain SF370.
Infections
Activation of plasminogen by staphylokinase reduces the severity of Staphylococcus aureus systemic infection.
Infections
Analysis of plasminogen-binding M proteins of Streptococcus pyogenes.
Infections
Babesia bovis (= argentina): changes in erythrophylic and associated proteins during acute infection of splenectomized and intact calves.
Infections
Bacille Calmette-Guérin infection in the mouse. Regulation of macrophage plasminogen activator by T lymphocytes and specific antigen.
Infections
Bacterial metastasis: the host plasminogen system in bacterial invasion.
Infections
Bacterial pathogens activate plasminogen to breach tissue barriers and escape from innate immunity.
Infections
Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice.
Infections
Binding of plasminogen to Escherichia coli adhesion proteins.
Infections
Borrelia burgdorferi infection-associated surface proteins ErpP, ErpA, and ErpC bind human plasminogen.
Infections
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Infections
Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection.
Infections
Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
Infections
Contribution of plasminogen activation towards the pathogenic potential of oral streptococci.
Infections
Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection.
Infections
Current Understanding of the Pathogenesis of Dengue Virus Infection.
Infections
Delayed invasion of the kidney and brain by Borrelia crocidurae in plasminogen-deficient mice.
Infections
Deletion of Braun lipoprotein gene (lpp) and curing of plasmid pPCP1 dramatically alter the virulence of Yersinia pestis CO92 in a mouse model of pneumonic plague.
Infections
Early syphilitic hepatitis concomitant with nephrotic syndrome followed by acute kidney injury.
Infections
Effect of ions and inhibitors on the catalytic activity and structural stability of S. aureus enolase.
Infections
Elevation of tear fluid plasmin in corneal disease.
Infections
Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells.
Infections
Exploration of the host haemostatic system by group A streptococcus: implications in searching for novel antimicrobial therapies.
Infections
Exploring the interaction between Mycobacterium tuberculosisEnolase and human plasminogen using computational methods and experimental techniques.
Infections
Expression, genetic localization and phylogenic analysis of NAPlr in piscine Streptococcus dysgalactiae subspecies dysgalactiae isolates and their patterns of adherence.
Infections
Fibrin and fibrinolysis in infection and host defense.
Infections
Gastric mucosal plasminogen activators in Helicobacter pylori infection.
Infections
Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.
Infections
Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study.
Infections
Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children.
Infections
Herpesviruses enhance fibrin clot lysis.
Infections
Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes.
Infections
Human Plasminogen Exacerbates Clostridioides difficile Enteric Disease and Alters the Spore Surface.
Infections
Humanized Plasminogen Mouse Model to Study Group A Streptococcus Invasive Disease.
Infections
Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.
Infections
Increased Mosquito Midgut Infection by Dengue Virus Recruitment of Plasmin Is Blocked by an Endogenous Kazal-type Inhibitor.
Infections
Induction of plasminogen activators in pregnant women with Toxoplasma gondii infection.
Infections
Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors.
Infections
Influence of plasma protease activation on electroimmunoassay and nephelometry of plasma fibronectin in sepsis.
Infections
Interaction of Trypanosoma evansi with the plasminogen-plasmin system.
Infections
Interleukin-6-induced plasminogen gene expression in murine hepatocytes is mediated by transcription factor CCAAT/enhancer binding protein beta (C/EBPbeta).
Infections
Intracellular/surface moonlighting proteins that aid in the attachment of gut microbiota to the host.
Infections
Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study.
Infections
Ischemic stroke outcome and early infection: its deleterious effect seems to operate also among tissue plasminogen activator-treated patients.
Infections
Linoleic and palmitoleic acid block streptokinase-mediated plasminogen activation and reduce severity of invasive group A streptococcal infection.
Infections
Low level of plasminogen increases risk for mortality in COVID-19 patients.
Infections
Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis?
Infections
M protein-mediated plasminogen binding is essential for the virulence of an invasive Streptococcus pyogenes isolate.
Infections
Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury.
Infections
Molecular characterization of a Trichinella spiralis enolase and its interaction with the host's plasminogen.
Infections
Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis.
Infections
Molecular cloning and expression analysis of coagulation factor VIII and plasminogen involved in immune response to GCRV, and immunity activity comparison of grass carp Ctenopharyngodon idella with different viral resistance.
Infections
Molecular mechanisms underlying group A streptococcal pathogenesis.
Infections
Moonlighting glycolytic protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH): an evolutionarily conserved plasminogen receptor on mammalian cells.
Infections
Myxomavirus serpin alters macrophage function and prevents diffuse alveolar hemorrhage in pristane-induced lupus.
Infections
Network of Surface-Displayed Glycolytic Enzymes in Mycoplasma pneumoniae and Their Interactions with Human Plasminogen.
Infections
No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort.
Infections
Nonfibrinolytic functions of plasminogen.
Infections
Oligosaccharide processing in the expression of human plasminogen cDNA by lepidopteran insect (Spodoptera frugiperda) cells.
Infections
Parasitism in optima forma: Exploiting the host fibrinolytic system for invasion.
Infections
Plasmin activity in the porcine airways is enhanced during experimental infection with Mycoplasma hyopneumoniae, is positively correlated with proinflammatory cytokine levels and is ameliorated by vaccination.
Infections
Plasmin(ogen) Acquisition by Group A Streptococcus Protects against C3b-Mediated Neutrophil Killing.
Infections
Plasmin, Immunity, and Surgical Site Infection.
Infections
Plasminogen activation by staphylokinase enhances local spreading of S. aureus in skin infections.
Infections
Plasminogen binding by group A streptococcal isolates from a region of hyperendemicity for streptococcal skin infection and a high incidence of invasive infection.
Infections
Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis.
Infections
Plasminogen improves lung lesions and hypoxemia in patients with COVID-19.
Infections
Plasminogen promotes influenza A virus replication through an annexin 2-dependent pathway in the absence of neuraminidase.
Infections
Plasmodium berghei: pulmonary oedema and changes in clotting and fibrinolysis during infection in mice.
Infections
Plasmodium falciparum proteases hydrolyze plasminogen, generating angiostatin-like fragments.
Infections
Preventing Candida albicans from subverting host plasminogen for invasive infection treatment.
Infections
Production of outer membrane vesicles by the plague pathogen Yersinia pestis.
Infections
Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.
Infections
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
Infections
Reevaluation of vitamin E supplementation of dairy cows: bioavailability, animal health and milk quality.
Infections
Role of plasminogen in propagation of scrapie.
Infections
Role of secreted glyceraldehyde-3-phosphate dehydrogenase in the infection mechanism of enterohemorrhagic and enteropathogenic Escherichia coli: interaction of the extracellular enzyme with human plasminogen and fibrinogen.
Infections
Role of the pleiotropic effects of plasminogen deficiency in infection experiments with plasminogen-deficient mice.
Infections
Secretion of the housekeeping protein glyceraldehyde-3-phosphate dehydrogenase by the LEE-encoded type III secretion system in enteropathogenic Escherichia coli.
Infections
Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells.
Infections
Staphylococcus aureus exploits cathelicidin antimicrobial peptides produced during early pneumonia to promote staphylokinase-dependent fibrinolysis.
Infections
Staphylokinase Promotes the Establishment of Staphylococcus aureus Skin Infections While Decreasing Disease Severity.
Infections
Streptococcus uberis plasminogen activator (SUPA) activates human plasminogen through novel species-specific and fibrin-targeted mechanisms.
Infections
Streptokinases produced by pathogenic group C streptococci demonstrate species-specific plasminogen activation.
Infections
Structural diversity of streptokinase and activation of human plasminogen.
Infections
Subunits of the Pyruvate Dehydrogenase Cluster of Mycoplasma pneumoniae Are Surface-Displayed Proteins that Bind and Activate Human Plasminogen.
Infections
Successful management of pleural infection with very low dose intrapleural tissue plasminogen activator/deoxyribonuclease regime.
Infections
Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion.
Infections
Syphilis and Human Immunodeficiency Virus (HIV)-1 Coinfection: Influence on CD4 T-Cell Count, HIV-1 Viral Load, and Treatment Response.
Infections
t-PA Suppresses the Immune Response and Aggravates Neurological Deficit in a Murine Model of Ischemic Stroke.
Infections
Targeting host cell proteases to prevent SARS-CoV-2 invasion.
Infections
The Bfp60 surface adhesin is an extracellular matrix and plasminogen protein interacting in Bacteroides fragilis.
Infections
The fibrinolytic system in dissemination and matrix protein deposition during a mycobacterium infection.
Infections
The interaction between bacterial enolase and plasminogen promotes adherence of Streptococcus pneumoniae to epithelial and endothelial cells.
Infections
The interaction between pathogens and the host coagulation system.
Infections
The interaction of Streptococcus dysgalactiae with plasmin and plasminogen.
Infections
The novel Leptospira interrogans protein Lsa32 is expressed during infection and binds laminin and plasminogen.
Infections
The novel leptospiral surface adhesin, Lsa20, binds laminin, human plasminogen and is probably expressed during infection.
Infections
The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis.
Infections
The procoagulant envelope virus surface: contribution to enhanced infection.
Infections
The recombinant LIC10508 is a plasma fibronectin, plasminogen, fibrinogen and C4BP-binding protein of Leptospira interrogans.
Infections
The staphylococcal transferrin-binding protein is a cell wall glyceraldehyde-3-phosphate dehydrogenase.
Infections
Tranexamic acid modulates the immune response and reduces postsurgical infection rates.
Infections
Trigger for group A streptococcal M1T1 invasive disease.
Infections
Vascular Leak and Hypercytokinemia Associated with Severe Fever with Thrombocytopenia Syndrome Virus Infection in Mice.
Infections
[Cleavage of influenza virus hemagglutinin as affected by serum plasmin in cell culture and in vivo]
Infections
[Enolase and parasitic infection].
Infections
[Hemostasis in burn patients and treatment with heparin. Relation to prognosis and infection. Pattern of blood levels of prekallikrein, alpha-2-macroglobulin, antithrombin III, plasminogen and alpha-2-antiplasmin]
Infections
[Hemostasis in patients with acute leukemia treated with high doses of cytosine-arabinoside: the effect of chemotherapy and infectious complications on hemostasis]
Infections
[The results of the measured oral infection of white mice with strains of the causative agent of plague differing in their plasmid profile]
Infertility
Possible role of the plasminogen activation system in human subfertility.
Infertility
Tissue-type plasminogen activator level is decreased in human seminal plasma with abnormal liquefaction.
Infertility
[Consequences for labile blood products of leukocyte depletion by whole blood filtration using the Leucoflex LST1 in-line filter. Evaluation of the Leucoflex LST1 filter]
Infertility, Female
[Serum plasminogen levels and timing of ovulation]
Inflammatory Bowel Diseases
Coagulation parameters in inflammatory bowel disease.
Inflammatory Bowel Diseases
D-dimer tests detect both plasmin and neutrophil elastase derived split products.
Inflammatory Bowel Diseases
Inflammatory Bowel Disease: A Gastrointestinal Presentation of Congenital Plasminogen Deficiency.
Inflammatory Bowel Diseases
Inhibition of Plasmin Protects Against Colitis in Mice by Suppressing Matrix Metalloproteinase 9-Mediated Cytokine Release From Myeloid Cells.
Inflammatory Bowel Diseases
Plasminogen activators in the intestine of patients with inflammatory bowel disease.
Inflammatory Bowel Diseases
The role of inflammatory cells and their proteases in extravascular fibrinolysis.
Inflammatory Bowel Diseases
Tranexamic Acid and Supportive Measures to Treat Wasting Marmoset Syndrome.
Influenza in Birds
Effect of annexin II-mediated conversion of plasmin from plasminogen on airborne transmission of H9N2 avian influenza virus.
Influenza in Birds
Neuraminidase-associated plasminogen recruitment enables systemic spread of natural avian Influenza viruses H3N1.
Influenza, Human
Annexin II incorporated into influenza virus particles supports virus replication by converting plasminogen into plasmin.
Influenza, Human
Assays for functional binding of plasminogen to viral proteins.
Influenza, Human
Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12.
Influenza, Human
Effect of annexin II-mediated conversion of plasmin from plasminogen on airborne transmission of H9N2 avian influenza virus.
Influenza, Human
Molecular mechanism of complex infection by bacteria and virus analyzed by a model using serratial protease and influenza virus in mice.
Influenza, Human
Plasmin-mediated activation of pandemic H1N1 influenza virus hemagglutinin independent of the viral neuraminidase.
Influenza, Human
Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis.
Influenza, Human
Plasminogen promotes influenza A virus replication through an annexin 2-dependent pathway in the absence of neuraminidase.
Influenza, Human
Proteolytic activation of the 1918 influenza virus hemagglutinin.
Influenza, Human
Proteolytic cleavage by plasmin of the HA polypeptide of influenza virus: host cell activation of serum plasminogen.
Influenza, Human
Unique transcriptional changes in coagulation cascade genes in SARS-CoV-2-infected lung epithelial cells: A potential factor in COVID-19 coagulopathies.
Influenza, Human
[Cleavage of influenza virus hemagglutinin as affected by serum plasmin in cell culture and in vivo]
Influenza, Human
[Role of neuraminidase in pathogenesis of influenza]
Insulin Resistance
Adiponectin levels may help assess the clinical repercussions of obesity irrespective of body mass index.
Insulin Resistance
Cardiovascular issues in hypogonadism and testosterone therapy.
Insulin Resistance
Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer.
Insulin Resistance
Differential gene expression between visceral and subcutaneous fat depots.
Insulin Resistance
Insulin resistance and elevated levels of tissue plasminogen activator in first-degree relatives of South Asian patients with ischemic cerebrovascular disease.
Insulin Resistance
Is There a Tendency for Thrombosis in Gestational Diabetes Mellitus?
Insulin Resistance
Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
Insulin Resistance
Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization.
Insulin Resistance
Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
Insulin Resistance
Variables of the insulin resistance syndrome are associated with reduced arterial distensibility in healthy non-diabetic middle-aged women.
Insulin Resistance
[Adipocitokines, adipose tissue and its relationship with immune system cells]
Intervertebral Disc Displacement
[A Japanese family with congenital abnormal plasminogen]
Intestinal Neoplasms
[Clinical study of hemostatic molecular markers expression in patients with cancer.]
Intestinal Obstruction
[Intraperitoneal administration of a solution of fibrinolysin, hydrocortisone and novocaine and its effect on blood coagulability in acute adhesive intestinal obstruction]
Intestinal Volvulus
Molecular cloning of an alpha-enolase from the human filarial parasite Onchocerca volvulus that binds human plasminogen.
Intra-Abdominal Hypertension
Tissue plasminogen activator-assisted hematoma evacuation to relieve abdominal compartment syndrome after endovascular repair of ruptured abdominal aortic aneurysm.
Intracranial Aneurysm
Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (AMCA).
Intracranial Aneurysm
Effect of dietary ? carotene on cerebral aneurysm and subarachnoid haemorrhage in the brain apo E(-/-) mice.
Intracranial Embolism
Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism.
Intracranial Embolism
Successful treatment of cerebral emboli with tissue plasminogen activator in a patient with takotsubo cardiomyopathy: A case report.
Intracranial Embolism
The thrombolytic effect of lumbrokinase is not as potent as urokinase in a rabbit cerebral embolism model.
Intracranial Embolism
Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits.
Intracranial Embolism
[Cerebral embolism after electric depolarization of a patient with cardiac fibrillation treated with fibrinolysin]
Intracranial Hemorrhages
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.
Intracranial Hemorrhages
Alteplase for Acute Ischemic Stroke: Outcomes by Clinically Important Subgroups in the Third International Stroke Trial.
Intracranial Hemorrhages
Correction to: Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Intracranial Hemorrhages
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
Intracranial Hemorrhages
Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury.
Intracranial Hemorrhages
Gender differences in the outcome of interventional cardiac procedures.
Intracranial Hemorrhages
Matrix metalloproteinase-2 or -9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion.
Intracranial Hemorrhages
Modulation by the Noble Gas Helium of Tissue Plasminogen Activator: Effects in a Rat Model of Thromboembolic Stroke.
Intracranial Hemorrhages
Neurotherapeutic potential of erythropoietin after ischemic injury of the central nervous system.
Intracranial Hemorrhages
Outcomes in acute ischemic strokes presenting with disabling neurologic deficits without intracranial vascular occlusion.
Intracranial Hemorrhages
Pharmacologic and clinical characteristics of thrombolytic agents.
Intracranial Hemorrhages
PI3K? (Phosphoinositide 3-Kinase-?) Inhibition Attenuates Tissue-Type Plasminogen Activator-Induced Brain Hemorrhage and Improves Microvascular Patency After Embolic Stroke.
Intracranial Hemorrhages
Relationship between abnormalities of coagulation and fibrinolysis and postoperative intracranial hemorrhage in head injury.
Intracranial Hemorrhages
Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Intracranial Hemorrhages
Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
Intracranial Hemorrhages
Shorter Intensive Care Unit Stays? The Majority of Post-Intravenous tPA (Tissue-Type Plasminogen Activator) Symptomatic Hemorrhages Occur Within 12 Hours of Treatment.
Intracranial Hemorrhages
Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.
Intracranial Hemorrhages
Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Intracranial Hemorrhages
Utilization of lysis percentage via thromboelastography for tissue plasminogen activator-induced symptomatic intracranial hemorrhage.
Intracranial Thrombosis
Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism.
Intracranial Thrombosis
Lysis of a Cerebral Thrombus with Fibrinolysin: A Case Report.
Intracranial Thrombosis
Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial.
Intracranial Thrombosis
Variations of alpha 2-plasmin inhibitor, antithrombin III, plasminogen in the serum of patients of cerebral thrombosis infused with urokinase.
Intracranial Thrombosis
[Preliminary study on the effects of coagulation factor XII on fibrinolysis]
Intracranial Thrombosis
[The use of fibrinolysin with heparin in developing cerebral thrombosis]
Invasive Fungal Infections
Plasminogen alleles influence susceptibility to invasive aspergillosis.
Invasive Fungal Infections
Preventing Candida albicans from subverting host plasminogen for invasive infection treatment.
Iridocyclitis
[Use of fibrinolysin in plastic iridocyclitis]
Iron Overload
Iron Overload Exacerbates the Risk of Hemorrhagic Transformation After tPA (Tissue-Type Plasminogen Activator) Administration in Thromboembolic Stroke Mice.
Ischemic Stroke
3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase.
Ischemic Stroke
?2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.
Ischemic Stroke
A nonfibrin macromolecular cofactor for tPA-mediated plasmin generation following cellular injury.
Ischemic Stroke
A qualitative assessment of practices associated with shorter door-to-needle time for thrombolytic therapy in acute ischemic stroke.
Ischemic Stroke
Advances in ischemic stroke treatment: neuroprotective and combination therapies.
Ischemic Stroke
Alpha 1-Antitrypsin Therapy Mitigated Ischemic Stroke Damage in Rats.
Ischemic Stroke
An emerging role of mast cells in cerebral ischemia and hemorrhage.
Ischemic Stroke
Angioedema after thrombolysis with tissue plasminogen activator: an airway emergency.
Ischemic Stroke
Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity.
Ischemic Stroke
Angioedema in Stroke Patients With Thrombolysis.
Ischemic Stroke
Antithrombotic Agents for tPA-Induced Cerebral Hemorrhage: A Systematic Review and Meta-Analysis of Preclinical Studies.
Ischemic Stroke
Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke.
Ischemic Stroke
Benefits of stroke treatment delivered using a mobile stroke unit trial.
Ischemic Stroke
Cerebral Ischemic Reperfusion Injury Following Recanalization of Large Vessel Occlusions.
Ischemic Stroke
Clinical neuroprotective drugs for treatment and prevention of stroke.
Ischemic Stroke
Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke.
Ischemic Stroke
Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model.
Ischemic Stroke
Comparison of Partial (.6 mg/kg) versus Full-Dose (.9 mg/kg) Intravenous Recombinant Tissue Plasminogen Activator Followed by Endovascular Treatment for Acute Ischemic Stroke: A Meta-Analysis.
Ischemic Stroke
Comparison of plasmin with recombinant tissue-type plasminogen activator in lysis of cerebral thromboemboli retrieved from patients with acute ischemic stroke.
Ischemic Stroke
Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke.
Ischemic Stroke
Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy.
Ischemic Stroke
Cost-effectiveness analysis of tissue plasminogen activator for acute ischemic stroke: a comparative review.
Ischemic Stroke
Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization.
Ischemic Stroke
Desmoteplase in the treatment of acute ischemic stroke.
Ischemic Stroke
Detection of prothrombotic state in ischemic stroke by monitoring plasma molecular markers.
Ischemic Stroke
Diagnostic testing for coagulopathies in patients with ischemic stroke.
Ischemic Stroke
Direct Mechanical Intervention Versus Combined Intravenous and Mechanical Intervention in Large Artery Anterior Circulation Stroke: A Matched-Pairs Analysis.
Ischemic Stroke
Disparities and Trends in Door-to-Needle Time: The FL-PR CReSD Study (Florida-Puerto Rico Collaboration to Reduce Stroke Disparities).
Ischemic Stroke
Does "time is brain" also mean "time is clot"? Time dependency of tissue-type plasminogen activator-induced recanalization in acute ischemic stroke.
Ischemic Stroke
Effects of alteplase in the treatment of acute ischemic stroke.
Ischemic Stroke
Effects of Stroke Unit Care in Acute Ischemic Stroke Patient Ineligible for Thrombolytic Treatment.
Ischemic Stroke
Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
Ischemic Stroke
Efficacy of telemedicine for thrombolytic therapy in acute ischemic stroke: a meta-analysis.
Ischemic Stroke
Emergency department nurses' perceived barriers and facilitators to caring for stroke patients.
Ischemic Stroke
Engineered Micro- and Nanoparticles for Fibrinolysis.
Ischemic Stroke
Estimating Weight of Patients With Acute Stroke When Dosing for Thrombolysis.
Ischemic Stroke
Evolution of a US County System for Acute Comprehensive Stroke Care.
Ischemic Stroke
Factors and outcomes associated with recanalization timing after thrombolysis.
Ischemic Stroke
Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review.
Ischemic Stroke
Fibrinolysis: from blood to the brain.
Ischemic Stroke
Frequency of Blood-Brain Barrier Disruption Post-Endovascular Therapy and Multiple Thrombectomy Passes in Acute Ischemic Stroke Patients.
Ischemic Stroke
Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK '92 Hemostasis Study.
Ischemic Stroke
Hemostatic markers in ischemic stroke of undetermined etiology.
Ischemic Stroke
Histopathological Characteristics of IV Recombinant Tissue Plasminogen -Resistant Thrombi in Patients with Acute Ischemic Stroke.
Ischemic Stroke
HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator.
Ischemic Stroke
Hyperbaric Oxygen Reduces Infarction Volume and Hemorrhagic Transformation Through ATP/NAD(+)/Sirt1 Pathway in Hyperglycemic Middle Cerebral Artery Occlusion Rats.
Ischemic Stroke
Impact of General Anesthesia on Safety and Outcomes in the Endovascular Arm of Interventional Management of Stroke (IMS) III Trial.
Ischemic Stroke
Impact of Participation in a Telestroke Network on Clinical Outcomes.
Ischemic Stroke
Impact of SMTP Targeting Plasminogen and Soluble Epoxide Hydrolase on Thrombolysis, Inflammation, and Ischemic Stroke.
Ischemic Stroke
Impact of time to treatment on tissue-type plasminogen activator-induced recanalization in acute ischemic stroke.
Ischemic Stroke
Increased brain plasmin levels following experimental ischemic stroke in male mice.
Ischemic Stroke
Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors.
Ischemic Stroke
Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
Ischemic Stroke
Intra-Arterial Adjunctive Medications for Acute Ischemic Stroke During Mechanical Thrombectomy: A Meta-Analysis.
Ischemic Stroke
Intravenous Recombinant Tissue Plasminogen Activator Does Not Impact Mortality in Acute Ischemic Stroke at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
Ischemic Stroke
Intravenous Thrombolysis for Acute Ischemic Stroke After Recent Myocardial Infarction: Case Series and Systematic Review.
Ischemic Stroke
Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study.
Ischemic Stroke
Intravenous thrombolytic therapy for acute ischemic stroke. Weighing the risks and benefits of tissue plasminogen activator.
Ischemic Stroke
Intravenous Tissue Plasminogen Activator in Stroke Mimics.
Ischemic Stroke
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke.
Ischemic Stroke
Iron Overload Exacerbates the Risk of Hemorrhagic Transformation After tPA (Tissue-Type Plasminogen Activator) Administration in Thromboembolic Stroke Mice.
Ischemic Stroke
Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism?
Ischemic Stroke
Ischemic stroke in PAR1 KO mice: Decreased brain plasmin and thrombin activity along with decreased infarct volume.
Ischemic Stroke
Ischemic stroke outcome and early infection: its deleterious effect seems to operate also among tissue plasminogen activator-treated patients.
Ischemic Stroke
LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH.
Ischemic Stroke
LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury.
Ischemic Stroke
Lingual angioedema with macroglossia during the treatment of acute ischemic stroke with alteplase.
Ischemic Stroke
Lipid Profile, Lipid-lowering Medications, and Intracerebral Hemorrhage After tPA in Get With The Guidelines-Stroke.
Ischemic Stroke
Looking for Our Ten Years Results for Coronary Heart Disease and Ischemic Stroke Group for the Standpoint of Haemostasis.
Ischemic Stroke
Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke.
Ischemic Stroke
Magnetic Resonance Imaging or Computed Tomography Before Treatment in Acute Ischemic Stroke.
Ischemic Stroke
Medicine. Stroke--tPA and the clinic.
Ischemic Stroke
Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke: A Systematic Review.
Ischemic Stroke
Melatonin decreases neurovascular oxidative/nitrosative damage and protects against early increases in the blood-brain barrier permeability after transient focal cerebral ischemia in mice.
Ischemic Stroke
Menstrual blood transplantation for ischemic stroke: Therapeutic mechanisms and practical issues.
Ischemic Stroke
Modulation by the Noble Gas Helium of Tissue Plasminogen Activator: Effects in a Rat Model of Thromboembolic Stroke.
Ischemic Stroke
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke.
Ischemic Stroke
Neuroprotection by urokinase plasminogen activator in the hippocampus.
Ischemic Stroke
Neuroserpin, a neuroprotective factor in focal ischemic stroke.
Ischemic Stroke
Neurovascular intervention in the acute phase of cerebral infarction.
Ischemic Stroke
Noncoding RNAs in ischemic stroke: time to translate.
Ischemic Stroke
Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: Intracranial bleeding associated with the treatment of ischemic stroke: thrombolytic treatment of ischemia-affected endothelial cells with tissue-type plasminogen activator.
Ischemic Stroke
NXY-059: a neuroprotective agent in acute stroke.
Ischemic Stroke
Optimized gene synthesis, expression and purification of active salivary plasminogen activator alpha2 (DSPAalpha2) of Desmodus rotundus in Pichia pastoris.
Ischemic Stroke
Outcomes Among Patients With Ischemic Stroke Treated With Intravenous tPA (Tissue-Type Plasminogen Activator) via Telemedicine.
Ischemic Stroke
Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke.
Ischemic Stroke
Pharmacologic management of ischemic stroke: relevance to stem cell therapy.
Ischemic Stroke
Phthalide derivative CD21 attenuates tissue plasminogen activator-induced hemorrhagic transformation in ischemic stroke by enhancing macrophage scavenger receptor 1-mediated DAMP (peroxiredoxin 1) clearance.
Ischemic Stroke
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Ischemic Stroke
Plasmin (Human) Administration in Acute Middle Cerebral Artery Ischemic Stroke: Phase 1/2a, Open-Label, Dose-Escalation, Safety Study.
Ischemic Stroke
Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank Samples.
Ischemic Stroke
Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?
Ischemic Stroke
Plasmin-loaded echogenic liposomes for ultrasound-mediated thrombolysis.
Ischemic Stroke
Plasminogen activation and thrombolysis for ischemic stroke.
Ischemic Stroke
Plasminogen Activation-Based Thrombolysis for Ischaemic Stroke: The Diversity of Targets may Demand New Approaches.
Ischemic Stroke
Plasminogen activator inhibitor-1 promotes synaptogenesis and protects against A?(1-42)-induced neurotoxicity in primary cultured hippocampal neurons.
Ischemic Stroke
Plasminogen Activators and Ischemic Stroke: Conditions for Acute Delivery.
Ischemic Stroke
Plasminogen activators in ischemic stroke: introduction.
Ischemic Stroke
Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke.
Ischemic Stroke
PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.
Ischemic Stroke
Regional Pediatric Acute Stroke Protocol: Initial Experience During 3 Years and 13 Recanalization Treatments in Children.
Ischemic Stroke
Relationships Between Imaging Assessments and Outcomes in Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke.
Ischemic Stroke
Releasable tissue plasminogen activators in ischemic stroke.
Ischemic Stroke
Renal Dysfunction and In-Hospital Outcomes in Patients With Acute Ischemic Stroke After Intravenous Thrombolytic Therapy.
Ischemic Stroke
Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2).
Ischemic Stroke
Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Ischemic Stroke
Role of tissue-type plasminogen activator in ischemic stroke.
Ischemic Stroke
Safety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic stroke.
Ischemic Stroke
Safety Outcomes After Thrombolysis for Acute Ischemic Stroke in Patients With Recent Stroke.
Ischemic Stroke
Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke.
Ischemic Stroke
Sex and Race-Ethnic Disparities in Door-to-CT Time in Acute Ischemic Stroke: The Florida Stroke Registry.
Ischemic Stroke
Stroke center characteristics which influence the administration of thrombolytic therapy for acute ischemic stroke: a national survey of stroke centers in Taiwan.
Ischemic Stroke
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice.
Ischemic Stroke
Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1.
Ischemic Stroke
Symptomatic Intracerebral Hemorrhage Among Eligible Warfarin-Treated Patients Receiving Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke.
Ischemic Stroke
t-PA, but not desmoteplase, induces a plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions which can be reversed within a limited time frame.
Ischemic Stroke
The -7351C/T polymorphism in the TPA Gene and ischemic stroke risk: a meta-analysis.
Ischemic Stroke
The Belgian experience with intravenous thrombolysis for acute ischemic stroke.
Ischemic Stroke
The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015.
Ischemic Stroke
The Nrf2 Pathway in Ischemic Stroke: A Review.
Ischemic Stroke
The Plasminogen Activation System Promotes Dendritic Spine Recovery and Improvement in Neurological Function After an Ischemic Stroke.
Ischemic Stroke
The role of plasminogen activators in stroke treatment: fibrinolysis and beyond.
Ischemic Stroke
Therapeutic spectrum of interferon-? in ischemic stroke.
Ischemic Stroke
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.
Ischemic Stroke
Thrombolysis with plasmin: implications for stroke treatment.
Ischemic Stroke
Thrombolytic therapy for patients who wake-up with stroke.
Ischemic Stroke
Thrombolytic therapy of acute ischemic stroke during pregnancy.
Ischemic Stroke
Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities.
Ischemic Stroke
Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial.
Ischemic Stroke
Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.
Ischemic Stroke
Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke.
Ischemic Stroke
Tissue-type plasminogen activator: a historical perspective and personal account.
Ischemic Stroke
tPA in the central nervous system: relations between tPA and cell surface LRPs.
Ischemic Stroke
tPA Mobilizes Immune Cells That Exacerbate Hemorrhagic Transformation in Stroke.
Ischemic Stroke
Translational initiatives in thrombolytic therapy.
Ischemic Stroke
Trends of r-tPA (Recombinant Tissue-Type Plasminogen Activator) Treatment and Treatment-Influencing Factors in Acute Ischemic Stroke.
Ischemic Stroke
Uneventful Pregnancy and Delivery after Thrombolysis Plus Thrombectomy for Acute Ischemic Stroke: Case Study and Literature Review.
Ischemic Stroke
Unilateral orolingual angioedema in a patient with sarcoidosis after intravenous thrombolysis due to acute stroke without improvement after treatment with icatibant.
Ischemic Stroke
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.
Ischemic Stroke
Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
Ischemic Stroke
Will delays in treatment jeopardize the population benefit from extending the time window for stroke thrombolysis?
Ischemic Stroke
[Development and response to intravenous treatment with tissue plasminogen activator with regard to referral hospitals. The experience of a stroke referral unit].
Ischemic Stroke
[Evaluation for antithrombotic agents by a thrombotic model in animals].
Ischemic Stroke
[Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age].
Ischemic Stroke
[Intravenous thrombolysis for acute ischemic stroke. A four years? experience in a Chilean public hospital].
Ischemic Stroke
[Thrombolytic therapy of ischemic stroke].
Jaw Cysts
Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
Joint Diseases
Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases.
Joint Diseases
Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis.
Joint Diseases
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Joint Diseases
Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease.
Joint Diseases
Plasminogen is a joint-specific positive- or negative-determinant of arthritis pathogenesis.
Keloid
Differential regulation of PAI-1 gene expression in human fibroblasts predisposed to a fibrotic phenotype.
Keloid
Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts.
Keratitis
A rapid fluorometric assay for tear fluid plasmin activity.
Keratoderma, Palmoplantar
Identification of novel homozygous SLURP1 mutation in a Javanese family with Mal de Meleda.
Kidney Diseases
A serine protease inhibitor attenuates aldosterone-induced kidney injuries via the suppression of plasmin activity.
Kidney Diseases
Physiology and pathophysiology of the plasminogen system in the kidney.
Kidney Diseases
Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease.
Kidney Diseases
Podocyte Injury: The Role of Proteinuria, Urinary Plasminogen and Oxidative Stress.
Kidney Diseases
Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography.
Kidney Failure, Chronic
Coagulation abnormalities in patients with end-stage renal disease treated with hemodialysis.
Kidney Failure, Chronic
Coagulation and fibrinolysis in chronic renal failure. Change in tissue-type plasminogen activator activity.
Kidney Failure, Chronic
Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: contribution of arteriovenous fistula.
Kidney Failure, Chronic
Factor VIII complex in chronic renal failure: influence of protein C, fibrinolysis and diabetes mellitus.
Kidney Failure, Chronic
Increased thrombin and plasmin generation in chronic renal failure.
Kidney Neoplasms
Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Kidney Neoplasms
Immunological analysis of plasminogen activators from cultured human cancer cells.
Laryngeal Neoplasms
[Fibrinase and antifibrinolytic activity of the blood in patients with laryngeal cancer]
Laryngeal Neoplasms
[Serum protein fractions in patients with laryngeal cancer undergoing radiation therapy. Possibility as a prognostic factor]
Laryngeal Neoplasms
[Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms]
Laryngitis
[A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs]
Leg Ulcer
Differential effects of acute and chronic wound fluids on urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and tissue-type plasminogen activator in cultured human keratinocytes and fibroblasts.
Leg Ulcer
Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration.
Leg Ulcer
Lipodermatosclerosis and the significance of proteolytic remodeling in the pathogenesis of venous ulceration (Review).
Leg Ulcer
Local ambulatory treatment of chronic leg ulcers with hyaluronidase, plasminogen, and antibiotics.
Leg Ulcer
Plasminogen activation in venous leg ulcers.
Leg Ulcer
Plasminogen activators, venous leg ulcers and reepithelialization.
Leg Ulcer
The role of the urokinase-type plasminogen activator (uPA) and its receptor (CD87) in lipodermatosclerosis.
Leg Ulcer
The safety and efficacy of a proteolytic ointment in the treatment of chronic ulcers of the lower extremity.
Leg Ulcer
Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers.
Leg Ulcer
Wound fluid from venous leg ulcers degrades plasminogen and reduces plasmin generation by keratinocytes.
Leg Ulcer
[Treatment of leg ulcers with plasmin and antibiotics]
Leishmaniasis
Enolase as a plasminogen binding protein in Leishmania mexicana.
Lens Subluxation
Lens subluxation after plasmin and SF6 injections in rabbit eyes.
Leprosy
Changes in the activity of blood plasmin after administration of 3-pyridyl acetic acid in leprosy patients. Correlation of activity changes with the Mitsuda reaction.
Leukemia
A plasminogen activator inhibitor-2 from a promyelocytic leukemia cell line, PL-21, binds to the carboxy-terminal chain of plasminogen activators.
Leukemia
Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients.
Leukemia
Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.
Leukemia
Alpha-2 antiplasmin in acute nonlymphoblastic leukemia.
Leukemia
An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface.
Leukemia
Annexin II: a plasminogen-plasminogen activator co-receptor.
Leukemia
Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
Leukemia
Blood plasminogen (profibrinolysin) levels in patients with leukemia and lymphoma.
Leukemia
Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases.
Leukemia
Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.
Leukemia
Fribrinolysis kinetics and its application.
Leukemia
Highly increased plasma concentrations of the nicked form of beta(2) glycoprotein I in patients with leukemia and with lupus anticoagulant: measurement with a monoclonal antibody specific for a nicked form of domain V.
Leukemia
In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy.
Leukemia
Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins ?M?2 and ?V?3.
Leukemia
Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells.
Leukemia
Monoclonal antibodies against receptor-induced binding sites detect cell-bound plasminogen in blood.
Leukemia
Persistence of plasmin-mediated pro-urokinase activation on the surface of human monocytoid leukemia cells in vitro.
Leukemia
Plasminogen activation in human leukemia and in normal hematopoietic cells.
Leukemia
Plasminogen activation on tumor cell surface and its involvement in human leukemia.
Leukemia
Plasminogen activator activity in differentiating leukemia cells.
Leukemia
Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation.
Leukemia
Regulation of S100A10 by the PML-RAR-{alpha} oncoprotein.
Leukemia
Sudden death due to undiagnosed acute promyelocytic leukemia: a case report.
Leukemia
The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity.
Leukemia
The endogenous peptides of normal human serum extracted from the acetonitrile-insoluble precipitate using modified aqueous buffer with analysis by LC-ESI-Paul ion trap and Qq-TOF.
Leukemia
[Bleeding complications in acute myeloblastic leukemia (author's transl)]
Leukemia
[Plasminogen activator in leukemic cell homogenate]
Leukemia, Lymphoid
[Proteolytic enzymes in human lymphocytic leukemia cells. I. Activity of dipeptidylaminopeptidase IV, plasminogen activator and cathepsins B and L in cells with different immunologic phenotype]
Leukemia, Lymphoid
[T-PA and PAI-1 in lymphocytes of patients with chronic lymphoid leukemia]
Leukemia, Monocytic, Acute
Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins ?M?2 and ?V?3.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The secretion of plasminogen activators by human myeloid leukemic cells in vitro.
Leukemia, Myeloid, Acute
Alpha-2 antiplasmin in acute nonlymphoblastic leukemia.
Leukemia, Myeloid, Acute
Changes in plasma levels of protease and fibrinolytic inhibitors induced by treatment in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Fribrinolysis kinetics and its application.
Leukemia, Myeloid, Acute
Hemostatic function on hyper-fibrinolytic disseminated intravascular coagulation.
Leukemia, Promyelocytic, Acute
An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface.
Leukemia, Promyelocytic, Acute
Annexin II: a plasminogen-plasminogen activator co-receptor.
Leukemia, Promyelocytic, Acute
Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases.
Leukemia, Promyelocytic, Acute
In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy.
Leukemia, Promyelocytic, Acute
Monoclonal antibodies against receptor-induced binding sites detect cell-bound plasminogen in blood.
Leukemia, Promyelocytic, Acute
Sudden death due to undiagnosed acute promyelocytic leukemia: a case report.
Leukocytosis
A mouse model to study the alterations in haemostatic and inflammatory parameters induced by Lonomia achelous caterpillar haemolymph.
Leukocytosis
Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation syndrome who actually developed thromboembolism.
Linear IgA Bullous Dermatosis
Plasmin Plays a Role in the In Vitro Generation of the Linear IgA Dermatosis Antigen LADB97.
Liver Abscess
Hepatic artery thrombosis after adult liver transplantation.
Liver Cirrhosis
Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease.
Liver Cirrhosis
Catabolism of human fibrinogen fragment D in normal subjects and patients with liver cirrhosis.
Liver Cirrhosis
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Liver Cirrhosis
Fibrinolytic Factors in Liver Fibrosis.
Liver Cirrhosis
Fibrinopeptide A and B beta 15-42 in liver cirrhosis.
Liver Cirrhosis
Haemostasis unbalance in Pugh-scored liver cirrhosis: characteristic changes of plasma levels of protein C versus protein S.
Liver Cirrhosis
Histidine-rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis.
Liver Cirrhosis
Importance of measuring plasma thrombin-antithrombin III complex levels when using antithrombin III concentrate therapy in fulminant hepatic failure.
Liver Cirrhosis
Increased concentrations of tumor necrosis factor and interleukin-6 contribute to the hemostatic abnormalities in advanced liver disease.
Liver Cirrhosis
Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
Liver Cirrhosis
Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis.
Liver Cirrhosis
Plasminogen in patients with liver cirrhosis.
Liver Cirrhosis
Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients.
Liver Cirrhosis
Retinoids in liver fibrosis and cancer.
Liver Cirrhosis
The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor.
Liver Cirrhosis
The plasminogen-activating system in hepatic stellate cells.
Liver Cirrhosis
[Alterations of hemostasis in liver cirrhosis of the dog]
Liver Cirrhosis
[Blood coagulation and fibrinolysis in relation to endotoxemia in liver cirrhosis and hepatocellular carcinoma]
Liver Cirrhosis
[Description of a new method of plasminogen determination. Its application to the study of liver cirrhosis]
Liver Cirrhosis
[Plasma serine protease inhibitors in patients with liver cirrhosis]
Liver Cirrhosis
[The mechanism of plasmin activation in the blood of cases with liver cirrhosis.]
Liver Cirrhosis, Alcoholic
Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage.
Liver Cirrhosis, Alcoholic
Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.
Liver Cirrhosis, Alcoholic
Plasminogen in patients with liver cirrhosis.
Liver Cirrhosis, Biliary
Observations of increased levels of blood coagulation factors and other plasma proteins in cholestatic liver disease.
Liver Diseases
Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease.
Liver Diseases
Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance.
Liver Diseases
Changes of coagulation inhibitors and fibrinolysis system in newborn infants with transitory neonatal cholestasis.
Liver Diseases
Circadian rhythms of fibrinogen antithrombin III and plasminogen in chronic liver diseases of increasing severity.
Liver Diseases
Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases.
Liver Diseases
Contribution of sinusoidal endothelial liver cells to liver fibrosis: expression of transforming growth factor-beta 1 receptors and modulation of plasmin-generating enzymes by transforming growth factor-beta 1.
Liver Diseases
Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence.
Liver Diseases
Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis.
Liver Diseases
Low plasminogen levels and liver disease.
Liver Diseases
Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group.
Liver Diseases
Plasma antithrombin III, alpha 2-plasmin inhibitor and plasminogen activities in cases of various liver diseases.
Liver Diseases
Plasma histidine-rich glycoprotein and plasminogen in patients with liver disease.
Liver Diseases
Plasminogen and plasminogen proactivator in liver diseases.
Liver Diseases
Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure.
Liver Diseases
Prognostic significance of antithrombin III, plasminogen and proactivator of plasminogen activity in viral hepatitis.
Liver Diseases
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
Liver Diseases
The alpha2-plasmin inhibitor levels in liver diseases.
Liver Diseases
The fibrinolytic system in human ascites.
Liver Diseases
The immune response to mouse hepatitis virus: expression of monocyte procoagulant activity and plasminogen activator during infection in vivo.
Liver Diseases
The significance of colocalization of plasminogen activator inhibitor-1 and vitronectin in hepatic fibrosis.
Liver Diseases
Thrombin and plasmin generation in patients with liver disease.
Liver Diseases
Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.
Liver Diseases
[Clinical evaluation of measurement of plasma antithrombin III, alpha 2-plasmin inhibitor and plasminogen in various liver disease]
Liver Diseases
[Clinical significance of thrombin-antithrombin III complex and plasmin-alpha 2 plasmin inhibitor complex in chronic liver diseases]
Liver Diseases
[Potential fibrinolytic activity of the blood in jaundice of parenchymal and mechanical origin]
Liver Diseases
[Research on the influence of vasculo-tissue factors on coagulation and on fibrinolysis. IX. Liberation of anticoagulants and plasminogen activators induced by venous stasis in subjects with chronic liver diseases]
Liver Diseases, Alcoholic
The hemostatic defect of chronic liver disease. Kinetic studies using 75Se-selenomethionine.
Liver Failure, Acute
Hepatocyte growth factor and plasminogen activation in fulminant hepatic failure.
Liver Failure, Acute
Importance of measuring plasma thrombin-antithrombin III complex levels when using antithrombin III concentrate therapy in fulminant hepatic failure.
Liver Failure, Acute
Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure.
Liver Failure, Acute
Treatment of severe coagulation disturbances as a condition of improved prognosis in fulminant liver failure.
Lung Diseases
Apoprotein-based synthetic surfactants inhibit plasmic cleavage of fibrinogen in vitro.
Lung Diseases
Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells.
Lung Diseases
Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome.
Lung Diseases
Inhibition of neutrophil elastase-induced interleukin-8 gene expression by urinary trypsin inhibitor in human bronchial epithelial cells.
Lung Diseases
Matrix metalloproteinase-1 activation via plasmin generated on alveolar epithelial cell surfaces.
Lung Diseases
Plasmin improves oedematous blood-gas barrier by cleaving epithelial sodium channels.
Lung Diseases
Serum plasminogen and lung surfactant in the respiratory distress syndrome.
Lung Diseases
The plasminogen activation system in lung disease.
Lung Diseases
[Evaluation of serum thrombomodulin in patients with interstitial pneumonia]
Lung Diseases, Interstitial
The plasminogen activation system: new targets in lung inflammation and remodeling.
Lung Injury
Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36.
Lung Injury
Characterization of low-dose ozone-induced murine acute lung injury.
Lung Injury
Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice.
Lung Injury
Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury.
Lung Injury
Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin.
Lung Injury
Procollagen-III in serum, plasminogen activation and fibronectin in bronchoalveolar lavage fluid during and following irradiation of human lung.
Lung Injury
Pulmonary coagulopathy as a new target in lung injury--a review of available pre-clinical models.
Lung Injury
Rat alveolar epithelial cells concomitantly express plasminogen activator inhibitor-1 and urokinase.
Lung Injury
Suppression of superantigen-induced lung injury and vasculitis by preadministration of human urinary trypsin inhibitor.
Lung Injury
The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.
Lung Injury
Tranexamic acid attenuates oleic-acid-induced pulmonary extravasation.
Lung Neoplasms
Abnormal haemostasis in small cell lung cancer.
Lung Neoplasms
ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway.
Lung Neoplasms
Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer.
Lung Neoplasms
Autoantibodies to plasminogen and their role in tumor diseases.
Lung Neoplasms
Cancer cells release a covalent complex containing disulfide-linked domains from urinary plasminogen activator, neural cell adhesion molecule, and haptoglobin alpha and beta chains.
Lung Neoplasms
Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Lung Neoplasms
Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer.
Lung Neoplasms
Clinical significance of urinary plasminogen and fibrinogen gamma chain as novel potential diagnostic markers for non-small-cell lung cancer.
Lung Neoplasms
Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases.
Lung Neoplasms
Detection of cathepsin B, plasminogen activators and plasminogen activator inhibitor in human non-small lung cancer cell lines.
Lung Neoplasms
DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.
Lung Neoplasms
Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
Lung Neoplasms
G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells.
Lung Neoplasms
HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis.
Lung Neoplasms
Immunological analysis of plasminogen activators from cultured human cancer cells.
Lung Neoplasms
Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer.
Lung Neoplasms
Influence of Stromal Components on Lung Cancer Carcinogenesis.
Lung Neoplasms
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Lung Neoplasms
Modulation of tumor cell motility by plasmin.
Lung Neoplasms
Nitrated and oxidized plasma proteins in smokers and lung cancer patients.
Lung Neoplasms
Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.
Lung Neoplasms
Plasminogen activators and plasmin in lung cancer.
Lung Neoplasms
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Lung Neoplasms
Plasminogen derivatives encoding kringles 1-4 and kringles 1-5 exert indirect antiangiogenic and direct antitumoral effects in experimental lung cancer.
Lung Neoplasms
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
Lung Neoplasms
Prognostic significance of blood coagulation tests in lung cancer.
Lung Neoplasms
Serpins promote cancer cell survival and vascular co-option in brain metastasis.
Lung Neoplasms
Serum levels of alpha1-antitrypsin and alpha2-macroglobulin in lung cancer.
Lung Neoplasms
Surface ?-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target.
Lung Neoplasms
The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer.
Lung Neoplasms
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.
Lung Neoplasms
The plasminogen activation system and its role in lung cancer. A review.
Lung Neoplasms
The role of inflammatory cells and their proteases in extravascular fibrinolysis.
Lung Neoplasms
Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors.
Lung Neoplasms
Urokinase-like plasminogen activators of unusually high molecular weight secreted by a cell line derived from a human lung cancer case.
Lupus Erythematosus, Systemic
Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Plasminogen activation in plasma of patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Risk factors for thrombosis in lupus patients.
Lupus Erythematosus, Systemic
[Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome].
Lupus Erythematosus, Systemic
[Regulation of coagulo-fibrinolytic activity and lupus anticoagulants in systemic lupus erythematosus]
Lupus Nephritis
?2AP is associated with the development of lupus nephritis through the regulation of plasmin inhibition and inflammatory responses.
Lupus Nephritis
Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis.
Lupus Nephritis
[The functional activity of plasminogen activators in the blood plasma and urine of patients with lupus nephritis]
Lyme Disease
Binding of human plasminogen and urokinase-type plasminogen activator to the Lyme disease spirochete, Borrelia burgdorferi.
Lyme Disease
Binding of human plasminogen to Borrelia burgdorferi.
Lyme Disease
Borrelia spirochetes upregulate release and activation of matrix metalloproteinase gelatinase B (MMP-9) and collagenase 1 (MMP-1) in human cells.
Lyme Disease
Endogenous and Borrowed Proteolytic Activity in the Borrelia.
Lyme Disease
Plasmin-coated borrelia Burgdorferi degrades soluble and insoluble components of the mammalian extracellular matrix.
Lyme Disease
Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice.
Lymphadenopathy
Plasminogen deficiency as a rare cause of conjunctivitis and lymphadenopathy.
Lymphangioleiomyomatosis
Imbalanced plasminogen system in lymphangioleiomyomatosis: potential role of serum response factor.
Lymphangioma, Cystic
Factors affecting coagulation: fibrinolysis in chronic subdural fluid collections.
Lymphangioma, Cystic
[The pathogenesis of chronic subdural hematomas and hydromas in children]
Lymphatic Metastasis
Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation.
Lymphatic Metastasis
Plasminogen Activation System in Rectal Adenocarcinoma.
Lymphatic Metastasis
The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study.
Lymphatic Metastasis
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Lymphoma
A T-cell-related proteinase expressed by T-lymphoma cells activates their endogenous pro-urokinase.
Lymphoma
Blood plasminogen (profibrinolysin) levels in patients with leukemia and lymphoma.
Lymphoma
Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix.
Lymphoma, Non-Hodgkin
Enhancement of the radiation effect by fibrinolysin and quantitative pattern of the change of tumor radiosensitivity.
Macrophage Activation Syndrome
Pharmacological targeting of plasmin prevents lethality in a murine model of macrophage activation syndrome.
Macrophage Activation Syndrome
The multifaceted role of plasminogen in inflammation.
Macular Degeneration
Hemorrhagic age-related macular degeneration managed with vitrectomy, subretinal injection of tissue plasminogen activator, gas tamponade, and upright positioning.
Macular Degeneration
Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization.
Macular Degeneration
Inhibitors of the proteolytic activity of urokinase type plasminogen activator.
Macular Degeneration
Intracameral concentrations of the fibrinolytic system components in patients with age-related macular degeneration.
Macular Degeneration
Intravitreal Bevacizumab, Plasminogen, and Pneumatic Retinopexy for Subfoveal Hemorrhage in Age-Related Macular Degeneration.
Macular Degeneration
OPTICAL COHERENCE TOMOGRAPHY FINDINGS AND SURGICAL OUTCOMES OF TISSUE PLASMINOGEN ACTIVATOR-ASSISTED VITRECTOMY FOR SUBMACULAR HEMORRHAGE SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Macular Degeneration
Subretinal hemorrhage removal with multiple retinotomy sites in age-related macular degeneration.
Macular Degeneration
Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trial.
Macular Degeneration
Tissue plasminogen activator-assisted vitrectomy for submacular hemorrhage due to age-related macular degeneration.
Macular Degeneration
Use of autologous plasmin during vitrectomy for diabetic maculopathy.
Macular Degeneration
Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: a comparison of submacular hemorrhage/membrane removal and submacular tissue plasminogen activator-assisted pneumatic displacement.
Macular Degeneration
[The intravitreal application of the tissue plasminogen activator in the treatment of submacular hemorrhage--a case report]
Macular Degeneration
[Treatment of hematomas in age related macular degeneration by vitrectomy and subretinal injection of r-tPA: Preliminary results (French translation of the article)].
Macular Edema
Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy.
Macular Edema
Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema.
Macular Edema
Intrasurgical plasmin enzyme in diabetic macular edema.
Macular Edema
Intravitreal autologous plasmin as a therapeutic modality for diffuse diabetic macular edema.
Macular Edema
Intravitreal Injection of Autologous Plasmin Enzyme for Macular Edema Associated with Branch Retinal Vein Occlusion.
Macular Edema
Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion.
Macular Edema
Intravitreal plasmin without associated vitrectomy as a treatment for refractory diabetic macular edema.
Macular Edema
Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion.
Macular Edema
Pharmacologic Vitreolysis in Diabetic Retinopathy.
Macular Edema
Predictability of vitreous detachment following intravitreal plasmin injection in diabetic macular edema associated with vitreomacular traction.
Macular Edema
Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema.
Macular Edema
Use of autologous plasmin during vitrectomy for diabetic maculopathy.
Macular Edema
[Enzymatic vitrectomy by intravitreal autologous plasmin injection, as initial treatment for diffuse diabetic macular edema.]
Malaria
Acquisition of human plasminogen facilitates complement evasion by the malaria parasite Plasmodium falciparum.
Malaria
Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice.
Malaria
Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes.
Malaria
Plasminogen activators are not required in the erythrocytic life cycle of malaria parasites.
Malaria
Plasmodium falciparum proteases hydrolyze plasminogen, generating angiostatin-like fragments.
Mastitis
Acute mastitis induces upregulation of expression of plasminogen activator-related genes by blood monocytes and neutrophils in dairy ewes.
Mastitis
Changes in milk protein fraction as affected by subclinical mastitis.
Mastitis
Characterization of hemolytic activity of Staphylococcus aureus strains isolated from bovine mastitic milk.
Mastitis
Development of magnetic nanoparticle based calorimetric assay for the detection of bovine mastitis in cow milk.
Mastitis
E. coli proteolytic activity in milk and casein breakdown.
Mastitis
Effect of frequent milkings on milk NAGase, plasmin, trypsin inhibitory capacity and the quality of whey as the growth medium for mastitis pathogens.
Mastitis
Effect of subclinical mastitis on milk plasminogen and plasmin compared with that on sodium, antitrypsin and N-acetyl-beta-D-glucosaminidase.
Mastitis
Effects of added plasmin on the formation and rheological properties of rennet-induced skim milk gels.
Mastitis
Plasmin and plasminogen in bovine milk: a relationship with involution?
Mastitis
Polymorphonuclear neutrophils and Escherichia coli proteases involved in proteolysis of casein during experimental E. coli mastitis
Mastitis
Reevaluation of vitamin E supplementation of dairy cows: bioavailability, animal health and milk quality.
Mastitis
Tailor made plasmin substrates as potential diagnostic tool to test for mastitis.
Mastocytoma
Plasminogen activator production from murine mastocytoma cells. Dissociation of plasminogen activator and histamine production by sodium butyrate.
Measles
Antibody spectrum and anticomplementary activity of a plasmin-treated human immunoglobulin preparation.
Measles
Avoidance of oxidative-stress perturbation in yeast bioprocesses by proteomic and genomic biostrategies?
Measles
Measles antibodies, anti-proteinase and plasminogen distribution in serum and plasma from patients affected with multiple sclerosis and patients affected with non-neurological diseases.
Melanoma
A potential role for the plasmin(ogen) system in the posttranslational cleavage of the neural cell adhesion molecule L1.
Melanoma
A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen).
Melanoma
Active transforming growth factor-beta in human melanoma cell lines: no evidence for plasmin-related activation of latent TGF-beta.
Melanoma
Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo.
Melanoma
Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.
Melanoma
Binding of tissue-type plasminogen activator to human melanoma cells.
Melanoma
Characterization of seven human melanoma cell lines: melanogenesis and secretion of plasminogen activators.
Melanoma
Comparative electrophoretic analysis of human and porcine plasminogen activators in SDS-polyacrylamide gels containing plasminogen and casein.
Melanoma
Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates.
Melanoma
Different roles for plasminogen activators and metalloproteinases in melanoma metastasis.
Melanoma
Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines.
Melanoma
Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
Melanoma
Fibrinolysis activity promotes tumor invasiveness of B16 melanoma cell lines through a reconstituted gel matrix.
Melanoma
Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Melanoma
Glycosylation at Asn-184 inhibits the conversion of single-chain to two-chain tissue-type plasminogen activator by plasmin.
Melanoma
High tPA-expression in primary melanoma of the limb correlates with good prognosis.
Melanoma
Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor.
Melanoma
Immunohistochemical localisation of tissue plasminogen activator and urokinase in the vessel wall.
Melanoma
Immunological characterization of plasminogen activators in human mixed saliva.
Melanoma
In vivo inhibition of angiogenesis by a soluble form of melanotransferrin.
Melanoma
Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody.
Melanoma
Inhibition of B16BL6 melanoma invasion by tyrosine and phenylalanine deprivation is associated with decreased secretion of plasminogen activators and increased plasminogen activator inhibitors.
Melanoma
Kinetic studies of plasminogen activation by epithelial tissue plasminogen activator.
Melanoma
Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator.
Melanoma
Low dose adjuvant angiostatin decreases hepatic micrometastasis in murine ocular melanoma model.
Melanoma
Mechanism of the stimulatory effect of phorbol 12-myristate 13-acetate on cellular production of plasminogen activator.
Melanoma
Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
Melanoma
Melanotransferrin induces human melanoma SK-Mel-28 cell invasion in vivo.
Melanoma
Modulation of plasminogen activation and type IV collagenase activity by a synthetic peptide derived from the laminin A chain.
Melanoma
Modulation of tumor cell motility by plasmin.
Melanoma
Molecular species of plasminogen activators secreted by normal and neoplastic human cells.
Melanoma
Partial purification and characterization of epidermal plasminogen activator and their inhibitor.
Melanoma
Plasmin in pericellular proteolysis and cellular invasion.
Melanoma
Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.
Melanoma
Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions.
Melanoma
Plasminogen activators in human malignant melanoma.
Melanoma
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
Melanoma
Proteolytic enzymes and plasminogen activator in melanoma.
Melanoma
Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line.
Melanoma
Regulation of plasminogen activation: a role for melanotransferrin (p97) in cell migration.
Melanoma
Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3.
Melanoma
Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes.
Melanoma
Serine enzymes released by cultured neoplastic cells.
Melanoma
Spatial orientation of tissue-type plasminogen activator bound at the melanoma cell surface.
Melanoma
Spitz naevi may express components of the plasminogen activation system.
Melanoma
Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: a key phenomenon for cell invasion.
Melanoma
Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy.
Melanoma
Synthesis and refolding of human tissue-type plasminogen activator in Bacillus subtilis.
Melanoma
Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
Melanoma
TGF-? signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells.
Melanoma
TGF-beta inhibits human cutaneous melanoma cell migration and invasion through regulation of the plasminogen activator system.
Melanoma
The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis.
Melanoma
The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice.
Melanoma
The involvement of thrombin RGD in metastasis: characterization of a cryptic adhesive site.
Melanoma
The plasminogen activation system in melanoma cell lines and in melanocytic lesions.
Melanoma
The tissue-type plasminogen activator story.
Melanoma
Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
Melanoma
Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas.
Melanoma
Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Melanoma
Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.
Melanoma
[The role of proteolytic enzymes in skin neoplasm progression and development of metastasis]
Melanoma, Experimental
Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion.
Melanoma, Experimental
Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin.
Melanosis
Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma.
Melanosis
Effect of tranexamic acid on melasma: a clinical trial with histological evaluation.
Melanosis
Laser-assisted delivery of tranexamic acid for melasma: Pilot study using a novel 1927 nm fractional thulium fiber laser.
Meningioma
[A plasminogen regulation system in brain tumors].
Meningitis
Angiostrongylus cantonensis: efficacy of albendazole-dexamethasone co-therapy against infection-induced plasminogen activators and eosinophilic meningitis.
Meningitis
Elevation of plasminogen activators in cerebrospinal fluid of mice with eosinophilic meningitis caused by Angiostrongylus cantonensis.
Meningitis
Enhancement of tissue plasminogen activator-catalyzed plasminogen activation by Escherichia coli S fimbriae associated with neonatal septicaemia and meningitis.
Meningitis, Bacterial
Role of the urokinase plasminogen activator system in patients with bacterial meningitis.
Meningococcal Infections
Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease.
Menorrhagia
Antifibrinolytics for heavy menstrual bleeding.
Menorrhagia
Browplasminin, a condensed tannin with anti-plasmin activity isolated from an aqueous extract of Brownea grandiceps Jacq. flowers.
Menorrhagia
Induction of endometrial plasminogen activator-inhibitor 1: a possible mechanism contributing to the effect of intrauterine levonorgestrel in the treatment of menorrhagia.
Menorrhagia
The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid.
Menorrhagia
Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas.
Menorrhagia
Tranexamic acid: a review of its use in the management of menorrhagia.
Menorrhagia
[Changes of peroxidase, plasminogen and fibrinolytic activity on menorrhagia induced by IUDS and the effect of treatment with vitamin E]
Mesenteric Ischemia
Diagnostic value of plasminogen activity level in acute mesenteric ischemia.
Mesothelioma
Expression of plasminogen activator and plasminogen activator inhibitor by rat mesothelioma induced by asbestos.
Mesothelioma
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Metabolic Syndrome
Association of Metabolic Syndrome with Serum Adipokines in Community-Living Elderly Japanese Women: Independent Association with Plasminogen Activator-Inhibitor-1.
Metabolic Syndrome
Controlled Exposure of Humans with Metabolic Syndrome to Concentrated Ultrafine Ambient Particulate Matter Causes Cardiovascular Effects.
Metabolic Syndrome
Sex-differences in the impact of metabolic syndrome on tissue plasminogen activator-induced recanalization.
Metabolic Syndrome
[The influence of antihypertensive agents on plasmatic and vascular-thrombocytic homeostasis in metabolic syndrome]
Metabolic Syndrome
[The markers of dysfunction of endothelium and cytokine profile in patients with metabolic syndrome and abdominal obesity.]
Metabolism, Inborn Errors
Inherited thrombophilia in pediatric ischemic stroke: an Egyptian study.
Metabolism, Inborn Errors
Stroke in children: inherited and acquired factors and age-related variations in the presentation of 48 paediatric patients.
Mouth Neoplasms
A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma.
Mouth Neoplasms
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Mouth Neoplasms
Plasminogen activation system in oral cancer: Relevance in prognosis and therapy (Review).
Moyamoya Disease
Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality.
Mucocele
Proteolytic enzymes in salivary extravasation mucoceles.
Mucocutaneous Lymph Node Syndrome
Low tissue plasminogen activator relative to plasminogen activator inhibitor-1 as a marker of cardiac complication in children with Kawasaki disease.
Mucositis
A controlled, cross-sectional exploratory study on markers for the plasminogen system and inflammation in crevicular fluid samples from healthy, mucositis and peri-implantitis sites.
Mucositis
Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature.
Mucositis
Molecular pathogenesis of plasminogen Hakodate: the second Japanese family case of severe type I plasminogen deficiency manifested late-onset multi-organic chronic pseudomembranous mucositis.
Multiple Myeloma
Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients.
Multiple Myeloma
The role of plasmin in the pathogenesis of murine multiple myeloma.
Multiple Sclerosis
Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation.
Multiple Sclerosis
Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.
Multiple Sclerosis
Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro.
Multiple Sclerosis
Common genetic variants in the plasminogen activation pathway are not associated with multiple sclerosis.
Multiple Sclerosis
Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice.
Multiple Sclerosis
Measles antibodies, anti-proteinase and plasminogen distribution in serum and plasma from patients affected with multiple sclerosis and patients affected with non-neurological diseases.
Multiple Sclerosis
Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system.
Multiple Sclerosis
Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage.
Multiple Sclerosis
Plasminogen deficiency and thrombosis after plasmapheresis therapy for multiple sclerosis.
Multiple Sclerosis
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
Multiple Sclerosis
Plasminogen in cerebrospinal fluid originates from circulating blood.
Multiple Sclerosis
Validation of semaphorin 7A and ala-?-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis.
Multiple Sclerosis
[The kinin and plasmin systems of the blood serum and cerebro- spinal fluid in patients with multiple sclerosis and schizophrenia]
Mumps
Antibody spectrum and anticomplementary activity of a plasmin-treated human immunoglobulin preparation.
Mumps
Avoidance of oxidative-stress perturbation in yeast bioprocesses by proteomic and genomic biostrategies?
Muscular Diseases
The plasminogen activation system in skeletal muscle regeneration: antagonistic roles of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1).
Muscular Dystrophies
Plasma plasmin inhibitors in Duchenne-type progressive muscular dystrophy.
Muscular Dystrophy, Duchenne
Alpha-enolase plasminogen receptor in myogenesis.
Muscular Dystrophy, Duchenne
Plasma plasmin inhibitors in Duchenne-type progressive muscular dystrophy.
Muscular Dystrophy, Duchenne
Plasmin generation dependent on alpha-enolase-type plasminogen receptor is required for myogenesis.
Musculoskeletal Diseases
Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease.
Myocardial Infarction
A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators.
Myocardial Infarction
A double-blind randomised dose-effect trial of anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction. The APSAC Research Group.
Myocardial Infarction
A placebo-controlled patency study of intravenous anisoylated plasminogen streptokinase activator complex 30U in acute myocardial infarction.
Myocardial Infarction
A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units.
Myocardial Infarction
A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial.
Myocardial Infarction
A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1.
Myocardial Infarction
A sequential study of plasma histidine-rich glycoprotein and plasminogen in patients with acute myocardial infarction and deep vein thrombosis.
Myocardial Infarction
A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction.
Myocardial Infarction
Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase.
Myocardial Infarction
Achievement of coronary artery patency by use of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Myocardial Infarction
Activation of coagulation and fibrinolysis after rehabilitative exercise in patients with coronary artery disease.
Myocardial Infarction
Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator.
Myocardial Infarction
Acute coronary occlusion and reperfusion. Reliability of angiographic classification and grading.
Myocardial Infarction
Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries.
Myocardial Infarction
Acute myocardial infarction in the young--the role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Myocardial Infarction
Acute myocardial infarction: is streptokinase really as effective as tissue plasminogen activator?
Myocardial Infarction
After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study.
Myocardial Infarction
AIMS. The design and conduct of a multicentre mortality study comparing placebo and anisoylated plasminogen streptokinase activator complex 30 units intravenously for the treatment of acute myocardial infarction of less than 6 hours duration. UK APSAC Advisory Committee.
Myocardial Infarction
An evaluation of fibrinolysin therapy in acute myocardial infarction.
Myocardial Infarction
An interim report of a double-blind placebo-controlled recanalisation study of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Myocardial Infarction
An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC).
Myocardial Infarction
An Uncommon Complication of Streptokinase: Large Spontaneous Iliopsoas Hematoma.
Myocardial Infarction
Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.
Myocardial Infarction
Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Myocardial Infarction
Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.
Myocardial Infarction
Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: a placebo-controlled arteriographic coronary recanalization study.
Myocardial Infarction
Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction.
Myocardial Infarction
Anisoylated plasminogen streptokinase activator complex versus streptokinase in acute myocardial infarction. Preliminary results of a randomised study.
Myocardial Infarction
Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Myocardial Infarction
Anti-clotting drugs best in afternoon.
Myocardial Infarction
Antibodies to factor XII are distinct from antibodies to prothrombin in patients with the anti-phospholipid syndrome.
Myocardial Infarction
Antibodies to prothrombin crossreact with plasminogen in patients developing myocardial infarction.
Myocardial Infarction
Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model.
Myocardial Infarction
Antiplatelet and anticoagulant therapy during coronary thrombolysis.
Myocardial Infarction
Assessment of left ventricular function in a randomised study of intravenous anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction. Preliminary results of the European Multicentre Study (Belgian Centres).
Myocardial Infarction
Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction.
Myocardial Infarction
Biological risk factors for sudden death in patients with coronary artery disease and without heart failure.
Myocardial Infarction
Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Myocardial Infarction
Biotechnological production of recombinant tissue plasminogen activator protein (reteplase) from transplastomic tobacco cell cultures.
Myocardial Infarction
Cardiac tamponade early after thrombolysis for acute myocardial infarction: a rare but not reported hemorrhagic complication.
Myocardial Infarction
Characterization of plasmin-induced platelet aggregation.
Myocardial Infarction
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Myocardial Infarction
Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction.
Myocardial Infarction
Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2).
Myocardial Infarction
Clinical outcome of percutaneous coronary intervention with antecedent mutant t-PA administration for acute myocardial infarction.
Myocardial Infarction
Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study.
Myocardial Infarction
Comparative efficacy of primary angioplasty with stent implantation and thrombolysis in restoring basal coronary artery flow in acute ST segment elevation myocardial infarction: quantitative assessment using the corrected TIMI frame count.
Myocardial Infarction
Comparative tolerability profiles of thrombolytic agents. A review.
Myocardial Infarction
Comparative tolerance and complications in a multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Myocardial Infarction
Comparison in acute myocardial infarction of anisoylated plasminogen streptokinase activator complex versus heparin evaluated by simultaneous thallium-201/technetium-99m pyrophosphate tomography.
Myocardial Infarction
Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.
Myocardial Infarction
Comparison of intravenous anisoylated plasminogen streptokinase activator complex with intracoronary streptokinase in acute myocardial infarction.
Myocardial Infarction
Comparison of results of intravenous infusion of anistreplase versus streptokinase in acute myocardial infarction.
Myocardial Infarction
Comparison of the safety and tolerance of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.
Myocardial Infarction
Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction.
Myocardial Infarction
Coronary artery disease, myocardial infarction, and brain embolism.
Myocardial Infarction
Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Myocardial Infarction
Critical role for white blood cell NAD(P)H oxidase-mediated plasminogen activator inhibitor-1 oxidation and ventricular rupture following acute myocardial infarction.
Myocardial Infarction
Current issues concerning thrombolytic therapy for acute myocardial infarction.
Myocardial Infarction
Dependence of assessment of coronary artery reperfusion during acute myocardial infarction on angiographic criteria and interobserver variability.
Myocardial Infarction
Depression of factor XII-dependent fibrinolytic activity in survivors of acute myocardial infarction at risk of reinfarction.
Myocardial Infarction
Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI).
Myocardial Infarction
Design of novel thrombolytic agents via domain modifications.
Myocardial Infarction
Discrepant changes in plasminogen by two different assays in patients receiving streptokinase.
Myocardial Infarction
Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction.
Myocardial Infarction
Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
Myocardial Infarction
Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction.
Myocardial Infarction
Dose-related efficacy and bleeding complications of double-chain tissue plasminogen activator in acute myocardial infarction. The Wellcome Tissue Plasminogen Activator Study Group.
Myocardial Infarction
Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.
Myocardial Infarction
Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. AIMS Trial Study Group.
Myocardial Infarction
Effect of post-solubilization conditions on the yield and efficiency of recombinant streptokinase purification at large-scale.
Myocardial Infarction
Effect of reperfusion on electrocardiographic and enzymatic infarct size: results of a randomized multicenter study of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) versus intracoronary streptokinase in acute myocardial infarction.
Myocardial Infarction
Effectiveness and safety of a single intravenous bolus injection of tissue-type plasminogen activator in acute myocardial infarction. Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST) Investigators.
Myocardial Infarction
Effects of Bulbus allii macrostemi on clinical outcomes and oxidized low-density lipoprotein and plasminogen in unstable angina/non-ST-segment elevation myocardial infarction patients.
Myocardial Infarction
Effects of intravenous SM-9527 (double-chain tissue plasminogen activator) on left ventricular function in the chronic stage of acute myocardial infarction.
Myocardial Infarction
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.
Myocardial Infarction
Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction.
Myocardial Infarction
Effects on infarct size and left ventricular function of early intravenous injection of anistreplase in acute myocardial infarction. The APSIM Study Investigators.
Myocardial Infarction
Electrocardiogram during experimental coronary thrombolysis.
Myocardial Infarction
Electrocardiographic and enzymatic infarct size in a randomised study of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Myocardial Infarction
Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators.
Myocardial Infarction
Evaluation of 2 intravenous thrombolytic agents (anisoylated plasminogen streptokinase activator complex versus streptokinase) in patients with acute myocardial infarction.
Myocardial Infarction
Evaluation of the efficacy and safety of anisoylated plasminogen streptokinase activator complex in early myocardial infarction. Preliminary results.
Myocardial Infarction
Expression of a novel chimeric-truncated tPA in Pichia pastoris with improved biochemical properties.
Myocardial Infarction
Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction.
Myocardial Infarction
Fibrinolysis and plasminogen concentration in aortic intima in relation to death following myocardial infarction.
Myocardial Infarction
Fibrinolytic and plasmin inhibitor activities in patients with acute myocardial infarction.
Myocardial Infarction
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Myocardial Infarction
Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
Myocardial Infarction
Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries.
Myocardial Infarction
Histidine-rich glycoprotein in thrombolytic therapy: has it clinical relevance?
Myocardial Infarction
Human fibrinogen heterogeneity. A study of limited fibrinogen degradation.
Myocardial Infarction
Imbalance of plasminogen activator inhibitor-I/ tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction.
Myocardial Infarction
Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group.
Myocardial Infarction
Impairment of the blood-brain barrier: a potential surrogate delineating the determinants of cerebral bleeding caused by fibrinolytic drugs.
Myocardial Infarction
Importance of ST-segment depression as a determinant of ventricular premature complex frequency after thrombolysis for acute myocardial infarction. Tissue Plasminogen Activator: Toronto (TPAT) Study Group.
Myocardial Infarction
Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS)
Myocardial Infarction
Improving thrombolysis with encapsulated plasminogen activators and clinical relevance to myocardial infarction and stroke.
Myocardial Infarction
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators.
Myocardial Infarction
Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction.
Myocardial Infarction
Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI-1 gene.
Myocardial Infarction
Increased survival after APSAC: 30-day and 12-month mortality data from the APSAC Intervention Mortality Study.
Myocardial Infarction
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Myocardial Infarction
Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.
Myocardial Infarction
Intracoronary streptokinase versus intravenous anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.
Myocardial Infarction
Intracoronary thrombolysis in acute myocardial infarction.
Myocardial Infarction
Intracoronary thrombolysis in evolving myocardial infarction.
Myocardial Infarction
Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction. Preliminary data from a randomised multicentre study.
Myocardial Infarction
Intravenous bolus application of streptokinase and of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Clinical and haemostaseological findings.
Myocardial Infarction
Intravenous fibrinolytic therapy of acute myocardial infarction: new perspectives from plasminogen activators?
Myocardial Infarction
Intravenous Thrombolysis for Acute Ischemic Stroke After Recent Myocardial Infarction: Case Series and Systematic Review.
Myocardial Infarction
Intravenous thrombolytic treatment for acute myocardial infarction. Effects of early intervention and early examination.
Myocardial Infarction
Left ventricular function after anisoylated plasminogen streptokinase activator complex.
Myocardial Infarction
Lingual haematoma after treatment with alteplase (recombinant tissue plasminogen activator) for acute myocardial infarction.
Myocardial Infarction
Lipoprotein(a) and the significance of the association between platelet glycoprotein IIIa polymorphisms and the risk of premature myocardial infarction.
Myocardial Infarction
Lipoprotein(a) levels in patients with myocardial infarction treated with anistreplase: no prediction of efficacy but inverse correlation with plasminogen activation in non-patency.
Myocardial Infarction
Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. AIMS Trial Study Group.
Myocardial Infarction
Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Myocardial Infarction
Making a case for the right "-ase" in acute ischemic stroke: alteplase, tenecteplase, and reteplase.
Myocardial Infarction
Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Myocardial Infarction
Monitoring of Functional Plasminogen in Blood of Patients Receiving Fibrinolytics.
Myocardial Infarction
Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator.
Myocardial Infarction
Monitoring of plasmin and plasminogen activator activity in blood of patients under fibrinolytic treatment by reteplase.
Myocardial Infarction
Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Myocardial Infarction
Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.
Myocardial Infarction
Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function.
Myocardial Infarction
Natural inhibitors and fibrinogen/fibrin degradation products in patients with myocardial infarction.
Myocardial Infarction
New developments in thrombolytic therapy.
Myocardial Infarction
One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction.
Myocardial Infarction
Overview: rationale of thrombolysis in treating acute myocardial infarction.
Myocardial Infarction
Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction.
Myocardial Infarction
Pathophysiology and prognostic significance of Holter-detected ST segment depression after myocardial infarction. The Tissue Plasminogen Activator: Toronto (TPAT) Study Group.
Myocardial Infarction
Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction.
Myocardial Infarction
Pharmacology of thrombolytic drugs.
Myocardial Infarction
Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men.
Myocardial Infarction
Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Myocardial Infarction
Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin.
Myocardial Infarction
Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII.
Myocardial Infarction
Plasminogen regulates cardiac repair after myocardial infarction through its non-canonical function in stem cell homing to the infarcted heart.
Myocardial Infarction
Platelet-dependent thrombin generation after in vitro fibrinolytic treatment.
Myocardial Infarction
Prehospital administration of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Myocardial Infarction
Prehospital thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.
Myocardial Infarction
Preliminary safety and tolerance data obtained in the comparative study of anisoylated plasminogen streptokinase activator complex versus heparin.
Myocardial Infarction
Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries.
Myocardial Infarction
Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Myocardial Infarction
Production and purification of urokinase: a comprehensive review.
Myocardial Infarction
Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Myocardial Infarction
Prolonged low-dose thrombolytic therapy: a novel adjunctive strategy in the management of an infected right atrial thrombus.
Myocardial Infarction
Properties of molecular variants of tissue-type plasminogen activator.
Myocardial Infarction
Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.
Myocardial Infarction
Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
Myocardial Infarction
Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.
Myocardial Infarction
Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection.
Myocardial Infarction
Rapid resolution of ST elevation and prediction of clinical outcome in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activator): results of the Israeli Study of Early Intervention in Myocardial Infarction.
Myocardial Infarction
Rash after treatment with anistreplase.
Myocardial Infarction
Recombinant tissue plasminogen activator: a brief review.
Myocardial Infarction
Reduction of myocardial infarct size by doxycycline: a role for plasmin inhibition.
Myocardial Infarction
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Myocardial Infarction
Regulation of nonproteolytic active site formation in plasminogen.
Myocardial Infarction
Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Myocardial Infarction
Reocclusion three months after successful thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activating complex.
Myocardial Infarction
Reperfusion in acute myocardial infarction. A multicentre randomised trial of early intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in the United States.
Myocardial Infarction
Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans.
Myocardial Infarction
Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
Myocardial Infarction
Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction.
Myocardial Infarction
Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarction.
Myocardial Infarction
Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Myocardial Infarction
Significance of initial ST segment elevation and depression for the management of thrombolytic therapy in acute myocardial infarction. European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator.
Myocardial Infarction
Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Myocardial Infarction
Spinal epidural hematoma associated with tissue plasminogen activator treatment of acute myocardial infarction.
Myocardial Infarction
ST-segment analysis: a useful marker for reperfusion after thrombolysis with APSAC? The Belgian EMS Study Group.
Myocardial Infarction
Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells.
Myocardial Infarction
Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1.
Myocardial Infarction
Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.
Myocardial Infarction
Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.
Myocardial Infarction
Tenecteplase (TNK tissue plasminogen activator): A new fibrinolytic for the acute treatment of myocardial infarction.
Myocardial Infarction
Textilinins from Pseudonaja textilis textilis. Characterization of two plasmin inhibitors that reduce bleeding in an animal model.
Myocardial Infarction
The APSAC interventional mortality study (AIMS) trial: mortality data.
Myocardial Infarction
The effect of thrombolytic therapy with anisoylated plasminogen streptokinase activator complex on the indicators of myocardial salvage.
Myocardial Infarction
The fibrinolytic system and use of fibrinolysin in myocardial infarction; preliminary report.
Myocardial Infarction
The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction.
Myocardial Infarction
The membrane attack complex of complement contributes to plasmin-induced synthesis of platelet-activating factor by endothelial cells and neutrophils.
Myocardial Infarction
The safety of anistreplase from the placebo-controlled AIMS study (anistreplase Intervention Mortality Study). The AIMS Study Group.
Myocardial Infarction
The safety of automatic versus manual blood pressure cuffs for patients receiving thrombolytic therapy.
Myocardial Infarction
The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk.
Myocardial Infarction
The thrombolytic paradox.
Myocardial Infarction
The tissue-type plasminogen activator story.
Myocardial Infarction
Thermal stability of the three domains of streptokinase studied by circular dichroism and nuclear magnetic resonance.
Myocardial Infarction
Third generation plasminogen activators in the treatment of acute myocardial infarction.
Myocardial Infarction
Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome.
Myocardial Infarction
Thrombolysin therapy in myocardial infarction.
Myocardial Infarction
Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators.
Myocardial Infarction
Thrombolytic agents--an overview.
Myocardial Infarction
Thrombolytic therapy and acute aortic dissection.
Myocardial Infarction
Thrombolytic therapy in acute coronary thrombosis.
Myocardial Infarction
Thrombolytic therapy in acute myocardial infarction in the elderly.
Myocardial Infarction
Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin.
Myocardial Infarction
Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.
Myocardial Infarction
Tissue-type plasminogen activator: a historical perspective and personal account.
Myocardial Infarction
Tissue-type plasminogen activator: characteristics, applications and production technology.
Myocardial Infarction
Translational initiatives in thrombolytic therapy.
Myocardial Infarction
Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex in a district hospital. Efficacy data.
Myocardial Infarction
Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex in a district hospital. Tolerance data.
Myocardial Infarction
Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.
Myocardial Infarction
Understanding the enzymology of fibrinolysis and improving thrombolytic therapy.
Myocardial Infarction
Use of thrombolytic drugs in non-coronary disorders.
Myocardial Infarction
Usefulness of late coronary thrombolysis (recombinant tissue-type plasminogen activator) in preserving left ventricular function in acute myocardial infarction.
Myocardial Infarction
Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
Myocardial Infarction
Value of electrocardiographic scoring systems for the assessment of thrombolytic therapy in acute myocardial infarction. The European Cooperative Study Group for Recombinant Tissue Type Plasminogen Activator.
Myocardial Infarction
Value of fibrinolysin in management of myocardial infarction. A preliminary report.
Myocardial Infarction
Value of myocardial defect size measured by thallium-201 SPECT: results of a multicenter trial comparing heparin and a new fibrinolytic agent.
Myocardial Infarction
Variability of thrombolytic coronary reperfusion: an angiographic study of streptokinase and anistreplase.
Myocardial Infarction
Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Myocardial Infarction
Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Myocardial Infarction
Ventricular arrhythmias during treatment with alteplase (recombinant tissue plasminogen activator) in suspected acute myocardial infarction.
Myocardial Infarction
[A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs]
Myocardial Infarction
[A double-blind comparative study of intracoronary administration of GE-0943 and urokinase: multicenter study]
Myocardial Infarction
[A trial of the use of a new thrombolytic preparation--recombinant tissue-type plasminogen activator--in myocardial infarct patients]
Myocardial Infarction
[Actilyse (a recombinant tissue-type plasminogen activator] in the treatment of acute myocardial infarct. Comparison of the effects of Actilyse and streptokinase]
Myocardial Infarction
[Alterations of plasma plasminogen and fibrinogen, serum fibrin degradation products and degree of ADP induced platelet aggregation in acute myocardial infarction (author's transl)]
Myocardial Infarction
[An echographic study of left ventricular function in acute myocardial infarct undergoing thrombolysis]
Myocardial Infarction
[An economic assessment of the use of abciximab as a coronary angioplasty preparation in the Italian health-care context]
Myocardial Infarction
[Anisoylated plasminogen streptokinase complex during the acute phase of myocardial infarction. Results of a multicenter double-blind study versus heparin]
Myocardial Infarction
[Antithrombogenic properties of the vascular walls and intravascular platelet activation in ischemic heart disease]
Myocardial Infarction
[Behavior of tissue plasminogen activators and plasmin inhibitors in experimental myocardial infarct with and without trasylol]
Myocardial Infarction
[Bolus injection of anisoylated plasminogen-streptokinase activator complex (BRL 26921) as an alternative concept of systemic lysis in acute myocardial infarct]
Myocardial Infarction
[Changes in fibrinolysis system in patients with acute myocardial infarction in intracoronary administration of fibrinolysin with heparin]
Myocardial Infarction
[Changes in the coagulation and anticoagulation systems of blood in myocardial infarct during the process of treatment with anticoagulants and fibrinolysin]
Myocardial Infarction
[Clinical features in 65 patients with acute myocardial infarction underwent successful thrombolytic therapy post cardiopulmonary resuscitation]
Myocardial Infarction
[Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator]
Myocardial Infarction
[Content of fibrinogen degradation products, soluble fibrin and the fibrinolytic activity of blood in myocardial infarct]
Myocardial Infarction
[Effect of fibrinolysin and heparin on the kinetic properties of the thrombocytes and the oxidation-reduction processes in myocardial infarct]
Myocardial Infarction
[Effectiveness of early use of fibrinolysin in acute myocardial infarct under conditions of emergency aid]
Myocardial Infarction
[Effects of intravenous administration of nasaruplase, a plasminogen pro-activator, on left ventricular function and systemic hemodynamics in a canine model of acute myocardial infarction]
Myocardial Infarction
[Electro-mechanical dissociation concomitant with myocardial reperfusion in the acute phase of myocardial infarction]
Myocardial Infarction
[Fibrinolysis or angioplasty in acute myocardial infarction?]
Myocardial Infarction
[Fibrinolytic and plasmin inhibitor activities in normal subjects and patients with acute myocardial infarction (author's transl)]
Myocardial Infarction
[Fibrinolytics: from the thrombolysis to the processes of blood vessels growth and remodeling, neurogenesis, carcinogenesis and fibrosis].
Myocardial Infarction
[Formation of left ventricular thrombus in acute myocardial infarction: significance of the determination of fibrinogen, of products of fibrinogen degradation, and of plasminogen]
Myocardial Infarction
[Functional disorders of thrombocytes and fibrinase activity in patients with myocardial infarct and chronic coronary insufficiency in the stage of exacerbation]
Myocardial Infarction
[Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events]
Myocardial Infarction
[Interrelation of the blood kallikrein-kinin and anticoagulation systems in experimental myocardial infarct]
Myocardial Infarction
[Intracoronary administration of fibrinolysin in acute myocardial infarct]
Myocardial Infarction
[Intravenous thrombolytic therapy in acute infarct of the myocardium]
Myocardial Infarction
[Ischemic cardiopathy (VIII). Thrombolysis with plasminogen activator in myocardial infarct]
Myocardial Infarction
[Plasmin and streptokinase in the treatment of myocardial infarction]
Myocardial Infarction
[Plasminogen activators as thrombolytic agents in myocardial infarction]
Myocardial Infarction
[Results and limits of fibrin-unspecific thrombolysis in acute myocardial infarct]
Myocardial Infarction
[State of the blood coagulation system in patients with myocardial infarct and chest pain and the changes in it during the use of anticoagulants and fibrinolysin]
Myocardial Infarction
[Study of new thrombolytic agents in myocardial infarction: a multicenter randomized trial (APSAC versus rt-PA)]
Myocardial Infarction
[STUDY OF THE EFFECTIVENESS OF THE USE OF FIBRINOLYSIN IN MYOCARDIAL INFARCT.]
Myocardial Infarction
[Study on the influence of vasculo-tissular factors on coagulation and fibrinolysis. X. Release of anticoagulants and plasminogen activators after induced venous stasis and behavior of the coagulative-fibrinolytic system in subjects with recent myocardial infarct]
Myocardial Infarction
[The effect of fibrinolysin and streptokinase preparations on the course and prognosis of acute myocardial infarction]
Myocardial Infarction
[The effect of fibrinolysin with heparin and thrombolytin on blood coagulation indices in myocardial infarct patients with thromboembolic complications]
Myocardial Infarction
[The fibrinolysis system in recurrent myocardial infarction]
Myocardial Infarction
[Various problems in the therapy of myocardial infarcts with fibrinolysin and heparin]
Myocardial Ischemia
Acute myocardial ischemia in a patient with heterozygous alpha-2-plasmin inhibitor deficiency.
Myocardial Ischemia
The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: comparison of plasma levels in arterial and coronary venous blood.
Myocardial Ischemia
The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair Urokinase attenuates ventricular remodeling.
Myocardial Ischemia
Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
Myocardial Ischemia
[Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia]
Myocardial Ischemia
[Effect of agents used in the therapy of acute ischemic heart disease on the histomorphological changes in the myocardium in acute dystrophy]
Myocardial Ischemia
[Gender differences in the state of the system of hemostasis in patients with ischemic heart disease]
Myocardial Ischemia
[Lipoprotein (a) and plasminogen in atherosclerosis]
Myocarditis
[Fermental (plasmin) blood system in patients with acute viral myocarditis]
Myoma
The relationship between urokinase plasminogen activator/plasminogen activator inhibitor type-1 expression in myoma/myometrium and mechanism of uterine artery occlusion by laparoscopy for uterine myoma treatment.
Myopia
The plasminogen protein is associated with high myopia as revealed by the iTRAQ-based proteomic analysis of the aqueous humor.
Myotonic Dystrophy
Assay of pig growth hormone preparations for metabolic activities in the rat and in man.
Myxoma
Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor.
Myxoma
Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways.
Myxoma
Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets.
Myxoma
Transplant vasculopathy: viral anti-inflammatory serpin regulation of atherogenesis.
Nasal Polyps
Plasminogen activators in human nasal polyps and mucosa.
Neoplasm Metastasis
4-Heterocyclohexanone-based inhibitors of the serine protease plasmin.
Neoplasm Metastasis
A comparison of cyclohexanone and tetrahydro-4H-thiopyran-4-one 1,1-dioxide as pharmacophores for the design of peptide-based inhibitors of the serine protease plasmin.
Neoplasm Metastasis
A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
Neoplasm Metastasis
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
Neoplasm Metastasis
Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA.
Neoplasm Metastasis
Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.
Neoplasm Metastasis
Activity Regulation by Fibrinogen and Fibrin of Streptokinase from Streptococcus Pyogenes.
Neoplasm Metastasis
ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway.
Neoplasm Metastasis
Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis.
Neoplasm Metastasis
Alpha-Enolase: Emerging Tumor-Associated Antigen, Cancer Biomarker, and Oncotherapeutic Target.
Neoplasm Metastasis
Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression.
Neoplasm Metastasis
Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.
Neoplasm Metastasis
Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase.
Neoplasm Metastasis
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
Neoplasm Metastasis
Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.
Neoplasm Metastasis
Annexin A2 expression during cellular differentiation in myeloid cell lines.
Neoplasm Metastasis
Annexin A2 regulates the levels of plasmin, S100A10 and Fascin in L5178Y cells.
Neoplasm Metastasis
Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells.
Neoplasm Metastasis
Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action.
Neoplasm Metastasis
Anticoagulants and cancer. A review.
Neoplasm Metastasis
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Neoplasm Metastasis
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Neoplasm Metastasis
Bacterial metastasis: the host plasminogen system in bacterial invasion.
Neoplasm Metastasis
Bacterial plasminogen activators and receptors.
Neoplasm Metastasis
Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Neoplasm Metastasis
Cancer invasion and metastasis: changing views.
Neoplasm Metastasis
Cancer metastasis: biological and clinical aspects.
Neoplasm Metastasis
Cancer therapy targeting the fibrinolytic system.
Neoplasm Metastasis
Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
Neoplasm Metastasis
Cellular mechanisms regulating non-haemostatic plasmin generation.
Neoplasm Metastasis
Characterization of the cellular binding site for the urinary trypsin inhibitor.
Neoplasm Metastasis
Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
Neoplasm Metastasis
Circulating fibrinolysin in a case of prostatic carcinoma with bony metastases.
Neoplasm Metastasis
Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.
Neoplasm Metastasis
Clinical evidence for correlation of insufficient tissue oxygen supply (hypoxia) and tumor-associated proteolysis in squamous cell carcinoma of the head and neck.
Neoplasm Metastasis
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.
Neoplasm Metastasis
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Neoplasm Metastasis
Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.
Neoplasm Metastasis
Coordinate regulation of fibronectin matrix assembly by the plasminogen activator system and vitronectin in human osteosarcoma cells.
Neoplasm Metastasis
Correlation of fibrinolytic activity with invasion and metastasis of R3230 AC rat mammary carcinoma cell lines.
Neoplasm Metastasis
Correlation of tissue and blood plasminogen activation system in breast cancer.
Neoplasm Metastasis
Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases.
Neoplasm Metastasis
CSF levels of growth factors and plasminogen activators in leptomeningeal metastases.
Neoplasm Metastasis
Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.
Neoplasm Metastasis
Decrease in pulmonary metastases: potentiation of nitrogen mustard effect by heparin and fibrinolysin.
Neoplasm Metastasis
Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells.
Neoplasm Metastasis
Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1).
Neoplasm Metastasis
Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation.
Neoplasm Metastasis
Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
Neoplasm Metastasis
Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug.
Neoplasm Metastasis
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Neoplasm Metastasis
Dexamethasone-induced plasminogen activator inhibitor: characterization, purification, and preparation of monoclonal antibodies.
Neoplasm Metastasis
Different roles for plasminogen activators and metalloproteinases in melanoma metastasis.
Neoplasm Metastasis
Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145.
Neoplasm Metastasis
Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1? pathway.
Neoplasm Metastasis
Effect of aprotinin on metastasis of Lewis lung tumor in mice.
Neoplasm Metastasis
Effect of human fibrinolysin on hepatic metastases in simulated colon carcinoma in rats.
Neoplasm Metastasis
Enterolactone Suppresses Proliferation, Migration and Metastasis of MDA-MB-231 Breast Cancer Cells Through Inhibition of uPA Induced Plasmin Activation and MMPs-Mediated ECM Remodeling
Neoplasm Metastasis
Exploitation of plasmin(ogen) by bacterial pathogens of veterinary significance.
Neoplasm Metastasis
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Neoplasm Metastasis
Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.
Neoplasm Metastasis
Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells.
Neoplasm Metastasis
Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation.
Neoplasm Metastasis
Expression of Tissue Factor Pathway Inhibitor 2 in Human Pancreatic Carcinoma and its Effect on Tumor Growth, Invasion, and Migration in vitro and in vivo.
Neoplasm Metastasis
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.
Neoplasm Metastasis
Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma.
Neoplasm Metastasis
Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Neoplasm Metastasis
Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators.
Neoplasm Metastasis
Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells.
Neoplasm Metastasis
Fibrinolytic Activity of Circulating Microvesicles Is Associated with Progression of Breast Cancer.
Neoplasm Metastasis
Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets.
Neoplasm Metastasis
Gender affects skin wound healing in plasminogen deficient mice.
Neoplasm Metastasis
Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells.
Neoplasm Metastasis
Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen.
Neoplasm Metastasis
Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.
Neoplasm Metastasis
Global secretome analysis identifies novel mediators of bone metastasis.
Neoplasm Metastasis
Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
Neoplasm Metastasis
Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.
Neoplasm Metastasis
Guanidinobenzoatase and UPA in high-grade human astrocytomas and after xenografting cell suspensions into the rat cerebral cortex: proteases for metastasis and disease progression.
Neoplasm Metastasis
HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis.
Neoplasm Metastasis
HEPATIC AND PULMONARY METASTASES FROM A RESECTABLE EXPERIMENTAL CECAL CARCINOMA: THE EFFECT OF HEPATIC PERFUSION WITH NITROGEN MUSTARD COMBINED WITH SYSTEMIC HEPARIN AND FIBRINOLYSIN.
Neoplasm Metastasis
Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.
Neoplasm Metastasis
High Migration and Invasion Ability of PGCCs and Their Daughter Cells Associated With the Nuclear Localization of S100A10 Modified by SUMOylation.
Neoplasm Metastasis
HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells.
Neoplasm Metastasis
Hormonal regulation of plasminogen activator in rat hepatoma cells.
Neoplasm Metastasis
Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties.
Neoplasm Metastasis
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Neoplasm Metastasis
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Neoplasm Metastasis
Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion.
Neoplasm Metastasis
Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Neoplasm Metastasis
Influence of Stromal Components on Lung Cancer Carcinogenesis.
Neoplasm Metastasis
Influence of urokinase on cell proliferation and invasion.
Neoplasm Metastasis
Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2.
Neoplasm Metastasis
Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model.
Neoplasm Metastasis
Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion.
Neoplasm Metastasis
Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis.
Neoplasm Metastasis
Inhibition of tumor cell invasion through matrigel by a peptide derived from the domain II region in urinary trypsin inhibition.
Neoplasm Metastasis
Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells.
Neoplasm Metastasis
Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro.
Neoplasm Metastasis
Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells.
Neoplasm Metastasis
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Neoplasm Metastasis
Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells.
Neoplasm Metastasis
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
Neoplasm Metastasis
Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR).
Neoplasm Metastasis
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
Neoplasm Metastasis
Limited proteolysis of angiogenin by elastase is regulated by plasminogen.
Neoplasm Metastasis
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Neoplasm Metastasis
Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
Neoplasm Metastasis
Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
Neoplasm Metastasis
Mechanisms of cellular invasiveness: a comparison of amnion invasion in vitro and metastatic behavior in vivo.
Neoplasm Metastasis
Met-HGF/SF: tumorigenesis, invasion and metastasis.
Neoplasm Metastasis
Metastasis of human colon tumor cells in vivo: correlation with the overexpression of plasminogen activators and 72 kDa gelatinase.
Neoplasm Metastasis
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Neoplasm Metastasis
Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation.
Neoplasm Metastasis
Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
Neoplasm Metastasis
Modulation of Ion Channels and Receptors by p11 (S100A10).
Neoplasm Metastasis
Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.
Neoplasm Metastasis
Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines.
Neoplasm Metastasis
Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human glioblastoma cell lines.
Neoplasm Metastasis
Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Neoplasm Metastasis
Molecular mechanisms of protease-mediated tumor invasiveness.
Neoplasm Metastasis
Molecular pattern of ductal pancreatic cancer.
Neoplasm Metastasis
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Neoplasm Metastasis
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).
Neoplasm Metastasis
New Insight on the Role of Plasminogen Receptor in Cancer Progression.
Neoplasm Metastasis
NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
Neoplasm Metastasis
PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
Neoplasm Metastasis
PAI-1 and functional blockade of SNAI1 in breast cancer cell migration.
Neoplasm Metastasis
PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells.
Neoplasm Metastasis
PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.
Neoplasm Metastasis
Phorbol-ester-stimulated human lymphoid cell lines produce a plasminogen activator modulator inducing cell-bound urokinase-type plasminogen activator in malignant tumor cell lines.
Neoplasm Metastasis
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Neoplasm Metastasis
Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy.
Neoplasm Metastasis
Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
Neoplasm Metastasis
Plasminogen Activation System in Rectal Adenocarcinoma.
Neoplasm Metastasis
Plasminogen activation: biochemistry, physiology, and therapeutics.
Neoplasm Metastasis
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Neoplasm Metastasis
Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer.
Neoplasm Metastasis
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
Neoplasm Metastasis
Plasminogen binding and cancer: promises and pitfalls.
Neoplasm Metastasis
Plasminogen receptors: the sine qua non of cell surface plasminogen activation.
Neoplasm Metastasis
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
Neoplasm Metastasis
Posttranscriptional regulation of PAI-1 gene expression.
Neoplasm Metastasis
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Neoplasm Metastasis
Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Neoplasm Metastasis
Prognostic significance of tissue factor pathway inhibitor-2 in pancreatic carcinoma and its effect on tumor invasion and metastasis.
Neoplasm Metastasis
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
Neoplasm Metastasis
Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
Neoplasm Metastasis
Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).
Neoplasm Metastasis
Proteolytic enzymes in proliferation and neoplastic metastases formation.
Neoplasm Metastasis
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Neoplasm Metastasis
Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis.
Neoplasm Metastasis
Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
Neoplasm Metastasis
Rapid identification of urokinase plasminogen activator inhibitors from Traditional Chinese Medicines based on ultrafiltration, LC-MS and in silico docking.
Neoplasm Metastasis
Recent Advances on Plasmin Inhibitors for the Treatment of Fibrinolysis-Related Disorders.
Neoplasm Metastasis
Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice.
Neoplasm Metastasis
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
Neoplasm Metastasis
Reduced secretion of MMPs, plasminogen activators and TIMPS from prostate cancer cells derived by repeated metastasis.
Neoplasm Metastasis
Regulation of plasminogen receptors.
Neoplasm Metastasis
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Neoplasm Metastasis
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
Neoplasm Metastasis
S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma.
Neoplasm Metastasis
S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors.
Neoplasm Metastasis
Seahorse-derived peptide suppresses invasive migration of HT1080 fibrosarcoma cells by competing with intracellular ?-enolase for plasminogen binding and inhibiting uPA-mediated activation of plasminogen.
Neoplasm Metastasis
Secretion of Annexin II via activation of insulin receptor and insulin-like growth factor receptor.
Neoplasm Metastasis
Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator.
Neoplasm Metastasis
Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer.
Neoplasm Metastasis
Serpins promote cancer cell survival and vascular co-option in brain metastasis.
Neoplasm Metastasis
Serpins shield tumor cells from antimetastatic brain defenses.
Neoplasm Metastasis
Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
Neoplasm Metastasis
Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
Neoplasm Metastasis
Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?
Neoplasm Metastasis
Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
Neoplasm Metastasis
Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors.
Neoplasm Metastasis
Spitz naevi may express components of the plasminogen activation system.
Neoplasm Metastasis
Spontaneous metastasis in congenic mice with transgenic breast cancer is unaffected by plasminogen gene ablation.
Neoplasm Metastasis
Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
Neoplasm Metastasis
Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin.
Neoplasm Metastasis
Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion.
Neoplasm Metastasis
Targeted Nanocurcumin Therapy Using Annexin A2 Anitbody Improves Tumor Accumulation and Therapeutic Efficacy Against Highly Metastatic Breast Cancer.
Neoplasm Metastasis
Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells.
Neoplasm Metastasis
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Neoplasm Metastasis
Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
Neoplasm Metastasis
Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in human colon cancer.
Neoplasm Metastasis
TGF-? signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells.
Neoplasm Metastasis
The accumulation of angiostatin-like fragments in human prostate carcinoma.
Neoplasm Metastasis
The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinosarcoma.
Neoplasm Metastasis
The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer.
Neoplasm Metastasis
The elastase-mediated pathway of fibrinolysis.
Neoplasm Metastasis
The fibrinolysis inhibitor ?2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer.
Neoplasm Metastasis
The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis.
Neoplasm Metastasis
The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice.
Neoplasm Metastasis
The mechanism of action of angiostatin: can you teach an old dog new tricks?
Neoplasm Metastasis
The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.
Neoplasm Metastasis
The Multifaceted Role of Plasminogen in Cancer.
Neoplasm Metastasis
The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study.
Neoplasm Metastasis
The plasminogen activation system in tumor growth, invasion, and metastasis.
Neoplasm Metastasis
The plasminogen activation system in tumour invasion and metastasis.
Neoplasm Metastasis
The plasminogen activator inhibitor "paradox" in cancer.
Neoplasm Metastasis
The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.
Neoplasm Metastasis
The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.
Neoplasm Metastasis
The role of plasminogen activators in metastasis.
Neoplasm Metastasis
The role of the plasminogen activation system in angiogenesis and metastasis.
Neoplasm Metastasis
The role of the plasminogen activation system in cancer.
Neoplasm Metastasis
The topology of plasminogen binding and activation on the surface of human breast cancer cells.
Neoplasm Metastasis
The urokinase plasminogen activating system in thyroid cancer: clinical implications.
Neoplasm Metastasis
The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Neoplasm Metastasis
The urokinase plasminogen activator system in breast cancer invasion and metastasis.
Neoplasm Metastasis
The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
Neoplasm Metastasis
The urokinase plasminogen activator system: a target for anti-cancer therapy.
Neoplasm Metastasis
The urokinase receptor as an entertainer of signal transduction.
Neoplasm Metastasis
The urokinase-type plasminogen activator system in cancer metastasis: a review.
Neoplasm Metastasis
The urokinase-type plasminogen activator system in prostate cancer metastasis.
Neoplasm Metastasis
Three are better than one: plasminogen receptors as cancer theranostic targets.
Neoplasm Metastasis
Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells.
Neoplasm Metastasis
Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas.
Neoplasm Metastasis
TRAUMA AS A CAUSE OF LOCALIZATION OF BLOOD-BORNE METASTASES: PREVENTIVE EFFECT OF HEPARIN AND FIBRINOLYSIN.
Neoplasm Metastasis
Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.
Neoplasm Metastasis
Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Neoplasm Metastasis
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Neoplasm Metastasis
Type-1 plasminogen activator inhibitor in human breast carcinomas.
Neoplasm Metastasis
u-PA expression in benign, borderline and malignant ovarian tumors.
Neoplasm Metastasis
uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
Neoplasm Metastasis
Urinary trypsin inhibitor efficiently inhibits urokinase production in tumor necrosis factor-stimulated cells.
Neoplasm Metastasis
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Neoplasm Metastasis
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Neoplasm Metastasis
Urokinase-dependent cell surface proteolysis and cancer.
Neoplasm Metastasis
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Neoplasm Metastasis
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.
Neoplasm Metastasis
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Neoplasm Metastasis
Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
Neoplasm Metastasis
VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis.
Neoplasm Metastasis
[Cell phenotype determines PAI-1 antiproliferative effect - suppressed proliferation of the lung cancer but not prostate cancer cells]
Neoplasm Metastasis
[Determination of plasminogen activator of the head and neck tumor tissue]
Neoplasm Metastasis
[Extracellular matrix degradation enzymes: important factors in liver metastasis of colorectal cancer and good targets for anticancer metastatic therapy]
Neoplasm Metastasis
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Neoplasm Metastasis
[Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis]
Neoplasm Metastasis
[Role of PAI-1 in gynaecological malignancies]
Neoplasm Metastasis
[Role of plasminogen activators in the development of tumors and the process of their metastasis]
Neoplasm Metastasis
[Role of proteases, plasminogen activators, fibrin fibrinogen degradation products and fibrinopeptides in the growth and development of neoplasms and neoplasm metastases]
Neoplasm Metastasis
[The clinical prospects for the study of the plasminogen activation system in breast cancer]
Neoplasm Metastasis
[The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer]
Neoplasm Metastasis
[The role of proteolytic enzymes in skin neoplasm progression and development of metastasis]
Neoplasm Metastasis
[Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms]
Neoplasm Metastasis
[Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer]
Neoplasm Metastasis
[Urokinase-type plasminogen activator (uPA) and its inhibitor--new prognostic factors in oral squamous cell carcinoma]
Neoplasm Micrometastasis
Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma.
Neoplasm, Residual
Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Neoplasms
1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases.
Neoplasms
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
Neoplasms
4-Heterocyclohexanone-based inhibitors of the serine protease plasmin.
Neoplasms
A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.
Neoplasms
A C/T polymorphism in the urokinase-type plasminogen activator gene in colorectal cancer.
Neoplasms
A clinical study on the use of a fluorogenic substrate assay of plasminogen.
Neoplasms
A comparative study of the localization of plasminogen and apolipoprotein(a) in human carcinomas.
Neoplasms
A comparison of cyclohexanone and tetrahydro-4H-thiopyran-4-one 1,1-dioxide as pharmacophores for the design of peptide-based inhibitors of the serine protease plasmin.
Neoplasms
A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
Neoplasms
A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
Neoplasms
A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines.
Neoplasms
A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Neoplasms
A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
Neoplasms
A mediator of cell surface-specific plasmin generation.
Neoplasms
A Multiscale Mathematical Model of Tumour Invasive Growth.
Neoplasms
A new ELISA for use in a 3-ELISA system to assess concentrations of VEGF splice variants and VEGF(110) in ovarian cancer tumors.
Neoplasms
A novel finding of a low-molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of mice.
Neoplasms
A Novel Invadopodia-Specific Marker for Invasive and Pro-Metastatic Cancer Stem Cells.
Neoplasms
A novel mode of intervention with serine protease activity: targeting zymogen activation.
Neoplasms
A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number.
Neoplasms
A novel strategy for the tumor angiogenesis-targeted gene therapy: generation of angiostatin from endogenous plasminogen by protease gene transfer.
Neoplasms
A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
Neoplasms
A plasmin-derived hexapeptide from the carboxyl end of osteocalcin counteracts oxytocin-mediated growth inhibition [corrected] of osteosarcoma cells.
Neoplasms
A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study.
Neoplasms
A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue.
Neoplasms
A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer.
Neoplasms
A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth.
Neoplasms
A site for direct integrin ?v?6·uPAR interaction from structural modelling and docking.
Neoplasms
Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung.
Neoplasms
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.
Neoplasms
Acetylcholine receptor: effects of proteolysis on receptor metabolism.
Neoplasms
Action of antibodies and plasmin on Ehrlich ascites tumour cells.
Neoplasms
Action of heparin and plasminogen inhibitor (EACA) on metastatic tumour spread in an isologous system.
Neoplasms
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
Neoplasms
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
Neoplasms
Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA.
Neoplasms
Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro.
Neoplasms
Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.
Neoplasms
Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.
Neoplasms
Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.
Neoplasms
Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth.
Neoplasms
Alpha 2-macroglobulin in the regulation of pericellular plasminogen activation of human tumor cells.
Neoplasms
Alpha-enolase is upregulated on the cell surface and responds to plasminogen activation in mice expressing a ?133p53? mimic.
Neoplasms
Alpha-Enolase: Emerging Tumor-Associated Antigen, Cancer Biomarker, and Oncotherapeutic Target.
Neoplasms
Alteration of Antithrombin III and D-dimer Levels in Clinically Localized Prostate Cancer.
Neoplasms
Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion.
Neoplasms
An inhibitor of urokinase and tissue plasminogen activators in Dunning R3327H prostate tumors of rats treated with D-Trp6-LH-RH.
Neoplasms
Analysis of NM23 protein and components of plasminogen activation system in tumors of patients with stomach cancer with consideration for disease clinical picture and morphology.
Neoplasms
Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, suppresses tumor growth in mice via impeding both angiogenesis and vascular permeability.
Neoplasms
Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression.
Neoplasms
Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.
Neoplasms
Angiostatic activity of human plasminogen fragments is highly dependent on glycosylation.
Neoplasms
Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26.
Neoplasms
Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression.
Neoplasms
Angiostatin fragments in urine from patients with malignant disease.
Neoplasms
Angiostatin generation by human tumor cell lines: involvement of plasminogen activators.
Neoplasms
Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase.
Neoplasms
Angiostatin is negatively associated with coronary collateral growth in patients with coronary artery disease.
Neoplasms
Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.
Neoplasms
Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo.
Neoplasms
Annexin A2 promotes glioma cell invasion and tumor progression.
Neoplasms
Annexin A2 regulates the levels of plasmin, S100A10 and Fascin in L5178Y cells.
Neoplasms
Annexin II: a plasminogen-plasminogen activator co-receptor.
Neoplasms
Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system.
Neoplasms
Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells.
Neoplasms
Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model.
Neoplasms
Anti-urokinase-type plasminogen activator monoclonal antibodies inhibit the proliferation of human breast cancer cell lines in vitro.
Neoplasms
Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model.
Neoplasms
Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action.
Neoplasms
Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors.
Neoplasms
Anticoagulants and cancer. A review.
Neoplasms
Antifibrinolytic therapy of experimentally grown malignant brain tumors.
Neoplasms
Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Neoplasms
Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan).
Neoplasms
Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein.
Neoplasms
ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer.
Neoplasms
Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Neoplasms
Assessment of breast cancer surgical margins with multimodal optical microscopy: A feasibility clinical study.
Neoplasms
Assessment of plasminogen synthesis in vitro by mouse tumor cells using a competition radioimmunoassay for mouse plasminogen.
Neoplasms
Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis.
Neoplasms
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Neoplasms
Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells.
Neoplasms
Autoantibodies to plasminogen and their role in tumor diseases.
Neoplasms
Baculovirus vector-mediated transfer of sodium iodide symporter and plasminogen kringle 5 genes for tumor radioiodide therapy.
Neoplasms
Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases.
Neoplasms
Beneficial effects of retinoic acid on extracellular matrix degradation and attachment behaviour in follicular thyroid carcinoma cell lines.
Neoplasms
Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer.
Neoplasms
Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Neoplasms
Biological regulation through protein disulfide bond cleavage.
Neoplasms
Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
Neoplasms
Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells.
Neoplasms
Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma.
Neoplasms
Borrelia burgdorferi and other bacterial products induce expression and release of the urokinase receptor (CD87).
Neoplasms
Bradykinin and nitric oxide in infectious disease and cancer.
Neoplasms
Brain tumors and plasmin inhibitors.
Neoplasms
Cancer cells in the blood in simulated colon cancer, resectable and unresectable: effect of fibrinolysin and heparin on growth potential.
Neoplasms
Cancer invasion and metastasis: changing views.
Neoplasms
Cancer metastasis: biological and clinical aspects.
Neoplasms
Cancer therapy targeting the fibrinolytic system.
Neoplasms
Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin.
Neoplasms
Cancer-associated stroke: Pathophysiology, detection and management (Review).
Neoplasms
Causes of venous thrombosis in fifty Chinese patients.
Neoplasms
Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours.
Neoplasms
Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10.
Neoplasms
Cell surface remodeling by plasmin: a new function for an old enzyme.
Neoplasms
Cell surface-dependent generation of angiostatin4.5.
Neoplasms
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Neoplasms
Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
Neoplasms
Cellular mechanisms regulating non-haemostatic plasmin generation.
Neoplasms
Cellular receptors in the regulation of plasmin generation.
Neoplasms
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Neoplasms
Characterization and biological activities of recombinant human plasminogen kringle 1-3 produced in Escherichia coli.
Neoplasms
Characterization of a family of high-molecular-weight plasminogen activators secreted by a lung tumor cell line.
Neoplasms
Characterization of a reduced form of plasma plasminogen as the precursor for angiostatin formation.
Neoplasms
Characterization of seven human melanoma cell lines: melanogenesis and secretion of plasminogen activators.
Neoplasms
Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18.
Neoplasms
Characterization of the cellular binding site for the urinary trypsin inhibitor.
Neoplasms
Characterization of the interaction between tumor necrosis factor-stimulated gene-6 and heparin: implications for the inhibition of plasmin in extracellular matrix microenvironments.
Neoplasms
Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer.
Neoplasms
Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
Neoplasms
Circulating plasminogen activator inhibitor-1 activity: a biomarker for resectable non-small cell lung cancer?
Neoplasms
Clinical evidence for correlation of insufficient tissue oxygen supply (hypoxia) and tumor-associated proteolysis in squamous cell carcinoma of the head and neck.
Neoplasms
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.
Neoplasms
Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer.
Neoplasms
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Neoplasms
Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients.
Neoplasms
Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.
Neoplasms
Clinical trials with anticoagulant and antiplatelet therapies.
Neoplasms
Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Neoplasms
Clot lysis: role of plasminogen activator inhibitors in haemostasis and therapy.
Neoplasms
Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect.
Neoplasms
Combined effects of angiostatin and ionizing radiation in antitumour therapy.
Neoplasms
Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Neoplasms
Combined use of haemostatic system indices for evaluation of upper respiratory tract cancer progression.
Neoplasms
Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis.
Neoplasms
Comparative localization of receptors for plasmin and for urokinase on MCF 7 cells.
Neoplasms
Comparative proteomic analysis reveals cytotoxicity induced by graphene oxide exposure in A549 cells.
Neoplasms
Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.
Neoplasms
Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue.
Neoplasms
Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Neoplasms
Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
Neoplasms
Components of the plasminogen activator system in astrocytes are modulated by tumor necrosis factor-alpha and interleukin-1 beta through similar signal transduction pathways.
Neoplasms
Computational Approaches and Analysis for a Spatio-Structural-Temporal Invasive Carcinoma Model.
Neoplasms
Conflicting results from clinical observations and murine models: what is the role of plasminogen activators in tumor growth?
Neoplasms
Content and characterization of plasminogen activators in human lung tumors and normal lung tissue.
Neoplasms
Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression.
Neoplasms
Coordinate regulation of fibronectin matrix assembly by the plasminogen activator system and vitronectin in human osteosarcoma cells.
Neoplasms
Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells.
Neoplasms
Correlation of tissue and blood plasminogen activation system in breast cancer.
Neoplasms
Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases.
Neoplasms
Cryptic and active plasminogen activators secreted by line 10 tumor cells in culture.
Neoplasms
Crystal structure of the beta-chain of human hepatocyte growth factor-like/macrophage stimulating protein.
Neoplasms
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Neoplasms
Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
Neoplasms
Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.
Neoplasms
Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Neoplasms
Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation.
Neoplasms
Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression.
Neoplasms
Decreased expression of the low-density lipoprotein receptor-related protein-1 (LRP-1) in rats with prostate cancer.
Neoplasms
Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells.
Neoplasms
Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1).
Neoplasms
Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation.
Neoplasms
Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
Neoplasms
Deficiency of plasminogen activator inhibitor-2 results in accelerated tumor growth.
Neoplasms
Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
Neoplasms
Demonstration of fibrin in early stages of experimental metastases.
Neoplasms
Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug.
Neoplasms
Destruction of extracellular matrices containing glycoproteins, elastin, and collagen by metastatic human tumor cells.
Neoplasms
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Neoplasms
Detection of the plasmin system in human mammary pathology using immunofluorescence.
Neoplasms
Development of Recombinant Adeno-Associated Virus Serotype 2/8 Carrying Kringle Domains of Human Plasminogen for Sustained Expression and Cancer Therapy.
Neoplasms
Diagnosis of primary hyperfibrinolysis and in vitro investigation of the inhibitory effects of tranexamic acid in a group of dogs with sarcomas - A pilot study.
Neoplasms
Diagnostic and Prognostic Value of TAT, PIC, TM, and t-PAIC in Malignant Tumor Patients With Venous Thrombosis.
Neoplasms
Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence.
Neoplasms
Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesis.
Neoplasms
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Neoplasms
Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs.
Neoplasms
Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1.
Neoplasms
Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Neoplasms
Differential production of angiostatin by concomitant antitumoral resistance-inducing cancer cells.
Neoplasms
Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer.
Neoplasms
Differential protease expression by cutaneous squamous and basal cell carcinomas.
Neoplasms
Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
Neoplasms
Differential regulation of collagen degradation by rabbit keratocytes and polymorphonuclear leukocytes.
Neoplasms
Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.
Neoplasms
Differential regulation of plasminogen activators by epidermal growth factor in normal and neoplastic human urothelium.
Neoplasms
Dimerization of Fab fragments enables ready screening of phage antibodies that affect hepatocyte growth factor/scatter factor activity on target cells.
Neoplasms
Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
Neoplasms
Directed migration of murine and human tumor cells to collagenases and other proteases.
Neoplasms
DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.
Neoplasms
Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids.
Neoplasms
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Neoplasms
Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1? pathway.
Neoplasms
Effect of aprotinin on metastasis of Lewis lung tumor in mice.
Neoplasms
Effect of autologous transplant of peripheral blood mononuclear cells in combination with proangiogenic factors during experimental revascularization of lower limb ischemia.
Neoplasms
Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis.
Neoplasms
Effect of earthworm (G-90) extract on formation and lysis of clots originated from venous blood of dogs with cardiopathies and with malignant tumors.
Neoplasms
Effect of fibrinolysin on spread of cancer.
Neoplasms
Effect of heparin and plasminogen inhibitor (EACA) in brief and prolonged treatment on intravenously injected tumour cells.
Neoplasms
Effect of heparin and plasminogen inhibitor (EACA) on intravenously injected ascites tumour cells.
Neoplasms
Effect of human Angiostatin protein on human angiogenesis in vitro.
Neoplasms
EFFECT OF PLASMIN THERAPY ON BLOOD COAGULATION AND ON PLASMA PROTEINS IN PATIENTS WITH CANCER.
Neoplasms
Effect of retinoic acid on plasminogen activator expression in human melanoma cells.
Neoplasms
Effect of TGF-beta 1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells.
Neoplasms
Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.
Neoplasms
Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5.
Neoplasms
Effects of Alcohol on Postoperative Adhesion Formation in Ischemic Myocardium and Pericardium.
Neoplasms
Effects of cellular transformation on expression of plasminogen activator inhibitors 1 and 2. Evidence for independent regulation.
Neoplasms
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Neoplasms
Effects of the ethyl acetate fraction of Spatholobi caulis on tumour cell aggregation and migration.
Neoplasms
Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells.
Neoplasms
Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells.
Neoplasms
Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA).
Neoplasms
Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization.
Neoplasms
Elevated plasminogen receptor expression occurs as a degradative phase event in cellular apoptosis.
Neoplasms
Endogenous peptides from biophysical and biochemical fractionation of serum analyzed by matrix-assisted laser desorption/ionization and electrospray ionization hybrid quadrupole time-of-flight.
Neoplasms
Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Neoplasms
Endothelial cell fibrinolytic assembly.
Neoplasms
Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis.
Neoplasms
Enhancement of the radiation effect by fibrinolysin and quantitative pattern of the change of tumor radiosensitivity.
Neoplasms
ENO1 monoclonal antibody inhibits invasion, proliferation and clone formation of cervical cancer cells.
Neoplasms
Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells.
Neoplasms
Estrogen receptor cleavage and plasminogen activation by enzymes in human breast tumor cytosol.
Neoplasms
Evidence for the clinical use of tumour markers.
Neoplasms
Evidence for the functional similarity between tumour cell surface guanidinobenzoatase and tissue type plasminogen activator.
Neoplasms
Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.
Neoplasms
Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
Neoplasms
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Neoplasms
Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.
Neoplasms
Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.
Neoplasms
Expression of 72 kDa type IV collagenase and invasion activity of human glioma cells.
Neoplasms
Expression of a urokinase-type plasminogen activator during tumor growth leads to angiogenesis via galanin activation in tumor-bearing mice.
Neoplasms
Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines.
Neoplasms
Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma.
Neoplasms
Expression of plasminogen activators in basal cell carcinoma.
Neoplasms
Expression of the catalytic activity of plasminogen activator under physiologic conditions.
Neoplasms
Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: purification of the recombinant proteins and generation of polyclonal antibodies in chicken.
Neoplasms
Expression of Tissue Factor Pathway Inhibitor 2 in Human Pancreatic Carcinoma and its Effect on Tumor Growth, Invasion, and Migration in vitro and in vivo.
Neoplasms
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.
Neoplasms
Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
Neoplasms
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.
Neoplasms
Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma.
Neoplasms
Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Neoplasms
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma.
Neoplasms
Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma.
Neoplasms
Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: role of oxygenation status and tumour size.
Neoplasms
Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators.
Neoplasms
Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation.
Neoplasms
Factors involved in the plasminogen activation system in human breast tumours.
Neoplasms
Fermented goat milk consumption improves cardiovascular health during anemia recovery.
Neoplasms
Fibrin and Fibrinolysis in Cancer.
Neoplasms
Fibrinogen and tumor cell metastasis.
Neoplasms
Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
Neoplasms
Fibrinolytic abnormalities associated with progression of pediatric solid tumors.
Neoplasms
Fibrinolytic Activity of Circulating Microvesicles Is Associated with Progression of Breast Cancer.
Neoplasms
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Neoplasms
Flow cytofluorometry in tumour cell receptor analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen activator (uPA).
Neoplasms
From plasminogen to plasmin: role of plasminogen receptors in human cancer.
Neoplasms
Full kringles of plasminogen (aa 1-566) mediate complete regression of human MDA-MB-231 breast tumor xenografted in nude mice.
Neoplasms
Functional evaluation of plasmin formation in primary breast cancer.
Neoplasms
Further inhibition studies on guanidinobenzoatase, a trypsin-like enzyme associated with tumour cells.
Neoplasms
Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets.
Neoplasms
Gender affects skin wound healing in plasminogen deficient mice.
Neoplasms
Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): No overt alteration in phenotype.
Neoplasms
Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells.
Neoplasms
Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen.
Neoplasms
Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.
Neoplasms
Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
Neoplasms
Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells.
Neoplasms
Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
Neoplasms
Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.
Neoplasms
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Neoplasms
Hemostatic and fibrinolytic indices in neonatal foals with presumed septicemia.
Neoplasms
Hemostatic function in cancer patients.
Neoplasms
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
Neoplasms
Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.
Neoplasms
High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Neoplasms
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Neoplasms
High Migration and Invasion Ability of PGCCs and Their Daughter Cells Associated With the Nuclear Localization of S100A10 Modified by SUMOylation.
Neoplasms
Hormonal regulation of plasminogen activator in rat hepatoma cells.
Neoplasms
Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.
Neoplasms
How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines.
Neoplasms
HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.
Neoplasms
Human and canine mammary tumors: A role for urokinase plasminogen activator?
Neoplasms
Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator.
Neoplasms
Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance.
Neoplasms
Human primary colon carcinomas xenografted into nude mice. I. Characterization of plasminogen activators expressed by primary tumors and their xenografts.
Neoplasms
Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment.
Neoplasms
Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.
Neoplasms
Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor.
Neoplasms
Identification of plasminogen in Matrigel and its activation by reconstitution of this basement membrane extract.
Neoplasms
Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy.
Neoplasms
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Neoplasms
Immunocytochemical localization of plasminogen activators in carcinomas in the cervix and vulva.
Neoplasms
Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: correlation with CEA distribution and tumor cell kinetics.
Neoplasms
Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer.
Neoplasms
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Neoplasms
Immunologic detection of the cellular receptor for urokinase plasminogen activator.
Neoplasms
Immunological analysis of plasminogen activators from cultured human cancer cells.
Neoplasms
Immunological analysis of plasminogen activators from normal and transformed hamster cells. Evidence that the plasminogen activators produced by SV40 virus-transformed hamster embryo cells and normal hamster lung cells are antigenically identical.
Neoplasms
Impact of apolipoprotein(a) on in vitro angiogenesis.
Neoplasms
Importance of viability and attachment to an ascites tumor in the release of plasminogen activator.
Neoplasms
In vitro tumor angiogenesis assays: plasminogen lysine binding site 1 inhibits in vitro tumor-induced angiogenesis.
Neoplasms
In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model.
Neoplasms
Inactivation of human anaphylatoxin C5a and C5a des-Arg through cleavage by the plasminogen activator activity of a human fibrosarcoma cell line.
Neoplasms
Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas.
Neoplasms
Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.
Neoplasms
Increased expression of alpha-enolase in c-jun transformed rat fibroblasts without increased activation of plasminogen.
Neoplasms
Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas.
Neoplasms
Increased plasminogen activator inhibition levels in malignancy.
Neoplasms
Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis.
Neoplasms
Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion.
Neoplasms
Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Neoplasms
Induction of the fibrinolytic system by cartilage extract mediates its antiangiogenic effect in mouse glioma.
Neoplasms
Influence of Stromal Components on Lung Cancer Carcinogenesis.
Neoplasms
Influence of urokinase on cell proliferation and invasion.
Neoplasms
Inhibition by bovine endothelial cells of degradation by HT-1080 fibrosarcoma cells of extracellular matrix proteins.
Neoplasms
Inhibition of growth of 3-methylcholanthrene-induced mouse skin tumor by protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate.
Neoplasms
Inhibition of human tumor cell-associated fibrinolysis by vascular bovine smooth muscle cells.
Neoplasms
Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2.
Neoplasms
Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones.
Neoplasms
Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model.
Neoplasms
Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.
Neoplasms
Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking.
Neoplasms
Inhibition of plasmin-mediated prostromelysin-1 activation by interaction of long chain unsaturated fatty acids with kringle 5.
Neoplasms
Inhibition of plasminogen activators and the growth of cultured human tumour cells.
Neoplasms
Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion.
Neoplasms
Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis.
Neoplasms
Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
Neoplasms
Inhibition of tumor cell invasion through matrigel by a peptide derived from the domain II region in urinary trypsin inhibition.
Neoplasms
Inhibition of tumor growth by plasminogen-related protein-B.
Neoplasms
Inhibition of tumor growth correlates with the expression level of a human angiostatin transgene in transfected B16F10 melanoma cells.
Neoplasms
Inhibition of tumor implantation at sites of trauma by plasminogen activators.
Neoplasms
Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin).
Neoplasms
Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells.
Neoplasms
Inhibitors of proteases as anticancer drugs.
Neoplasms
Inhibitors of the protease domain of urokinase-type plasminogen activator.
Neoplasms
Inhibitors of the proteolytic activity of urokinase type plasminogen activator.
Neoplasms
Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro.
Neoplasms
Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells.
Neoplasms
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Neoplasms
Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells.
Neoplasms
Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains.
Neoplasms
Insulin-induced epidermal growth factor activation in vascular smooth muscle cells is ADAM-dependent.
Neoplasms
Integrin alpha(v)beta(3), metalloproteinases, and sphingomyelinase-2 mediate urokinase mitogenic effect.
Neoplasms
Interaction of tissue plasminogen activator inhibitor with cell surface guanidinobenzoatase and urokinase plasminogen activator.
Neoplasms
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
Neoplasms
Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression.
Neoplasms
Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR).
Neoplasms
Intra-articular TSG-6 delivery from heparin-based microparticles reduces cartilage damage in a rat model of osteoarthritis.
Neoplasms
Investigation of serum proteome alterations in human glioblastoma multiforme.
Neoplasms
Involvement of plasmin-mediated extracellular activation of progalanin in angiogenesis.
Neoplasms
Kinin-generating cascade in advanced cancer patients and in vitro study.
Neoplasms
Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78.
Neoplasms
Lactoferrin is a natural inhibitor of plasminogen activation.
Neoplasms
Laminin degradation by human colon carcinoma cells: a role for urinary and tissue plasminogen activators.
Neoplasms
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.
Neoplasms
Lentinan augments skin reaction induced by bradykinin: its correlation with vascular dilatation and hemorrhage responses and antitumor activities.
Neoplasms
Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model.
Neoplasms
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Neoplasms
Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.
Neoplasms
Limited proteolysis of tumor cells increases their plasmin-binding ability.
Neoplasms
Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency.
Neoplasms
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Neoplasms
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Neoplasms
Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
Neoplasms
Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
Neoplasms
Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis.
Neoplasms
Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis.
Neoplasms
Malignant mouse melanoma cells do not form tumors when mixed with cells of a non-malignant subclone: relationships between plasminogen activator expression by the tumor cells and the host's immune response.
Neoplasms
Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
Neoplasms
Maspin inhibits cell migration in the absence of protease inhibitory activity.
Neoplasms
Mathematical modeling of cancer cell invasion of tissue: biological insight from mathematical analysis and computational simulation.
Neoplasms
Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions.
Neoplasms
Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-kappa B activity leading to apoptosis in breast tumors.
Neoplasms
Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas.
Neoplasms
Matrix metalloproteinase-9, -10, and -12, MDM2 and p53 expression in mouse liver during dimethylnitrosamine-induced oxidative stress and genomic injury.
Neoplasms
Matrix metalloproteinases generate angiostatin: effects on neovascularization.
Neoplasms
Measurement of plasminogen activator activity from human fibrosarcoma cells by a new microassay.
Neoplasms
Mechanism of the stimulatory effect of phorbol 12-myristate 13-acetate on cellular production of plasminogen activator.
Neoplasms
Mechanisms and pathobiology of ovulation.
Neoplasms
Mechanisms of cellular invasiveness: a comparison of amnion invasion in vitro and metastatic behavior in vivo.
Neoplasms
Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
Neoplasms
Melanotransferrin induces human melanoma SK-Mel-28 cell invasion in vivo.
Neoplasms
Melanotransferrin stimulates t-PA-dependent activation of plasminogen in endothelial cells leading to cell detachment.
Neoplasms
Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer.
Neoplasms
Metalloproteinases in tumor progression: the contribution of MMP-9.
Neoplasms
Metastasis of human colon tumor cells in vivo: correlation with the overexpression of plasminogen activators and 72 kDa gelatinase.
Neoplasms
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Neoplasms
Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Neoplasms
Micro RNA 146a gene variant / TNF-? / IL-6 / IL-1 ?; A cross-link axis inbetween oxidative stress, endothelial dysfunction and neuro-inflammation in acute ischemic stroke and chronic schizophrenic patients.
Neoplasms
Microassay for the photometric quantitation of cell-associated plasminogen activator using a chromogenic tripeptide substrate.
Neoplasms
Microglial cells prevent nitric oxide-induced neuronal apoptosis in vitro.
Neoplasms
Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.
Neoplasms
Modulation of Ion Channels and Receptors by p11 (S100A10).
Neoplasms
Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor beta.
Neoplasms
Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells.
Neoplasms
Modulation of tumor cell motility by plasmin.
Neoplasms
Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines.
Neoplasms
Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human glioblastoma cell lines.
Neoplasms
Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Neoplasms
Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Neoplasms
Molecular mechanisms of protease-mediated tumor invasiveness.
Neoplasms
Molecular species of plasminogen activators secreted by normal and neoplastic human cells.
Neoplasms
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Neoplasms
Mortality and major complications after emergency laparotomy: A pilot study of risk prediction model development by preoperative blood-based immune parameters.
Neoplasms
Mouse macrophage metalloelastase generates angiostatin from plasminogen and suppresses tumor angiogenesis in murine colon cancer.
Neoplasms
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Neoplasms
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).
Neoplasms
Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Neoplasms
Mutation of human plasminogen kringle 1-5 enhances anti-angiogenic action via increased interaction with integrin alpha(v)beta(3).
Neoplasms
Natural and engineered plasmin inhibitors: applications and design strategies.
Neoplasms
New concepts in fibrinolysis and angiogenesis.
Neoplasms
New Insight on the Role of Plasminogen Receptor in Cancer Progression.
Neoplasms
No association between the 4g/5G polymorphism of the plasminogen activator inhibitor-1 gene promoter and autistic disorder.
Neoplasms
Novel cardiovascular risk factors do not completely explain the higher prevalence of peripheral arterial disease among African Americans. The San Diego Population Study.
Neoplasms
Novel patents and cancer therapies for transforming growth factor-beta and urokinase type plasminogen activator: potential use of their interplay in tumorigenesis.
Neoplasms
NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
Neoplasms
Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue.
Neoplasms
Occurrence of components of fibrinolytic pathways in situ in laryngeal cancer.
Neoplasms
On the changes of plasmin activity caused by radiation treatment in cancer patients and effects of antiplasmin (ipsilon) administration.
Neoplasms
On the contribution of S100A10 and annexin A2 to plasminogen activation and oncogenesis: an enduring ambiguity.
Neoplasms
On the regulation of the plasminogen activator inhibitor-1 gene expression.
Neoplasms
Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management.
Neoplasms
Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.
Neoplasms
Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53.
Neoplasms
p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells.
Neoplasms
p22 is a novel plasminogen fragment with antiangiogenic activity.
Neoplasms
PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
Neoplasms
PAI-1 and functional blockade of SNAI1 in breast cancer cell migration.
Neoplasms
PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck.
Neoplasms
PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis.
Neoplasms
Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides.
Neoplasms
Pathogenesis of venous thromboembolism: when the cup runneth over.
Neoplasms
Pathways of coagulation/fibrinolysis activation in malignancy.
Neoplasms
PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.
Neoplasms
Phorbol-ester-stimulated human lymphoid cell lines produce a plasminogen activator modulator inducing cell-bound urokinase-type plasminogen activator in malignant tumor cell lines.
Neoplasms
Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo.
Neoplasms
Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase.
Neoplasms
Physiological mechanisms for metalloproteinase activation.
Neoplasms
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Neoplasms
Plasmid transfer of plasminogen K1-5 reduces subcutaneous hepatoma growth by affecting inflammatory factors.
Neoplasms
Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy.
Neoplasms
Plasmin cleaves tumor necrosis factor alpha exodomain from sheep follicular endothelium: implication in the ovulatory process.
Neoplasms
Plasmin in pericellular proteolysis and cellular invasion.
Neoplasms
Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitment.
Neoplasms
Plasmin produces an E-cadherin fragment that stimulates cancer cell invasion.
Neoplasms
Plasmin reduction by phosphoglycerate kinase is a thiol-independent process.
Neoplasms
Plasmin releases the anti-tumor peptide from the NC1 domain of collagen XIX.
Neoplasms
Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Neoplasms
Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard.
Neoplasms
Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin.
Neoplasms
Plasmin-catalyzed proteolysis in colorectal neoplasia.
Neoplasms
Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner.
Neoplasms
Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKbeta-mediated NF-kappaB activation.
Neoplasms
Plasmin-tumour necrosis factor interaction in the ovulatory process.
Neoplasms
Plasmin: Its Role in the Extracellular Processing of Progalanin in Tumor Tissue.
Neoplasms
Plasminogen activation and cancer.
Neoplasms
Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.
Neoplasms
Plasminogen activation in human acute leukaemias.
Neoplasms
Plasminogen activation in human leukemia and in normal hematopoietic cells.
Neoplasms
Plasminogen activation in melanocytic neoplasia.
Neoplasms
Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
Neoplasms
Plasminogen activation on tumor cell surface and its involvement in human leukemia.
Neoplasms
Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
Neoplasms
Plasminogen activation transforms the morphology of quiescent 3T3 cell monolayers and initiates growth.
Neoplasms
Plasminogen activation: biochemistry, physiology, and therapeutics.
Neoplasms
Plasminogen activator activity in clonogenic cell populations separated from a murine fibrosarcoma.
Neoplasms
Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo.
Neoplasms
Plasminogen activator and nuclear androgen receptor in rat prostate tumors after treatment with D-Trp-6-LH-RH.
Neoplasms
Plasminogen activator and plasmin-like activities in experimental rat tumours.
Neoplasms
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.
Neoplasms
Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis.
Neoplasms
Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.
Neoplasms
Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.
Neoplasms
Plasminogen activator inhibitor-1 secretion of endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: evidence for a key role of endothelial cells in thrombolytic resistance.
Neoplasms
Plasminogen activator inhibitors in endometrial adenocarcinoma.
Neoplasms
Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions.
Neoplasms
Plasminogen activator regulation by transforming growth factor-beta in normal and neoplastic human urothelium.
Neoplasms
Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Neoplasms
Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Neoplasms
Plasminogen activators (urokinase) mediate neovascularization: possible role in tumor angiogenesis.
Neoplasms
Plasminogen activators and cancer.
Neoplasms
Plasminogen activators and inhibitors in the neuromuscular system: III. The serpin protease nexin I is synthesized by muscle and localized at neuromuscular synapses.
Neoplasms
Plasminogen activators and plasmin in lung cancer.
Neoplasms
Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer.
Neoplasms
Plasminogen activators and plasminogen activator inhibitor before and after surgery in patients with and without gastric malignancy.
Neoplasms
Plasminogen activators and plasminogen activator inhibitor in portal blood from patients with and without gastric malignancy.
Neoplasms
Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
Neoplasms
Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells.
Neoplasms
Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
Neoplasms
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Neoplasms
Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors.
Neoplasms
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Neoplasms
Plasminogen activators and tiaprofenic acid in inflammation. A preliminary study.
Neoplasms
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Neoplasms
Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids.
Neoplasms
Plasminogen activators as markers of tumor colonization potential.
Neoplasms
Plasminogen activators in (pre)malignant conditions of the colorectum.
Neoplasms
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?
Neoplasms
Plasminogen activators in human colorectal neoplasia.
Neoplasms
Plasminogen activators in human colorectal neoplasia: Authors' reply.
Neoplasms
Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype.
Neoplasms
Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas.
Neoplasms
Plasminogen activators in ovarian tumours.
Neoplasms
Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines.
Neoplasms
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
Neoplasms
Plasminogen activators, tissue degradation, and cancer.
Neoplasms
Plasminogen activators: regulators of tumor cell adherence to sites of lower urinary tract surgical trauma.
Neoplasms
PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS.
Neoplasms
Plasminogen and plasminogen proactivator in liver diseases.
Neoplasms
Plasminogen binding and cancer: promises and pitfalls.
Neoplasms
Plasminogen derivatives encoding kringles 1-4 and kringles 1-5 exert indirect antiangiogenic and direct antitumoral effects in experimental lung cancer.
Neoplasms
Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model.
Neoplasms
Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.
Neoplasms
Plasminogen is a master regulator and a potential drug candidate for the healing of radiation wounds.
Neoplasms
Plasminogen is tethered with high affinity to the cell surface by the plasma protein, histidine-rich glycoprotein.
Neoplasms
Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways.
Neoplasms
Plasminogen kringle 5 suppresses gastric cancer via regulating HIF-1? and GRP78.
Neoplasms
Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression.
Neoplasms
Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages.
Neoplasms
Plasminogen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites.
Neoplasms
Plasminogen Receptors in Human Malignancies: Effects on Prognosis and Feasibility as Targets for Drug Development.
Neoplasms
Plasminogen receptors: the sine qua non of cell surface plasminogen activation.
Neoplasms
Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency.
Neoplasms
Plasminogen-dependent fibrinolytic activity in normal human lymphocytes: diminished lymphocyte plasminogen activator in chronic lymphocytic leukemia.
Neoplasms
Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
Neoplasms
PO-17 - Identification of IgG bound to plasminogen in oncologic diseases.
Neoplasms
Polymeric prodrug for release of an antitumoral agent by specific enzymes.
Neoplasms
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
Neoplasms
Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system.
Neoplasms
Posttranscriptional regulation of PAI-1 gene expression.
Neoplasms
Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Neoplasms
Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin.
Neoplasms
Preoperative radiotherapy and extracellular matrix remodeling in rectal mucosa and tumour matrix metalloproteinases and plasminogen components.
Neoplasms
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
Neoplasms
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
Neoplasms
Pro-invasive stimuli and the interacting protein Hsp70 favour the route of alpha-enolase to the cell surface.
Neoplasms
Production of plasminogen activator and plasminogen activator inhibitor by bovine lymphatic endothelial cells: modulation by TNF-alpha.
Neoplasms
Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation.
Neoplasms
Profibrinolytic properties characterize a stably transformed human endothelial cell line.
Neoplasms
Prognostic molecular markers in early breast cancer.
Neoplasms
Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Neoplasms
Prognostic role of tumor-associated proteases in colorectal cancer.
Neoplasms
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.
Neoplasms
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
Neoplasms
Prognostic significance of tissue factor pathway inhibitor-2 in pancreatic carcinoma and its effect on tumor invasion and metastasis.
Neoplasms
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
Neoplasms
Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
Neoplasms
Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
Neoplasms
Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate.
Neoplasms
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Neoplasms
Proteases as prognostic markers in cancer.
Neoplasms
Proteases during the growth of Ehrlich ascites tumor. I. The fibrinolysin system.
Neoplasms
Proteases in human tumors.
Neoplasms
Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
Neoplasms
Proteinase activity in invasive cancer of the breast. Correlation with tumor progression.
Neoplasms
Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.
Neoplasms
Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).
Neoplasms
Proteolysis of CCN1 by plasmin: functional implications.
Neoplasms
Proteolytic and cellular death mechanisms in ovulatory ovarian rupture.
Neoplasms
Proteolytic and metastatic activities of clones derived from a methylcholanthrene-induced murine fibrosarcoma.
Neoplasms
Proteolytic enzymes in proliferation and neoplastic metastases formation.
Neoplasms
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Neoplasms
Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.
Neoplasms
Protumorigenic Activity of Plasminogen Activator Inhibitor-1 Through an Antiapoptotic Function.
Neoplasms
Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
Neoplasms
Purification and identification of a novel and four known serine proteinase inhibitors secreted by human glioblastoma cells.
Neoplasms
Purification of the plasmin receptor from human carcinoma cells and comparison to alpha-enolase.
Neoplasms
Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis.
Neoplasms
Quantification of autoantibodies to plasminogen in plasma of patients with cancer.
Neoplasms
Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer.
Neoplasms
Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
Neoplasms
Quantitative trait locus on chromosome 12q14.1 influences variation in plasma plasminogen levels in the San Antonio Family Heart Study.
Neoplasms
Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures.
Neoplasms
Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator.
Neoplasms
Receptor for plasmin on human carcinoma cells.
Neoplasms
Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice.
Neoplasms
Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma.
Neoplasms
Regional differences in protein production by human adipose tissue.
Neoplasms
Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
Neoplasms
Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance.
Neoplasms
Regulation of collagenolysis and cell death by plasmin within the formative stigma of preovulatory ovine follicles.
Neoplasms
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Neoplasms
Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor.
Neoplasms
Regulation of fibrinolysis by S100A10 in vivo.
Neoplasms
Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells.
Neoplasms
Regulation of matrix metalloproteinases: an overview.
Neoplasms
Regulation of plasminogen receptors.
Neoplasms
Regulation of S100A10 Gene Expression.
Neoplasms
Regulation of the synthesis and secretion of plasminogen activators by endothelial cells.
Neoplasms
Regulation of tumor dormancy and role of microenvironment: a mathematical model.
Neoplasms
Relationship between circulating plasminogen activators and tumor development in mice.
Neoplasms
Relationship between expression of NM23 protein and clinical morphological factors and content of plasminogen activation system components in tumors of patients with gastric cancer.
Neoplasms
Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes.
Neoplasms
Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Neoplasms
Release of various molecular forms of plasminogen activators during culture of human ovarian tumours.
Neoplasms
Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure.
Neoplasms
Revisiting the role of fat mass in the life extension induced by caloric restriction.
Neoplasms
Rhenium-188 labeled recombinant human plasminogen kringle5 (rhk5) and preliminary biodistribution. Evaluation in mice bearing A549 tumours.
Neoplasms
RhGM-CSF in bone marrow transplantation: experience in pediatric patients.
Neoplasms
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Neoplasms
RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells.
Neoplasms
Role of annexin II tetramer in plasminogen activation.
Neoplasms
Role of heparanase in platelet and tumor cell interactions with the subendothelial extracellular matrix.
Neoplasms
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
Neoplasms
Role of integrins in invasion of endometrial cancer cell lines.
Neoplasms
Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo.
Neoplasms
Role of mesenchymal stem cell-derived fibrinolytic factor in tissue regeneration and cancer progression.
Neoplasms
Role of plasminogen activator-plasmin system in tumor angiogenesis.
Neoplasms
Role of plasminogen in matrix breakdown by neoplastic cells.
Neoplasms
Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization.
Neoplasms
Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
Neoplasms
Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.
Neoplasms
Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Neoplasms
S100A10 Has a Critical Regulatory Function in Mammary Tumor Growth and Metastasis: Insights Using MMTV-PyMT Oncomice and Clinical Patient Sample Analysis.
Neoplasms
S100A10 regulates plasminogen-dependent macrophage invasion.
Neoplasms
S100A10, a novel biomarker in pancreatic ductal adenocarcinoma.
Neoplasms
S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors.
Neoplasms
Seahorse-derived peptide suppresses invasive migration of HT1080 fibrosarcoma cells by competing with intracellular ?-enolase for plasminogen binding and inhibiting uPA-mediated activation of plasminogen.
Neoplasms
Secretion of Annexin II via activation of insulin receptor and insulin-like growth factor receptor.
Neoplasms
Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation.
Neoplasms
Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases.
Neoplasms
Secretion of plasminogen activators by human colorectal and gastric tumor explants.
Neoplasms
Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma.
Neoplasms
Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator.
Neoplasms
Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer.
Neoplasms
Sequential dynamics of inflammatory cytokine, angiogenesis inducing factor and matrix degrading enzymes during spontaneous resorption of the herniated disc.
Neoplasms
SERPINE1 intron polymorphisms affecting gene expression are associated with diffuse-type gastric cancer susceptibility.
Neoplasms
Serpins promote cancer cell survival and vascular co-option in brain metastasis.
Neoplasms
Serpins shield tumor cells from antimetastatic brain defenses.
Neoplasms
Serum amyloid A - A prime candidate for identification of neonatal sepsis.
Neoplasms
Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients.
Neoplasms
Serum proteomics for gastric cancer.
Neoplasms
Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.
Neoplasms
Significance of coagulation and fibrinolysis markers for benign and malignant soft tissue tumors.
Neoplasms
Significance of fibrin formation and dissolution in the pathogenesis and treatment of cancer.
Neoplasms
Simultaneous three color and electronic cell volume analysis with a single UV excitation source.
Neoplasms
Single-chain, urokinase-type plasminogen activator in a tumor model linked to metastatic potential.
Neoplasms
Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
Neoplasms
Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.
Neoplasms
Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?
Neoplasms
Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report.
Neoplasms
Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro.
Neoplasms
Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors.
Neoplasms
Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice.
Neoplasms
Spontaneous metastasis in congenic mice with transgenic breast cancer is unaffected by plasminogen gene ablation.
Neoplasms
STIM1/ORAI1-mediated Ca2+ Influx Regulates Enolase-1 Exteriorization.
Neoplasms
Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation.
Neoplasms
Stromal cell involvement in cancer.
Neoplasms
Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
Neoplasms
Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
Neoplasms
Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy.
Neoplasms
Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy.
Neoplasms
Studies on the fibrinolysis in tumor bearing mice. 3. Demonstration of the plasminogen activator in Ehrlich ascites tumor cells.
Neoplasms
Studies on the fibrinolysis in tumor bearing mice. IV. Mechanism of ascites retention with special reference to plasmin activity of tumor cell origin.
Neoplasms
Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation.
Neoplasms
Suppression of integrin alphaupsilonbeta6 by RNA interference in colon cancer cells inhibits extracellular matrix degradation through the MAPK pathway.
Neoplasms
Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin.
Neoplasms
Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor.
Neoplasms
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Neoplasms
Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion.
Neoplasms
Surgical treatment of tumor metastases: general considerations and results.
Neoplasms
Synergism among oxidants, proteinases, phospholipases, microbial hemolysins, cationic proteins, and cytokines.
Neoplasms
Synthesis and biological characterization of protease-activated prodrugs of doxazolidine.
Neoplasms
Synthesis and HPLC analysis of enzymatically cleavable linker consisting of poly(ethylene glycol) and dipeptide for the development of immunoconjugate.
Neoplasms
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Neoplasms
Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
Neoplasms
Synthetic urokinase inhibitors as potential antitumor drugs.
Neoplasms
Targeted Nanocurcumin Therapy Using Annexin A2 Anitbody Improves Tumor Accumulation and Therapeutic Efficacy Against Highly Metastatic Breast Cancer.
Neoplasms
Targeting of the ?6 gene to suppress degradation of ECM via inactivation of the MAPK pathway in breast adenocarcinoma cells.
Neoplasms
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Neoplasms
Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.
Neoplasms
Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
Neoplasms
Tetranectin Binds to the Kringle 1-4 Form of Angiostatin and Modifies Its Functional Activity.
Neoplasms
Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in human colon cancer.
Neoplasms
TGF-?-mediated regulation of plasminogen activators is human telomerase reverse transcriptase dependent in cancer cells.
Neoplasms
The 9E3/CEF4 cytokine: kinetics of secretion, processing by plasmin, and interaction with extracellular matrix.
Neoplasms
The accumulation of angiostatin-like fragments in human prostate carcinoma.
Neoplasms
The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent.
Neoplasms
The chicken Chemotactic and Angiogenic Factor (cCAF), a CXC chemokine.
Neoplasms
The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer.
Neoplasms
The elastase-mediated pathway of fibrinolysis.
Neoplasms
The endogenous peptides of normal human serum extracted from the acetonitrile-insoluble precipitate using modified aqueous buffer with analysis by LC-ESI-Paul ion trap and Qq-TOF.
Neoplasms
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
Neoplasms
The fibrinolysis inhibitor ?2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer.
Neoplasms
The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis.
Neoplasms
The fibrinolytic system in experimental prostate tumor.
Neoplasms
The fibrinolytic system in human ascites.
Neoplasms
The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice.
Neoplasms
The Function of ?2-glycoprotein I in Angiogenesis and Its in Vivo Distribution in Tumor Xenografts.
Neoplasms
The hemostatic system and angiogenesis in malignancy.
Neoplasms
The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.
Neoplasms
The molecular biology of colorectal cancer development and the associated genetic events.
Neoplasms
The Multifaceted Role of Plasminogen in Cancer.
Neoplasms
The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study.
Neoplasms
The plasmin system in human colonic tumors: an immunofluorescence study.
Neoplasms
The plasminogen activation system and its role in lung cancer. A review.
Neoplasms
The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.
Neoplasms
The plasminogen activation system in melanoma cell lines and in melanocytic lesions.
Neoplasms
The plasminogen activation system in tumor growth, invasion, and metastasis.
Neoplasms
The plasminogen activation system in tumour invasion and metastasis.
Neoplasms
The plasminogen activator inhibitor "paradox" in cancer.
Neoplasms
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
Neoplasms
The plasminogen activator system and cancer.
Neoplasms
The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
Neoplasms
The plasminogen-activation system in ovarian tumors.
Neoplasms
The plasminogen-plasmin system in malignancy.
Neoplasms
The procoagulant state of the VX-2 tumor in rabbit lung in vivo--relative accumulation of fibrinogen, prothrombin, plasminogen, antithrombin and heparin cofactor II within the tumor.
Neoplasms
The prognostic value of S100A10 expression in cancer.
Neoplasms
The protease inhibitor bikunin, a novel anti-metastatic agent.
Neoplasms
The relationship of plasminogen activators and oncogenes to tumour invasion.
Neoplasms
The relevance of plasminogen activators to neoplastic growth. A review of recent literature.
Neoplasms
The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
Neoplasms
The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.
Neoplasms
The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications.
Neoplasms
The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.
Neoplasms
The role of lysosomes in cancer chemotherapy. 3. Influence of plasmin on the lysosomes of tumor cells and on the cytocidal effect of mitomycin-C.
Neoplasms
The role of plasminogen in cell-mediated collagen degradation.
Neoplasms
The role of plasminogen-plasmin system in cancer.
Neoplasms
The role of the fibrinolytic system in corneal angiogenesis.
Neoplasms
The role of the plasminogen activation system in cancer.
Neoplasms
The secretion of fibrinolysin by cultured rat ovarian tumor cells.
Neoplasms
The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface.
Neoplasms
The topology of plasminogen binding and activation on the surface of human breast cancer cells.
Neoplasms
The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3.
Neoplasms
The urokinase plasminogen activating system in thyroid cancer: clinical implications.
Neoplasms
The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Neoplasms
The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis.
Neoplasms
The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer.
Neoplasms
The urokinase plasminogen activator system in breast cancer invasion and metastasis.
Neoplasms
The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
Neoplasms
The urokinase plasminogen activator system: a target for anti-cancer therapy.
Neoplasms
The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction.
Neoplasms
The urokinase receptor as a potential target in cancer therapy.
Neoplasms
The urokinase receptor as an entertainer of signal transduction.
Neoplasms
The urokinase receptor associated protein (uPARAP/endo180): a novel internalization receptor connected to the plasminogen activation system.
Neoplasms
The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue.
Neoplasms
The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications.
Neoplasms
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Neoplasms
The urokinase-type plasminogen activator system in cancer metastasis: a review.
Neoplasms
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
Neoplasms
Three are better than one: plasminogen receptors as cancer theranostic targets.
Neoplasms
Three receptor genes for plasminogen related growth factors in the genome of the puffer fish Fugu rubripes.
Neoplasms
Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells.
Neoplasms
Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
Neoplasms
Thromboplastic and fibrinolytic activities of V2 and V7 carcinomas of rabbit, with special reference to fibrin deposition and thrombus formation in the tumors.
Neoplasms
Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro.
Neoplasms
Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.
Neoplasms
Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride.
Neoplasms
Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells.
Neoplasms
Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate.
Neoplasms
Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients.
Neoplasms
Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
Neoplasms
Tranexamic acid can inhibit tongue squamous cell carcinoma invasion in vitro.
Neoplasms
Transcriptional activation of the urokinase receptor gene in invasive colon cancer.
Neoplasms
Transferrin, C3 complement, haptoglobin, plasminogen and alpha 2-microglobulin in patients with urogenital tumors.
Neoplasms
Transformation of immortal, non-tumorigenic osteoblast-like human osteosarcoma cells to the tumorigenic phenotype by nickel sulfate.
Neoplasms
Transforming Growth Factor-Beta and Urokinase Type Plasminogen Interplay in Cancer.
Neoplasms
Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.
Neoplasms
Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Neoplasms
Treatment of cancer patients with infusions of plasmin.
Neoplasms
Treatment of collagen-induced arthritis with recombinant plasminogen-related protein B: a novel inhibitor of angiogenesis.
Neoplasms
Treatment of malignancy by activation of the plasminogen system.
Neoplasms
Tumor associated proteases -- prognostic markers of colorectal cancer.
Neoplasms
Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
Neoplasms
Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice.
Neoplasms
Tumor Necrosis Factor Alpha Modulates the Dynamics of the Plasminogen-Mediated Early Interaction between Bifidobacterium animalis subsp. lactis and Human Enterocytes.
Neoplasms
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Neoplasms
Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.
Neoplasms
Tumorigenicity of EJ-ras oncogene transformed NIH 3T3 cells and expression of plasminogen activators.
Neoplasms
Tumorigenicity of herpesvirus-transformed cells correlates with production of plasminogen activator.
Neoplasms
Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.
Neoplasms
Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Neoplasms
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Neoplasms
Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.
Neoplasms
Type-1 plasminogen activator inhibitor in human breast carcinomas.
Neoplasms
u-PA expression in benign, borderline and malignant ovarian tumors.
Neoplasms
Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.
Neoplasms
Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor.
Neoplasms
uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
Neoplasms
uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells.
Neoplasms
uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.
Neoplasms
uPAR: a versatile signalling orchestrator.
Neoplasms
Update on tumor cell procoagulant factors.
Neoplasms
Upregulation of cell-surface-associated plasminogen activation in cultured keratinocytes by interleukin-1 beta and tumor necrosis factor-alpha.
Neoplasms
Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice.
Neoplasms
Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion.
Neoplasms
Urinary trypsin inhibitor efficiently inhibits urokinase production in tumor necrosis factor-stimulated cells.
Neoplasms
Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
Neoplasms
Urokinase and macrophages in tumour angiogenesis.
Neoplasms
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
Neoplasms
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Neoplasms
Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Neoplasms
Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors.
Neoplasms
Urokinase and tissue plasminogen activators and their PAI-1 inhibitor in tumors of patients with oral mucosal cancer: relationship with the main clinical morphological factors.
Neoplasms
Urokinase expression in mononuclear phagocytes: cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha.
Neoplasms
Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix.
Neoplasms
Urokinase induces receptor mediated brain tumor cell migration and invasion.
Neoplasms
Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active.
Neoplasms
Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas.
Neoplasms
Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes.
Neoplasms
Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth.
Neoplasms
Urokinase receptor orchestrates the plasminogen system in airway epithelial cell function.
Neoplasms
Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells.
Neoplasms
Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer.
Neoplasms
Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
Neoplasms
Urokinase-dependent cell surface proteolysis and cancer.
Neoplasms
Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.
Neoplasms
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Neoplasms
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.
Neoplasms
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Neoplasms
Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
Neoplasms
Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Neoplasms
VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis.
Neoplasms
Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA.
Neoplasms
Visualization of the plasmin receptor on sections of human mammary carcinoma cells.
Neoplasms
Vitronectin in human breast carcinomas.
Neoplasms
Volume 223, Number 2 (1996), in the article "Upregulation of Cell-Surface-Associated Plasminogen Activation in Cultured Keratinocytes by Interleukin-1beta and Tumor Necrosis Factor-alpha," by Michael J. Bechtel, Jeannette Reinartz, Jutta M. Rox, Stefan Inndorf, Birgit M. Schaefer, and Michael D. Kramer, pages 395-404: On page 398
Neoplasms
[A plasminogen regulation system in brain tumors].
Neoplasms
[Adipose tissue as an endocrine organ].
Neoplasms
[Advance in the biology of pancreatic of cancer].
Neoplasms
[Advancement in the diagnosis of disseminated intravascular coagulation for the surgeon]
Neoplasms
[Assessment of variables relative to prethrombotic state after operation in patients with gynecological malignancies]
Neoplasms
[Blood coagulation system in oncological patients treated with rubomycin, adriamycin and carminomycin]
Neoplasms
[Cell interactions in the extracellular matrix in tumoral invasion in mammary pathology]
Neoplasms
[Cell phenotype determines PAI-1 antiproliferative effect - suppressed proliferation of the lung cancer but not prostate cancer cells]
Neoplasms
[Change in endogeous hydrogen sulfide in patients with acute pancreatitis and its relationship to coagulation function].
Neoplasms
[Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia]
Neoplasms
[Chronic recurrent pulmonary thromboembolism associated with sedentary work]
Neoplasms
[Clinical and etiopathogenetic role of plasminogen and metaloproteinase systems in the tumor growth. Pericellular proteolysis of extracellular matrix and tumor growth].
Neoplasms
[Clinical and prognostic significance of tumor-associated proteases in gynecologic oncology]
Neoplasms
[Clinical prospects of tumor-associated proteases and their tissue inhibitors investigation in oncologic patient].
Neoplasms
[Determination of plasminogen activator of the head and neck tumor tissue]
Neoplasms
[Effect of high-dose medroxyprogesterone acetate on coagulative and fibrinolytic factors in patients with gynecological cancers]
Neoplasms
[Effect of large fibrinolysin doses on the degree of hematogenous metastasizing of experimental tumors]
Neoplasms
[Endothelial cell proteases and their modulation by platelets]
Neoplasms
[Experimental and clinical studies on cancer chemotherapy--enhancement of the cytocidal effect of Mitomycin-C by one of lysosome labilizer, plasmin]
Neoplasms
[Extracellular matrix degradation enzymes: important factors in liver metastasis of colorectal cancer and good targets for anticancer metastatic therapy]
Neoplasms
[Hematological disorders in patients with gastric cancer]
Neoplasms
[Hemostatic indices of oncological patients with different forms of jaundice]
Neoplasms
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Neoplasms
[Laser hyperthermia of tumors with the use of golden nanoparticles under the control of optical coherent tomography and acoustothermometry].
Neoplasms
[Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor]
Neoplasms
[Mechanism of formation of blocking factors and method of antiblocking immunotherapy in malignant tumors]
Neoplasms
[Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis]
Neoplasms
[Modern prospects for molecular-biochemical methods for evaluating biological "behavior" of breast neoplasms]
Neoplasms
[Molecular pathways of pancreatic carcinogenesis]
Neoplasms
[New molecular targets in pancreatic cancer]
Neoplasms
[New prognostic and predictive factors in advanced colorectal cancer]
Neoplasms
[On the changes of plasmin activity caused by radiation treatment in cancer patients and effects of antiplasmin (Ipsilon) administration.]
Neoplasms
[Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer]
Neoplasms
[Plasminogen activators in malignant tissues and lungs of mice during metastatic spreading and administration of various pharmacological agents]
Neoplasms
[Plasminogen activators in tumor tissue]
Neoplasms
[Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases]
Neoplasms
[Preparation and functional study of an adenovirus vector expressing human plasminogen kringle 5 gene]
Neoplasms
[Prognostic and predictive factors in breast cancer]
Neoplasms
[Protease activities in gastric and colon cancer tissues]
Neoplasms
[Proteases and breast carcinoma]
Neoplasms
[Regulation of microglial cell function by ATP]
Neoplasms
[Role of PAI-1 in gynaecological malignancies]
Neoplasms
[Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis]
Neoplasms
[Role of plasminogen activator inhibitor type 1 in tumor angiogenesis]
Neoplasms
[Role of plasminogen activators in cancer dissemination. Clinical perspectives]
Neoplasms
[Role of plasminogen activators in the development of tumors and the process of their metastasis]
Neoplasms
[Role of proteases, plasminogen activators, fibrin fibrinogen degradation products and fibrinopeptides in the growth and development of neoplasms and neoplasm metastases]
Neoplasms
[Serum protein fractions in patients with laryngeal cancer undergoing radiation therapy. Possibility as a prognostic factor]
Neoplasms
[Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors].
Neoplasms
[Studies on fibrinolysis and ascites accumulation associated with peritonitis carcinomatosa--inducer of plasminogen activator (IPA) in malignant ascites tumor]
Neoplasms
[Study of coagulation and fibrinolysis in 131 cases of recurrent deep vein thrombosis]
Neoplasms
[Study on the plasma plasminogen activators in patients with malignant gynecologic tumors]
Neoplasms
[The clinical prospects for the study of the plasminogen activation system in breast cancer]
Neoplasms
[The influence of plasmin on the metastasizing of implanted tumors in the rat]
Neoplasms
[The investigation on early diagnosis of the bladder tumor. II: A study on urinary cytology, urinary fibrin/fibrinogen degradation products, tissue fibrin deposition and tissue plasminogen activator activity in patients with bladder tumors (author's transl)]
Neoplasms
[The location of components of fibrinolytic system in laryngeal cancer]
Neoplasms
[The role of proteases in the growth, invasion and spread of cancer cells]
Neoplasms
[The role of proteolytic enzymes in skin neoplasm progression and development of metastasis]
Neoplasms
[The role of urokinase type plasminogen activator in invasion of bile duct carcinoma]
Neoplasms
[The urokinase-type plasminogen activator system and its role in tumor progression].
Neoplasms
[Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms]
Neoplasms
[Tumor plasminogen activators and their clinical significance]
Neoplasms
[Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2]
Neoplasms
[Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]
Neoplasms
[Urokinase plasminogen activation system and its role in cancer progression]
Neoplasms
[Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer]
Neoplasms
[Urokinase-type plasminogen activator (uPA) and its inhibitor--new prognostic factors in oral squamous cell carcinoma]
Neoplasms
[Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia]
Neoplasms, Germ Cell and Embryonal
Evidence for the clinical use of tumour markers.
Nephritis
Identification of an extracellular plasmin binding protein from nephritogenic streptococci.
Nephritis
IgA nephritis associated with plasminogen abnormalities.
Nephritis
Intraglomerular deposition of intact cross-linked fibrin in IgA nephropathy and Henoch-Schönlein purpura nephritis.
Nephritis
Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis.
Nephritis
Opposing effects of interleukin-1 and transforming growth factor-beta on the regulation of tissue-type plasminogen activator and plasminogen activator inhibitor type-1 expression by human mesangial cells.
Nephritis
Participation of kallikrein, coagulation/fibrinolysis parameters in the development of glomerulonephritis.
Nephritis
The occurrence of nephritis plasmin binding protein (SPEB) in the extracellular products of group C nephritogenic Streptococcus zooepidemicus.
Nephrosis
Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria.
Nephrotic Syndrome
Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
Nephrotic Syndrome
Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome.
Nephrotic Syndrome
Association of Plasminuria with Overhydration in Patients with CKD.
Nephrotic Syndrome
Association of Urinary Plasminogen-Plasmin with Edema and Epithelial Sodium Channel Activation in Patients with Nephrotic Syndrome.
Nephrotic Syndrome
Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: An in vitro study using plasma from children with idiopathic nephrotic syndrome.
Nephrotic Syndrome
Inhibition of fibrinolysis by lipoprotein(a).
Nephrotic Syndrome
Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
Nephrotic Syndrome
Mechanisms of renal NaCl retention in proteinuric disease.
Nephrotic Syndrome
Nephrotic syndrome resulting in thromboembolic disease and disseminated intravascular coagulation in a dog.
Nephrotic Syndrome
Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin).
Nephrotic Syndrome
Over- or underfill: not all nephrotic states are created equal.
Nephrotic Syndrome
Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
Nephrotic Syndrome
Plasmin and sodium retention in nephrotic syndrome.
Nephrotic Syndrome
Plasmin in nephrotic urine activates the epithelial sodium channel.
Nephrotic Syndrome
Plasminogen activator in nephrotic syndrome.
Nephrotic Syndrome
Plasminogen and antithrombin III deficiencies in the childhood nephrotic syndrome associated with plasminogenuria and antithrombinuria.
Nephrotic Syndrome
Plasminogen deficiency does not prevent sodium retention in a genetic mouse model of experimental nephrotic syndrome.
Nephrotic Syndrome
Proteinuric diseases with sodium retention: Is plasmin the link?
Nephrotic Syndrome
Regulation of sodium transport by ENaC in the kidney.
Nephrotic Syndrome
Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC.
Nephrotic Syndrome
Urinary Plasmin Activates Collecting Duct ENaC Current in Preeclampsia.
Nephrotic Syndrome
Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria.
Nephrotic Syndrome
Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome.
Nephrotic Syndrome
Use of noninvasive laboratory testing in the prediction of thrombosis in the nephrotic syndrome.
Nephrotic Syndrome
[A coagulation of fibrinolytic study in children with nephrotic syndrome: evaluation of hypercoagulability by measuring with plasmin- alpha 2 plasmin inhibitor complex and FDP D-dimer]
Nephrotic Syndrome
[Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome]
Nervous System Diseases
A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity.
Nervous System Diseases
Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.
Nervous System Diseases
Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
Nervous System Diseases
Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
Nervous System Diseases
Magnitude of Benefit of Combined Endovascular Thrombectomy and Intravenous Fibrinolysis in Large Vessel Occlusion Ischemic Stroke.
Nervous System Diseases
Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial.
Nervous System Neoplasms
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.
Neuralgia
Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury.
Neurilemmoma
Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
Neuritis
Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases.
Neuritis, Autoimmune, Experimental
Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases.
Neuroblastoma
A multimolecular signaling complex including PrPC and LRP1 is strictly dependent on lipid rafts and is essential for the function of tissue plasminogen activator.
Neuroblastoma
Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation.
Neuroblastoma
Binding of tissue-type plasminogen activator to the glucose-regulated protein 78 (GRP78) modulates plasminogen activation and promotes human neuroblastoma cell proliferation in vitro.
Neuroblastoma
Changes in gene expression of kringle domain-containing proteins in murine brains and neuroblastoma cells infected by prions.
Neuroblastoma
Degradation of fibrin-? amyloid co-aggregate: A novel function attributed to ubiquitin.
Neuroblastoma
Modulation of the proteolytic balance plasminogen activator/plasminogen activator inhibitor by enhanced N-myc oncogene expression or application of genistein.
Neuroblastoma
Regulation of neuronal migration and neuritogenesis by distinct surface proteases. Relative contribution of plasmin and a thrombin-like protease.
Neuroblastoma
Role of insulin-like growth factor binding protein-2 and its limited proteolysis in neuroblastoma cell proliferation: modulation by transforming growth factor-beta and retinoic acid.
Neuroblastoma
[Effects of plasminogen and streptokinase on the vital functions of nervous tissue cells in culture]
Neuroblastoma
[Effects of plasminogen, streptokinase and their equimolar complexes with pyruvate kinase on the human neuroblastoma IMR-32 cells]
Neurodegenerative Diseases
An inhibitor of serine proteases, neuroserpin, acts as a neuroprotective agent in a mouse model of neurodegenerative disease.
Neurodegenerative Diseases
Beta-amyloidolysis and glutathione in Alzheimer's disease.
Neurodegenerative Diseases
Plasminogen Activators in Neurovascular and Neurodegenerative Disorders.
Neuroendocrine Tumors
Cleavage of chromogranin A N-terminal domain by plasmin provides a new mechanism for regulating cell adhesion.
Neurofibroma
Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
Neurofibromatoses
Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
Neurofibromatoses
Von Recklinghausen neurofibromatosis and hereditary plasminogen deficiency.
Neuroinflammatory Diseases
Astrocytes regulate the balance between plasminogen activation and plasmin clearance via cell-surface actin.
Neuroinflammatory Diseases
Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease.
Neuroinflammatory Diseases
Hemorrhagic transformation after ischemic stroke in animals and humans.
Neuroinflammatory Diseases
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
Neuroinflammatory Diseases
The plasminogen activation system in neuroinflammation.
Neuroinflammatory Diseases
Using antifibrinolytics to tackle neuroinflammation.
Nevus
TGF-? signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells.
Nevus
[Histochemical studies of transepidermal elimination of nevus cells in nevus cell nevi of the corium]
Nevus
[Indicators of plasminogen activation system and growth factors in the tissue of nevi and skin melanoma].
Noonan Syndrome
Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
Obesity
Assessing Plasmin Generation in Health and Disease.
Obesity
Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity.
Obesity
Haemostatic and other cardiovascular risk factors, and socioeconomic status among middle-aged Finnish men and women.
Obesity
In vivo plasminogen deficiency reduces fat accumulation.
Obesity
Pathogenesis of venous thromboembolism: when the cup runneth over.
Obesity
Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1.
Obesity
Reductions in plasmin inhibitor and fibrinogen predict the improved fibrin clot lysis 6?months after obesity surgery.
Obesity
Relation between the tumor necrosis factor-alpha (TNF-alpha) gene and protein expression, and clinical, biochemical, and genetic markers: age, body mass index and uric acid are independent predictors for an elevated TNF-alpha plasma level in a complex risk model.
Obesity
Risk Factors for Thrombosis Development in Mexican Patients.
Obesity
Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity.
Obesity
Strain- and tissue-dependent induction of plasminogen activator inhibitor-1 gene expression in fasted mice.
Obesity
The effect of BMI on haemostasis: Implications for thrombosis in women's health.
Obesity
[Chronic recurrent pulmonary thromboembolism associated with sedentary work]
Obesity
[Hemostasis profiles in thrombotic disease]
Obesity, Abdominal
Cardiovascular issues in hypogonadism and testosterone therapy.
Obesity, Abdominal
[The markers of dysfunction of endothelium and cytokine profile in patients with metabolic syndrome and abdominal obesity.]
Obstetric Labor, Premature
Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition.
Obstetric Labor, Premature
Uneventful Pregnancy and Delivery after Thrombolysis Plus Thrombectomy for Acute Ischemic Stroke: Case Study and Literature Review.
Obstetric Labor, Premature
[Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor]
Oral Manifestations
Hypoplasminogenaemia, gingival swelling and ulceration.
Osteoarthritis
Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders.
Osteoarthritis
Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Osteoarthritis
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Osteoarthritis
Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Osteoarthritis
Fibrin dissolution in synovial fluid.
Osteoarthritis
Intra-articular TSG-6 delivery from heparin-based microparticles reduces cartilage damage in a rat model of osteoarthritis.
Osteoarthritis
Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients.
Osteoarthritis
Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.
Osteoarthritis
Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis.
Osteoarthritis
Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees.
Osteoarthritis
Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface.
Osteoarthritis
Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet derived growth factor.
Osteoarthritis
Variation patterns of two degradation enzyme systems in articular cartilage in different stages of osteoarthritis: regulation by dehydroepiandrosterone.
Osteoarthritis
[Activity of plasminogen activators and plasmin inhibitors in the joint capsule in various articular diseases (author's transl)]
Osteonecrosis
Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor.
Osteoporosis
Fibrin accumulation secondary to loss of plasmin-mediated fibrinolysis drives inflammatory osteoporosis.
Osteoporosis
Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease.
Osteoporosis, Postmenopausal
??-Antiplasmin is involved in bone loss induced by ovariectomy in mice.
Osteosarcoma
Binding and activation of plasminogen on the surface of osteosarcoma cells.
Osteosarcoma
Humoral hypercalcemia of malignancy.
Osteosarcoma
Induction of morphological transformation, anchorage-independent growth and plasminogen activators in non-tumorigenic human osteosarcoma cells by lead chromate.
Osteosarcoma
Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells.
Osteosarcoma
Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex.
Osteosarcoma
Localization of plasmin activity on osteosarcoma cells: cell surface proteolysis of insulin-like growth factor binding proteins.
Osteosarcoma
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Osteosarcoma
Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors.
Osteosarcoma
Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha.
Osteosarcoma
Synthesis and secretion of plasminogen activators and collagenases in human cells transformed by Kirsten murine sarcoma virus and N-methyl-N'-nitro-N-nitrosoguanidine.
Osteosarcoma
The course of fibrinolytic proteins in children with malignant bone tumours.
Otitis Media
Fibrinolytic activity of middle ear fluid in otitis media with effusion.
Otitis Media
Spontaneous development of otitis media in plasminogen-deficient mice.
Otitis Media
The fibrinolysin system in otitis media with effusion.
Otitis Media with Effusion
Antifibrinolytic activity in middle ear effusion.
Otitis Media with Effusion
Fibrinolytic activity of middle ear fluid in otitis media with effusion.
Otitis Media with Effusion
Plasmin and fibronectin degradation in chronic secretory otitis media.
Otitis Media with Effusion
The fibrinolysin system in otitis media with effusion.
Out-of-Hospital Cardiac Arrest
Relationship Between Severity of Fibrinolysis Based on Rotational Thromboelastometry and Conventional Fibrinolysis Markers.
Ovarian Cysts
Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Ovarian Cysts
Fluid characteristics of benign ovarian cysts: correlation with recurrence after puncture.
Ovarian Cysts
Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids.
Ovarian Neoplasms
Adeno-associated virus-mediated delivery of kringle 5 of human plasminogen inhibits orthotopic growth of ovarian cancer.
Ovarian Neoplasms
Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer.
Ovarian Neoplasms
Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Ovarian Neoplasms
Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer.
Ovarian Neoplasms
Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells.
Ovarian Neoplasms
Evidence for the clinical use of tumour markers.
Ovarian Neoplasms
Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Ovarian Neoplasms
Expression of urokinase-type plasminogen-activator (upa) and its receptor (upar) in human ovarian-cancer cells and in-vitro invasion capacity.
Ovarian Neoplasms
Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
Ovarian Neoplasms
Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma.
Ovarian Neoplasms
The role of annexin A2 in tumorigenesis and cancer progression.
Overweight
Comprehensive Assessment of the Hemostatic System in Polycystic Ovarian Syndrome.
Overweight
Hemostatic status and fibrinolytic response potential at different phases of the menstrual cycle.
Pancreatic Diseases
Plasminogen in pancreatic disease and in pancreatic secretion.
Pancreatic Neoplasms
Generation of multiple angiogenesis inhibitors by human pancreatic cancer.
Pancreatic Neoplasms
Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Pancreatic Neoplasms
Molecular pattern of ductal pancreatic cancer.
Pancreatic Neoplasms
Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer.
Pancreatic Neoplasms
S100A10, a novel biomarker in pancreatic ductal adenocarcinoma.
Pancreatic Neoplasms
Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro.
Pancreatic Neoplasms
[Effects of human plasminogen Kringle 5 gene therapy on pancreatic cancer]
Pancreatitis
Acute pancreatitis in Soweto, South Africa: relationship between trypsinogen load, trypsinogen activation, and fibrinolysis.
Pancreatitis
Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan).
Pancreatitis
Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence.
Pancreatitis
Experimental pancreatitis and fibrinolysin.
Pancreatitis
Indirect strong inhibition by acid-stable trypsin-plasmin inhibitor (ASTPI) of the activations of elastase and plasma fibrinolysis in a dog model of acute pancreatitis.
Pancreatitis
Peritoneal lavage efficiently eliminates protease-alpha-2-macroglobulin complexes and components of the contact system from the peritoneal cavity in patients with severe acute pancreatitis.
Pancreatitis
The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
Pancreatitis
[Changes in some of the kallikrein-kinin system indices in patients with acute pancreatitis]
Pancreatitis
[Hemostatic indices of oncological patients with different forms of jaundice]
Pancreatitis, Acute Hemorrhagic
Prevention of hemorrhagic pancreatitis with fibrinolysin or heparin.
Pancreatitis, Acute Necrotizing
The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
Pancreatitis, Chronic
Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis.
Pancreatitis, Chronic
Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer.
Paralysis
Pathogenesis of venous thromboembolism: when the cup runneth over.
Paralysis
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
Paraproteinemias
Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). population-based reference values in an area with low incidence of cardiovascular disease.
Parasitemia
A new method for factor VII deficient substrate preparation and coagulation studies in malaria.
Parasitemia
Hematological and coagulation studies in malaria.
Parasitic Diseases
Complete Molecular and Immunoprotective Characterization of Babesia microti Enolase.
Parkinson Disease
Proteolytic cleavage of extracellular ?-synuclein by plasmin: implications for Parkinson disease.
Pemphigoid Gestationis
An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid.
Pemphigoid, Bullous
An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid.
Pemphigoid, Bullous
Collagen XVII Processing and Blistering Skin Diseases.
Pemphigoid, Bullous
Enhanced association of plasminogen/plasmin with lesional epidermis of bullous pemphigoid.
Pemphigoid, Bullous
Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT).
Pemphigoid, Bullous
Plasmin-like proteinase associated with high molecular weight complexes in blister fluid of bullous pemphigoid.
Pemphigoid, Bullous
Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis.
Pemphigoid, Bullous
The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.
Pemphigoid, Bullous
[The autoimmune dermatosis bullous pemphigoid: deposition and activation of plasminogen in affected epidermis]
Pemphigus
Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation.
Pemphigus
Complement fixation by pemphigus antibody. II. Complement enhanced detachment of epidermal cells.
Pemphigus
Complement fixation by pemphigus antibody. III. Altered epidermal cell membrane integrity mediated by pemphigus antibody and complement.
Pemphigus
Complement fixation by pemphigus antibody. IV. Enhanced epidermal cell detachment in the absence of human plasminogen.
Pemphigus
Different effects of pemphigus antibody and plasmin on the distribution of keratin intermediate filaments and desmoplakins between cultured oral and epidermal keratinocytes.
Pemphigus
Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT).
Pemphigus
Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG.
Pemphigus
Pathogenesis of pemphigus. The role of epidermal plasminogen activators in acantholysis.
Pemphigus
Pemphigus IgG induces expression of urokinase plasminogen activator receptor on the cell surface of cultured keratinocytes.
Pemphigus
Penicillamine-induced pemphigus. Immunoglobulin from this patient induces plasminogen activator synthesis by human epidermal cells in culture: mechanism for acantholysis in pemphigus.
Pemphigus
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Pemphigus
Plasmin induces acantholysis in skin organ cultures.
Pemphigus
Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann.
Pemphigus
Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis.
Pemphigus, Benign Familial
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Pemphigus, Benign Familial
Cell adhesion in Hailey-Hailey disease and Darier's disease: immunocytological and explant-tissue-culture studies.
Pemphigus, Benign Familial
Plasmin induces acantholysis in skin organ cultures.
Peptic Ulcer
Plasminogen binding and activation at the surface of Helicobacter pylori CCUG 17874.
Peri-Implantitis
A controlled, cross-sectional exploratory study on markers for the plasminogen system and inflammation in crevicular fluid samples from healthy, mucositis and peri-implantitis sites.
Peri-Implantitis
Discriminating Microbial Community Structure Between Peri-Implantitis and Periodontitis With Integrated Metagenomic, Metatranscriptomic, and Network Analysis.
Peri-Implantitis
Relevance of the plasminogen system in physiology, pathology, and regeneration of oral tissues - From the perspective of dental specialties.
Pericarditis
Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases.
Perinatal Death
Syphilis-associated perinatal and infant mortality in rural Malawi.
Periodontal Diseases
Association of gene polymorphisms for plasminogen activators with alveolar bone loss.
Periodontal Diseases
Destructive Membranous Periodontal Disease (Ligneous Gingivitis): A Literature Review.
Periodontal Diseases
Destructive membranous periodontal disease (ligneous periodontitis): a case report and 3 years follow-up.
Periodontal Diseases
Gingival crevicular fluid plasmin activity in different clinical conditions and after periodontal treatment.
Periodontal Diseases
Ligneous periodontal lesions in a young child with severe plasminogen deficiency: a case report.
Periodontal Diseases
Ligneous periodontitis and gingival antioxidant status: report of two cases.
Periodontal Diseases
Ligneous periodontitis in a child with plasminogen deficiency.
Periodontal Diseases
Ligneous Periodontitis in a Patient with Type 1 Plasminogen Deficiency: A Case Report and Review of the Literature.
Periodontal Diseases
Periodontitis associated with plasminogen deficiency: a case report.
Periodontal Diseases
Plasmin is essential in preventing periodontitis in mice.
Periodontal Diseases
Plasminogen activating capacity in gingival fluid from deteriorating and stable periodontal pockets.
Periodontal Diseases
Plasminogen activation by fibroblasts from periodontal ligament and gingiva is not directly affected by chemokines in vitro.
Periodontal Diseases
Plasminogen activator in human periodontal health and disease.
Periodontal Pocket
Plasminogen activating capacity in gingival fluid from deteriorating and stable periodontal pockets.
Periodontitis
A ligneous periodontitis and conjunctival lesions in a patient with plasminogen deficiency.
Periodontitis
Acquisition of plasmin activity by Fusobacterium nucleatum subsp. nucleatum and potential contribution to tissue destruction during periodontitis.
Periodontitis
Altered functional activity patterns of fibroblasts related to periodontitis by systemic plasminogen deficiency (ligneous periodontitis).
Periodontitis
Assessing a multiplex-targeted proteomics approach for the clinical diagnosis of periodontitis using saliva samples.
Periodontitis
Cellular source, activation and inhibition of dental plaque collagenase.
Periodontitis
Genetic Evidence for PLASMINOGEN as a Shared Genetic Risk Factor of Coronary Artery Disease and Periodontitis.
Periodontitis
Gingival crevicular fluid tissue/blood vessel-type plasminogen activator and plasminogen activator inhibitor-2 levels in patients with rheumatoid arthritis: effects of nonsurgical periodontal therapy.
Periodontitis
Immunohistochemical analysis of the gingiva with periodontitis of type I plasminogen deficiency compared to gingiva with gingivitis and periodontitis and healthy gingiva.
Periodontitis
Ligneous conjunctivitis with oral mucous membrane involvement and decreased plasminogen level.
Periodontitis
Ligneous periodontal lesions in a young child with severe plasminogen deficiency: a case report.
Periodontitis
Ligneous periodontitis and Ehlers-Danlos syndrome.
Periodontitis
Ligneous periodontitis and gingival antioxidant status: report of two cases.
Periodontitis
Ligneous periodontitis in a child with plasminogen deficiency.
Periodontitis
Ligneous Periodontitis in a Patient with Type 1 Plasminogen Deficiency: A Case Report and Review of the Literature.
Periodontitis
Pathogenic potential of Tannerella forsythia enolase.
Periodontitis
Periodontitis associated with plasminogen deficiency: a case report.
Periodontitis
Plasmin is essential in preventing periodontitis in mice.
Periodontitis
Relevance of the plasminogen system in physiology, pathology, and regeneration of oral tissues - From the perspective of dental specialties.
Periodontitis
Salivary collagenase. Origin, characteristics and relationship to periodontal health.
Periodontitis
The plasminogen activation system in periodontal tissue (Review).
Peripheral Arterial Disease
Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease.
Peripheral Arterial Disease
Hypercoagulability Markers in Patients With Peripheral Arterial Disease: Association to Ankle-brachial Index.
Peripheral Arterial Disease
Translational initiatives in thrombolytic therapy.
Peripheral Nerve Injuries
Tissue plasminogen activator in primary afferents induces dorsal horn excitability and pain response after peripheral nerve injury.
Peripheral Vascular Diseases
Inhibition of human plasmin activity using humic acids with arsenic.
Peripheral Vascular Diseases
[Lipoprotein(a) and plasminogen patients with diabetes mellitus complicated with peripheral angiopathy and hypertension]
Peritonitis
Lp(a)/apo(a) Modulate MMP-9 Activation and Neutrophil Cytokines in Vivo in Inflammation to Regulate Leukocyte Recruitment.
Peritonitis
PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-beta 1.
Peritonitis
Protein C as an early marker of severe septic complications in diffuse secondary peritonitis.
Persistent Infection
Glycoproteomic analysis of serum from patients with gastric precancerous lesions.
Persistent Infection
Plasmin in Parasitic Chronic Infections: Friend or Foe?
Persistent Infection
The plasminogen activation system in periodontal tissue (Review).
Pharyngitis
Streptococcal fibrinolysin; a study of this substance and its antibody in group A hemolytic streptococcus sore throat.
Pharyngitis
[A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs]
Pheochromocytoma
Increased vascular plasminogen activity in patients with pheochromocytoma.
Pituitary ACTH Hypersecretion
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis.
Plague
A Yersinia pestis-specific DNA fragment encodes temperature-dependent coagulase and fibrinolysin-associated phenotypes.
Plague
Deletion of Braun lipoprotein and plasminogen activating protease-encoding genes attenuates Yersinia pestis in mouse models of bubonic and pneumonic plague.
Plague
Dissociation of Tissue Destruction and Bacterial Expansion during Bubonic Plague.
Plague
Fibrin and fibrinolysis in infection and host defense.
Plague
Impact of the Pla protease substrate ?2-antiplasmin on the progression of primary pneumonic plague.
Plague
Lack of O-antigen is essential for plasminogen activation by Yersinia pestis and Salmonella enterica.
Plague
Mutation in the pla gene of Yersinia pestis alters the course of the plague bacillus-flea (Siphonaptera: Ceratophyllidae) interaction.
Plague
Polyphosphate and omptins: novel bacterial procoagulant agents.
Plague
Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.
Plague
Proteolytic inactivation of tissue factor pathway inhibitor by bacterial omptins.
Plague
Temperature-Induced Changes in the Lipopolysaccharide of Yersinia pestis Affect Plasminogen Activation by the Pla Surface Protease.
Plague
[Detection and characterization of the plasmids of the plague microbe which determine the synthesis of pesticin I, fraction I antigen and "mouse" toxin exotoxin]
Plague
[Extracellular resistance of Yersinia pestis to phagocytosis]
plasmin deficiency
A functional overlap of plasminogen and MMPs regulates vascularization during placental development.
plasmin deficiency
A K19E missense mutation in the plasminogen gene is a common cause of familial hypoplasminogenaemia.
plasmin deficiency
A large deletion in the Plasminogen gene is associated with ligneous membranitis in a Maltese dog.
plasmin deficiency
A lethal phenotype associated with tissue plasminogen deficiency in humans.
plasmin deficiency
A ligneous periodontitis and conjunctival lesions in a patient with plasminogen deficiency.
plasmin deficiency
A novel combined treatment for plasminogen deficiency with lung involvement.
plasmin deficiency
A novel missense mutation in two families with congenital plasminogen deficiency: identification of an Ala675 to Thr675 substitution.
plasmin deficiency
A patient with congenital plasminogen deficiency manifesting primary pulmonary hypertension.
plasmin deficiency
Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.
plasmin deficiency
Active Plasma Kallikrein Localizes to Mast Cells and Regulates Epithelial Cell Apoptosis, Adipocyte Differentiation, and Stromal Remodeling during Mammary Gland Involution.
plasmin deficiency
Altered functional activity patterns of fibroblasts related to periodontitis by systemic plasminogen deficiency (ligneous periodontitis).
plasmin deficiency
An international registry of patients with plasminogen deficiency (HISTORY).
plasmin deficiency
Anterior Segment Surgeries Under Topical Fresh Frozen Plasma Treatment in Ligneous Conjunctivitis.
plasmin deficiency
Antithrombin III, plasminogen, plasmin, and alpha-2-antiplasmin in donor blood and plasma components.
plasmin deficiency
Asymptomatic coinheritance of heterozygous plasminogen deficiency and the factor VLeiden mutation.
plasmin deficiency
Atypical Microglandular Hyperplasia of Endocervix as the Presenting Feature of Plasminogen Deficiency.
plasmin deficiency
Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases.
plasmin deficiency
Calciphylaxis: A Disease of Pannicular Thrombosis.
plasmin deficiency
Causes of venous thrombosis in fifty Chinese patients.
plasmin deficiency
Central retinal vein and branch artery occlusion associated with inherited plasminogen deficiency and high lipoprotein(a) levels: a case report.
plasmin deficiency
Cerebral venous sinus thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia.
plasmin deficiency
Cerebral venous thrombosis with plasminogen deficiency.
plasmin deficiency
Characterization of plasminogen variants in healthy subjects and plasminogen mutants in patients with inherited plasminogen deficiency by isoelectric focusing gel electrophoresis.
plasmin deficiency
Clinical disorders of fibrinolysis: a critical review.
plasmin deficiency
Clinical manifestations due to severe plasminogen deficiency: a case report.
plasmin deficiency
Clinical, histopathological, and genetic aspects in one case of ligneous conjunctivitis.
plasmin deficiency
Coagulation disorders in young adults with acute cerebral ischaemia.
plasmin deficiency
Coagulopathies and arterial stroke.
plasmin deficiency
Combined Ala601-Thr-type dysplasminogenaemia and antiphospholipid antibody syndrome in a patient with recurrent thrombosis.
plasmin deficiency
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
plasmin deficiency
Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis.
plasmin deficiency
Comprehensive Genetic Analysis of Complement and Coagulation Genes in Atypical Hemolytic Uremic Syndrome.
plasmin deficiency
Congenital deficiency of plasminogen and its relationship to venous thrombosis.
plasmin deficiency
Congenital heterozygous plasminogen deficiency associated with a severe thrombotic tendency.
plasmin deficiency
Congenital hydrocephalus as a rare association with ligneous conjunctivitis and type I plasminogen deficiency.
plasmin deficiency
Congenital plasminogen deficiency associated with venous thromboembolism: therapeutic trial with stanozolol.
plasmin deficiency
Congenital plasminogen deficiency caused by a Ser572 to Pro mutation.
plasmin deficiency
Congenital plasminogen deficiency with long standing pseudomembranous conjunctival and genital lesions.
plasmin deficiency
Conjunctival instillation of plasminogen eliminates ocular lesion in B6.129P2-Plg(tm1Jld) transgenic mice, a model of ligneous conjunctivitis.
plasmin deficiency
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis.
plasmin deficiency
Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models.
plasmin deficiency
Destructive Membranous Periodontal Disease (Ligneous Gingivitis): A Literature Review.
plasmin deficiency
Destructive membranous periodontal disease (ligneous periodontitis): a case report and 3 years follow-up.
plasmin deficiency
Development and application of global assays of hyper- and hypofibrinolysis.
plasmin deficiency
Diagnosis of a case of ligneous gingivitis in a patient with moderate plasminogen deficiency.
plasmin deficiency
Duodenal ulceration in a patient with celiac disease and plasminogen I deficiency: coincidence or cofactors?
plasmin deficiency
Dysfunctional fibrinolysis and cerebral venous thrombosis.
plasmin deficiency
Effective treatment of ligneous conjunctivitis with topical plasminogen.
plasmin deficiency
Endoluminal arterial injury in plasminogen-deficient mice.
plasmin deficiency
Extensive fibrin accumulation and accompanying epithelial changes in the pathogenesis of ligneous mucosal disease (ligneous periodontitis).
plasmin deficiency
Familial association of hypoplasminogenemia and heterozygous factor V deficiency.
plasmin deficiency
Familial coagulation-inhibiting and fibrinolytic protein deficiencies in juvenile transient ischaemic attacks.
plasmin deficiency
Familial occurrence of membranous obstruction of the inferior vena cava: arguments in favor of a congenital etiology.
plasmin deficiency
Features and outcome of a glomerulonephropathy associated with ligneous conjunctivitis in a Doberman pinscher dog.
plasmin deficiency
Fibrinase deficiency.
plasmin deficiency
Fibrinogen deficiency, but not plasminogen deficiency, increases mortality synergistically in combination with sickle hemoglobin SAD in transgenic mice.
plasmin deficiency
Fibrinogen heterogeneity in homozygous plasminogen deficiency type I: further evidence that plasmin is not involved in formation of LMW- and LMW'-fibrinogen.
plasmin deficiency
Fibrinolysis and the risk of venous and arterial thrombosis.
plasmin deficiency
First Treatment for Plasminogen Deficiency Is Approved.
plasmin deficiency
Functional Fibrinolysis Assays Reveal Different Mechanisms underlying Plasminogen Dysfunction in Ligneous Conjunctivitis.
plasmin deficiency
Functional overlap between two classes of matrix-degrading proteases in wound healing.
plasmin deficiency
Gender affects skin wound healing in plasminogen deficient mice.
plasmin deficiency
Growth and behavioral development in plasminogen gene-targeted mice.
plasmin deficiency
Heparin in the long-term management of ligneous conjunctivitis: a case report and review of literature.
plasmin deficiency
Heterozygous type I plasminogen deficiency is associated with an increased risk for thrombosis: a statistical analysis in 20 kindreds.
plasmin deficiency
Homozygous and compound-heterozygous type I plasminogen deficiency is a common cause of ligneous conjunctivitis.
plasmin deficiency
Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis.
plasmin deficiency
Homozygous type I plasminogen deficiency.
plasmin deficiency
Human homozygous type I plasminogen deficiency and ligneous conjunctivitis.
plasmin deficiency
HUS and atypical HUS.
plasmin deficiency
Hypercoagulable states and lower limb ischemia in young adults.
plasmin deficiency
Hypercoagulable states.
plasmin deficiency
Hypoplasminogenaemia, gingival swelling and ulceration.
plasmin deficiency
Identification of three novel plasminogen (PLG) gene mutations in a series of 23 patients with low PLG activity.
plasmin deficiency
IgA nephritis associated with plasminogen abnormalities.
plasmin deficiency
Immunohistochemical analysis of the gingiva with periodontitis of type I plasminogen deficiency compared to gingiva with gingivitis and periodontitis and healthy gingiva.
plasmin deficiency
In vivo plasminogen deficiency reduces fat accumulation.
plasmin deficiency
Increased neurite development and plasminogen activator expression by exposure of human neuroblastoma cells to plasminogen-deficient growth medium.
plasmin deficiency
Induction of bilateral ligneous conjunctivitis with the use of a prosthetic eye.
plasmin deficiency
Inflammatory bowel disease promotes venous thrombosis earlier in life.
plasmin deficiency
Inflammatory Bowel Disease: A Gastrointestinal Presentation of Congenital Plasminogen Deficiency.
plasmin deficiency
Influence of plasminogen deficiency on the contribution of polymorphonuclear leucocytes to fibrin/ogenolysis: studies in plasminogen knock-out mice.
plasmin deficiency
Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature.
plasmin deficiency
Is plasminogen deficiency a thrombotic risk factor? A study on 23 thrombophilic patients and their family members.
plasmin deficiency
Isolated familial plasminogen deficiency may not be a risk factor for thrombosis.
plasmin deficiency
Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study).
plasmin deficiency
Laryngeal obstruction in congenital plasminogen deficiency.
plasmin deficiency
Ligneous (pseudomembranous) inflammation involving the female genital tract associated with type-1 plasminogen deficiency.
plasmin deficiency
Ligneous alveolar gingivitis in the absence of plasminogen deficiency.
plasmin deficiency
Ligneous cervicitis and endometritis: A gynaecological presentation of congenital plasminogen deficiency.
plasmin deficiency
Ligneous Cervicitis in a Woman With Plasminogen Deficiency Associated With an Atypical Form of Microglandular Hyperplasia: A Case Report and Review of Literature.
plasmin deficiency
Ligneous conjunctivitis associated with type I plasminogen deficiency: A rare case.
plasmin deficiency
Ligneous conjunctivitis in a Dandy-Walker syndrome: A rare case report.
plasmin deficiency
Ligneous conjunctivitis in a girl with severe type I plasminogen deficiency.
plasmin deficiency
Ligneous conjunctivitis in a plasminogen-deficient dog: clinical management and 2-year follow-up.
plasmin deficiency
Ligneous conjunctivitis in plasminogen-deficient mice.
plasmin deficiency
Ligneous conjunctivitis secondary to a congenital plasminogen deficiency in a dog.
plasmin deficiency
Ligneous conjunctivitis with plasminogen deficiency.
plasmin deficiency
Ligneous conjunctivitis, hydrocephalus, hydrocele, and pulmonary involvement in a child with homozygous type I plasminogen deficiency.
plasmin deficiency
Ligneous conjunctivitis.
plasmin deficiency
Ligneous conjunctivitis: a local manifestation of a systemic disorder?
plasmin deficiency
Ligneous gingivitis associated with plasminogen deficiency: a challenge in diagnosis.
plasmin deficiency
Ligneous gingivitis secondary to plasminogen deficiency: a multidisciplinary diagnostic challenge.
plasmin deficiency
Ligneous periodontal lesions in a young child with severe plasminogen deficiency: a case report.
plasmin deficiency
Ligneous periodontitis and Ehlers-Danlos syndrome.
plasmin deficiency
Ligneous periodontitis and gingival antioxidant status: report of two cases.
plasmin deficiency
Ligneous periodontitis in a child with plasminogen deficiency.
plasmin deficiency
Ligneous Periodontitis in a Patient with Type 1 Plasminogen Deficiency: A Case Report and Review of the Literature.
plasmin deficiency
Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency.
plasmin deficiency
Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation.
plasmin deficiency
Lupus-like anticoagulants and lower extremity arterial occlusive disease.
plasmin deficiency
Management of hydrocephalus in children with plasminogen deficiency.
plasmin deficiency
Management of ligneous conjunctivitis in a child with plasminogen deficiency.
plasmin deficiency
Minor Role of Plasminogen in Complement Activation on Cell Surfaces.
plasmin deficiency
Molecular and clinical spectrum of type I plasminogen deficiency: A series of 50 patients.
plasmin deficiency
Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis.
plasmin deficiency
Molecular pathogenesis of plasminogen Hakodate: the second Japanese family case of severe type I plasminogen deficiency manifested late-onset multi-organic chronic pseudomembranous mucositis.
plasmin deficiency
Molecular pathogenesis of type I congenital plasminogen deficiency: expression of recombinant human mutant plasminogens in mammalian cells.
plasmin deficiency
Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group.
plasmin deficiency
Nonsynonymous SNPs in LPA homologous to plasminogen deficiency mutants represent novel null apo(a) alleles.
plasmin deficiency
Novel homozygous mutation of plasminogen in ligneous conjunctivitis: a case report and literature review.
plasmin deficiency
Novel plasminogen gene mutations in Turkish patients with type I plasminogen deficiency.
plasmin deficiency
Novel preclinical murine model of trauma-induced elbow stiffness.
plasmin deficiency
Oral and Maxillofacial Pathology Case of the Month. Plasminogen Deficiency (Ligneous Periodontitis).
plasmin deficiency
Oral lesions indicative of plasminogen deficiency (hypoplasminogenemia).
plasmin deficiency
Orthomolecular nutritional therapy for plasminogen deficiency: report of a case that showed positive results.
plasmin deficiency
Otolaryngological manifestations of ligneous conjunctivitis.
plasmin deficiency
Pathophysiology of the plasminogen/plasmin system.
plasmin deficiency
Periodontitis associated with plasminogen deficiency: a case report.
plasmin deficiency
Phase I study of intraventricular recombinant tissue plasminogen activator for treatment of posthaemorrhagic hydrocephalus.
plasmin deficiency
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
plasmin deficiency
Plasma values for u-PA in children.
plasmin deficiency
Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice.
plasmin deficiency
Plasmin deficiency in Alzheimer's disease brains: causal or casual?
plasmin deficiency
Plasmin Deficiency Leads to Fibrin Accumulation and a Compromised Inflammatory Response in the Mouse Brain.
plasmin deficiency
Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner.
plasmin deficiency
Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure.
plasmin deficiency
Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis.
plasmin deficiency
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
plasmin deficiency
Plasminogen deficiency and thrombosis after plasmapheresis therapy for multiple sclerosis.
plasmin deficiency
Plasminogen deficiency as a rare cause of conjunctivitis and lymphadenopathy.
plasmin deficiency
Plasminogen deficiency attenuates postnatal erythropoiesis in male C57BL/6 mice through decreased activity of the LH-testosterone axis.
plasmin deficiency
Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice.
plasmin deficiency
Plasminogen deficiency causes reduced corticospinal axonal plasticity and functional recovery after stroke in mice.
plasmin deficiency
Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.
plasmin deficiency
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
plasmin deficiency
Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice.
plasmin deficiency
Plasminogen deficiency does not prevent sodium retention in a genetic mouse model of experimental nephrotic syndrome.
plasmin deficiency
PLASMINOGEN DEFICIENCY IN HODGKIN'S DISEASE.
plasmin deficiency
Plasminogen deficiency is associated with improved glucose tolerance, and lower DPP-4 activity.
plasmin deficiency
Plasminogen deficiency leads to impaired lobular reorganization and matrix accumulation after chronic liver injury.
plasmin deficiency
Plasminogen deficiency leads to impaired remodeling after a toxic injury to the liver.
plasmin deficiency
Plasminogen deficiency results in poor clearance of non-fibrin matrix and persistent activation of hepatic stellate cells after an acute injury.
plasmin deficiency
Plasminogen deficiency.
plasmin deficiency
Plasminogen deficiency: an additional risk factor for thrombosis in a family with factor V R506Q mutation?
plasmin deficiency
Plasminogen directs the pleiotropic effects of uPA in liver injury and repair.
plasmin deficiency
Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency.
plasmin deficiency
Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency.
plasmin deficiency
Polymorphonuclear elastase in patients with homozygous type I plasminogen deficiency and ligneous conjunctivitis.
plasmin deficiency
Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study.
plasmin deficiency
Post-traumatic membranous obstruction of the inferior vena cava associated with a hypercoagulable state.
plasmin deficiency
Prenatal diagnosis in a family with severe type I plasminogen deficiency, ligneous conjunctivitis and congenital hydrocephalus.
plasmin deficiency
Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease.
plasmin deficiency
Prevention of ligneous conjunctivitis by topical and subconjunctival fresh frozen plasma.
plasmin deficiency
Prophylactic protocol for dental care in ligneous gingivitis due to severe plasminogen deficiency: Case report and review of literature.
plasmin deficiency
Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan.
plasmin deficiency
Proteolytic activation of monocyte chemoattractant protein-1 by plasmin underlies excitotoxic neurodegeneration in mice.
plasmin deficiency
Pseudomembranous disease (ligneous inflammation) of the female genital tract, peritoneum, gingiva, and paranasal sinuses associated with plasminogen deficiency.
plasmin deficiency
Pulmonary involvement in a child with ligneous conjunctivitis and homozygous type I plasminogen deficiency.
plasmin deficiency
Recurrence of superficial vein thrombosis in patients with varicose veins.
plasmin deficiency
Recurrent recalcitrant gingival hyperplasia and plasminogen deficiency: a case report.
plasmin deficiency
Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency.
plasmin deficiency
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
plasmin deficiency
Replacement Therapy with Glu-Plasminogen for the Treatment of Severe Respiratory and Auditory Complications of Congenital Plasminogen Deficiency.
plasmin deficiency
Role of the pleiotropic effects of plasminogen deficiency in infection experiments with plasminogen-deficient mice.
plasmin deficiency
Root dentin anomaly and a PLG mutation.
plasmin deficiency
Screening for thrombophilic risk factors among 25 German patients with cerebral venous thrombosis.
plasmin deficiency
Serine proteases, inhibitors and receptors in renal fibrosis.
plasmin deficiency
Severe thrombotic tendency associated with a type I plasminogen deficiency.
plasmin deficiency
Spontaneous versus secondary thrombosis in congenital heterozygous plasminogen deficiency.
plasmin deficiency
Successful treatment of ligneous conjunctivitis with topical fresh frozen plasma in an infant.
plasmin deficiency
Successful treatment of ligneous gingivitis with warfarin.
plasmin deficiency
Symptomatic versus asymptomatic patients in congenital hypoplasminogenemia: a statistical analysis.
plasmin deficiency
Systemic and topical fresh-frozen plasma treatment in a newborn with ligneous conjunctivitis.
plasmin deficiency
The fibrinolytic system and thrombotic tendency.
plasmin deficiency
The first two Japanese cases of severe type I congenital plasminogen deficiency with ligneous conjunctivitis: Successful treatment with direct thrombin inhibitor and fresh plasma.
plasmin deficiency
The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis.
plasmin deficiency
The search for new approaches to treating type 1 plasminogen deficiency.
plasmin deficiency
The Tissue Fibrinolytic System Contributes to the Induction of Macrophage Function and CCL3 during Bone Repair in Mice.
plasmin deficiency
The Unravelling of the Genetic Architecture of Plasminogen Deficiency and its Relation to Thrombotic Disease.
plasmin deficiency
The ventriculocholecystic shunt: two case reports and a review of the literature.
plasmin deficiency
Therapeutic approaches in the treatment of ligneous conjunctivitis, the most common clinical manifestation of a systemic disease, caused by severe type I plasminogen deficiency.
plasmin deficiency
Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency.
plasmin deficiency
Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency.
plasmin deficiency
Thrombophilia found in patients with moyamoya disease.
plasmin deficiency
Thrombotic manifestations in plasminogen deficiency and in plasminogen abnormalities.
plasmin deficiency
Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds.
plasmin deficiency
Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis.
plasmin deficiency
Transient ischaemic attacks in two sisters with plasminogen deficiency and factor V Leiden.
plasmin deficiency
Treatment of hereditary and acquired thrombophilic disorders.
plasmin deficiency
Treatment of ligneous conjunctivitis with fresh frozen plasm in twin babies.
plasmin deficiency
Treatment of ligneous conjunctivitis with topical plasmin and topical plasminogen.
plasmin deficiency
Treatment of plasminogen deficiency patients with fresh frozen plasma.
plasmin deficiency
Type 1 Plasminogen Deficiency With Pulmonary Involvement: Novel Treatment and Novel Mutation.
plasmin deficiency
Type I congenital plasminogen deficiency is not a risk factor for thrombosis.
plasmin deficiency
Unusual thrombotic-like retinopathy (Coats' disease) associated with congenital plasminogen deficiency type I.
plasmin deficiency
Von Recklinghausen neurofibromatosis and hereditary plasminogen deficiency.
plasmin deficiency
[Clinical diagnosis of thrombosis and blood coagulation tests]
plasmin deficiency
[Congenital plasminogen deficiency in a Japanese family]
plasmin deficiency
[Ligneous conjunctivitis in a patient with plasminogen type I deficiency--case report with review of literature]
plasmin deficiency
[Ligneous conjunctivitis: complication of inborn plasminogen deficiency (a case report)]
plasmin deficiency
[Ligneous conjunctivitis].
plasmin deficiency
[Molecular abnormalities in recurrent thromboembolic disease]
plasmin deficiency
[Molecular biological approach for congenital abnormality of blood coagulation]
plasmin deficiency
[On the demonstration of plasmin deficiency in retracted clots of full blood and on its significance in the lysis with streptokinase]
plasmin deficiency
[Pharmaceutical supply of human plasminogen replacement therapy for the treatment of ligneous conjunctivitis: Logistics for a university hospital].
plasmin deficiency
[Plasminogen deficiencies in 2 Spanish families. Response to the administration of DDAVP]
plasmin deficiency
[Protein-S deficiency in young patients with thrombotic brain infarction]
plasmin deficiency
[Recurrent arterial thromboembolism in hereditary hypoplasminogenaemia]
Pleural Effusion
Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models.
Pleural Effusion
Fibrinolytic and inflammatory processes in pleural effusions.
Pleural Effusion
The dynamics and clinical significance of alpha 2 plasmin inhibitor-plasmin complex and thrombin-antithrombin complex in postoperative pleural effusion following a pulmonary lobectomy.
Pleural Effusion
Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis.
Pleural Effusion
[Assessment of the activity of plasminogen activators in the differential diagnosis of pleural effusion]
Pleural Effusion
[The effect of intrapleural pingyangmycin administration on activity of fibrinolytic system and transforming growth factor-beta1 in malignant pleural effusion]
Pleurisy
Effect of invertebrate serine proteinase inhibitors on carrageenan-induced pleural exudation and bradykinin release.
Pneumoconiosis
[Blood coagulating system in miners and the effectiveness of the therapeutic use of fibrinolysin with heparin in pneumoconiosis]
Pneumonia
An alternative elastase-mediated degradation of fibrinogen and fibrin observed in a patient with herpes simplex encephalitis and pneumonia.
Pneumonia
Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors.
Pneumonia
Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis.
Pneumonia
The development of granulomatous pulmonary inflammation in rabbits by aerosol challenge. I. Release of plasminogen activator by alveolar macrophages.
Pneumonia
The plasminogen activation system: new targets in lung inflammation and remodeling.
Pneumonia
Tranexamic Acid Influences the Immune Response, but not Bacterial Clearance in a Model of Post-Traumatic Brain Injury Pneumonia.
Pneumonia
[Comparative evaluation of the efficacy of electrophoresis of heparin and heparin combined with fibrinolysin in protracted pneumonias]
Pneumonia
[Evaluation of haemostasis and endothelial dysfunction characteristics in patient with community-acquired pneumonia].
Pneumonia, Ventilator-Associated
Plasminogen activation inhibitor concentrations in bronchoalveolar lavage fluid distinguishes ventilator-associated pneumonia from colonization in mechanically ventilated pediatric patients.
Pneumonia, Viral
[The vascular wall and fibrinolysis--pathologic aspects]
Poliomyelitis
Activator of plasminogen and protease from various cell cultures and present in poliomyelitis vaccine.
Polycystic Ovary Syndrome
Expression of the plasminogen system in the physiological mouse ovary and in the pathological polycystic ovary syndrome (PCOS) state.
Polymicrogyria
Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR.
Porphyria, Variegate
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Postpartum Hemorrhage
PATHOPHYSIOLOGY OF PLASMIN SYSTEM. V. PLASMIN SYSTEM AND POSTPARTUM HEMORRHAGE.
Postpartum Hemorrhage
TRAAP2 - TRAnexamic Acid for Preventing postpartum hemorrhage after cesarean delivery: a multicenter randomized, doubleblind, placebo- controlled trial - a study protocol.
Postthrombotic Syndrome
[The vascular wall and fibrinolysis--pathologic aspects]
Prader-Willi Syndrome
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Pre-Eclampsia
Coagulation, fibrinolysis, platelet and kinin-forming systems during toxemia of pregnancy.
Pre-Eclampsia
Coagulation/fibrinolysis disorder in patients with severe preeclampsia.
Pre-Eclampsia
Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors.
Pre-Eclampsia
Fibronectin, plasminogen activator inhibitor type 1 (PAI-1) and uterine artery Doppler velocimetry as markers of preeclampsia.
Pre-Eclampsia
Hyperglycemia impairs cytotrophoblast function via stress signaling.
Pre-Eclampsia
Increased blood flow resistance in placental circulation and levels of plasminogen activator inhibitors types 1 and 2 in severe preeclampsia.
Pre-Eclampsia
Influence of pre-eclampsia on concentrations of haemostatic factors in mothers and infants.
Pre-Eclampsia
Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia.
Pre-Eclampsia
Mechanisms of renal NaCl retention in proteinuric disease.
Pre-Eclampsia
Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia.
Pre-Eclampsia
Studies on the purification and characterization of human urinary plasminogen and plasmin.
Pre-Eclampsia
Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin.
Pre-Eclampsia
The imbalance of plasminogen activators and inhibitor in preeclampsia.
Pre-Eclampsia
Urinary fibrinolysis in toxemia of pregnancy.
Pre-Eclampsia
Urinary Plasmin Activates Collecting Duct ENaC Current in Preeclampsia.
Pre-Eclampsia
Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria.
Pre-Eclampsia
Urine albumin is a superior predictor of preeclampsia compared to urine plasminogen in type I diabetes patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Plasminogen activator in leukemic cell homogenate]
Pregnancy, Ectopic
Difference in mRNA expression and occurrence of plasminogen activator inhibitors in intrauterine decidua of normal and ectopic human pregnancies.
Pressure Ulcer
Cultured pressure ulcer fibroblasts show replicative senescence with elevated production of plasmin, plasminogen activator inhibitor-1, and transforming growth factor-beta1.
Pressure Ulcer
Involvement of proteolytic enzymes--plasminogen activators and matrix metalloproteinases--in the pathophysiology of pressure ulcers.
Pressure Ulcer
Prospective and randomised evaluation of the protease-modulating effect of oxidised regenerated cellulose/collagen matrix treatment in pressure sore ulcers.
Pressure Ulcer
Prospective randomized double-blind study of the wound-debriding effects of collagenase and fibrinolysin/deoxyribonuclease in pressure ulcers.
Priapism
FIBRINOLYSIN THERAPY FOR THROMBOSIS OF PRIAPISM.
Priapism
Priapism: surgical or medical treatment?
Primary Myelofibrosis
Enhanced expression of urokinase activity on U 937 cell line by 1,25-dihydroxyvitamin D3 induction.
Prion Diseases
A novel real-time ultrasonic method for prion protein detection using plasminogen as a capture molecule.
Prion Diseases
Cellular mechanisms regulating non-haemostatic plasmin generation.
Prion Diseases
Plasminogen activation is stimulated by prion protein and regulated in a copper-dependent manner.
Prion Diseases
The suppression of prion propagation using poly-L-lysine by targeting plasminogen that stimulates prion protein conversion.
Progeria
Reduction of unscheduled DNA synthesis and plasminogen activator activity in Hutchinson-Gilford fibroblasts during passaging in vitro: partial correction by interferon-beta.
Prostatic Hyperplasia
Autoantibodies to plasminogen and their role in tumor diseases.
Prostatic Hyperplasia
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Prostatic Hyperplasia
Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.
Prostatic Hyperplasia
Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.
Prostatic Hyperplasia
[Histochemical studies on the content of plasmin in the normal and hyperplastic prostate (author's transl)]
Prostatic Hyperplasia
[Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor]
Prostatic Neoplasms
213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model.
Prostatic Neoplasms
A piece in prostate cancer puzzle: Future perspective of novel molecular signatures.
Prostatic Neoplasms
Alteration of Antithrombin III and D-dimer Levels in Clinically Localized Prostate Cancer.
Prostatic Neoplasms
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Prostatic Neoplasms
Autoantibodies to plasminogen and their role in tumor diseases.
Prostatic Neoplasms
Bioassay of prostate-specific antigen (PSA) using microcantilevers.
Prostatic Neoplasms
Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model.
Prostatic Neoplasms
Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells.
Prostatic Neoplasms
Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesis.
Prostatic Neoplasms
Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145.
Prostatic Neoplasms
Growth factor regulation of secreted matrix metalloproteinase and plasminogen activators in prostate cancer cells, normal prostate fibroblasts and normal osteoblasts.
Prostatic Neoplasms
Increased Blood Concentration of IgG Degradation Products in Prostate Cancer.
Prostatic Neoplasms
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Prostatic Neoplasms
Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells.
Prostatic Neoplasms
New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.
Prostatic Neoplasms
New circulating biomarkers for prostate cancer.
Prostatic Neoplasms
Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms.
Prostatic Neoplasms
Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.
Prostatic Neoplasms
Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype.
Prostatic Neoplasms
Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence.
Prostatic Neoplasms
Prostate Cancer Cell Surface-Associated Keratin 8 and Its Implications for Enhanced Plasmin Activity.
Prostatic Neoplasms
Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate.
Prostatic Neoplasms
Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer.
Prostatic Neoplasms
Reduced secretion of MMPs, plasminogen activators and TIMPS from prostate cancer cells derived by repeated metastasis.
Prostatic Neoplasms
Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
Prostatic Neoplasms
Role of coagulation and fibrinolytic system in prostate cancer.
Prostatic Neoplasms
Separation and study of the range of plasminogen isoforms in patients with prostate cancer.
Prostatic Neoplasms
Specific isoforms of plasminogen in patients with prostate cancer.
Prostatic Neoplasms
The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer.
Prostatic Neoplasms
The fibrinolytic system in experimental prostate tumor.
Prostatic Neoplasms
The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer.
Prostatic Neoplasms
The role of angiostatin in the spontaneous bone and prostate cancers of pet dogs.
Prostatic Neoplasms
Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells.
Prostatic Neoplasms
Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.
Prostatic Neoplasms
Variations of components of the plasminogen activation system with the cell cycle in benign prostate tissue and prostate cancer.
Protein C Deficiency
Causes of venous thrombosis in fifty Chinese patients.
Protein C Deficiency
Clinical and functional assessment after anticoagulant therapy of acute deep vein thrombosis involving the lower limb.
Protein C Deficiency
Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan.
Protein C Deficiency
Homozygous protein C deficiency combined with heterozygous dysplasminogenemia found in a 21-year-old thrombophilic male.
Protein C Deficiency
Hypercoagulable states and lower limb ischemia in young adults.
Protein C Deficiency
Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study).
Protein C Deficiency
Lupus-like anticoagulants and lower extremity arterial occlusive disease.
Protein C Deficiency
Prothrombotic risk factors in childhood stroke and venous thrombosis.
Protein C Deficiency
[Protein-S deficiency in young patients with thrombotic brain infarction]
Protein Deficiency
Massive acute pulmonary embolism in protein S deficiency--a case report.
Protein Deficiency
[Analyses on activation and regulation of blood coagulation]
Protein Deficiency
[Proteasome degradation of protein C and plasmin inhibitor mutants: molecular mechanism of congenital protein deficiency]
Protein S Deficiency
Causes of venous thrombosis in fifty Chinese patients.
Protein S Deficiency
Clinical and functional assessment after anticoagulant therapy of acute deep vein thrombosis involving the lower limb.
Protein S Deficiency
Coagulation disorders in young adults with acute cerebral ischaemia.
Protein S Deficiency
Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan.
Protein S Deficiency
Hypercoagulable states.
Protein S Deficiency
Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study).
Protein S Deficiency
Lupus-like anticoagulants and lower extremity arterial occlusive disease.
Protein S Deficiency
Prothrombotic states in young people with idiopathic stroke. A prospective study.
Protein S Deficiency
The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis.
Protein S Deficiency
The surgical implications of primary hypercoagulable states.
Protein S Deficiency
Treatment of hereditary and acquired thrombophilic disorders.
Protein S Deficiency
[Protein-S deficiency in young patients with thrombotic brain infarction]
protein-glutamine gamma-glutamyltransferase deficiency
Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency.
Proteinuria
Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
Proteinuria
Alterations of serum levels of plasminogen, TNF-?, and IDO in granulomatosis with polyangiitis patients.
Proteinuria
Association of Plasminuria with Overhydration in Patients with CKD.
Proteinuria
Cathepsin B increases ENaC activity leading to hypertension early in nephrotic syndrome.
Proteinuria
Elevated lipoprotein (a) levels in primary nephrotic syndrome.
Proteinuria
Factor XII and other hemostatic protein abnormalities in nephrotic syndrome patients.
Proteinuria
Ligneous conjunctivitis in a plasminogen-deficient dog: clinical management and 2-year follow-up.
Proteinuria
Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
Proteinuria
Over- or underfill: not all nephrotic states are created equal.
Proteinuria
Physiology and pathophysiology of the plasminogen system in the kidney.
Proteinuria
Plasmin activates epithelial Na+ channels by cleaving the gamma subunit.
Proteinuria
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
Proteinuria
Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease.
Proteinuria
Podocyte Injury: The Role of Proteinuria, Urinary Plasminogen and Oxidative Stress.
Proteinuria
Salt-Sensitive Hypertension in Chronic Kidney Disease: Distal Tubular Mechanisms.
Proteinuria
Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy.
Proteinuria
Studies on the purification and characterization of human urinary plasminogen and plasmin.
Proteinuria
Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin.
Proteinuria
Urinary plasmin inhibits TRPV5 in nephrotic-range proteinuria.
Proteinuria
Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria.
Proteinuria
Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice.
Proteinuria
[Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome]
Pseudorabies
Expression of three recombinant proteins using baculovirus vectors in 23 insect cell lines.
Psoriasis
A further study on the mechanism of deposition of plasma protein in psoriasis scale.
Psoriasis
Composition and mechanism of deposition of the intercellular substance in parakeratotic psoriatic epidermis.
Psoriasis
Concepts in psoriasis: psoriasis and the extracellular matrix.
Psoriasis
Expression of plasminogen activator enzymes in psoriatic epidermis.
Psoriasis
Human skin proteases. Fractionation of psoriasis scale proteases and separation of a plasminogen activator and a histone hydrolysing protease.
Psoriasis
Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT).
Psoriasis
Plasmin plays an essential role in amplification of psoriasiform skin inflammation in mice.
Psoriasis
Plasminogen activation in psoriasis.
Psoriasis
Reduction in tissue plasmin: a new mechanism of action of narrowband ultraviolet B in psoriasis.
Pulmonary Disease, Chronic Obstructive
Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells.
Pulmonary Disease, Chronic Obstructive
Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group.
Pulmonary Disease, Chronic Obstructive
Moraxella catarrhalis Binds Plasminogen To Evade Host Innate Immunity.
Pulmonary Disease, Chronic Obstructive
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
Pulmonary Disease, Chronic Obstructive
The plasminogen activation system: new targets in lung inflammation and remodeling.
Pulmonary Edema
Is Spironolactone the Preferred Renin-Angiotensin-Aldosterone Inhibitor for Protection Against COVID-19?
Pulmonary Edema
Might life-threatening acute pulmonary edema occur after using recombinant tissue plasminogen activator? A case report.
Pulmonary Embolism
Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism.
Pulmonary Embolism
Clot penetration and retention by plasminogen activators promote fibrinolysis.
Pulmonary Embolism
COMBINED FIBRINOLYSIN AND ANTICOAGULANT THERAPY OF VENOUS THROMBOSIS AND PULMONARY EMBOLISM.
Pulmonary Embolism
Comparative tolerability profiles of thrombolytic agents. A review.
Pulmonary Embolism
Congenital abnormal plasminogen, Frankfurt I, a cause for recurrent venous thrombosis.
Pulmonary Embolism
Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation.
Pulmonary Embolism
Effect of low-molecular-weight heparin on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
Pulmonary Embolism
Effects of flow on recombinant tissue plasminogen activator-induced pulmonary thrombolysis.
Pulmonary Embolism
Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
Pulmonary Embolism
Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism.
Pulmonary Embolism
Factor XIIIa cross-linking of the Marburg fibrin: formation of alpham.gamman-heteromultimers and the alpha-chain-linked albumin. gamma complex, and disturbed protofibril assembly resulting in acquisition of plasmin resistance relevant to thrombophila.
Pulmonary Embolism
Fibrinolysin Therapy of Thrombophlebitis and Pulmonary Embolism.
Pulmonary Embolism
Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator.
Pulmonary Embolism
Massive pulmonary embolism in a young boy with T-cell leukaemia. Successful thrombolytic therapy by recombinant tissue plasminogen activator (rtPA).
Pulmonary Embolism
One-Year Echocardiographic, Functional, and Quality of Life Outcomes After Ultrasound-Facilitated Catheter-Based Fibrinolysis for Pulmonary Embolism.
Pulmonary Embolism
PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2.
Pulmonary Embolism
Plasminogen and moderate doses of urokinase in the treatment of acute pulmonary embolism.
Pulmonary Embolism
Prevention of postoperative deep venous thrombosis. Low-dose heparin versus graded pressure stockings.
Pulmonary Embolism
Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and ?2-Antiplasmin Inactivation.
Pulmonary Embolism
Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality.
Pulmonary Embolism
SMTP (Stachybotrys microspora triprenyl phenol) enhances clot clearance in a pulmonary embolism model in rats.
Pulmonary Embolism
Subacute massive pulmonary embolism treated with plasminogen and streptokinase.
Pulmonary Embolism
Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature.
Pulmonary Embolism
The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin.
Pulmonary Embolism
The treatment of pulmonary embolism with fibrinolysin.
Pulmonary Embolism
Thrombin-antithrombin III complexes as an additional diagnostic aid in pulmonary embolism.
Pulmonary Embolism
THROMBOLYSIN TREATMENT OF PULMONARY EMBOLISM FOLLOWING SURGERY. A REPORT OF TWO CASES.
Pulmonary Embolism
Thrombolytic agents--an overview.
Pulmonary Embolism
Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.
Pulmonary Embolism
Tissue-type plasminogen activator: a historical perspective and personal account.
Pulmonary Embolism
[Abnormal plasminogen accompanying pulmonary embolism]
Pulmonary Embolism
[Experimental pulmonary embolisms treated with fibrinolysin and epsilon-aminocaproic acid]
Pulmonary Embolism
[Fibrinolytic therapy of patients with pulmonary artery thromboembolism by tissue plasminogen activator and streptokinase preparations]
Pulmonary Embolism
[Fibrinolytic treatment of thrombus of the right atrium causing severe pulmonary embolism]
Pulmonary Embolism
[Level of tissue plasminogen activator protein in pulmonary artery in acute pulmonary thromboembolism in rabbit]
Pulmonary Embolism
[Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism]
Pulmonary Embolism
[Pulmonary thromboembolism accompanied by abnormal plasminogen]
Pulmonary Embolism
[SUCCESSFUL USE OF FIBRINOLYSIN IN PULMONARY THROMBOEMBOLISM.]
Pulmonary Embolism
[Thrombolysis in massive pulmonary embolism with moderate doses of plasminogen tissue activator in 2 octagenarians]
Pulmonary Embolism
[Treatment of pulmonary embolism by fibrinolysin. Experimental research.]
Pulmonary Fibrosis
A novel mechanism of plasmin-induced mitogenesis in fibroblasts.
Pulmonary Fibrosis
A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia.
Pulmonary Fibrosis
Glycogen Synthase Kinase-3? Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis.
Pulmonary Fibrosis
Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice.
Pulmonary Fibrosis
Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin.
Pulmonary Fibrosis
The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.
Pulmonary Fibrosis
The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.
Pulmonary Fibrosis
The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis.
Pulmonary Fibrosis
The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism.
Pulmonary Heart Disease
Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction.
Pulpitis
Relevance of the plasminogen system in physiology, pathology, and regeneration of oral tissues - From the perspective of dental specialties.
Purpura
Intraglomerular deposition of intact cross-linked fibrin in IgA nephropathy and Henoch-Schönlein purpura nephritis.
Purpura
Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function.
Purpura
Painful purpura: an adverse effect to a thrombolysin.
Purpura
Rash after treatment with anistreplase.
Purpura, Thrombotic Thrombocytopenic
Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.
Purpura, Thrombotic Thrombocytopenic
Comparison of ADAMTS13 and Von Willebrand factor levels and activities, and plasminogen levels, in plasma products currently available for the treatment of thrombotic thrombocytopenic purpura in South Africa.
Purpura, Thrombotic Thrombocytopenic
Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1-A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro.
Purpura, Thrombotic Thrombocytopenic
Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura.
Radicular Cyst
Fibrinolytic activity in cystic lesions of jaw bones.
Radicular Cyst
Immunohistochemical localization of tissue-type plasminogen activator and type I plasminogen activator inhibitor in radicular cysts.
Radiodermatitis
Plasminogen activation is required for the development of radiation-induced dermatitis.
Rectal Neoplasms
[Changes in markers of proliferation, neoangiogenesis and plasminogen activation system in rectal cancer tissue].
Rectal Prolapse
Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.
Rectal Prolapse
Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency.
Relapsing Fever
Dual binding specificity of a Borrelia hermsii-associated complement regulator-acquiring surface protein for factor H and plasminogen discloses a putative virulence factor of relapsing fever spirochetes.
Relapsing Fever
Endogenous and Borrowed Proteolytic Activity in the Borrelia.
Relapsing Fever
Identification of an antiparallel coiled-coil/loop domain required for ligand binding by the Borrelia hermsii FhbA protein: additional evidence for the role of FhbA in the host-pathogen interaction.
Relapsing Fever
The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis.
Renal Insufficiency
Alteration in insulin-like growth factor-binding proteins (IGFBPs) and IGFBP-3 protease activity in serum and urine from acute and chronic renal failure.
Renal Insufficiency
Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure.
Renal Insufficiency
Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia.
Renal Insufficiency
[Effect of hemodialysis on the concentration of beta 2-microglobulin and acute phase proteins in the serum of patients with chronic renal failure]
Renal Insufficiency, Chronic
Impaired fibrinolysis and protein C increase after cadaver kidney transplantation.
Renal Insufficiency, Chronic
Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis.
Reperfusion Injury
Direct induction of complement activation by pharmacologic activation of plasminogen.
Reperfusion Injury
Plasmin administration during ex vivo lung perfusion ameliorates lung ischemia-reperfusion injury.
Reperfusion Injury
Reduction of post-ischemic lung reperfusion injury by fibrinolytic activity suppression.
Reperfusion Injury
Tissue plasminogen activator and plasmin independently decrease human neutrophil activation.
Reperfusion Injury
Tissue plasminogen activator-induced reperfusion injury after stroke revisited.
Respiratory Distress Syndrome
Changes in the fibrinolysin system in infantile and adult respiratory distress syndrome (ARDS), caused by trauma and/or septic shock in patients and in experimental animals.
Respiratory Distress Syndrome
Fibrinolysis inhibition in acute respiratory distress syndrome.
Respiratory Distress Syndrome
Plasma plasminogen levels in early respiratory distress syndrome.
Respiratory Distress Syndrome
Plasminogen did not affect lung function in surfactant-treated preterm lambs.
Respiratory Distress Syndrome
Serum plasminogen and lung surfactant in the respiratory distress syndrome.
Respiratory Distress Syndrome
Studies on the prevention of respiratory distress syndrome of infants due to hyaline membrane disease with plasminogen.
Respiratory Distress Syndrome
The fibrinolysin system and its relationship to disease in the newborn.
Respiratory Distress Syndrome
THE USE OF FIBRINOLYSIN IN THE TREATMENT OF RESPIRATORY DISTRESS SYNDROME.
Respiratory Distress Syndrome
Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak.
Respiratory Distress Syndrome
[Fibrinolysis in respiratory distress syndrome. Plasminogen levels in the plasma of premature infants]
Respiratory Insufficiency
[Serum plasminogen and alpha-2-antiplasmin levels in chronic bronchopneumopathology with respiratory insufficiency]
Respiratory Tract Infections
Network of Surface-Displayed Glycolytic Enzymes in Mycoplasma pneumoniae and Their Interactions with Human Plasminogen.
Retinal Arterial Macroaneurysm
Management of submacular hemorrhage associated with retinal arterial macroaneurysms.
Retinal Artery Occlusion
Central retinal artery occlusion successfully treated with plasmin.
Retinal Detachment
Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.
Retinal Detachment
High osmolarity effect of intravitreal plasmin enzyme on rabbit retina.
Retinal Detachment
Secretion of plasminogen activators by cells cultured from subretinal fluid.
Retinal Detachment
Tissue-type plasminogen activator in subretinal fluid.
Retinal Detachment
[Coagulation factors and fibrinolytic system in subretinal liquid in patients with rheumatogenous retinal detachment]
Retinal Diseases
An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach.
Retinal Diseases
Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
Retinal Diseases
Plasminogen activators promote excitotoxicity-induced retinal damage.
Retinal Neovascularization
Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5.
Retinal Neovascularization
Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1? pathway.
Retinal Neovascularization
Inhibition of Pathological Retinal Neovascularization by a Small Peptide Derived from Human Tissue-Type Plasminogen Kringle 2.
Retinal Neovascularization
Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats.
Retinal Perforations
A new approach to stage 3 macular holes.
Retinal Perforations
Autolytic degradation of ocriplasmin: a complex mechanism unraveled by mutational analysis.
Retinal Perforations
Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.
Retinal Perforations
Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy.
Retinal Perforations
Efficacy of autologous plasmin for idiopathic macular hole surgery.
Retinal Perforations
Ocriplasmin for pharmacologic vitreolysis.
Retinal Perforations
Pediatric traumatic macular hole: results of autologous plasmin enzyme-assisted vitrectomy.
Retinal Perforations
Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holes.
Retinal Perforations
Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study.
Retinal Vein Occlusion
Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion.
Retinal Vein Occlusion
An unusual case of central retinal vein occlusion, treated successfully with intravenous fibrinolysin.
Retinal Vein Occlusion
Experimental retinal vein occlusion and treatment with fibrinolysin.
Retinal Vein Occlusion
Fibrinolytic treatment of retinal vein thrombosis. The use of Fibrinolysin Human Lyovac (Merck).
Retinal Vein Occlusion
Intravitreal functional plasminogen in eyes with branch retinal vein occlusion.
Retinal Vein Occlusion
Intravitreal functional plasminogen is elevated in central retinal vein occlusion.
Retinal Vein Occlusion
Intravitreal Injection of Autologous Plasmin Enzyme for Macular Edema Associated with Branch Retinal Vein Occlusion.
Retinal Vein Occlusion
Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion.
Retinal Vein Occlusion
Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion.
Retinal Vein Occlusion
Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion.
Retinal Vein Occlusion
The successful treatment of a case of central retinal vein thrombosis with intravenous fibrinolysin.
Retinal Vein Occlusion
Therapy of retinal vein occlusion. Use of fibrinolysin and anticoagulants.
Retinal Vein Occlusion
[Clinical significance of the determination of several hemostatic parameters in the lacrimal fluid of patients with vascular diseases of the retina]
Retinal Vein Occlusion
[Fibrinolysin (Merck) treatment of retinal vein thrombosis.]
Retinopathy of Prematurity
Autologous plasmin-assisted vitrectomy for stage 5 retinopathy of prematurity: a preliminary trial.
Retinopathy of Prematurity
Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity.
Retinoschisis
Plasmin enzyme-assisted vitreoretinal surgery in congenital X-linked retinoschisis: surgical techniques based on a new classification system.
Rhabdomyosarcoma
Serine enzymes released by cultured neoplastic cells.
Rhabdomyosarcoma
Stimulation of cell surface plasminogen activation by heparin and related polyionic substances.
Rheumatic Diseases
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Rheumatic Diseases
Regulation of plasminogen activators and their inhibitors in rheumatic diseases: new understanding and the potential for new directions.
Rheumatic Diseases
Serum inhibitors of elastase, trypsin, and plasmin in chronic rheumatic diseases.
Rheumatic Diseases
The urokinase-type plasminogen activator system and inflammatory joint diseases.
Rheumatic Diseases
[BLOOD LEVEL OF PLASMINOGEN IN CHRONIC PROTOTYPIC RHEUMATISM.]
Rheumatic Diseases
[The rate of activation of plasminogen and intrasvascular thrombus formation in rheumatism and atherosclerosis]
Rheumatic Fever
Fibrin dissolution in synovial fluid.
Rheumatic Fever
Quantitative studies on the total plasmin and the trypsin inhibitor of human blood serum; variations in the blood concentration of total plasmin and of trypsin inhibitor in streptococcal diseases with special reference to rheumatic fever.
Rheumatic Fever
[ON FIBRINOLYSIS IN THE FIELD OF ORTHOPEDIC SURGERY. (2) ON CHANGES IN PLASMIN IN CHRONIC RHEUMATIC FEVER.]
Rubella
Antibody spectrum and anticomplementary activity of a plasmin-treated human immunoglobulin preparation.
Rubella
Avoidance of oxidative-stress perturbation in yeast bioprocesses by proteomic and genomic biostrategies?
Sarcoma
Acetylcholine receptor: effects of proteolysis on receptor metabolism.
Sarcoma
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
Sarcoma
Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptor in HT1080 sarcoma cells.
Sarcoma
Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids.
Sarcoma
Enhancement of the radiation effect by fibrinolysin and quantitative pattern of the change of tumor radiosensitivity.
Sarcoma
High-level secretion of the four salivary plasminogen activators from the vampire bat Desmodus rotundus by stably transfected baby hamster kidney cells.
Sarcoma
Horse v-fes feline sarcoma viral oncogene homologue; pyruvate kinase, muscle type 2; plasminogen; beta spectrin, non-erythrocytic 1; thymidylate synthetase; and microsatellite LEX078 map to 1q14-q15, 1q21, 31q12-q14, 15q22, 8q12-q14, and 14q27, respectively.
Sarcoma
Identification of plasminogen in Matrigel and its activation by reconstitution of this basement membrane extract.
Sarcoma
Peptides cleaved from fibrinogen by plasmin enhance the progression of L-1 sarcoma in BALB/c mice.
Sarcoma
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Sarcoma
Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors.
Sarcoma
Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages.
Sarcoma
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Sarcoma
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.
Sarcoma
Synthesis and secretion of plasminogen activators and collagenases in human cells transformed by Kirsten murine sarcoma virus and N-methyl-N'-nitro-N-nitrosoguanidine.
Sarcoma
[Studies on the cytolytic action of plasmin on Yoshida ascites sarcoma]
Sarcoma, Avian
An inhibitor of plasminogen activator in rabbit endothelial cells.
Sarcoma, Avian
Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard.
Sarcoma, Avian
Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin.
Sarcoma, Avian
Plasminogen-independent fibrinolysis by proteases produced by transformed chick embryo fibroblasts.
Sarcoma, Avian
Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts.
Sarcoma, Avian
The extracellular matrix of normal chick embryo fibroblasts: its effect on transformed chick fibroblasts and its proteolytic degradation by the transformants.
Sarcoma, Ewing
The course of fibrinolytic proteins in children with malignant bone tumours.
Sarcoma, Yoshida
The cytotoxic effect of plasmin on Yoshida sarcoma cells.
Sarcoma, Yoshida
[The cytotoxic effect of plasmin on yoshida sarcoma cells]
Schistosomiasis
A case control study on the structural equation model of the mechanism of coagulation and fibrinolysis imbalance in chronic schistosomiasis.
Schistosomiasis
Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis.
Schistosomiasis
Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni.
Schistosomiasis
The pathogenesis of accelerated fibrinolysis in hepatosplenic schistosomiasis.
Scleroderma, Diffuse
Circadian variations of plasma levels of blood coagulation/fibrinolysis molecular markers in progressive systemic sclerosis (PSS).
Scleroderma, Systemic
Cutaneous and plasma fibrinolytic activity in systemic sclerosis. Evidence of normal plasminogen activation.
Scleroderma, Systemic
Decrease in matrix metalloproteinase?3 activity in systemic sclerosis fibroblasts causes ?2?antiplasmin and extracellular matrix deposition, and contributes to fibrosis development.
Scleroderma, Systemic
Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis.
Scrapie
A novel real-time ultrasonic method for prion protein detection using plasminogen as a capture molecule.
Scrapie
Plasminogen stimulates propagation of protease-resistant prion protein in vitro.
Scrapie
Role of plasminogen in propagation of scrapie.
Seizures
Incidence and Association of Reperfusion Therapies With Poststroke Seizures: A Systematic Review and Meta-Analysis.
Seizures
Incidence of early poststroke seizures during reperfusion therapies in patients with acute ischemic stroke: An observational prospective study: (TESI study: "Trombolisi/Trombectomia e crisi Epilettiche precoci nello Stroke Ischemico").
Seizures
Incidence of seizure in stroke patients treated with recombinant tissue plasminogen activator: A systematic review and meta-analysis.
Seizures
Plasmin-mediated processing of protein tyrosine phosphatase receptor type Z in the mouse brain.
Seizures
Propofol treatment modulates neurite extension regulated by immunologically challenged rat primary astrocytes: a possible role of PAI-1.
Seizures
Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent.
Seizures
Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system?
Sepsis
A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis.
Sepsis
Actin accelerates plasmin generation by tissue plasminogen activator.
Sepsis
Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
Sepsis
Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease.
Sepsis
Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice.
Sepsis
Binding to carboxypeptidase M mediates protective effects of fibrinopeptide B?15-42.
Sepsis
Changes in fibrinolysis in the intensive care patient.
Sepsis
Combined biomarkers discriminate a low likelihood of bacterial infection among surgical intensive care unit patients with suspected sepsis.
Sepsis
Combined Biomarkers Predict Acute Mortality Among Critically Ill Patients With Suspected Sepsis.
Sepsis
Comparison of immunological and functional assays for measurement of soluble fibrin.
Sepsis
COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity.
Sepsis
D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis.
Sepsis
Degradation of fibrinogen and cross-linked fibrin by human neutrophil elastase generates D-like fragments detected by ELISA but not latex D-dimer test.
Sepsis
Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis.
Sepsis
Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice.
Sepsis
Evaluation of severity and prognosis in early stages of septicemia by means of chromogenic peptide substrate assays.
Sepsis
Fibrinolysis in disseminated intravascular coagulation.
Sepsis
Fibrinolysis inhibition in acute respiratory distress syndrome.
Sepsis
Fibrinolytic changes in a patient with toxic shock syndrome; release of active u-PA.
Sepsis
Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors.
Sepsis
Klebsiella pneumoniae enolase-like membrane protein interacts with human plasminogen.
Sepsis
Management of Pleural Infection.
Sepsis
Mini-plasminogen like molecule in septic patients.
Sepsis
Modulators of coagulation. A critical appraisal of their role in sepsis.
Sepsis
Neutrophils are a main source of circulating suPAR predicting outcome in critical illness.
Sepsis
Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease.
Sepsis
Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
Sepsis
Plasminogen activators in inflammation and sepsis.
Sepsis
Plasminogen: an important hemostatic parameter in septic patients.
Sepsis
Protein C as an early marker of severe septic complications in diffuse secondary peritonitis.
Sepsis
Proteinase inhibitors in severe inflammatory processes (septic shock and experimental endotoxaemia): biochemical, pathophysiological and therapeutic aspects.
Sepsis
The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation.
Sepsis
The role of inflammatory cells and their proteases in extravascular fibrinolysis.
Sepsis
Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.
Sepsis
Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis.
Sepsis
Treatment of sepsis in the surgical patient evaluated by means of chromogenic peptide substrate assays.
Sepsis
[Advancement in the diagnosis of disseminated intravascular coagulation for the surgeon]
Sepsis
[Approbation of a new test system determining the activity of a plasmin inhibitor in patients with sepsis]
Sepsis
[Effect on hemostasis and thrombogenesis by septic processes especially in childhood]
Sepsis
[Usefulness of plasminogen activating factor in meningococcal sepsis]
Severe Acute Respiratory Syndrome
Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
Severe Dengue
Peptide Bbeta(15-42) preserves endothelial barrier function in shock.
Sexually Transmitted Diseases
Avoidance of oxidative-stress perturbation in yeast bioprocesses by proteomic and genomic biostrategies?
Sexually Transmitted Diseases
Lues maligna.
Sexually Transmitted Diseases
Syphilis-associated perinatal and infant mortality in rural Malawi.
Shock, Cardiogenic
Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Shock, Cardiogenic
Recombinant tissue type plasminogen activator treatment of thrombosed mitral valve prosthesis during pregnancy.
Shock, Cardiogenic
Successful surgical management of left ventricular free wall rupture in the course of myocardial infarction.
Shock, Cardiogenic
[Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events]
Shock, Septic
Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
Shock, Septic
Alterations of plasmin activity, plasminogen levels and activity of antiplasmins during endotoxin shock in dogs.
Shock, Septic
Changes in plasminogen levels, plasmin activity and activity of antiplasmins during endotoxin shock in dogs.
Shock, Septic
Changes in the fibrinolysin system in infantile and adult respiratory distress syndrome (ARDS), caused by trauma and/or septic shock in patients and in experimental animals.
Shock, Septic
Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome.
Shock, Septic
DNA-bound elastase of neutrophil extracellular traps degrades plasminogen, reduces plasmin formation, and decreases fibrinolysis: proof of concept in septic shock plasma.
Shock, Septic
Endotoxin shock in the New Zealand white rabbit. An evaluation of fibrinolysin therapy.
Shock, Septic
INTRAVASCULAR COAGULATION AND FIBRINOLYSIN THERAPY IN ENDOTOXIN SHOCK.
Shock, Septic
Neutrophil elastase, thrombin and plasmin in septic shock.
Shock, Septic
Plasminogen concentrations and functional activities and concentrations of plasmin inhibitors in plasma samples from normal subjects and patients with septic shock.
Shock, Septic
The role of inflammatory cells and their proteases in extravascular fibrinolysis.
Shock, Septic
[Characteristics of hemostatic disorders in septic shock in children]
Silicosis
[Changes in the activity of the phagocytosis stimulating centers in the hypothalamus and fibrinolysin in silicosis]
Sinus Thrombosis, Intracranial
Direct endovascular thrombolytic therapy for dural sinus thrombosis: infusion of alteplase.
Sinusitis
Studies on proactivator from the paranasal mucous membrane in chronic sinusitis.
Skin Diseases
Expression and ultrastructural localization of plasmin(ogen) in the terminally differentiated layers of normal human epidermis.
Skin Diseases
Expression of plasminogen activator enzymes in psoriatic epidermis.
Skin Diseases
Plasmin Plays a Role in the In Vitro Generation of the Linear IgA Dermatosis Antigen LADB97.
Skin Diseases
Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression.
Skin Diseases
The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.
Skin Diseases
[The autoimmune dermatosis bullous pemphigoid: deposition and activation of plasminogen in affected epidermis]
Skin Neoplasms
Gender affects skin wound healing in plasminogen deficient mice.
Skin Neoplasms
Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner.
Sleep Apnea, Obstructive
Obstructive Sleep Apnea Hypopnea Syndrome as a Reason for Active Management of Pulmonary Embolism.
Sleep Apnea, Obstructive
The Plasminogen System and Transforming Growth Factor-? in Subjects With Obstructive Sleep Apnea Syndrome: Effects of CPAP Treatment.
Sleep Deprivation
Negative Influence of Insufficient Sleep on Endothelial Vasodilator and Fibrinolytic Function in Hypertensive Adults.
Small Cell Lung Carcinoma
Abnormal haemostasis in small cell lung cancer.
Small Cell Lung Carcinoma
Involvement of plasmin-mediated extracellular activation of progalanin in angiogenesis.
Small Cell Lung Carcinoma
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
Small Cell Lung Carcinoma
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Soft Tissue Injuries
Novel preclinical murine model of trauma-induced elbow stiffness.
Spasm
Plasmin and thrombin inhibitors in essentially untreated patients with coronary artery spasm.
Spinal Cord Injuries
Plasminogen activator promotes recovery following spinal cord injury.
Spinal Cord Injuries
Role of plasminogen activator in spinal cord remodeling after spinal cord injury.
Spinal Cord Injuries
The Serine Protease Plasmin Cleaves the Amino-terminal Domain of the NR2A Subunit to Relieve Zinc Inhibition of the N-Methyl-D-aspartate Receptors.
Spinal Cord Injuries
Tissue-type plasminogen activator-primed human iPSC-derived neural progenitor cells promote motor recovery after severe spinal cord injury.
Spinal Cord Injuries
tPA-mediated generation of plasmin is catalyzed by the proteoglycan NG2.
Spondylarthropathies
Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction.
Squamous Cell Carcinoma of Head and Neck
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Squamous Cell Carcinoma of Head and Neck
Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion.
Squamous Cell Carcinoma of Head and Neck
Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin.
Squamous Cell Carcinoma of Head and Neck
Proteolytic patterns of head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Squamous Cell Carcinoma of Head and Neck
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma]
Squamous Cell Carcinoma of Head and Neck
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Squamous Cell Carcinoma of Head and Neck
[The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma]
ST Elevation Myocardial Infarction
An Uncommon Complication of Streptokinase: Large Spontaneous Iliopsoas Hematoma.
ST Elevation Myocardial Infarction
Comparative efficacy of primary angioplasty with stent implantation and thrombolysis in restoring basal coronary artery flow in acute ST segment elevation myocardial infarction: quantitative assessment using the corrected TIMI frame count.
ST Elevation Myocardial Infarction
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
ST Elevation Myocardial Infarction
Recombinant tissue-type plasminogen activators: "time matters".
ST Elevation Myocardial Infarction
Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial.
ST Elevation Myocardial Infarction
Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome.
Staphylococcal Infections
Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis.
Stevens-Johnson Syndrome
Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.
Stillbirth
Syphilis-associated perinatal and infant mortality in rural Malawi.
Stomach Neoplasms
Analysis of NM23 protein and components of plasminogen activation system in tumors of patients with stomach cancer with consideration for disease clinical picture and morphology.
Stomach Neoplasms
Global transcriptomic analysis identifies SERPINE1 as a prognostic biomarker associated with epithelial-to-mesenchymal transition in gastric cancer.
Stomach Neoplasms
Immunological analysis of plasminogen activators from cultured human cancer cells.
Stomach Neoplasms
In vitro activity of probiotic Lactobacillus reuteri against gastric cancer progression by downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression.
Stomach Neoplasms
Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining.
Stomach Neoplasms
Plasminogen kringle 5 suppresses gastric cancer via regulating HIF-1? and GRP78.
Stomach Neoplasms
Relationship between expression of NM23 protein and clinical morphological factors and content of plasminogen activation system components in tumors of patients with gastric cancer.
Stomach Neoplasms
The plasminogen activation system and its role in lung cancer. A review.
Stomach Neoplasms
Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries.
Stomach Neoplasms
Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma.
Stomach Neoplasms
[Protease activities in gastric and colon cancer tissues]
Stomach Neoplasms
[Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]
Stomach Neoplasms
[Wound healing, blood coagulation and fibrinolysis during operations involving gastric cancer surgery]
Stomach Ulcer
Gastric fibrinolysis.
Stomatitis
[Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase)]
Strabismus
Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in an 8-Week-Old Female Infant.
Streptococcal Infections
Bacterial pathogens activate plasminogen to breach tissue barriers and escape from innate immunity.
Streptococcal Infections
Glomerular Deposition of Nephritis-Associated Plasmin Receptor (NAPlr) and Related Plasmin Activity: Key Diagnostic Biomarkers of Bacterial Infection-related Glomerulonephritis.
Streptococcal Infections
In Vivo Tracking of Streptococcal Infections of Subcutaneous Origin in a Murine Model.
Streptococcal Infections
Linoleic and palmitoleic acid block streptokinase-mediated plasminogen activation and reduce severity of invasive group A streptococcal infection.
Streptococcal Infections
Plasminogen is a critical host pathogenicity factor for group A streptococcal infection.
Stroke
"Hesitating and Puzzling": The Experiences and Decision Process of Acute Ischemic Stroke Patients with Prehospital Delay after the Onset of Symptoms.
Stroke
16(R)-hydroxyeicosatetraenoic acid, a novel cytochrome P450 product of arachidonic acid, suppresses activation of human polymorphonuclear leukocyte and reduces intracranial pressure in a rabbit model of thromboembolic stroke.
Stroke
4.5 Hours. The New Time Window for Tissue Plasminogen Activator in Stroke.
Stroke
A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators.
Stroke
A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity.
Stroke
A step toward understanding the mechanism of action of audit and feedback: a qualitative study of implementation strategies.
Stroke
Acute 'strokenomics': efficacy and economic analyses of alteplase for acute ischemic stroke.
Stroke
Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic therapy.
Stroke
Acute endovascular recanalization: lessons from randomized controlled trials.
Stroke
Advances in ischemic stroke treatment: neuroprotective and combination therapies.
Stroke
Alpha 1-Antitrypsin Therapy Mitigated Ischemic Stroke Damage in Rats.
Stroke
Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis.
Stroke
Antithrombotic and thrombolytic therapy for ischemic stroke.
Stroke
Antithrombotic therapy of acute stroke: thrombolytic agents.
Stroke
Benefits of stroke treatment delivered using a mobile stroke unit trial.
Stroke
Blood coagulation and fibrinolysis in acute ischaemic and haemorrhagic (intracerebral and subarachnoid haemorrhage) stroke: does decreased plasmin inhibitor indicate increased fibrinolysis in subarachnoid haemorrhage compared to other types of stroke?
Stroke
Calculated Decisions: tPA (Tissue Plasminogen Activator) Dosing for Stroke Calculator
Stroke
Can Quality-Adjusted Life-Years and Subgroups Help Us Decide Whether to Treat Late-Arriving Stroke Patients With Tissue Plasminogen Activator?
Stroke
Catheter-Directed Thrombectomy for Pulmonary Embolism in the Setting of Acute Stroke.
Stroke
Cerebral Ischemic Reperfusion Injury Following Recanalization of Large Vessel Occlusions.
Stroke
Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator-related hemorrhagic transformation.
Stroke
Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease.
Stroke
Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke.
Stroke
Combined X-ray angiography and diffusion-perfusion MRI for studying stroke evolution after rt-PA treatment in rats.
Stroke
Comparison of outcomes of patients with inpatient or outpatient onset ischemic stroke.
Stroke
Coronary artery disease, myocardial infarction, and brain embolism.
Stroke
Correction to: Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Stroke
Cuprizone-induced demyelination under physiological and post-stroke condition leads to decreased neurogenesis response in adult mouse brain.
Stroke
Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.
Stroke
Development of thrombolytic therapy for stroke: a perspective.
Stroke
Differential expression of oxidized/native lipoprotein(a) and plasminogen in human carotid and cerebral artery plaques.
Stroke
Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes.
Stroke
Direct Mechanical Intervention Versus Combined Intravenous and Mechanical Intervention in Large Artery Anterior Circulation Stroke: A Matched-Pairs Analysis.
Stroke
Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
Stroke
Does sex influence the response to intravenous thrombolysis in ischemic stroke?: answers from safe implementation of treatments in Stroke-International Stroke Thrombolysis Register.
Stroke
Early disruption of the blood-brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke.
Stroke
Early Infarct Growth Rate Correlation With Endovascular Thrombectomy Clinical Outcomes: Analysis From the SELECT Study.
Stroke
Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
Stroke
Effects of nitric oxide on reactive oxygen species production and infarction size after brain reperfusion injury.
Stroke
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.
Stroke
Effects of Stroke Unit Care in Acute Ischemic Stroke Patient Ineligible for Thrombolytic Treatment.
Stroke
Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
Stroke
Efficacy and safety of i.v. alteplase therapy up to 4.5 hours after acute ischemic stroke onset.
Stroke
Emergent Management of Tandem Lesions in Acute Ischemic Stroke.
Stroke
Enhanced Detection of Edema in Malignant Anterior Circulation Stroke (EDEMA) Score: A Risk Prediction Tool.
Stroke
Ethnic Differences in 90-Day Poststroke Medication Adherence.
Stroke
Extracellular proteolytic pathophysiology in the neurovascular unit after stroke.
Stroke
Fn-EDA (Fibronectin Containing Extra Domain A) in the Plasma, but Not Endothelial Cells, Exacerbates Stroke Outcome by Promoting Thrombo-Inflammation.
Stroke
Frequency of Blood-Brain Barrier Disruption Post-Endovascular Therapy and Multiple Thrombectomy Passes in Acute Ischemic Stroke Patients.
Stroke
Functional and morphologic evidence of the presence of tissue-plasminogen activator in vascular nerves: implications for a neurologic control of vessel wall fibrinolysis and rigidity.
Stroke
Functional Outcome Measures of Recombinant Tissue Plasminogen Activator-Treated Stroke Patients in the Telestroke Technology.
Stroke
Guidelines for Intravenous Thrombolysis (Recombinant Tissue-type Plasminogen Activator), the Third Edition, March 2019: A Guideline from the Japan Stroke Society.
Stroke
HandiStroke: a handheld tool for the emergent evaluation of acute stroke patients.
Stroke
Hemostatic disturbances in acute ischemic stroke: a study of 86 patients.
Stroke
Human neural stem cells improve early stage stroke outcome in delayed tissue plasminogen activator-treated aged stroke brains.
Stroke
Human placenta mesenchymal stem cell protection in ischemic stroke is angiotensin converting enzyme-2 and masR receptor-dependent.
Stroke
Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
Stroke
Imaging Negative Stroke: Diagnoses and Outcomes in Intravenous Tissue Plasminogen Activator-Treated Patients.
Stroke
Impact of General Anesthesia on Safety and Outcomes in the Endovascular Arm of Interventional Management of Stroke (IMS) III Trial.
Stroke
Impact of Initial Imaging Protocol on Likelihood of Endovascular Stroke Therapy.
Stroke
Impact of the Extended Thrombolysis Time Window on the Proportion of Recombinant Tissue-Type Plasminogen Activator-Treated Stroke Patients and on Door-to-Needle Time.
Stroke
Improving thrombolysis with encapsulated plasminogen activators and clinical relevance to myocardial infarction and stroke.
Stroke
Incidence and Association of Reperfusion Therapies With Poststroke Seizures: A Systematic Review and Meta-Analysis.
Stroke
Incidence of seizure in stroke patients treated with recombinant tissue plasminogen activator: A systematic review and meta-analysis.
Stroke
Increased Access to and Use of Endovascular Therapy Following Implementation of a 2-Tiered Regional Stroke System.
Stroke
Increased brain plasmin levels following experimental ischemic stroke in male mice.
Stroke
Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators.
Stroke
Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction.
Stroke
Insulin resistance and elevated levels of tissue plasminogen activator in first-degree relatives of South Asian patients with ischemic cerebrovascular disease.
Stroke
Intraarterial Thrombolysis as Rescue Therapy for Large Vessel Occlusions.
Stroke
Intracerebral hirudin injection attenuates ischemic damage and neurologic deficits without altering local cerebral blood flow.
Stroke
Intravenous Tissue Plasminogen Activator in Stroke Mimics.
Stroke
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke.
Stroke
Iron Overload Exacerbates the Risk of Hemorrhagic Transformation After tPA (Tissue-Type Plasminogen Activator) Administration in Thromboembolic Stroke Mice.
Stroke
Lack of association between pretreatment neurology consultation and subsequent protocol deviation in tissue plasminogen activator-treated patients with stroke.
Stroke
Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
Stroke
Letter by Katsanos and Tsivgoulis Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment".
Stroke
Letter by Tan and Xu Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment".
Stroke
Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke.
Stroke
Lys-plasminogen as an adjunct to local intra-arterial fibrinolysis for carotid territory stroke: laboratory and clinical findings.
Stroke
Magnitude of Benefit of Combined Endovascular Thrombectomy and Intravenous Fibrinolysis in Large Vessel Occlusion Ischemic Stroke.
Stroke
Management of Pediatric Strokes With Alteplase (Tissue Plasminogen Activator).
Stroke
Medical therapy for ischemic stroke.
Stroke
Mesenchymal stem cells in the treatment of ischemic stroke: progress and possibilities.
Stroke
Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.
Stroke
Mild Hypothermia Reduces Tissue Plasminogen Activator-Related Hemorrhage and Blood Brain Barrier Disruption After Experimental Stroke.
Stroke
Mild hypothermia reduces tissue plasminogen activator-related hemorrhage and blood brain barrier disruption after experimental stroke: editorial commentary on tang et Al., 2013.
Stroke
Misdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomes.
Stroke
Molecule of the Month. PDGFR-alpha antagonist Gleevec reduces blood vessel leakage and increases the therapeutic window associated with tissue plasminogen activator stroke treatment.
Stroke
Mouse model of in situ thromboembolic stroke and reperfusion.
Stroke
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke.
Stroke
National Institutes of Health Stroke Scale Item Profiles as Predictor of Patient Outcome: External Validation on Safe Implementation of Thrombolysis in Stroke-Monitoring Study Data.
Stroke
National Practice Patterns of Obtaining Informed Consent for Stroke Thrombolysis.
Stroke
New interventions in cerebrovascular disease: the role of thrombolytic therapy and balloon angioplasty.
Stroke
Nurse-Initiated Acute Stroke Care in Emergency Departments.
Stroke
On the contribution of S100A10 and annexin A2 to plasminogen activation and oncogenesis: an enduring ambiguity.
Stroke
One-Year Home-Time and Mortality After Thrombolysis Compared With Nontreated Patients in a Propensity-Matched Analysis.
Stroke
Organ damage in shock, disseminated intravascular coagulation, and stroke.
Stroke
Oxidative stress after thrombolysis-induced reperfusion in human stroke.
Stroke
Paradoxically accelerated fatal brain herniation following thrombolytic therapy in acute ischemic stroke.
Stroke
Patients with the malignant profile within 3 hours of symptom onset have very poor outcomes after intravenous tissue-type plasminogen activator therapy.
Stroke
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Stroke
Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.
Stroke
Plasmin (Human) Administration in Acute Middle Cerebral Artery Ischemic Stroke: Phase 1/2a, Open-Label, Dose-Escalation, Safety Study.
Stroke
Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank Samples.
Stroke
Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4.
Stroke
Plasminogen activation and thrombolysis for ischemic stroke.
Stroke
Plasminogen and stroke: more is better.
Stroke
Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice.
Stroke
Plasminogen deficiency causes reduced corticospinal axonal plasticity and functional recovery after stroke in mice.
Stroke
Poststroke Sonic Hedgehog Agonist Treatment Improves Functional Recovery by Enhancing Neurogenesis and Angiogenesis.
Stroke
Potentially Missed Diagnosis of Ischemic Stroke in the Emergency Department in the Greater Cincinnati/Northern Kentucky Stroke Study.
Stroke
Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial.
Stroke
Primary Thrombectomy in tPA (Tissue-Type Plasminogen Activator) Eligible Stroke Patients With Proximal Intracranial Occlusions.
Stroke
Production and purification of urokinase: a comprehensive review.
Stroke
Proteolytic cascade enzymes increase in focal cerebral ischemia in rat.
Stroke
Prothrombotic disorders and ischemic stroke in children.
Stroke
Puerperium Stroke and Subsequent Tissue-Type Plasminogen Activator-Induced Hemorrhage: A Case Report.
Stroke
Rates, Characteristics, and Outcomes of Patients Transferred to Specialized Stroke Centers for Advanced Care.
Stroke
Real-World Treatment Trends in Endovascular Stroke Therapy.
Stroke
Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice.
Stroke
Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
Stroke
Regional Learning Collaboratives Produce Rapid and Sustainable Improvements in Stroke Thrombolysis Times.
Stroke
Regional Pediatric Acute Stroke Protocol: Initial Experience During 3 Years and 13 Recanalization Treatments in Children.
Stroke
Regulatory T cells ameliorate tissue plasminogen activator-induced brain haemorrhage after stroke.
Stroke
Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Stroke
Response by Flint et al to Letter Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment".
Stroke
Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia.
Stroke
Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment.
Stroke
Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Stroke
Role of fibrinolytic markers in acute stroke.
Stroke
Role of transcranial Doppler ultrasonography in evaluation of patients with cerebrovascular disease.
Stroke
Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
Stroke
Safety of intravenous fibrinolysis in imaging-confirmed single penetrator artery infarcts.
Stroke
Sequential combination of two intravenous thrombolytics (recombinant tissue plasminogen activator/tenecteplase) in a patient with stroke and cardioembolic basilar artery occlusion.
Stroke
Shorter Intensive Care Unit Stays? The Majority of Post-Intravenous tPA (Tissue-Type Plasminogen Activator) Symptomatic Hemorrhages Occur Within 12 Hours of Treatment.
Stroke
Simplified modified Rankin Scale questionnaire correlates with stroke severity.
Stroke
Streamlined Hyperacute Magnetic Resonance Imaging Protocol Identifies Tissue-Type Plasminogen Activator-Eligible Stroke Patients When Clinical Impression Is Stroke Mimic.
Stroke
Stroke center characteristics which influence the administration of thrombolytic therapy for acute ischemic stroke: a national survey of stroke centers in Taiwan.
Stroke
Stroke in a young adult with familial plasminogen disorder.
Stroke
Strokes and their relationship to hypertension.
Stroke
Systemic inflammation affects reperfusion following transient cerebral ischaemia.
Stroke
Targeted Delivery of Plasminogen Activators for Thrombolytic Therapy: An Integrative Evaluation.
Stroke
Telemedicine versus face-to-face evaluation in the delivery of thrombolysis for acute ischaemic stroke: a single centre experience.
Stroke
The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results.
Stroke
The coagulopathy of heat stroke: alterations in coagulation and fibrinolysis in heat stroke patients during the pilgrimage (Haj) to Makkah.
Stroke
The Combination of Clinical Features, Transcranial Doppler, and Alberta Stroke Program Early Computed Tomography Score (Computed Tomography Angiography) in Predicting Outcome in Intravenous Recombinant Tissue Plasminogen Activator-Treated Patients.
Stroke
The effect of oral antiplatelet agents on tissue plasminogen activator-mediated thrombolysis in a rabbit model of thromboembolic stroke.
Stroke
The emerging role of mechanical and topographical factors in the development and treatment of nervous system disorders: dark and light sides of the force.
Stroke
The evaluation of intracranial pressure evaluation by optic nerve sheath diameter measurement on bedside ultrasonography after ischemic stroke.
Stroke
The impact of a statewide stroke quality improvement program: Colorado Stroke Alliance and Colorado Stroke Registry.
Stroke
The intranigral injection of tissue plasminogen activator induced blood-brain barrier disruption, inflammatory process and degeneration of the dopaminergic system of the rat.
Stroke
The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.
Stroke
The Protective Role of Immunomodulators on Tissue-Type Plasminogen Activator-Induced Hemorrhagic Transformation in Experimental Stroke: A Systematic Review and Meta-Analysis.
Stroke
The role of plasminogen activators in stroke treatment: fibrinolysis and beyond.
Stroke
Thrombi of different pathologies: implications for diagnosis and treatment.
Stroke
Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.
Stroke
Thrombolysis with plasmin: implications for stroke treatment.
Stroke
Thrombolytic properties of leukocytes from peripheral blood in healthy subjects and in patients with acute cerebral ischemia.
Stroke
Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients.
Stroke
Time to Decision and Treatment With tPA (Tissue-Type Plasminogen Activator) Using Telemedicine Versus an Onboard Neurologist on a Mobile Stroke Unit.
Stroke
Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.
Stroke
Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition.
Stroke
Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke.
Stroke
Tissue plasminogen activator-induced reperfusion injury after stroke revisited.
Stroke
Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke.
Stroke
Tissue-Type Plasminogen Activator-A296-299 Prevents Impairment of Cerebral Autoregulation After Stroke Through Lipoprotein-Related Receptor-Dependent Increase in cAMP and p38.
Stroke
Tissue-type plasminogen activator: characteristics, applications and production technology.
Stroke
Ultrasound in the treatment of ischaemic stroke.
Stroke
Understanding the enzymology of fibrinolysis and improving thrombolytic therapy.
Stroke
Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes.
Stroke
Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.
Stroke
Using the behavioral flexibility operant task to detect long-term deficits in rats following middle cerebral artery occlusion.
Stroke
Validation assessment of risk scores to predict postthrombolysis intracerebral haemorrhage.
Stroke
[Blood-brain barrier pathophysiology and ischaemic brain oedema]
Stroke
[Endovascular thrombectomy for ischemic stroke].
Stroke
[Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease]
Stroke
[Revising the principles and improving the methods of differential therapy of ischemic stroke]
Stroke, Lacunar
Hemostatic Factors and Subclinical Brain Infarction in a Community-Based Sample: The ARIC Study.
Subarachnoid Hemorrhage
Effect of tissue plasminogen activator on intimal platelet accumulation in cerebral arteries after subarachnoid hemorrhage in cats.
Subarachnoid Hemorrhage
Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Modification of experimental post-subarachnoid hemorrhage vasculopathy with intracisternal plasmin.
Subarachnoid Hemorrhage
Source of fibrin/fibrinogen degradation products in the CSF after subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Thrombolytic therapy with tissue plasminogen activator for prevention of vasospasm in experimental subarachnoid hemorrhage: its efficacy and problems.
Subarachnoid Hemorrhage
Treatment of cerebral vasospasm with biocompatible controlled-release systems for intracranial drug delivery.
Subarachnoid Hemorrhage
Using antifibrinolytics to tackle neuroinflammation.
Subarachnoid Hemorrhage
[Correlations among FPB beta 15-42, PAC and D-dimer]
Subarachnoid Hemorrhage
[Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease]
Superior Vena Cava Syndrome
[Iatrogenic superior vena cava syndrome. Successful thrombolysis with recombinant tissue plasminogen activator (r-tPA)]
Suppuration
[Several components of plasma hemostasis in patients with suppurative processes in the abdominal cavity]
Surgical Wound Infection
Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.
Surgical Wound Infection
Plasmin, Immunity, and Surgical Site Infection.
Syncope
A Rare Case of Acute Pulmonary Embolism after Coronary Angiography due to Sand Bag Compression.
Synovitis
Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders.
Synovitis
Collagenase in synovitis of rheumatoid arthritis.
Syphilis
Don't Forget What You Can't See: A Case of Ocular Syphilis.
Syphilis
Early syphilitic hepatitis concomitant with nephrotic syndrome followed by acute kidney injury.
Syphilis
Integration of antenatal syphilis screening in an urban HIV clinic: a feasibility study.
Syphilis
Single Mothers and Female Sex Workers in Zambia Have Similar Risk Profiles.
Syphilis
Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis.
Syphilis
Syphilis and Human Immunodeficiency Virus (HIV)-1 Coinfection: Influence on CD4 T-Cell Count, HIV-1 Viral Load, and Treatment Response.
Syphilis
Syphilis-associated perinatal and infant mortality in rural Malawi.
Syphilis
The Number of Interviews Needed to Yield New Syphilis and Human Immunodeficiency Virus Cases Among Partners of People Diagnosed With Syphilis, North Carolina, 2015.
Syphilis
The resurgence of congenital syphilis: a cocaine-related problem.
Syphilis
Utility of rapid plasmin reagin titres in assessing treatment response and re-infection for infectious syphilis.
Syphilis, Congenital
The resurgence of congenital syphilis: a cocaine-related problem.
t-plasminogen activator deficiency
Blood protein defects associated with thrombosis. Laboratory assessment.
t-plasminogen activator deficiency
Haematologic disorders and cerebral venous thrombosis.
t-plasminogen activator deficiency
Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease.
t-plasminogen activator deficiency
Role of the pleiotropic effects of plasminogen deficiency in infection experiments with plasminogen-deficient mice.
t-plasminogen activator deficiency
Syndromes of hypercoagulability and thrombosis: a review.
t-plasminogen activator deficiency
The surgical implications of primary hypercoagulable states.
t-plasminogen activator deficiency
Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior.
t-plasminogen activator deficiency
[Thrombophilic states]
Takotsubo Cardiomyopathy
Successful treatment of cerebral emboli with tissue plasminogen activator in a patient with takotsubo cardiomyopathy: A case report.
Telangiectasis
[A case of Osler-Rendu disease with simultaneous thrombopenia and a factor VIII inhibitor]
Temporomandibular Joint Disorders
Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders.
Tetanus
Effect of fragmentation of tetanus immune globulin (human) on neutralization of tetanus toxin.
Tetanus
Possible involvement of plasmin in long-term potentiation of rat hippocampal slices.
Thrombasthenia
Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation.
Thrombasthenia
Plasminogen interacts with human platelets through two distinct mechanisms.
Thromboangiitis Obliterans
Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease).
Thrombocytopenia
Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection.
Thrombocytopenia
Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice.
Thrombocytopenia
Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury.
Thrombocytopenia
Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia.
Thrombocytopenia
Giant hemangioma of the liver (Kasabach-Merritt syndrome): successful suppression of intravascular coagulation permitting surgical removal.
Thrombocytopenia
Haemostatic changes during open heart surgery with extracorporeal circulation and deep hypothermia in children.
Thrombocytopenia
Hemostatic consequences of a non-fresh or reconstituted whole blood small volume cardiopulmonary bypass prime in neonates and infants.
Thrombocytopenia
Massive pulmonary embolism presenting as disseminated intravascular coagulation.
Thrombocytopenia
Occurrence of disseminated intravascular coagulation (DIC) in obstructive jaundice and its relation to biliary tract infection.
Thrombocytopenia
Plasminogen activation in human leukemia and in normal hematopoietic cells.
Thrombocytopenia
Urokinase receptor (uPAR, CD87) is a platelet receptor important for kinetics and TNF-induced endothelial adhesion in mice.
Thrombocytopenia
[A case of Osler-Rendu disease with simultaneous thrombopenia and a factor VIII inhibitor]
Thrombocytopenia
[Disorders of hemostasis in dysthyroidism]
Thrombocytopenia
[Thrombocyte function and plasma coagulation following poisoning with organophosphates]
Thrombocytosis
POEMS syndrome with vascular lesions and renal carcinoma - possible role of cytokines.
Thromboembolism
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Thromboembolism
Acute femoral arterial thromboembolism. Successful treatment with fibrinolysin.
Thromboembolism
Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation syndrome who actually developed thromboembolism.
Thromboembolism
Congenital deficiency of plasminogen and its relationship to venous thrombosis.
Thromboembolism
FIBRINOLYSIN TREATMENT OF THROMBOEMBOLISM.
Thromboembolism
LYSIS OF INTRACEREBRAL THROMBOEMBOLISM WITH FIBRINOLYSIN. REPORT OF A CASE.
Thromboembolism
Pathogenesis of venous thromboembolism: when the cup runneth over.
Thromboembolism
Perfusion with fibrinolysin in experimental iliofemoral thromboembolism.
Thromboembolism
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Thromboembolism
Targeted Delivery of Plasminogen Activators for Thrombolytic Therapy: An Integrative Evaluation.
Thromboembolism
THERAPEUTIC THROMBOLYSIS IN CEREBRAL THROMBOEMBOLISM. DOUBLE-BLIND EVALUATION OF INTRAVENOUS PLASMIN THERAPY IN CAROTID AND MIDDLE CEREBRAL ARTERIAL OCCLUSION.
Thromboembolism
Thrombolysis with fibrinolysin (plasmin)-new therapeutic approach to thromboembolism.
Thromboembolism
Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia.
Thromboembolism
[A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs]
Thromboembolism
[Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome]
Thromboembolism
[Fibrinolysin therapy of thromboembolism of the major vessles]
Thromboembolism
[Healing of a patient with thromboembolism of the bifurcation of the aorta with a mixture of fibrinolysin and heparin]
Thromboembolism
[Problems of the early diagnosis and treatment of thromboembolism of the pulmonary artery. Results of the use of fibrinolysin]
Thromboembolism
[Pulmonary thromboembolism accompanied by abnormal plasminogen]
Thromboembolism
[Treatment of thromboembolism of the aortic bifurcation with fibrinolysin and heparin]
Thrombophilia
"TEG talk": expanding clinical roles for thromboelastography and rotational thromboelastometry.
Thrombophilia
A case of acute pulmonary embolism associated with dysplasminogenemia.
Thrombophilia
A protein C and plasminogen compound heterozygous mutation and a compound heterozygote of protein C in two related Chinese families.
Thrombophilia
Abnormal plasminogen: a genetically determined cause of hypercoagulability.
Thrombophilia
Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study.
Thrombophilia
Arterial thrombosis in homozygous antithrombin deficiency.
Thrombophilia
Blood coagulation studies in domestic pigs (Hanover breed) and minipigs (Goettingen breed).
Thrombophilia
Calciphylaxis: A Disease of Pannicular Thrombosis.
Thrombophilia
Changes in Biomarkers of Coagulation, Fibrinolytic, and Endothelial Functions for Evaluating the Predisposition to Venous Thromboembolism in Patients With Hereditary Thrombophilia.
Thrombophilia
Coagulation profile of COVID-19 patients admitted to the ICU: An exploratory study.
Thrombophilia
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Thrombophilia
Common C677T polymorphism in the methylenetetrahydrofolate reductase gene increases the risk for deep vein thrombosis in patients with predisposition of thrombophilia.
Thrombophilia
Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma.
Thrombophilia
Disturbances of the coagulating equilibrium of blood in diabetes mellitus.
Thrombophilia
Effect of endotoxin on clotting mechanism. III. On the relationship between hypercoagulability, plasminogen activator activity, and antithrombin activity.
Thrombophilia
Enzymatic Functional Assays of Coagulation Using Small Sample Volumes.
Thrombophilia
Familial association of hypoplasminogenemia and heterozygous factor V deficiency.
Thrombophilia
Hematological causes of venous thrombosis in young people: high incidence of myeloproliferative disorder as underlying disease in patients with splanchnic venous thrombosis.
Thrombophilia
Hemostasis in Overt and Subclinical Hyperthyroidism.
Thrombophilia
Hemostatic disorders associated with arterial hypertension and peripheral arterial disease.
Thrombophilia
Hypercoagulability and thrombosis.
Thrombophilia
Is there a phase of hypercoagulability when aprotinin is used in cardiac surgery?
Thrombophilia
Is veno-occlusive disease a specific syndrome or the exacerbation of physiopathologic hemostatic changes in hematopoietic stem cell transplantation (HSCT)?
Thrombophilia
Laboratory screening of inherited thrombotic syndromes.
Thrombophilia
Late changes in hemostatic parameters following open-heart surgery.
Thrombophilia
Markers of thrombin and plasmin generation in patients with inherited thrombophilia.
Thrombophilia
Migraine associated with patent foramen ovale may be caused by reactivation of cerebral toxoplasmosis triggered by arterial blood oxygen desaturation.
Thrombophilia
Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group.
Thrombophilia
Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis.
Thrombophilia
Natural inhibitors and fibrinogen/fibrin degradation products in patients with myocardial infarction.
Thrombophilia
Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease.
Thrombophilia
Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan.
Thrombophilia
Protocol and preliminary results of a clinical study for comparison of solvent/detergent-inactivated plasma VIP versus FFP with special consideration of the balance of hemostasis.
Thrombophilia
Risk Factors for Thrombosis Development in Mexican Patients.
Thrombophilia
Sclerotherapy for varicose veins of the lower legs in patients with dysplasminogenemia.
Thrombophilia
The relationship between the fibrinogen D domain self-association/cross-linking site (gammaXL) and the fibrinogen Dusart abnormality (Aalpha R554C-albumin): clues to thrombophilia in the "Dusart syndrome".
Thrombophilia
Thrombophilia found in patients with moyamoya disease.
Thrombophilia
Trimester-specific reference intervals of TAT, TM, tPAI-C and PIC for healthy Chinese pregnant women.
Thrombophilia
[A coagulation of fibrinolytic study in children with nephrotic syndrome: evaluation of hypercoagulability by measuring with plasmin- alpha 2 plasmin inhibitor complex and FDP D-dimer]
Thrombophilia
[A method for determining plasminogen with a Russian chromogenic substrate and its diagnostic significance]
Thrombophilia
[Comparison of urokinase and tissue-type plasminogen activator in transcatheter arterial fibrinolysis]
Thrombophilia
[Diagnosis and treatment of coagulation disorders]
Thrombophilia
[Etiological analysis of thrombophilia]
Thrombophilia
[Evaluating the origin of thrombophilia: indications and implementation]
Thrombophilia
[Genetic polymorphism and risk of thromboses]
Thrombophilia
[Immunoradiometric determination of blood/tissue plasminogen activators in thrombophilia]
Thrombophilia
[Pregnancy and thrombophilia in women with congenital deficit of antithrombin III, protein C, protein S or plasminogen: analysis of 39 cases]
Thrombophlebitis
Congenital abnormal plasminogen, Frankfurt I, a cause for recurrent venous thrombosis.
Thrombophlebitis
Fibrinolysin (plasmin) therapy in acute deep thrombophlebitis. A controlled study.
Thrombophlebitis
Fibrinolysin therapy of thrombophlebitis and pulmonary embolism--a double-blind study.
Thrombophlebitis
Fibrinolysin Therapy of Thrombophlebitis and Pulmonary Embolism.
Thrombophlebitis
Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation.
Thrombophlebitis
The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin.
Thrombophlebitis
[Acute thrombophlebitis and its treatment with fibrinolysin and anticoagulants]
Thrombophlebitis
[The influence of the intra-tissue electrical phonophoresis on the hemostasis system in the treatment of acute thrombophlebitis and phlebothrombosis]
Thrombophlebitis
[The use of fibrinolysin and heparin in the treatment of acute thrombophlebitis, thrombosis and embolism]
Thrombosis
"Plasminogen steal" and clot lysis.
Thrombosis
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
Thrombosis
99mTc-plasmin test in deep vein thrombosis of the leg.
Thrombosis
A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator.
Thrombosis
A clinical approach in regression of glomerulosclerosis.
Thrombosis
A fibrin specific monoclonal antibody which interferes with the fibrinolytic effect of tissue plasminogen activator.
Thrombosis
A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion.
Thrombosis
A lethal phenotype associated with tissue plasminogen deficiency in humans.
Thrombosis
A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma.
Thrombosis
A multi-modal approach to the management of bypass graft failure.
Thrombosis
A new treatment for traumatic shock and ARDS.
Thrombosis
A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion.
Thrombosis
A plasmin-activatable thrombin inhibitor reduces experimental thrombosis and assists experimental thrombolysis in murine models.
Thrombosis
A plasminogen-related gene is expressed in cancer cells.
Thrombosis
A potential basis for the thrombotic risks associated with lipoprotein(a).
Thrombosis
A region of tissue plasminogen activator that affects plasminogen activation differentially with various fibrin(ogen)-related stimulators.
Thrombosis
A sequential study of plasma histidine-rich glycoprotein and plasminogen in patients with acute myocardial infarction and deep vein thrombosis.
Thrombosis
A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis.
Thrombosis
Abnormal plasminogen, a case of recurrent thrombosis.
Thrombosis
Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis.
Thrombosis
Abnormal plasminogen: a genetically determined cause of hypercoagulability.
Thrombosis
Abnormalities of the fibrinolytic system as a cause of upper extremity ischemia: a preliminary report.
Thrombosis
Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase.
Thrombosis
Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis.
Thrombosis
Activity of coagulation and fibrinolytic system components in the vein thrombus.
Thrombosis
Acute arterial thrombosis associated with inadvertent high dose of tranexamic acid.
Thrombosis
Acute deep vein thrombosis treated with porcine plasmin. A double blind trial.
Thrombosis
Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis.
Thrombosis
Alfimeprase: a novel recombinant direct-acting fibrinolytic.
Thrombosis
Alpha2-antiplasmin: potential therapeutic roles in fibrin survival and removal.
Thrombosis
Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.
Thrombosis
Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia.
Thrombosis
An activated state of blood coagulation and fibrinolysis in patients with abdominal aortic aneurysm.
Thrombosis
Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus.
Thrombosis
Annexin A2 autoantibodies in thrombosis and autoimmune diseases.
Thrombosis
Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.
Thrombosis
Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp).
Thrombosis
Antithrombin III, plasminogen, plasmin, and alpha-2-antiplasmin in donor blood and plasma components.
Thrombosis
Antithrombotic effects and related mechanisms of Salvia deserta Schang root EtOAc extracts.
Thrombosis
Antithrombotic effects of odorless garlic powder both in vitro and in vivo.
Thrombosis
Antithrombotic therapy of acute stroke: thrombolytic agents.
Thrombosis
Apo(a) promotes thrombosis in a vascular injury model by a mechanism independent of plasminogen.
Thrombosis
Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.
Thrombosis
Approach to thrombotic occlusion related to long-term catheters of hemodialysis patients: a narrative review.
Thrombosis
Arterial expression of the plasminogen activator system early after cardiac transplantation.
Thrombosis
Assembly of plasmin-generating proteins on the surface of human endothelial cells.
Thrombosis
Assessment of antithrombotic properties of sodium ibuprofen.
Thrombosis
Association of inherited dysfibrinogenaemia and protein C deficiency in two unrelated families.
Thrombosis
Augmented pulse-spray thrombolysis with tPA by early pulsed intrathrombic plasminogen enrichment.
Thrombosis
Bafibrinase: A non-toxic, non-hemorrhagic, direct-acting fibrinolytic serine protease from Bacillus sp. strain AS-S20-I exhibits in vivo anticoagulant activity and thrombolytic potency.
Thrombosis
Biological control of tissue plasminogen activator-mediated fibrinolysis.
Thrombosis
Breaking boundaries-coagulation and fibrinolysis at the neurovascular interface.
Thrombosis
Capturing host plasmin(ogen): a common mechanism for invasive pathogens?
Thrombosis
Causes of venous thrombosis in fifty Chinese patients.
Thrombosis
Central venous line thrombosis in premature infants: a case management and literature review.
Thrombosis
Cerebrospinal fluid proteomics in children during induction for acute lymphoblastic leukemia: A pilot study.
Thrombosis
Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
Thrombosis
Characterization of a recombinant single-chain molecule comprising the variable domains of a monoclonal antibody specific for human fibrin fragment D-dimer.
Thrombosis
Characterization of recombinant plasminogen activator production by primate endothelial cells transduced with retroviral vectors.
Thrombosis
Chimeric derivative of fibrolase, a fibrinolytic enzyme from southern copperhead venom, possesses inhibitory activity on platelet aggregation.
Thrombosis
Clinical disorders of fibrinolysis: a critical review.
Thrombosis
Clinical experience with alteplase in the management of intracardiac and major cardiac vessels thrombosis in pediatrics: a case series.
Thrombosis
Clone, expression and plasminogen binding property of three fructose-1,6-bisphosphate aldolases from Clonorchis sinensis.
Thrombosis
Cloning and characterization of a plasminogen-binding surface-associated enolase from Schistosoma bovis.
Thrombosis
Clot accumulation characteristics of plasminogen-bearing liposomes in a flow-system. Groningen Utrecht Institute for Drug Exploration.
Thrombosis
Coagulation studies in thrombotic thrombocytopenic purpura, with special reference to von Willebrand factor and protein S.
Thrombosis
Coagulative and fibrinolytic activity in parietal thrombus of aortic aneurysm.
Thrombosis
Coagulopathies and arterial stroke.
Thrombosis
Coevolutionary patterns in plasminogen activation.
Thrombosis
Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model.
Thrombosis
Combined Ala601-Thr-type dysplasminogenaemia and antiphospholipid antibody syndrome in a patient with recurrent thrombosis.
Thrombosis
Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli.
Thrombosis
Combined use of fibrinolysin and endarterectomy. Results in stenosis with recent carotid artery thrombosis.
Thrombosis
Comparative anticoagulant effects of coumadin, heparin, and fibrinolysin on direct-current thrombosis of rat mesoappendix vessels.
Thrombosis
Comparative study on the inhibition of plasmin and delta-plasmin via benzamidine derivatives.
Thrombosis
Comparative tolerability profiles of thrombolytic agents. A review.
Thrombosis
Comparison between 99Tcm-porcine plasmin and 99Tcm-labelled erythrocytes in diagnosis of deep vein thrombosis.
Thrombosis
Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature.
Thrombosis
Comparison of plasma total plasmin activities in male and female hypertensive rats.
Thrombosis
Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin.
Thrombosis
Composition and susceptibility to thrombolysis of human arterial thrombi and the influence of their age.
Thrombosis
Conformational quiescence of ADAMTS13 prevents proteolytic promiscuity.
Thrombosis
Congenital abnormal plasminogen, Frankfurt I, a cause for recurrent venous thrombosis.
Thrombosis
Construction and biological activities of human tPA eukaryotic expression plasmid.
Thrombosis
Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.
Thrombosis
Coronary arterial and other intravascular thromboses treated with fibrinolysin. Experimental and clinical results.
Thrombosis
Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis.
Thrombosis
Cross-species pharmacologic evaluation of plasmin as a direct-acting thrombolytic agent: ex vivo evaluation for large animal model development.
Thrombosis
Crystal structure of the catalytic domain of human plasmin complexed with streptokinase.
Thrombosis
Current concepts in coronary thrombolysis.
Thrombosis
Current Trends on Glomerulosclerosis Regression.
Thrombosis
Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis.
Thrombosis
Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Thrombosis
Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance.
Thrombosis
Delivery system for targeted thrombolysis without the risk of hemorrhage.
Thrombosis
Demonstration of 99mTc-labelled plasmin on the surface of ex vivo thrombi.
Thrombosis
Design of novel thrombolytic agents via domain modifications.
Thrombosis
Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.
Thrombosis
Detection and treatment of intravascular thrombi with magnetofluorescent nanoparticles.
Thrombosis
Detection of an Ala601Thr mutation of plasminogen gene in 3 out of 36 Korean patients with deep vein thrombosis.
Thrombosis
Determinants of fibrin formation, structure, and function.
Thrombosis
Determination of fast-acting plasmin inhibitor (alpha2-antiplasmin) in plasma from patients with tendency to thrombosis and increased fibrinolysis.
Thrombosis
Development of an immunoaffinity method for purification of streptokinase.
Thrombosis
Development of catheter-directed intrathrombus thrombolysis with plasmin for the treatment of acute lower extremity arterial occlusion.
Thrombosis
Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots.
Thrombosis
Dimerized plasmin fragment D as a potential biomarker to predict successful catheter-directed thrombolysis therapy in acute deep vein thrombosis.
Thrombosis
Disequilibrium of Blood Coagulation and Fibrinolytic System in Patients With Coronary Artery Ectasia.
Thrombosis
Distinction by radioisotope technique of a subgroup with increased thrombophilic potential among patients submitted to major abdominal surgery.
Thrombosis
Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?
Thrombosis
Drug treatment of acute ischemic stroke.
Thrombosis
Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation.
Thrombosis
Early myocardial reperfusion: an assessment of current strategies in acute myocardial infarction.
Thrombosis
Echocardiographic assessment of right atrial thrombus related to the implanted port device in patient receiving chemotherapy for non-Hodgkin's lymphoma.
Thrombosis
Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo.
Thrombosis
Effect of anti plasminogen monoclonal antibodies on whole blood clot lysis.
Thrombosis
Effect of mutalysin II on vascular recanalization after thrombosis induction in the ear of the hairless mice model.
Thrombosis
Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Thrombosis
Effect of SanOrg123781A, a synthetic hexadecasaccharide, on clot-bound thrombin and factor Xa in vitro and in vivo.
Thrombosis
Effect of Two Lipoprotein (a)-Associated Genetic Variants on Plasminogen Levels and Fibrinolysis.
Thrombosis
Effect of volume expanders on the lysability of ex vivo thrombi in the rabbit.
Thrombosis
Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease.
Thrombosis
Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model.
Thrombosis
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice.
Thrombosis
Effects of flow on recombinant tissue plasminogen activator-induced pulmonary thrombolysis.
Thrombosis
Effects of hemocoagulase agkistrodon on the coagulation factors and its procoagulant activities.
Thrombosis
Effects of heparin, plasmin, dextran and low-molecular-weight dextran on electrically induced thromboses.
Thrombosis
Effects of heparin, plasmin, dextran, and low molecular dextran on bioelectrically induced thromboses.
Thrombosis
Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
Thrombosis
Effects of lipids on thrombotic mechanisms in atherosclerosis.
Thrombosis
Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction.
Thrombosis
Effects of lipoprotein(a) on thrombolysis.
Thrombosis
Effects of oral stanozolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity.
Thrombosis
Effects of plasmin on rabbit platelets.
Thrombosis
Effects of statins in reducing thrombotic risk and modulating plaque vulnerability.
Thrombosis
Efficacy of different doses of alteplase thrombolysis on acute ischemic stroke in patients.
Thrombosis
Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Thrombosis
Electron microscopic study on the outer membrane of chronic subdural hematoma.
Thrombosis
Elevated levels of plasmin-alpha2 antiplasmin complexes in unstable angina.
Thrombosis
Endocytosis of the recombinant tissue plasminogen activator alteplase by hepatic endothelial cells.
Thrombosis
Endothelial cell injury induced by plasmin in vitro.
Thrombosis
Engineered Micro- and Nanoparticles for Fibrinolysis.
Thrombosis
Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models.
Thrombosis
Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy.
Thrombosis
Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors.
Thrombosis
Enhanced spontaneous thrombolysis: a new therapeutic challenge.
Thrombosis
Enhancement of the thrombolytic efficacy of prourokinase by lys-plasminogen in a dog model of arterial thrombosis.
Thrombosis
Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
Thrombosis
Enolase, a plasminogen receptor isolated from salivary gland transcriptome of the ixodid tick Haemaphysalis flava.
Thrombosis
Epsilon amino caproic acid inhibits streptokinase-plasminogen activator complex formation and substrate binding through kringle-dependent mechanisms.
Thrombosis
Epsilon Aminocaproic Acid Pretreatment Provides Neuroprotection Following Surgically Induced Brain Injury in a Rat Model.
Thrombosis
Erythrocyte Fraction Within Retrieved Thrombi Contributes to Thrombolytic Response in Acute Ischemic Stroke.
Thrombosis
Evaluation of intravenous human fibrinolysin as a treatment for recent intravascular thrombosis.
Thrombosis
Experimental study of biosoluble drugs. Thrombus lysis with biosoluble immobilized fibrinolysin in experiment.
Thrombosis
Expression of an anchored urokinase in the apical endothelial cell membrane. Preservation of enzymatic activity and enhancement of cell surface plasminogen activation.
Thrombosis
Factor XIIIa cross-linking of the Marburg fibrin: formation of alpham.gamman-heteromultimers and the alpha-chain-linked albumin. gamma complex, and disturbed protofibril assembly resulting in acquisition of plasmin resistance relevant to thrombophila.
Thrombosis
Factors Affecting Clot Lysis Rates in Patients With Spontaneous Intraventricular Hemorrhage.
Thrombosis
Familial association of hypoplasminogenemia and heterozygous factor V deficiency.
Thrombosis
Familial dysplasminogenemia with central retinal vein and cilioretinal artery occlusion.
Thrombosis
Feedback regulation of endothelial cell surface plasmin generation by PKC dependent phosphorylation of annexin A2.
Thrombosis
Fibrin formation and dissolution in women receiving oral contraceptive drugs.
Thrombosis
Fibrin, lipoprotein(a), plasmin interactions: a model linking thrombosis and atherogenesis.
Thrombosis
Fibrinogen and a Triad of Thrombosis, Inflammation, and the Renin-Angiotensin System in Premature Coronary Artery Disease in Women: A New Insight into Sex-Related Differences in the Pathogenesis of the Disease.
Thrombosis
Fibrinogen anomalies and disease. A clinical update.
Thrombosis
Fibrinogen counteracts the antiadhesive effect of fibrin-bound plasminogen by preventing its activation by adherent U937 monocytic cells.
Thrombosis
Fibrinogen Nijmegen: congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA.
Thrombosis
Fibrinolysin for thrombosis.
Thrombosis
FIBRINOLYSIN THERAPY FOR THROMBOSIS OF PRIAPISM.
Thrombosis
Fibrinolysis and the risk of venous and arterial thrombosis.
Thrombosis
Fibrinolysis is amplified by converting alpha-antiplasmin from a plasmin inhibitor to a substrate.
Thrombosis
Fibrinolysis: from blood to the brain.
Thrombosis
Fibrinolytic treatment of retinal vein thrombosis. The use of Fibrinolysin Human Lyovac (Merck).
Thrombosis
From Cerius(2) based stereoview to mouse and enzyme: the model systems for discovery of novel urokinase inhibitors.
Thrombosis
Functionalized carriers for the improved delivery of plasminogen activators.
Thrombosis
Further characterization and thrombolytic activity in a rat model of a fibrinogenase from Vipera lebetina venom.
Thrombosis
Further studies on an inhibitor of plasminogen activation in human serum. Release of the inhibitor during coagulation and thrombus formation.
Thrombosis
Gender affects skin wound healing in plasminogen deficient mice.
Thrombosis
Generation and role of angiostatin in human platelets.
Thrombosis
Generation of fibrinolytic activity by infusion of activated protein C into dogs.
Thrombosis
Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.
Thrombosis
Glucose Concentration Affects Fibrin Clot Structure and Morphology as Evidenced by Fluorescence Imaging and Molecular Simulations.
Thrombosis
Haemostatic changes in patients with deep vein thrombosis.
Thrombosis
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Thrombosis
Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children.
Thrombosis
Heterozygous type I plasminogen deficiency is associated with an increased risk for thrombosis: a statistical analysis in 20 kindreds.
Thrombosis
High-level expression, purification, and enzymatic characterization of truncated human plasminogen (Lys531-Asn791) in the methylotrophic yeast Pichia pastoris.
Thrombosis
Homocysteine-Enhanced Proteolytic and Fibrinolytic Processes in Thin Intraluminal Thrombus and Adjacent Wall of Abdominal Aortic Aneurysm: Study In Vitro.
Thrombosis
Human fibrinogen.
Thrombosis
Human plasminogen catalytic domain undergoes an unusual conformational change upon activation.
Thrombosis
Hypercoagulability and thrombosis.
Thrombosis
Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin.
Thrombosis
Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses.
Thrombosis
IgG antibodies to plasminogen and their relationship to IgG anti-beta(2)-glycoprotein 1 antibodies and thrombosis.
Thrombosis
Immobilization of bioactive plasmin reduces the thrombogenicity of metal surfaces.
Thrombosis
Immunologic and hematologic properties of antibodies to prothrombin and plasminogen in a mouse model.
Thrombosis
Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial.
Thrombosis
Improving thrombolysis with encapsulated plasminogen activators and clinical relevance to myocardial infarction and stroke.
Thrombosis
In vitro comparison of complementary interactions between synthetic linear/branched oligo/poly-L-lysines and tissue plasminogen activator by means of high-performance monolithic-disk affinity chromatography.
Thrombosis
In vitro Simulation of Therapeutic Thrombolysis With Microtiter Plate Clot-Lysis Assay.
Thrombosis
In Vivo Anticoagulant and Thrombolytic Activities of a Fibrinolytic Serine Protease (Brevithrombolase) With the k-Carrageenan-Induced Rat Tail Thrombosis Model.
Thrombosis
In vivo behaviour of vesicular urokinase.
Thrombosis
Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis.
Thrombosis
Increased production of thromboxane A2 by coronary arteries after thrombolysis.
Thrombosis
Increased risk of venous thrombosis in carriers of natural anticoagulant deficiencies. Results of the family studies of the Spanish Multicenter Study on Thrombophilia (EMET study).
Thrombosis
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Thrombosis
Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood.
Thrombosis
Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes.
Thrombosis
Influence of intrinsic and extrinsic plasminogen upon the lysis of thrombi in vitro.
Thrombosis
Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces.
Thrombosis
Inhibition of vascular endothelial cell prostacyclin synthesis by plasmin.
Thrombosis
Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells.
Thrombosis
Insertion of fibrin peptides into urokinase enhances fibrin affinity.
Thrombosis
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.
Thrombosis
Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis.
Thrombosis
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.
Thrombosis
International collaborative study for the establishment of the second International Reference Preparation of plasmin.
Thrombosis
Intracoronary thrombolysis in acute myocardial infarction: experimental background and clinical experience.
Thrombosis
Intraluminal thrombus enhances proteolysis in abdominal aortic aneurysms.
Thrombosis
Intravascular fibrinolysis of small-vessel thrombosis.
Thrombosis
Intravenous Fibrinolysin in the Treatment of Intravascular Thrombosis.
Thrombosis
Intravenous Human Fibrinolysin in the Treatment of Intravascular Thrombosis.
Thrombosis
Investigation of a congenital abnormal plasminogen, Frankfurt I, and its relationship to thrombosis.
Thrombosis
Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms.
Thrombosis
Isolated familial plasminogen deficiency may not be a risk factor for thrombosis.
Thrombosis
Ixonnexin from Tick Saliva Promotes Fibrinolysis by Interacting with Plasminogen and Tissue-Type Plasminogen Activator, and Prevents Arterial Thrombosis.
Thrombosis
Kallikrein inhibition and C1-esterase inhibitor levels in patients with the lupus inhibitor.
Thrombosis
Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator.
Thrombosis
Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier?
Thrombosis
Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease.
Thrombosis
Lipoprotein (a): an emerging risk factor for atherosclerosis.
Thrombosis
Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.
Thrombosis
Lipoprotein(a) and ischemic heart disease-A causal association? A review.
Thrombosis
Lipoprotein(a) as a risk factor for coronary artery disease.
Thrombosis
Lipoprotein(a), atherosclerosis and thrombosis.
Thrombosis
Lipoprotein(a): an emerging cardiovascular risk factor.
Thrombosis
Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease?
Thrombosis
Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA).
Thrombosis
Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis.
Thrombosis
Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
Thrombosis
Lonomia genus caterpillar envenomation: clinical and biological aspects.
Thrombosis
Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency.
Thrombosis
Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis?
Thrombosis
Low prevalence of thrombophilic coagulation defects in patients with deep vein thrombosis of the upper limbs.
Thrombosis
LYS-plasminogen shortens the duration of local thrombolytic treatment of peripheral arterial occlusions--a randomized controlled trial.
Thrombosis
Lysis of intravascular blood clots. Fibrinolysin therapy. Indications, contraindications, and results.
Thrombosis
Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
Thrombosis
Management of hydrocephalus in children with plasminogen deficiency.
Thrombosis
Management of postvitrectomy diabetic vitreous hemorrhage with tissue plasminogen activator (t-PA) and volume homeostatic fluid-fluid exchanger.
Thrombosis
Mechanism of formation of vascular thrombosis and its treatment with fibrinolysin.
Thrombosis
Mechanisms by which thrombolytic therapy results in nonuniform lysis and residual thrombus after reperfusion.
Thrombosis
Microfluidic Modeling of Thrombolysis.
Thrombosis
Modelling fibrinolysis: a 3D stochastic multiscale model.
Thrombosis
Modification of fibrin structure as a possible cause of thrombolytic resistance.
Thrombosis
Molecular analysis of blood vessel formation and disease.
Thrombosis
Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.
Thrombosis
Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues.
Thrombosis
Monolithic peptidyl sorbents for comparison of affinity properties of plasminogen activators.
Thrombosis
Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis.
Thrombosis
Negative selectivity and the evolution of protease cascades: the specificity of plasmin for peptide and protein substrates.
Thrombosis
Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin).
Thrombosis
New developments in thrombolytic therapy.
Thrombosis
New insights into the size and stoichiometry of the plasminogen activator inhibitor type-1.vitronectin complex.
Thrombosis
Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis.
Thrombosis
NMR secondary structure of the plasminogen activator protein staphylokinase.
Thrombosis
Non-penetrating trauma to the carotid artery with secondary thrombosis and embolism: treatment by thrombolysin.
Thrombosis
Nonfibrinolytic functions of plasminogen.
Thrombosis
Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
Thrombosis
Novel and emerging therapies: thrombus-targeted fibrinolysis.
Thrombosis
Novel Pheretima guillelmi-derived antithrombotic protein DPf3: Identification, characterization, in vitro evaluation and antithrombotic mechanisms investigation.
Thrombosis
One year in review 2017: Behçet's syndrome.
Thrombosis
Our fibrinolytic potential.
Thrombosis
Outcome of Acute Deep Venous Thrombosis Using Standard Treatment versus Thrombolytics: A Literature Review.
Thrombosis
PAI-1 Inhibition - Another Therapeutic Option for Cardiovascular Protection.
Thrombosis
Pathophysiology of thrombophilic states.
Thrombosis
Penetration of macromolecules into contracted blood clot.
Thrombosis
Perioperative changes in coagulative and fibrinolytic function during surgical treatment of abdominal aortic aneurysm and arteriosclerosis obliterans.
Thrombosis
PGE1 accelerates thrombolysis by tissue plasminogen activator.
Thrombosis
Pharmacologic and Pharmacomechanical Thrombolysis for Acute Deep Vein Thrombosis: Focus on ATTRACT CME.
Thrombosis
Pharmacology of cyclooxygenase-2 inhibitors and preemptive analgesia in acute pain management.
Thrombosis
Pharmacology of fibrinolysis.
Thrombosis
Phase 1 study of human plasma-derived plasmin (TAL-05-00018) in hemodialysis graft occlusion.
Thrombosis
Photonic activation of plasminogen induced by low dose UVB.
Thrombosis
Physical determinants of fibrinolysis in single fibrin fibers.
Thrombosis
Physiologic regulation and pathologic disorders of fibrinolysis.
Thrombosis
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Thrombosis
Physiological consequences of over- or under-expression of fibrinolytic system components in transgenic mice.
Thrombosis
Physiological role of alpha 2-plasmin inhibitor in rats.
Thrombosis
Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events.
Thrombosis
Plasma D-dimer for the diagnosis of thromboembolic disorders in dogs.
Thrombosis
Plasma Lipoprotein(a) and its relationship with disease activity in patients with Behçet's disease.
Thrombosis
Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice.
Thrombosis
Plasmin inactivation in plasma.
Thrombosis
Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner.
Thrombosis
Plasminflammation-An Emerging Pathway to Bradykinin Production.
Thrombosis
Plasminogen acceleration of urokinase thrombolysis.
Thrombosis
Plasminogen activation and lysis of blood clots induced by cells in vitro.
Thrombosis
Plasminogen Activation-Based Thrombolysis for Ischaemic Stroke: The Diversity of Targets may Demand New Approaches.
Thrombosis
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.
Thrombosis
Plasminogen Activator Inhibitor with Very Long Half-life (VLHL PAI-1) can Reduce Bleeding in PAI-1-deficient Patients.
Thrombosis
Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.
Thrombosis
Plasminogen activator inhibitor-1 in vascular thrombosis.
Thrombosis
Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism.
Thrombosis
Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease.
Thrombosis
Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow.
Thrombosis
Plasminogen deficiency and thrombosis after plasmapheresis therapy for multiple sclerosis.
Thrombosis
Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.
Thrombosis
Plasminogen deficiency.
Thrombosis
Plasminogen deficiency: an additional risk factor for thrombosis in a family with factor V R506Q mutation?
Thrombosis
Plasminogen in cerebrospinal fluid originates from circulating blood.
Thrombosis
Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents.
Thrombosis
Plasminogen Paris I: congenital abnormal plasminogen and its incidence in thrombosis.
Thrombosis
Plasminogen San Antonio: an abnormal plasminogen with a more cathodic migration, decreased activation and associated thrombosis.
Thrombosis
Platelet GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and rethrombosis in the canine carotid artery.
Thrombosis
Platelets: connecting clotting and lysis.
Thrombosis
Pneumococcal phosphoglycerate kinase interacts with plasminogen and its tissue activator.
Thrombosis
Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study.
Thrombosis
Post-traumatic membranous obstruction of the inferior vena cava associated with a hypercoagulable state.
Thrombosis
Postoperative venous thromboembolism and brain tumors: Part II. Hemostatic profile.
Thrombosis
Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.
Thrombosis
Prediction of the three-dimensional structure of the enzymatic domain of t-PA.
Thrombosis
Prevention of arterial thrombosis following experimental endarterectomy with plasmin (fibrinolysin).
Thrombosis
Prevention of femoral vein occlusion by local injection of Thrombolysin in the rat.
Thrombosis
Prevention of microvascular thrombosis with short-term infusion of human tissue-type plasminogen activator.
Thrombosis
Prevention of thromboplastininduced thrombosis in rabbits by means of plasmin.
Thrombosis
Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
Thrombosis
Production of a recombinant antithrombotic and fibrinolytic protein, PLATSAK, in Escherichia coli.
Thrombosis
Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects.
Thrombosis
Properties of molecular variants of tissue-type plasminogen activator.
Thrombosis
Prothrombotic effects of thrombolytic therapy in a rat (Rattus norvegicus) model of venous thrombolysis.
Thrombosis
Prothrombotic State in Patients With a Left Atrial Appendage Thrombus of Unknown Origin and Cerebrovascular Events.
Thrombosis
Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition.
Thrombosis
Radioiodinated plasminogen: an imaging agent for pre-existing thrombi.
Thrombosis
Radiological stenting provides effective palliation in malignant central venous obstruction.
Thrombosis
Recanalization and flow regulate venous thrombus resolution and matrix metalloproteinase expression in vivo.
Thrombosis
Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery.
Thrombosis
Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
Thrombosis
Recombinant tissue type plasminogen activator treatment of thrombosed mitral valve prosthesis during pregnancy.
Thrombosis
Reduction in stent and vascular graft thrombosis and enhancement of thrombolysis by recombinant Lys-plasminogen in nonhuman primates.
Thrombosis
Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus.
Thrombosis
Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis.
Thrombosis
Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin.
Thrombosis
Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and ?2-Antiplasmin Inactivation.
Thrombosis
Remaining perspectives of mutant and chimeric plasminogen activators.
Thrombosis
Reminiscences of my contributions to Thrombosis and Haemostasis: urine tissue factor and plasma plasmin inhibitor.
Thrombosis
Renal vein thrombosis in a newborn with prothrombotic genetic risk factors.
Thrombosis
Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Thrombosis
Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies.
Thrombosis
Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator.
Thrombosis
Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
Thrombosis
RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets.
Thrombosis
Risk factors for chronic thromboembolic pulmonary hypertension.
Thrombosis
Risk factors for thrombosis in lupus patients.
Thrombosis
Role of neutrophil membrane proteases in fibrin degradation.
Thrombosis
SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis.
Thrombosis
Schistosoma mansoni glyceraldehyde-3-phosphate dehydrogenase enhances formation of the blood-clot lysis protein plasmin.
Thrombosis
Schistosomes Enhance Plasminogen Activation: The Role of Tegumental Enolase.
Thrombosis
Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality.
Thrombosis
Selective binding of plasmin in the presence of excess plasminogen by certain anionic polystyrene resins.
Thrombosis
Seminars in thrombosis, thrombolysis and vascular biology. 4. Fibrinolysis.
Thrombosis
Sequential treatment of arterial occlusions with porcine plasmin and low dose streptokinase.
Thrombosis
Sequential treatment of deep leg vein thrombosis with porcine plasmin and low dose streptokinase.
Thrombosis
Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy.
Thrombosis
Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease.
Thrombosis
SMTP (Stachybotrys microspora triprenyl phenol) enhances clot clearance in a pulmonary embolism model in rats.
Thrombosis
Soluble expression, purification, and characterization of active recombinant human tissue plasminogen activator by auto-induction in E. coli.
Thrombosis
Soluble fibrin species in arterial thrombi.
Thrombosis
Specific determination of plasmin inhibitor activity in plasma: documentation of specificity of manual and automated procedures.
Thrombosis
Spontaneous thrombolysis: a forgotten determinant of life or death.
Thrombosis
Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with tranexamic acid (AMCA). Report of three cases.
Thrombosis
Spontaneous versus secondary thrombosis in congenital heterozygous plasminogen deficiency.
Thrombosis
Statistical optimization of fibrinolytic enzyme production using agroresidues by Bacillus cereus IND1 and its thrombolytic activity in vitro.
Thrombosis
Streptococcus uberis plasminogen activator (SUPA) activates human plasminogen through novel species-specific and fibrin-targeted mechanisms.
Thrombosis
Streptokinase inhibits acute platelet thrombus formation in stenosed dog coronary arteries.
Thrombosis
Streptokinase@alumina nanoparticles as a promising thrombolytic colloid with prolonged action.
Thrombosis
Structure and activity of plasmin and other direct thrombolytic agents.
Thrombosis
Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
Thrombosis
Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Thrombosis
Studies on the synthesis and Antithrombosis Activity of the Analogue of Fibrin Decomposed Product-Related Peptide.
Thrombosis
Subclinical activation of fibrinolysis in atherosclerotic disease detected by B beta 15-42 assay.
Thrombosis
Successful endovascular therapy for acute basilar thrombosis in an adolescent.
Thrombosis
Successful treatment of central venous catheter induced superior vena cava syndrome with ultrasound accelerated catheter-directed thrombolysis.
Thrombosis
Sulfenamide and Sulfonamide Derivatives of Metformin - A New Option to Improve Endothelial Function and Plasma Haemostasis.
Thrombosis
Superior mesenteric vein thrombosis after colectomy for inflammatory bowel disease: a not uncommon cause of postoperative acute abdominal pain.
Thrombosis
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.
Thrombosis
Symptomatic versus asymptomatic patients in congenital hypoplasminogenemia: a statistical analysis.
Thrombosis
Synthesis of recombinant human single-chain urokinase-type plasminogen activator variants resistant to plasmin and thrombin.
Thrombosis
t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension.
Thrombosis
Targeted thrombolysis by using of magnetic mesoporous silica nanoparticles.
Thrombosis
Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
Thrombosis
Textilinin-1, an alternative anti-bleeding agent to aprotinin: Importance of plasmin inhibition in controlling blood loss.
Thrombosis
Textilinins from Pseudonaja textilis textilis. Characterization of two plasmin inhibitors that reduce bleeding in an animal model.
Thrombosis
The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility.
Thrombosis
The annexin A2/S100A10 system in health and disease: emerging paradigms.
Thrombosis
The beneficial effect of lys-plasminogen upon the thrombolytic efficacy of urokinase in a dog model of peripheral arterial thrombosis.
Thrombosis
The effect of fibrinolysin on the incidence of thrombosis in small-artery suturing.
Thrombosis
The effect of fibrinolytic enzyme FII(a) from Agkistrodon acutus venom on disseminated intravascular coagulation in rabbits.
Thrombosis
THE EXPERIMENTAL USE OF THROMBOLYSIN TO DISSOLVE A BLOOD CLOT PLACED WITHIN THE PLEURAL SPACE OF DOGS.
Thrombosis
The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015.
Thrombosis
The fibrinolytic system in man.
Thrombosis
The fibrinolytic system of the vascular wall.
Thrombosis
The Fibrinolytic System-More Than Fibrinolysis?
Thrombosis
The hemostatic system in children undergoing intensive plasma exchange.
Thrombosis
The human plasma fibrinolytic system: regulation and control.
Thrombosis
The inactivation of hemostatic factors by hematin.
Thrombosis
The influence of transport parameters and enzyme kinetics of the fibrinolytic system on thrombolysis: mathematical modelling of two idealised cases.
Thrombosis
The Internal Dynamics of Fibrinogen and Its Implications for Coagulation and Adsorption.
Thrombosis
The lipoprotein(a). Significance and relation to atherosclerosis.
Thrombosis
The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor.
Thrombosis
The physiopathology of lipoprotein (a).
Thrombosis
The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made.
Thrombosis
The release of B beta 1-42 from fibrinogen and fibrin by plasmin.
Thrombosis
The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
Thrombosis
The role of beta2-glycoprotein I (beta(2)GPI) in the activation of plasminogen.
Thrombosis
The role of beta2-glycoprotein I (beta2GPI) in the activation of plasminogen.
Thrombosis
The role of lipoproteins and apolipoproteins in prediction of coronary heart disease risk.
Thrombosis
The role of the annexin A2 heterotetramer in vascular fibrinolysis.
Thrombosis
The role of the monocyte in the generation and dissolution of arterial and venous thrombi.
Thrombosis
The Role of the Plasminogen Activation System in Angioedema: Novel Insights on the Pathogenesis.
Thrombosis
The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis.
Thrombosis
The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk.
Thrombosis
The single-chain form of tissue-type plasminogen activator has catalytic activity: studies with a mutant enzyme that lacks the cleavage site.
Thrombosis
The study of gene-environment interactions that influence thrombosis and fibrinolysis. Genetic variation at the loci for factor VII and plasminogen activator inhibitor-1.
Thrombosis
The successful treatment of a case of central retinal vein thrombosis with intravenous fibrinolysin.
Thrombosis
The ternary microplasmin-staphylokinase-microplasmin complex is a proteinase-cofactor-substrate complex in action.
Thrombosis
The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure.
Thrombosis
The tissue plasminogen activator and urokinase response in vivo during natural resolution of venous thrombus.
Thrombosis
The tissue-type plasminogen activator story.
Thrombosis
The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans.
Thrombosis
The Unravelling of the Genetic Architecture of Plasminogen Deficiency and its Relation to Thrombotic Disease.
Thrombosis
The use of fibrinolysin in the prevention of thrombus formation in small artery anastomoses.
Thrombosis
The use of plasmin in the treatment of intravascular thromboses.
Thrombosis
Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Thrombosis
Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome.
Thrombosis
Thromboembolic diseases in neonates and children.
Thrombosis
Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
Thrombosis
Thrombolysis for intravascular thrombosis in neonates and children.
Thrombosis
Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris.
Thrombosis
Thrombolysis of palmar and digital arterial thrombosis by intra-arterial Thrombolysin.
Thrombosis
Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2tu-PA) in rabbits.
Thrombosis
Thrombolytic agents--an overview.
Thrombosis
Thrombolytic Agents.
Thrombosis
Thrombolytic Agents: Nanocarriers in Controlled Release.
Thrombosis
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons.
Thrombosis
Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model.
Thrombosis
Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis.
Thrombosis
Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model.
Thrombosis
Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
Thrombosis
Thrombolytic properties of an inactive proenzyme form of human urokinase secreted from human kidney cells.
Thrombosis
Thrombolytic therapy for deep vein thrombosis: potential application of plasmin.
Thrombosis
Thrombolytic therapy in acute myocardial infarction: Part II--rt-PA.
Thrombosis
Thrombolytic therapy in peripheral arterial occlusive disease: mechanisms of action and drugs available.
Thrombosis
Thrombolytic therapy-associated acute myocardial infarction in patients with acute ischemic stroke: A treatment dilemma.
Thrombosis
Thrombolytic therapy.
Thrombosis
Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities.
Thrombosis
Thrombomodulin is associated with increased mortality and organ failure in mechanically ventilated children with acute respiratory failure: biomarker analysis from a multicenter randomized controlled trial.
Thrombosis
Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds.
Thrombosis
Thromboxane antagonism in experimental canine carotid artery thrombosis.
Thrombosis
Tissue plasminogen activator is a potent activator of PDGF-CC.
Thrombosis
Tissue plasminogen activator: an evaluation of clinical efficacy in acute myocardial infarction.
Thrombosis
Tissue-type plasminogen activator gene is on chromosome 8.
Thrombosis
Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis.
Thrombosis
Tissue-type plasminogen activator: a historical perspective and personal account.
Thrombosis
Topology of the fibrinolytic system within the mural thrombus of human abdominal aortic aneurysms.
Thrombosis
Towards safer thrombolytic therapy.
Thrombosis
tPA in the injured central nervous system: different scenarios starring the same actor?
Thrombosis
Tranexamic acid can inhibit tongue squamous cell carcinoma invasion in vitro.
Thrombosis
Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
Thrombosis
Treatment of cerebrovascular thrombosis with fibrinolysin. Preliminary report.
Thrombosis
Treatment of cerebrovascular thrombosis with plasmin and plasminogen activators.
Thrombosis
Treatment of Recurrent Prosthetic Mitral Valve Thrombosis with Reteplase: A Report of Four Cases.
Thrombosis
Treatment of thrombosis with fibrinolysin (plasmin).
Thrombosis
Trends and future developments in the pharmacological treatment of acute ischaemic stroke.
Thrombosis
Two types of abnormal genes for plasminogen in families with a predisposition for thrombosis.
Thrombosis
Type I congenital plasminogen deficiency is not a risk factor for thrombosis.
Thrombosis
Ultrasound affects distribution of plasminogen and tissue-type plasminogen activator in whole blood clots in vitro.
Thrombosis
Ultrasound-Enhanced Thrombolytic Effect of Tissue Plasminogen Activator-Loaded Echogenic Liposomes in an In Vivo Rabbit Aorta Thrombus Model.
Thrombosis
Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface.
Thrombosis
Unusual thrombotic-like retinopathy (Coats' disease) associated with congenital plasminogen deficiency type I.
Thrombosis
Update on the electrolytic IVC model for pre-clinical studies of venous thrombosis.
Thrombosis
Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism.
Thrombosis
Urokinase-immobilization suppresses inflammatory responses to polyurethane tubes implanted in rabbit muscles.
Thrombosis
Use of fibrinolysin in experimental thrombosis.
Thrombosis
Use of newly developed assays for protein C and plasminogen in horses with signs of colic.
Thrombosis
Use of noninvasive laboratory testing in the prediction of thrombosis in the nephrotic syndrome.
Thrombosis
Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection.
Thrombosis
Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis.
Thrombosis
Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review).
Thrombosis
Vascular functions of the plasminogen activation system.
Thrombosis
Vasoactive agents and production of thrombosis during intravascular coagulation 1--comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP) treated rabbits.
Thrombosis
Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of ?2-antiplasmin.
Thrombosis
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
Thrombosis
X-ray crystal structure of plasmin with tranexamic acid-derived active site inhibitors.
Thrombosis
[A Japanese family with congenital abnormal plasminogen]
Thrombosis
[A successful perioperative anticoagulation therapy and monitoring of a patient with hereditary plasminogen abnormality undergoing aortic valve replacement]
Thrombosis
[Abnormal plasminogen and thrombosis]
Thrombosis
[Acute thrombosis of the portal system. Treatment with alteplase and heparin or with heparin alone in 10 patients]
Thrombosis
[Clinical significance of the determination of several hemostatic parameters in the lacrimal fluid of patients with vascular diseases of the retina]
Thrombosis
[Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis]
Thrombosis
[COMBINED FIBRINOLYSIN AND HEPARIN THERAPY OF VASCULAR THROMBOSIS.]
Thrombosis
[Comparison of urokinase and tissue-type plasminogen activator in transcatheter arterial fibrinolysis]
Thrombosis
[Diagnosis and treatment of coagulation disorders]
Thrombosis
[Diagnosis of thrombosis resulting from tension (Paget-Schroetter syndrome) and its treatment with fibrinolysin and heparin]
Thrombosis
[Enzymatic debridement of wounds. Comparison of 2 commercial preparations]
Thrombosis
[Etiological analysis of thrombophilia]
Thrombosis
[EXPERIENCE WITH THE TREATMENT OF THROMBOSIS AND EMBOLISM WITH FIBRINOLYSIN AND HEPARIN.]
Thrombosis
[Experimental substantiation of diagnosis of thrombosis by means of I-131-labeled fibrinolysin]
Thrombosis
[Features of thrombophilia in nephrotic syndrome in children]
Thrombosis
[Fibrinolysin (Merck) treatment of retinal vein thrombosis.]
Thrombosis
[Fibrinolytic system and a central retinal vein thrombosis]
Thrombosis
[Fibrinolytic treatment of thrombus of the right atrium causing severe pulmonary embolism]
Thrombosis
[Fibrinolytics: from the thrombolysis to the processes of blood vessels growth and remodeling, neurogenesis, carcinogenesis and fibrosis].
Thrombosis
[Formation of left ventricular thrombus in acute myocardial infarction: significance of the determination of fibrinogen, of products of fibrinogen degradation, and of plasminogen]
Thrombosis
[Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events]
Thrombosis
[Hemostasis system and inflammation acute-phase proteins in thrombogenic pathologies]
Thrombosis
[Hemostatic changes in idiopathic venous thrombosis in childhood and adolescence]
Thrombosis
[Hereditary deficiency of antithrombin III, protein C, protein S and factor XII in 121 patients with venous or arterial thrombosis]
Thrombosis
[Hypercoagulable state in Duchenne muscular dystrophy]
Thrombosis
[Increasing the local concentration of fibrinolysin and thrombolysis rate using magnetic fluid in a model of occlusive thrombosis]
Thrombosis
[Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age].
Thrombosis
[Inferior vena cava thrombosis after laparoscopy].
Thrombosis
[Intensification of the effect of exogenous plasminogen activators on lysis of fibrin blood clots due to a decrease in the level of alpha-2- antiplasmin by a plasmasorption method]
Thrombosis
[Lipoprotein (a)--a further risk factor in arteriosclerosis?]
Thrombosis
[Lipoprotein (a). An additional marker of atherosclerosis]
Thrombosis
[Lipoprotein Lp(a) and CETP (cholesterol ester transfer protein): contribution of transgenic mice]
Thrombosis
[Lipoprotein(a). Its importance as an additional atherosclerosis marker]
Thrombosis
[Liver cirrhosis--procoagulant stasis].
Thrombosis
[Local low-dose thrombolytic treatment with sequential urokinase-plasminogen in deep central venous thrombosis]
Thrombosis
[MEASURE OF PLASMA RESISTANCE TO LYSIS BY STREPTOKINASE. APPLICATION TO PATHOLOGIC THROMBOSIS. NEW TECHNIQUE FOR THE MEASUREMENT OF ACTIVATION OF PLASMINOGEN INHIBITORS.]
Thrombosis
[Molecular biology of tissue-type plasminogen activator (t-PA) and clinical application of recombinant t-PA]
Thrombosis
[Molecular defects of coagulation factors and of the fibrinolytic system associated with thromboembolism]
Thrombosis
[New data about lipoprotein(a): a curious molecule or a causal cardiovascular risk factor?]
Thrombosis
[Pathogenesis and laboratory diagnosis of venous thrombosis]
Thrombosis
[Physiopathological shifts in the blood coagulation system in embolism of major arteries of the limbs]
Thrombosis
[Plasmin & therapy of thrombosis.]
Thrombosis
[Plasminogen activation and regulation of fibrinolysis].
Thrombosis
[Plasminogen activator of tissue type. Physiology, pathophysiology and clinical value]
Thrombosis
[Plasminogen depletion and incorporation in experimental venous thrombosis]
Thrombosis
[Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome].
Thrombosis
[Preliminary results of the treatment of thrombosis with domestic fibrinolysin.]
Thrombosis
[PREVENTION OF EXPERIMENTAL THROMBOSIS IN SPLENECTOMIZED ANIMALS BY INTRAVENOUS ADMINISTRATION OF FIBRINOLYSIN WITH HEPARIN.]
Thrombosis
[RESULTS OBTAINED BY FIBRINOLYSIN IN RECENT VENOUS AND ARTERIAL THROMBOSIS.]
Thrombosis
[Staphylokinase--a specific plasminogen activator]
Thrombosis
[Structure and functions of plasminogen/plasmin system].
Thrombosis
[Studies on fibrinolysin activities in thrombosis.]
Thrombosis
[Study of coagulation and fibrinolysis in 131 cases of recurrent deep vein thrombosis]
Thrombosis
[Symposium: Arteriosclerosis (with special reference to thrombosis and anticoagulants). 2. Significance of plasmin in arteriosclerosis.]
Thrombosis
[t-PA in thrombolytic therapy of acute myocardial infarct]
Thrombosis
[The application of fibrinolysin in thromboses and its effect on some indices of the blood coagulation system (preliminary report)]
Thrombosis
[The mysteries of lipoprotein (a): a bridge between thrombosis and atheroma]
Thrombosis
[The rate of activation of plasminogen and intrasvascular thrombus formation in rheumatism and atherosclerosis]
Thrombosis
[The resolution of a mitral valve prosthesis thrombosis with low-dose plasminogen tissue activator and the role of Doppler echocardiographic monitoring]
Thrombosis
[The State of Coagulation Hemostasis and Fibrinolysis in Children With Essential Arterial Hypertension].
Thrombosis
[The use of fibrinolysin and heparin in the treatment of acute thrombophlebitis, thrombosis and embolism]
Thrombosis
[The use of thrombolytic preparations for the functional restoration of the arteriovenous fistula in patients on programmed hemodialysis]
Thrombosis
[Thrombolytic properties of the heparin-tissue plasminogen activator complex and its effect on the fibrinolytic and coagulating systems of the blood in animals]
Thrombosis
[Thrombosis and ischemia: experimental data]
Thrombosis
[Thrombosis of ovarian veins in puerperium associated with heparin-induced thrombocytopenia type II]
Thrombosis
[Thrombosis prophylaxis using plasmin and its combination with alpha-adrenoreceptor antagonists]
Thrombosis
[Tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI)]
Thrombosis
[Treatment of thrombosis and embolisms with human fibrinolysin.]
Thrombosis
[Treatment of thrombosis as a result of stress (the Paget-Schroetter syndrome) in diabetes with fibrinolysin and anticoagulants]
Thrombosis
[Use of fibrinolysin in experimental thrombosis.]
Thrombotic Microangiopathies
Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney.
Thrombotic Microangiopathies
Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy.
Thrombotic Stroke
Activation of coagulation and fibrinolytic systems following stroke.
Thrombotic Stroke
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Thrombotic Stroke
Interventional use of plasminogen activators in central nervous system diseases.
Thrombotic Stroke
Investigational use of tPA in acute stroke.
Thrombotic Stroke
Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI.
Thrombotic Stroke
Pharmacological Modulation of Neutrophil Extracellular Traps Reverses Thrombotic Stroke tPA (Tissue-Type Plasminogen Activator) Resistance.
Thyroid Cancer, Papillary
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Thyroid Diseases
[Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases]
Thyroid Neoplasms
Beneficial effects of retinoic acid on extracellular matrix degradation and attachment behaviour in follicular thyroid carcinoma cell lines.
Thyroid Neoplasms
Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
Thyroid Neoplasms
Molecular regulation of thyroid gland function.
Thyroid Neoplasms
Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
Thyroid Neoplasms
The Importance of Caveolin-1 as Key-Regulator of Three-Dimensional Growth in Thyroid Cancer Cells Cultured under Real and Simulated Microgravity Conditions.
Thyroid Neoplasms
The urokinase plasminogen activating system in thyroid cancer: clinical implications.
Tonsillitis
Arthus tonsillitis in the rabbit. Histological findings and fibrinolytic activity in the blood.
Tonsillitis
Control of Arthus tonsillitis by the administration of an antiplasminic agent.
Tonsillitis
Fibrinolytic activity in patients with acute tonsillitis.
Tonsillitis
[A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs]
Tonsillitis
[Activity of fibrinase in patients with chronic tonsillitis]
Tooth Mobility
Periodontitis associated with plasminogen deficiency: a case report.
Toxemia
Coagulation, fibrinolysis, platelet and kinin-forming systems during toxemia of pregnancy.
Toxemia
Coagulation-fibrinolytic and kinin-forming systems in toxemia of pregnancy.
Toxemia
Studies on the purification and characterization of human urinary plasminogen and plasmin.
Toxemia
Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin.
Toxemia
Urinary fibrinolysis in toxemia of pregnancy.
Toxemia
[Blood coagulation and fibrinolytic studies in patients with toxemia of pregnancy]
Toxoplasmosis
Induction of plasminogen activators in pregnant women with Toxoplasma gondii infection.
Tuberculosis
Binding and activation of human plasminogen by Mycobacterium tuberculosis.
Tuberculosis
Bioactivation of latent transforming growth factor beta1 by Mycobacterium tuberculosis in human mononuclear phagocytes.
Tuberculosis
Enolase of Mycobacterium tuberculosis is a surface exposed plasminogen binding protein.
Tuberculosis
Exploring the interaction between Mycobacterium tuberculosisEnolase and human plasminogen using computational methods and experimental techniques.
Tuberculosis
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Tuberculosis
Interaction of mycobacteria with Plasmin(ogen) affects phagocytosis and granuloma development.
Tuberculosis, Meningeal
Bacterial Fibrinolysin, its Possible Therapeutic Application in Tuberculous Meningitis.
Tuberculosis, Meningeal
Bacterial fibrinolysin, its possible therapeutic application in tuberculous meningitis.
Tularemia
[Adjuvant immunotherapy for patients with cancer of corpus uteri]
Tympanic Membrane Perforation
A reply to the commentary on "Animal models of chronic tympanic membrane perforation: in response to plasminogen initiates and potentiates the healing of acute and chronic tympanic membrane perforations in mice" by Wang AY, Shen Y, Wang JT, Eikelboom RH and Dilley RJ; Clin Translat Med, 2014; 3:5.
Tympanic Membrane Perforation
Animal models of chronic tympanic membrane perforation: in response to plasminogen initiates and potentiates the healing of acute and chronic tympanic membrane perforations in mice.
Tympanic Membrane Perforation
Lack of plasminogen does not alter the early inflammatory response following a tympanic membrane perforation: a study in plasminogen-deficient mice.
u-plasminogen activator deficiency
Plasmin and matrix metalloproteinases in vascular remodeling.
Ureteral Obstruction
Serine proteases, inhibitors and receptors in renal fibrosis.
Urinary Bladder Neoplasms
Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5.
Urinary Bladder Neoplasms
Immunological analysis of plasminogen activators from cultured human cancer cells.
Urinary Bladder Neoplasms
Is interferon gamma one key of metastatic potential increase in human bladder carcinoma?
Urinary Bladder Neoplasms
Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Urinary Bladder Neoplasms
[The investigation on early diagnosis of the bladder tumor. II: A study on urinary cytology, urinary fibrin/fibrinogen degradation products, tissue fibrin deposition and tissue plasminogen activator activity in patients with bladder tumors (author's transl)]
Urogenital Neoplasms
Transferrin, C3 complement, haptoglobin, plasminogen and alpha 2-microglobulin in patients with urogenital tumors.
Urologic Neoplasms
Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer.
Uterine Cervical Neoplasms
ENO1 monoclonal antibody inhibits invasion, proliferation and clone formation of cervical cancer cells.
Uterine Cervical Neoplasms
[Studies on serum protein fractions of patients with uterine cervical cancer undergoing radiotherapy: relationship between changes in serum protein fractions and prognosis]
Uterine Cervicitis
Ligneous cervicitis and endometritis: A gynaecological presentation of congenital plasminogen deficiency.
Uterine Cervicitis
Ligneous Cervicitis in a Woman With Plasminogen Deficiency Associated With an Atypical Form of Microglandular Hyperplasia: A Case Report and Review of Literature.
Uterine Hemorrhage
[Changes in the hemostatic system in anomalous uterine hemorrhages and uterine myoma at perimenopause]
Uterine Hemorrhage
[The relation of fibrinolysin in uterine bleeding.]
Uveitis
Don't Forget What You Can't See: A Case of Ocular Syphilis.
Uveitis
Regulation of anterior chamber fibrinolysis.
Vaccinia
The activation-resistant conformation of recombinant human plasminogen is stabilized by basic residues in the amino-terminal hinge region.
Vaginitis
Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature.
Varicose Ulcer
Lower levels of PAI-2 may contribute to impaired healing in venous ulcers - a preliminary study.
Varicose Veins
Causes of venous thrombosis in fifty Chinese patients.
Varicose Veins
Fibrinolytic parameters during acute haematemesis in endemic hepatosplenomegaly.
Varicose Veins
Pathogenesis of venous thromboembolism: when the cup runneth over.
Varicose Veins
Polymorphisms of serum proteins in Japanese patients with vascular diseases. I. Factor XIIIB, plasminogen and complement types in primary varicose veins.
Varicose Veins
Sclerotherapy for varicose veins of the lower legs in patients with dysplasminogenemia.
Varicose Veins
Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices.
Varicose Veins
Superficial thrombophlebitis of the lower limbs in patients with varicose veins.
Vascular Diseases
Arterial expression of the plasminogen activator system early after cardiac transplantation.
Vascular Diseases
Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice.
Vascular Diseases
Genetic studies on the role of proteinases and growth factors in atherosclerosis and aneurysm formation.
Vascular Diseases
Hemostatic disorders associated with arterial hypertension and peripheral arterial disease.
Vascular Diseases
Inhibition of plasmin-mediated prostromelysin-1 activation by interaction of long chain unsaturated fatty acids with kringle 5.
Vascular Diseases
PARD: platelet aggregation as a risk factor in diabetics: results of a prospective study.
Vascular Diseases
Polymorphisms of serum proteins in Japanese patients with vascular diseases. I. Factor XIIIB, plasminogen and complement types in primary varicose veins.
Vascular Diseases
Young women with advanced aortoiliac occlusive disease: new insights.
Vascular Diseases
[Clinical significance of the determination of several hemostatic parameters in the lacrimal fluid of patients with vascular diseases of the retina]
Vascular Diseases
[Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease]
Vascular System Injuries
Alpha(2)-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injury.
Vascular System Injuries
Apo(a) promotes thrombosis in a vascular injury model by a mechanism independent of plasminogen.
Vascular System Injuries
Lack of alpha 2-antiplasmin promotes re-endothelialization via over-release of VEGF after vascular injury in mice.
Vascular System Injuries
Lp(a)/apo(a) Modulate MMP-9 Activation and Neutrophil Cytokines in Vivo in Inflammation to Regulate Leukocyte Recruitment.
Vascular System Injuries
Plasmin and matrix metalloproteinases in vascular remodeling.
Vascular System Injuries
Proteolytic inactivation of ADAMTS13 by thrombin and plasmin.
Vascular System Injuries
Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury.
Vascular System Injuries
Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process.
Vascular System Injuries
Thrombin-induced lung vascular injury. Roles of fibrinogen and fibrinolysis.
Vasculitis
Anti-Plasminogen Antibodies Compromise Fibrinolysis and Associate with Renal Histology in ANCA-Associated Vasculitis.
Vasculitis
Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis.
Vasculitis
Coagulation abnormalities in rheumatoid disease.
Vasculitis
Impaired activation of the fibrinolytic system in children with Henoch-Schönlein purpura: beneficial effect of hydrocortisone plus Sigma-aminocaproic acid therapy on disappearance rate of cutaneous vasculitis and fibrinolysis.
Vasculitis
The role of inflammatory cells and their proteases in extravascular fibrinolysis.
Vasculitis
Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Vasculitis
[A case of Behçet's disease with chronic and repeated sudden hearing loss: successful treatment with intravenous cyclophosphamide pulse therapy]
Vasculitis, Leukocytoclastic, Cutaneous
[Hypersensitivity vasculitis after thrombolytic therapy with APSAC (anisoylated plasminogen streptokinase activator complex). Presentation of a clinical case and review of the literature]
Vasospasm, Intracranial
Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Vasospasm, Intracranial
Role of plasmin, thrombin, and antithrombin III as etiological factors in delayed cerebral vasospasm.
Vasospasm, Intracranial
The evidence for a role of vasospasm in the pathogenesis of cerebral malaria.
Venous Insufficiency
Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration.
Venous Thromboembolism
Congenital plasminogen deficiency associated with venous thromboembolism: therapeutic trial with stanozolol.
Venous Thromboembolism
High pretreatment plasma D-dimer levels are related to shorter overall survival in endometrial carcinoma.
Venous Thromboembolism
Impaired plasminogen binding in patients with venous thromboembolism: Association with protein carbonylation.
Venous Thromboembolism
Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism?
Venous Thromboembolism
Is plasminogen deficiency a thrombotic risk factor? A study on 23 thrombophilic patients and their family members.
Venous Thromboembolism
Markers of thrombin and plasmin generation in patients with inherited thrombophilia.
Venous Thromboembolism
Massive acute pulmonary embolism in protein S deficiency--a case report.
Venous Thromboembolism
Plasminogen Tochigi mice exhibit phenotypes similar to wild-type mice under experimental thrombotic conditions.
Venous Thromboembolism
Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism.
Venous Thromboembolism
[Hemostatic changes in idiopathic venous thrombosis in childhood and adolescence]
Venous Thrombosis
99mTc plasmin in 394 consecutive patients with suspected deep venous thrombosis.
Venous Thrombosis
99mTc-plasmin test in deep vein thrombosis of the leg.
Venous Thrombosis
A K19E missense mutation in the plasminogen gene is a common cause of familial hypoplasminogenaemia.
Venous Thrombosis
A sequential study of plasma histidine-rich glycoprotein and plasminogen in patients with acute myocardial infarction and deep vein thrombosis.
Venous Thrombosis
Acute deep vein thrombosis treated with porcine plasmin. A double blind trial.
Venous Thrombosis
Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis.
Venous Thrombosis
Acyl-enzymes as thrombolytic agents in dog models of venous thrombosis and pulmonary embolism.
Venous Thrombosis
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Venous Thrombosis
Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
Venous Thrombosis
Blood tests for the diagnosis of venous and arterial thrombosis.
Venous Thrombosis
Cerebral venous thrombosis with plasminogen deficiency.
Venous Thrombosis
Cervical Cancer Associated Biomarkers of Identify High Risk of Venous Thrombosis.
Venous Thrombosis
Clinical observations in the treatment of phlebothrombosis with fibrinolysin.
Venous Thrombosis
Coagulopathies and arterial stroke.
Venous Thrombosis
COMBINED FIBRINOLYSIN AND ANTICOAGULANT THERAPY OF VENOUS THROMBOSIS AND PULMONARY EMBOLISM.
Venous Thrombosis
Comparison between 99Tcm-porcine plasmin and 99Tcm-labelled erythrocytes in diagnosis of deep vein thrombosis.
Venous Thrombosis
COMPARISON OF A FIBRINOLYSIN AND HEPARIN ON INDUCED VENOUS THROMBOSIS AND THROMBOLYSIS.
Venous Thrombosis
Comparison of immunological and functional assays for measurement of soluble fibrin.
Venous Thrombosis
Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin.
Venous Thrombosis
Congenital abnormal plasminogen, Frankfurt I, a cause for recurrent venous thrombosis.
Venous Thrombosis
Congenital deficiency of plasminogen and its relationship to venous thrombosis.
Venous Thrombosis
Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Venous Thrombosis
Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis.
Venous Thrombosis
Detection of an Ala601Thr mutation of plasminogen gene in 3 out of 36 Korean patients with deep vein thrombosis.
Venous Thrombosis
Diagnosis of deep venous thrombosis with 99mTc plasmin using the gamma camera.
Venous Thrombosis
Dimerized plasmin fragment D as a potential biomarker to predict successful catheter-directed thrombolysis therapy in acute deep vein thrombosis.
Venous Thrombosis
Distinction by radioisotope technique of a subgroup with increased thrombophilic potential among patients submitted to major abdominal surgery.
Venous Thrombosis
Effect of exceptional valine replacement for highly conserved alanine-55 on the catalytic site structure of chymotrypsin-like serine protease.
Venous Thrombosis
Effects of oral stanozolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity.
Venous Thrombosis
Effects of porcine plasmin on the coagulation and fibrinolytic systems in humans.
Venous Thrombosis
Familial association of hypoplasminogenemia and heterozygous factor V deficiency.
Venous Thrombosis
Fibrinolysin treatment of induced venous thrombosis in the dog.
Venous Thrombosis
Fibrinolysis. II. Evaluation of enzymatic thrombolysis: Experiments with plasmin preparations in arterial, venous thrombosis.
Venous Thrombosis
Haemostatic changes in patients with deep vein thrombosis.
Venous Thrombosis
Homozygous protein C deficiency combined with heterozygous dysplasminogenemia found in a 21-year-old thrombophilic male.
Venous Thrombosis
Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis?
Venous Thrombosis
Inflammatory bowel disease promotes venous thrombosis earlier in life.
Venous Thrombosis
Inherited hypercoagulable states in children.
Venous Thrombosis
Investigation of a congenital abnormal plasminogen, Frankfurt I, and its relationship to thrombosis.
Venous Thrombosis
Lipoprotein (a) levels in normal pregnancy and in pregnancy complicated with pre-eclampsia.
Venous Thrombosis
Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation.
Venous Thrombosis
Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis.
Venous Thrombosis
Pharmacologic and Pharmacomechanical Thrombolysis for Acute Deep Vein Thrombosis: Focus on ATTRACT CME.
Venous Thrombosis
Physiological role of alpha 2-plasmin inhibitor in rats.
Venous Thrombosis
Plasmin and matrix metalloproteinase system in deep venous thrombosis resolution.
Venous Thrombosis
Plasmin generation in dogs with venous thrombosis.
Venous Thrombosis
Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.
Venous Thrombosis
Plasminogen levels in healthy volunteers--influence of age, sex, smoking and oral contraceptives.
Venous Thrombosis
Platelet adhesiveness and fibrinolysis after recent cerebro-vascular accidents and their relationship with subsequent deep venous thrombosis of the legs.
Venous Thrombosis
Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study.
Venous Thrombosis
Prevention of fibrinolytic shut-down after major surgery by intramuscular stanozolol.
Venous Thrombosis
Prothrombotic risk factors in childhood stroke and venous thrombosis.
Venous Thrombosis
Recurring thromboembolic disease and pulmonary hypertension associated with severe hypoplasminogenemia.
Venous Thrombosis
Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality.
Venous Thrombosis
Some haemostatic parameters in patients with deep and superficial venous thrombosis.
Venous Thrombosis
The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis.
Venous Thrombosis
The impact of the fibrinolytic system on the risk of venous and arterial thrombosis.
Venous Thrombosis
The molecular genetics of familial venous thrombosis.
Venous Thrombosis
The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis.
Venous Thrombosis
Thrombin and plasmin activity and platelet activation in the development of venous thrombosis.
Venous Thrombosis
Thrombolysis for intravascular thrombosis in neonates and children.
Venous Thrombosis
Thrombolytic agents--an overview.
Venous Thrombosis
Thrombolytic therapy for deep vein thrombosis: potential application of plasmin.
Venous Thrombosis
Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients.
Venous Thrombosis
Tissue-type plasminogen activator: a historical perspective and personal account.
Venous Thrombosis
Translational initiatives in thrombolytic therapy.
Venous Thrombosis
Treatment of deep-vein thrombosis with intermittent streptokinase and plasminogen infusion.
Venous Thrombosis
Use of plasminogen activators in venous thrombosis.
Venous Thrombosis
Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of ?2-antiplasmin.
Venous Thrombosis
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
Venous Thrombosis
[Congenital abnormalities related to coagulation and the fibrinolytic system in patients with vein thrombosis of the lower extremities]
Venous Thrombosis
[Effects of potentiation and rapid action in models of venous thrombosis in dogs upon combined administration of the plasminogen tissue activator and urokinase modified by fibrinogen]
Venous Thrombosis
[Etiological analysis of thrombophilia]
Venous Thrombosis
[Fibrinolytic therapy of deep venous thrombosis. Streptokinase, urokinase, plasminogen substitution]
Venous Thrombosis
[Local low-dose thrombolytic treatment with sequential urokinase-plasminogen in deep central venous thrombosis]
Venous Thrombosis
[Plasminogen depletion and incorporation in experimental venous thrombosis]
Venous Thrombosis
[Problems posed by etiologic research on thrombotic conditions]
Venous Thrombosis
[Quantitative determination of tissue-type plasminogen activator in varicose soleus veins]
Venous Thrombosis
[Results of surgical treatment of acute ileofemoral venous thrombosis with subsequent fibrinolysin and anticoagulant therapy]
Venous Thrombosis
[Role of plasminogen activators in the treatment of deep venous thrombosis]
Venous Thrombosis
[Scintigraphic studies with J123 miniplasmin in patients with suspected deep venous thrombosis of the leg: comparison of the diagnostic value of J123 miniplasmin scintigraphy and Tc99m plasmin test]
Venous Thrombosis
[Studies on thrombolytic therapy for venous thrombosis in the extremities--dynamics of plasmin inhibitor and FDP following administration of urokinase (author's transl)]
Venous Thrombosis
[The influence of the intra-tissue electrical phonophoresis on the hemostasis system in the treatment of acute thrombophlebitis and phlebothrombosis]
Venous Thrombosis
[Thrombolytic treatment of venous thrombi with combined use of streptokinase and human plasminogen (author's transl)]
Venous Thrombosis
[Use of fibrinolysin and anticoagulants in the treatment of venous thrombosis of the extremities]
Ventricular Premature Complexes
Importance of ST-segment depression as a determinant of ventricular premature complex frequency after thrombolysis for acute myocardial infarction. Tissue Plasminogen Activator: Toronto (TPAT) Study Group.
Vertigo
Acute sensorineural hearing loss and vertigo in a young adult with congenital plasminogen disorder.
Vertigo
Inhibitors of coagulation-fibrinolysis system and platelet function in patients with vertigo.
Virus Diseases
Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection.
Virus Diseases
Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection.
Virus Diseases
Elevation of tear fluid plasmin in corneal disease.
Virus Diseases
Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis.
Vitamin A Deficiency
Neutrophil cathepsin G is specifically decreased under vitamin A deficiency.
Vitreoretinopathy, Proliferative
Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.
Vitreoretinopathy, Proliferative
Plasmin in subretinal fluid.
Vitreoretinopathy, Proliferative
Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy.
Vitreoretinopathy, Proliferative
uPA, tPA and PAI-1 mRNA expression in periretinal membranes.
Vitreous Detachment
AUTOLOGOUS PLASMIN FOR PHARMACOLOGIC VITREOLYSIS PREPARED 1 HOUR BEFORE SURGERY.
Vitreous Detachment
Effect of intravitreal plasmin on vitreous removal through a 25-gauge cutting system in the rabbit in vivo.
Vitreous Detachment
Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy.
Vitreous Detachment
Efficacy of autologous plasmin for idiopathic macular hole surgery.
Vitreous Detachment
Enzymatic Vitrectomy and Pharmacologic Vitreodynamics.
Vitreous Detachment
Enzymatic vitreolysis.
Vitreous Detachment
In Vivo Retinal Vein Bypass Surgery in a Porcine Model.
Vitreous Detachment
Intrasurgical plasmin enzyme in diabetic macular edema.
Vitreous Detachment
Intravitreal functional plasminogen is elevated in central retinal vein occlusion.
Vitreous Detachment
Intravitreal plasmin injection activates endogenous matrix metalloproteinase-2 in rabbit and human vitreous.
Vitreous Detachment
Nonclinical safety and pharmacokinetics of intravitreally administered human-derived plasmin in rabbits and minipigs.
Vitreous Detachment
Pharmacologic induction of posterior vitreous detachment in the rabbit.
Vitreous Detachment
Pharmacologic vitreodynamics and molecular flux.
Vitreous Detachment
Pharmacological Vitreolysis.
Vitreous Detachment
Plasmin treatment accelerates vascular endothelial growth factor clearance from rabbit eyes.
Vitreous Detachment
Posterior vitreous detachment induced by injection of plasmin and sulfur hexafluoride in the rabbit vitreous.
Vitreous Detachment
Posterior vitreous detachment with plasmin in the isolated human eye.
Vitreous Detachment
Predictability of vitreous detachment following intravitreal plasmin injection in diabetic macular edema associated with vitreomacular traction.
Vitreous Detachment
PVD following plasmin but not hyaluronidase: implications for combination pharmacologic vitreolysis therapy.
Vitreous Detachment
Safety and efficacy of dispase and plasmin in pharmacologic vitreolysis.
Vitreous Detachment
Successful closure of traumatic macular holes.
Vitreous Detachment
The efficacy of plasminogen-urokinase combination in inducing posterior vitreous detachment.
Vitreous Detachment
The role of recombinant lysine-plasminogen and recombinant urokinase and sulfur hexafluoride combination in inducing posterior vitreous detachment.
Vitreous Detachment
Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy.
Vitreous Detachment
[An experimental study on dissolving and detaching vitreoretinal interface with enzymes]
Vitreous Detachment
[Pharmacologic vitieolysis in diabetic rats]
Vitreous Detachment
[Preparation of high-purity and safe autologous plasmin and its clinical application]
Vitreous Detachment
[Relationship between vitrectomy and the morphology and function of the retina]
Vitreous Detachment
[Research update of ocriplasmin for symptomatic vitreomacular adhesion].
von Willebrand Disease, Type 2
Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin.
von Willebrand Disease, Type 2
[A case of combined abnormalities with plasminogen abnormality, type IIA von Willebrand disease, hypofibrinogenemia and hemolysis]
von Willebrand Disease, Type 3
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
von Willebrand Diseases
Absence of functional activity of tissue plasminogen activator in patients with severe forms of von Willebrand's disease.
von Willebrand Diseases
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis.
von Willebrand Diseases
Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin.
von Willebrand Diseases
Platelets modulate the proteolysis of factor VIII:C protein by plasmin.
von Willebrand Diseases
Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor.
von Willebrand Diseases
[A case of combined abnormalities with plasminogen abnormality, type IIA von Willebrand disease, hypofibrinogenemia and hemolysis]
von Willebrand Diseases
[Combined abnormalities of plasminogen abnormality, von Willebrand disease, hypofibrinogenemia and increased erythrocyte membrane fragility. A new hereditary syndrome?]
Warts
[Immunohistologic alterations of epidermal cytokeratins following cryotherapy]
Wasting Syndrome
Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.
Whooping Cough
Characterization of Phospholipase A(2) Activation by Plasmin in Cultured Bovine Endothelial Cells.
Whooping Cough
Domain-dependent action of urokinase on smooth muscle cell responses.
Whooping Cough
Human plasmin induces a receptor-mediated arachidonate release coupled with G proteins in endothelial cells.
Whooping Cough
Mechanisms of kringle fragment of urokinase-induced vascular smooth muscle cell migration.
Whooping Cough
Plasmin induces smooth muscle cell proliferation.
Whooping Cough
Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Yaws
Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.